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GRACE RENEE WILLIAMS. PTH1R Signaling in Osteoblasts Stimulated with 
Functionally Selective Ligands:  Phosphoproteomics Reveals Unique Signaling 




 The past 20 years have seen G-protein coupled receptor (GPCR) theory 
advance significantly. Receptors are now thought of as adopting multiple conformations 
in a state of dynamic equilibrium. The study of GPCR biased agonism has emerged 
from this changing concept of receptors and introduced the field to “pluridimensional 
efficacy.”  It is thought that a single readout of efficacy is no longer sufficient and 
multiple parameters of efficacy must be measured in drug screens to improve the ability 
to predict in vivo effects. While several GPCRs have multiple cognate ligands that elicit 
functionally-selective responses, the present study focused on biased signaling of the 
parathyroid hormone receptor (PTH1R).  Parathyroid hormone (PTH) maintains serum 
calcium and is a key regulator of bone remodeling.  Human PTH1-34 (Forteo) is the 
only FDA approved drug used for treatment of osteoporosis that acts via its anabolic 
actions on osteoblasts. However, the therapeutic utilization of PTH1-34 is limited by its 
catabolic effects, mediated in part by protein kinase A, which after two years culminate 
in net bone resporption through the activation of osteoclasts by RANKL.  The 
experimental, biased ligand of the PTH1R, bovine parathyroid hormone residues 7-34 
with D-Trp12 and Tyr34 (bPTH(7-34)), does not exhibit the catabolic effects of PTH1-
34.  In vivo administration of the conventional ligand, PTH 1-34, and the biased ligand, 
bPTH(7-34), for eight weeks increased bone mineral density (BMD) in mice.  The 
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anabolic effect of bPTH(7-34) in vivo was lost in β-arrestin deficient mice, revealing a 
dependence on β-arrestin mediated signaling.  Further analysis of osteoblast and 
osteoclast number, transcript expression, and the generation of second messengers 
revealed the anabolic effect of each ligand was achieved by different mechanisms.    
 To elucidate the unique, proximal signaling events activated by acute stimulation 
of the PTH1R with the biased agonist, this study focused on characterization and 
comparison of the phosphorylation-mediated signaling profiles of osteoblasts stimulated 
with each osteogenic agonist. Relative changes in phosphorylation were measured 
using a SILAC-based phosphoproteomic screen following acute stimulation of MC3T3-
E1 preosteoblast cells with hPTH(1-34) or bPTH(7-34) for 5 minutes. The experiments 
were performed in proliferating preosteoblasts (Day 0) and differentiating osteoblasts 
(Day 10).  Over ten thousand sites of phosphorylation were observed.   
 Regulated phosphosites and phosphoproteins were examined for putative kinase 
activity, targeted signaling pathways, and biological processes.  Differences were 
observed in the kinases stimulated by each agonist.  For example, bPTH(7-34) 
treatment activated MAPK1 and increased phosphorylation of downstream substrates, 
while phosphorylation of predicted MAPK1 substrates were decreased with hPTH(1-34) 
activation. While both drugs regulated phosphorylation of proteins in signaling pathways 
involving GPCR signaling (PLC, MTOR, Rho GTPases); Ingenuity Pathway Analysis 
(IPA) also revealed discrete signaling networks engaged by each drug.  PTH (1-34) 
treatment yielded regulated proteins involved in cytoskeletal dynamics and the Wnt/β-
catenin pathway, whereas bPTH(7-34) treatment modulated pathways related to 
survival (ATM, CDKs, and p70S6K) and transcription (Jak/Stat, and PPARα). Cell-
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based assays confirmed hPTH(1-34) and bPTH(7-34) both confer resistance to 
etoposide-induced apoptosis and bPTH(7-34) increases proliferation in MC3T3-E1 cells. 
At the biological process level, both ligands modulated proteins involved in cell survival, 
migration, growth, and bone metabolism.  
 Comparison of regulated phosphoproteins at two time points during osteogenic 
differentiation unexpectedly revealed that the bPTH(7-34) gave a more robust effect in 
proliferating preosteoblasts, whereas hPTH(1-34) stimulated more sites of 
phosphorylation in differentiating osteoblasts.  This observation indicates the differential 
effects of each agonist may result from changes in signaling mediators that are 
expressed at these two time points.  While the PTH receptor was present at both time 
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1.1 Introduction and Background 
 
Over 30% of pharmaceuticals target G-protein coupled receptors (GPCRs) (Hopkins 
and Groom, 2002) and this demonstrates their important position in modern disease 
treatment. Historically drug discovery in this area has been focused on the development 
of agonists and antagonists; however, there is a growing body of evidence that GPCR’s 
mediate a diverse array of downstream effectors in addition to the canonical G-protein 
coupling observed. Some GPCR ligands possess biochemical and structural properties 
which lead the ligand-bound receptor to preferentially couple to one downstream 
effector over another, favoring of one downstream biological process over another. 
These so-called “biased agonists” or “functionally selective” drugs hold potential as 
highly selective therapeutics, capable of increased targeting precision and reduced drug 
side-effects.   A conventional agonist fully activates the receptor, coupling the bound 
receptor to all known effectors; however, a biased agonist partially activates the 
receptor by favoring engagement of one of these effectors over the others. One way to 
observe the unique actions of these ligands is characterization of the signaling events 
initiated by a GPCR stimulated with a conventional agonist or a biased agonist. This 
study will focus on the global phosphorylation-mediated signaling events initiated by 
engagement of the parathyroid-hormone type-I receptor (PTH1R) to a known biased and 
conventional agonist of the receptor. It has been demonstrated in vivo that hPTH(1-34) 
and bPTH(7-34) both initiate an anabolic response in murine bone by engaging the 
PTH1R, but knock-out studies and gene microarray data indicate this is accomplished 
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through distinct mechanisms. We hypothesize that there is a unique, phosphorylation 
mediated, osteogenic signal transduction network engaged by stimulation of the PTH1R 
with bPTH(7-34) when compared to that of PTH(1-34). This hypothesis was tested 
using an unbiased, quantitative phosphoproteomic approached, comprehensive 
bioinformatic analysis and functional interrogation of the data, and confirmative 
biochemical and cell based assays. This information is applicable to the study of biased 
agonism and the treatment of metabolic bone diseases such as osteoporosis. Other 
GPCRs have also demonstrated amenability to ligand-bias, notably the µ-opioid 
receptor, which holds great promise for the safe treatment of chronic pain with reduced 
adverse effects.  Several pre-clinical, proof-of-principle studies have demonstrated both 
G-protein and arrestin-selective agonists can promote advantageous biological effects 
while diminishing detrimental ones.  We believe a greater understanding of acute biased 
agonist signaling events of the PTH1R will shed light on the compelling field of functional 
selectivity and provide information to assist in the future development of biased agonists 




1.1.1 Historical Perspective of G-protein Coupled Receptors 
 
“Perhaps the most important single concept in pharmacology is that of the receptor and 
that of its role as the primary recognition unit for neurotransmitters and hormones.” 
Terry Kenakin (Rang 2002) 
 
1.1.1.1 Receptor Theory 
The concept of a GPCR is so pervasive in biology today, it is hard to imagine a time 
when these transducers were unknown and even a controversial topic. Studies of 
receptor action began long before the signature 7 transmembrane domain molecular 
structure was determined. Our current model of GPCR structure and function has 
evolved tremendously over the past 100 years, beginning in 1905 when John Newport 
Langley theorized the presence of a “receptive substance.” He observed that striated 
muscles contracted in response to adrenaline even if the nerves had degenerated, 
proving the contractility of the tissue to adrenaline was not dependent on an active 
nerve but a substance in the muscle itself (Langley 1905). At the turn of the century 
Paul Ehrlich began his experiments which allowed for the development of a “therapeutic 
index” to describe dosage effects.  In 1907 Ehrlich systematically altered the chemical 
structure of aniline dyes giving them different chemical properties.  He proposed the 
existence “chemoreceptors” for drugs to explain the differential selectivity of the dyes for 
certain tissues. He later used these same methods to develop the first syphilis drug 
“Salvarsan”; this organoarsenic compound was the first modern chemotherapeutic 
agent. Initially the idea of a molecular receptor was met with considerable resistance in 
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the scientific community. Other pervading theories such as the physical theory, the 
physicochemical theory, and the Arndt-Schultz Law were more popular and the receptor 
model was heavily criticized.  Most important of these was the physical theory based 
largely on the work of Walther Straub, which proposed the surface tension of the cells 
allowed for a concentration gradient to form and determine the effect of the drug on the 
system. In a 1912 lecture Straub stated Ehrlich’s theory of molecular receptors was 
“going too far” (Prull 2006).  
Alfred Joseph Clarke is considered the father of receptor theory and introduced 
quantitative methods to the previously qualitative field of receptor study. His systematic 
applications of mathematical modeling and prediction greatly increased support for 
receptor theory. In an elegant display of logical simplicity, Clarke calculated that based 
on molecular sizes and the low concentrations needed for a cellular response, it was not 
physically possible that drugs were creating a monolayer on the cell membrane, and 
must be binding only to a subset of loci on the cell surface. Clarke demonstrated in 
1927 that the binding of acetylcholine on the ventricle of a frog heart could be modeled 
by using Langmuir’s binding isotherms (Clarke 1927). These isotherms model the 
binding of one molecule to a single site and thus postulated receptors obey the law of 
mass action, i.e.: the fraction of the receptors occupied was directly proportional to the 
response of the tissue. Together this was published in 1937 and called Receptor 
Occupancy Theory (Clarke 1937). While Occupancy Theory worked very well for some 
early data, it became clear that it was inadequate to fully explain the dose-response 
relationship of many drugs. The model was unable to explain the unpredicted 
shallowness or steepness of some dose-response curves and why examples of a 
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saturating dose of drug were unable to elicit a maximal response. In fact, Clark pointed 
out that there needed to be a way to differentiate “the capacity to bind and the capacity 
to excite.”  
  
1.1.1.2 Linkage Models 
Modifications of Occupancy Theory (OT) were proposed to describe the experimental 
results which scientists were unable to reconcile with the monotonic model. A limitation 
of Occupancy Theory was highlighted by the observation intrinsic activity. Everhardus 
Jacobus (E.J.) Ariëns observed that for some compounds, even when tissues were 
exposed to concentrations that clearly exceeded the KA values (i.e. receptors were 
saturated with drug), not all drugs produced a maximal effect. Ariëns introduced the 
concept of intrinsic activity as a proportionality factor between the response of the tissue 
and the occupancy of the receptor. This observation yielded further understanding of 
receptor biology and yielded a method to characterize molecules as agonists, 
antagonists, and partial agonists (Ariens 1957).  
To resolve the non-proportionality observed in the situations where OT fell short another 
parameter was needed. Robert P. Stephenson realized that receptor activation could 
not be accounted for by an equilibrium constant alone and introduced the concept of 
efficacy. He proposed three principles to explain the data which conflicted with the linear 
law of mass action (Stephenson 1956).  
1) A maximum effect can be produced by an agonist when occupying only a small 
portion of the receptors;  
2) The response is not linearly proportional to the number of receptors occupied  
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3) Different drugs may have varying capabilities to initiate a response and 
consequently occupy different proportions of the receptor when producing equal 
responses. This property is referred to as efficacy of the drug. In this setting, a 
pure competitive antagonist would have zero efficacy. 
Together these theoretical components are called Classical Receptor Function Theory. 
Thus, the original definition of efficacy was the read-out of one assay, and was the 
maximum response achievable from an applied or dosed agent.  
Two state theory describes a functional equilibrium between two receptors and states R 
(inactive), R* (active) controlled by an equilibrium constant K. The theory was originally 
proposed in Katz and Thesleff (Katz and Theslef 1957) regarding the action of ion 
channels and was later adopted for use in receptor studies (Karlin 1967, Colquhoun 
1973, Thron 1973). This theory was able to describe many aspects of receptor 
activation and also importantly predicted the action of inverse agonists such that the 
agonist may have a greater affinity for the inactive R state over R*.   
The ternary complex model was the first to introduce the actions of G-proteins to the 
receptor system as opposed to viewing the receptor in isolation (Lefkowitz 1980), The 
ternary (def. -composed of 3 parts) complex model proposed that receptors translocate 
in the plasma membrane to interact with these other components and was a radical shift 
in receptor concept. The three parts accounted for were receptors, drugs, and G-
proteins. This model introduced the gamma term, which could represent the affinity of 
the G-protein for the ligand-bound receptor, or represent the affinity of the ligand for the 
G-protein bound receptor. i.e. guanine nucleotides could affect the affinity of agonists 
but not antagonists, suggesting two-stage binding of ligand to receptor and 
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subsequently complex to a G-protein. The Black/Leff operational model was also 
introduced in 1983 and allowed for a mathematical treatment of the efficacy parameter 
(Black and Leff 1983). This model essentially treats the tissue as a Michaelis-Menten 
enzyme system allowing for a more physiological understanding of efficacy and is 
based on the observation that the relationship between agonist concentration and tissue 
response is most often hyperbolic. This allows for response to be expressed in terms of 
receptor and tissue parameters (Kenakin 2009). The Black-Leff model also allows for 
the tau or “transducer ratio” term to be defined by more than one experimental readout 
and thus allows for a more complete characterization.  The Black/Leff model is still used 
as the Gold Standard for modeling receptor kinetics.  
To unite and expand upon two-state theory and ternary complex model, Samama 
published the extended ternary complex model (Samama 1993). In addition to uniting 
the two theories, they also introduced the β-term which formally indicated that there are 
thermodynamic differences between the bound and unbound state of the receptor 
(Kenakin and JA Angus 2000).  The extended ternary complex model: 
…describes the spontaneous formation of an activated receptor. the fact that 
recombinant GPCR systems demonstrate constitutive activity shows that 
receptors spontaneously from active states capable of producing a response 
through G-protein s in the absence of agonists. This describes the phenomenon 
of the difference in affinity of the GPCR for G-protein s in the agonist-bound 
versus unbound states. So if the gamma term is 10, then this means the receptor 
has a ten-fold greater affinity for the G-protein than the ligand unbound receptor. 
The term alpha refers to the multiple differences in affinity for the ligand for R* 
over R. It can be determined then, that alpha and gamma together can quantify 
the ability of the ligand to selectively cause the receptor to couple to G-protein s, 
become the manifestation of efficacy. So, if a ligand stabilizes the inactive state 
of the receptor (alpha<1) or reduces the affinity of the receptor for G-protein s 
(gamma<1), then it will have negative efficacy and will decrease constitutive 





1.1.1.3 Multistate Receptor Models and Probabilistic Theory 
The above models fall under the category of “Linkage models” wherein the protein 
interactions are all described using their relative prevalence in the system. For a more 
precise description it is useful to consider the proteins as thermodynamic entities 
capable of multiple conformations of unknown identity coexisting. In 1965, the ‘Monod-
Wyann-Changeaux’ model of receptor allosteric transitions was proposed. This model 
postulated the protein can exist in at least two different conformational states in the 
absence of a ligand and that the ligand would stabilize one of these conformations 
leading to a physiological effect. The ‘Monod-Wyann-Changeaux’ model gave rise to the 
term “conformational equilibrium” to describe the oscillations of the protein as an 
unbound entity and is more reflective of true protein dynamics. (Monod, Wyann, 
Changeaux, 1965; Burgan 1981). Nuclear magnetic resonance–detected 
hydrogen/deuterium exchange experiments have indicated proteins experience 
constant local unfolding reactions occurring independently of each other in different 
regions of the protein termed “microstates” (Bai 1995, Jeng 1981). Constantly moving 
due to changes in thermal energy, each of these microstates has an associated 
probability. The collection of these probabilities can then be modeled as a Gaussian 
distribution, where the binding of a ligand to the receptor changes the probability 
distribution of the receptor microstates such that it’s proclivity to interact with 
downstream effectors is altered. If it be an agonist and favors receptor interaction with 
G-alpha S, then an increase in cAMP can be observed. Conversely, if the ligand is an 
inverse agonist with binding that disfavors the interaction with G-alpha-s, then we may 
observe a decrease in basal cAMP dependent on the constitutive activity of the receptor 
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if that receptor has constitutive activity for cAMP. As the protein cycles through this 
series of conformations, each has a differential affinity for cytosolic ligands which will 
dock and stabilize an active state of the receptor. Conformational equilibrium also 
implies that the individual receptor conformations will have discrete affinities or binding 
probabilities for secondary effectors on the interior of the cell. In summation, multistate 
and probabilistic models assert that receptors have multiple active states and the active 
state stabilized by the ligand will lead the receptor to preferentially signal through one 
secondary effector over another. 
These kinds of multistate models are necessary to describe the nuances of receptor 
signaling and ligand functional selectivity. These models consider the probability of one 
receptor state plus the affinity of the ligand and G-protein for that state. Every ligand 
and G-protein has characteristic values of the fractional stabilization of a state for each 
receptor state and it is these values that constitute ligand affinity and efficacy. Using 
these values, it is then possible to create a mathematical model of collections of 
receptors in different activation states, or ensembles. Thus, the pharmacological effects 
of a ligand may then be simulated. This is extremely useful in the description of agonist 
functional selectivity where unique agonists activate different portions of stimulus-
response cascades through activation of the same receptor (Kenakin 2009). 
 
1.1.3 Receptor Structural Studies 
Prior to the cloning of the β-2 adrenergic receptor (β2AR)(Dixon 1986), it was not fully 
appreciated that rhodopsin and diffused ligand GPCR’s like the β2AR were part of a 
huge super family of 7 transmembrane domain receptor proteins. The analogous 
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downstream signaling with G-protein-αs, cAMP, and phosphodiesterase (PDE) was 
appreciated between the two types but the homologous structural relationship was 
unexpected.  
 
1.1.3.1 Crystallization of Rhodopsin 
Membrane proteins are particularly difficult to crystallize because of the amphipathic 
nature of their surfaces. The large, hydrophobic membrane-spanning regions of the 
7TMR family (including GPCRs), large disordered regions, and unstable nature of this 
protein class all make for a challenging system to crystallize. The mammalian vision 
pigment rhodopsin and bacteriorhodopsin proved to be the most amenable to 
crystallization of the 7TMR family and were the subjects of most of the early landmark 
studies in this field. In 1975, two members of Gerhart Schretler’s laboratory produced 
the first clues about the structure of rhodopsin. R. Henderson and P.N Unwin produced 
a 7 Å resolved electron micrograph of bacterial “purple membrane,” later determined to 
be composed largely of bacteriorhodopsin. This study was the first to highlight the 
arrangement of the 7 helices in the bacterial membrane. Later that same year, Khorana 
et al published the amino acid sequence of bacteriorhodopsin that enabled cloning of 
the receptor (Khorana, 1975). Shortly after, Hartmut Michel crystallized 
bacteriorhodopsin, for which he won the 1988 Nobel Prize in chemistry (Nobelprize.org). 
1983 produced two huge developments in the study of GPCR structure; first, the 
Hargrave group published the complete amino acid sequence of bovine rhodopsin 
(Hargrave 1983). Later that year, Nathans and Hogness published the gene sequence 
of bovine rhodopsin. Dixon et al published the gene sequence of the human β -
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adrenergic receptor gene sequence in 1986.  These seminal studies allowed for the 
next big step in 7TMR characterization, the first crystallization of a GPCR, Rhodopsin.   
Palczewski et al published the first crystal structure of a GPCR, bovine rhodopsin 
(Palczewski 2000). In addition to rhodopsin’s natural abundance in the retina, the 
molecule’s stability made it a logical choice for crystallization. Rhodopsin contains the 
light activated chromophore, 11-cis retinal deep within its binding pocket. When the 
retinal detects a photon, it changes conformation to trans-retinal and activates the 
rhodopsin receptor. Due to the precise nature of vision, it is necessary to have tight 
control of receptor activation and this gives rhodopsin some unique properties.  Dark-
adapted rhodopsin contains an “ionic lock,” an intramolecular interaction between the 
3rd and 6th helix, which tightly constrains it in the “off” position and imparts the molecular 
rigidity often necessary for the formation of a crystal. The publication of the rhodopsin 
crystal structure provided the first detailed arrangement of GPCR helix arrangement and 
binding pocket chemistry. With the rise of sequencing and cloning technology, 
specifically the β/α-2 adrenergic receptors, it became very apparent that the 7TMR 
architecture was not limited to rhodopsins. The publication of the 2001 human genome 
significantly elevated the tally of potential G-protein coupled receptors to approximately 
800 and demonstrated the GPCR superfamily to be the largest and most diverse of the 
receptor types (Venter 2001;Lander 2001). This versatility permits GPCRs to be act as 
signal transducers for a wide variety of extracellular stimuli including hormones, 
cytokines, and neurotransmitters. These diffused ligands bind and activate the receptor 
while part of the extracellular milieu and are responsible for a vast array of homeostatic 
processes, it was also known then that many of the therapeutics available were targeted 
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to these types of GPCRs. In contrast to rhodopsin, however, many other GPCRs exhibit 
complex conformations and significant basal, agonist-independent G protein activation. 
This basal activation is associated with conformational instability and is relative the 
ability of ligands to act as inverse agonists or activating agonists for a particular 
receptor. To further our understanding of how ligands bind and activate these receptors, 
a crystal structure of a diffused-ligand GPCR was needed.  
 
1.1.3.2 Crystallization of the β2-adrenergic Receptor                                                
It was 7 years after rhodopsin crystallization that the first diffused-ligand GPCR was 
crystallized in the Kobilka laboratory group (Rasmussen 2007), using a nanobody to 
stabilize the protein to form crystals. This allowed for the basic crystal structure but had 
a low resolution. The high-resolution crystal structure was then published in 
collaboration with the Stevens laboratory (Cherezov 2007). Due to the low abundance 
of the β2AR, it was necessary to produce large amounts of the receptor sufficient for 
crystallization. The inherent basal activity and flexibility of diffused ligand GPCR’s led to 
some modifications of the receptor in an attempt to stabilize a single isomer for 
crystallization. The most successful approach was the use of protein engineering to 
replace the troublesome 3rd cytoplasmic loop with the more amenable T4 lysozyme 
(T4L) thus creating a more conformationally stable fusion protein and increasing the 
polar surface area for lattice formation. The results demonstrate structural insights into 
basal activity of the receptor. Rhodopsin has no detectable basal activity, a feature 
necessary for vision. In contrast, even when bound to inverse agonist carazolol, the 
relative basal activity of β2AR is reduced by only 50%, therefore inverse agonist-bound 
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β2AR is not functionally equivalent to dark-adapted rhodopsin. While the overall 
arrangement of the helices in the β2AR is similar to rhodopsin, the β2AR has a more 
open structure. The high-resolution structure of dark-adapted rhodopsin demonstrates 
E134 and R135 in TM3 and E247 in TM6 form a network of hydrogen bonds and charge 
interactions referred to as the ionic lock.  These residues may perform a similar function 
in other GPCRs as mutation leads to constitutive activity. However, the transmembrane 
structures of β2AR have a more open conformation in this region and the structure 
around this region in the β2AR shows R135 and E247 are separated by 4.1 Å, thus this 
area’s topography is more similar to light adapted rhodopsin.   This revelation had 
tremendous implications for the models of receptor activity, possibly confirming the 
existence of multiple active states for the receptor. The rhodopsin model had appeared 
to confirm the earlier description of GPCRs as “molecular switches,” with two discrete 
states- “on and off”. What the adrenergic receptor structure demonstrated is that 
rhodopsin could be the structural exception and not the rule. The adrenergic receptor 
did not possess the tertiary structure that would enable the conformationally restraining 
ionic lock and thus possibly adopted a variety of conformations during normal functions. 
In the past 20 or so years of studies, it has become clear that this conformational 
variability is significant when considering downstream signaling effects of GPCR 
activation. 
 
1.1.4. Fluorescent Studies Reveal Dynamic Receptors 
In addition to contributing to the first sequence of a GPCR in the 1980’s and 
crystallization of the first diffused-ligand GPCR years later, Brian Kobilka has made 
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other significant contributions to the field of GPCR study. In 2012, Dr. Kobilka shared 
the Nobel Prize in Chemistry with Robert Lefkowitz for their collection of seminal studies 
which greatly advanced our understanding of GPCRs. Starting in the mid-1990’s, Brian 
Kobilka performed a series of experiments using fluorescent reporters which 
characterized the receptor dynamics involved in the docking of different ligands. Using 
increasingly sophisticated techniques, the Kobilka laboratory provided the first direct 
evidence for ligand-specific conformational changes occurring in a GPCR. Eventually 
this work led them to postulate that the receptor responded in a distinct manner to 
different agonists and to localize these movements to transmembrane, extracellular or 
cytosolic regions of the receptor. 
In a 1995 J. Biol. Chem. paper, Gether and Kobilka fluorescently labeled the purified 
β2AR with a cysteine reactive fluorescent probe sensitive to changes in the polarity of 
its environment. These experiments revealed the fluorescence profile of agonists, 
antagonists, and inverse agonists were unique (Gether 1995). Also, the correlation 
between the magnitude of change and ligand efficacy suggested that this change in 
fluorescent emission is due to the same conformational change as involved in agonist 
activation of the receptor. This supported the theory that the ligand-receptor complex is 
a unique signaling entity.  Localization of the fluorophore was not an available technique 
at the time but this was resolved by Ghanouni (Ghanouni 2001). Knowing the specific 
residue on which the probe was labeled allowed the investigators to determine which 
region of the protein was shifting in response to ligand. In this case Cys265 on the 
cytosolic face of TM6 is in the G-protein coupling domain and labeled with FM 
(fluorescein maleimide), then the cells were stimulated with epinephrine or 
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isoproterenol. To determine directionality, fluorescence quenchers are in different 
positions in the protein. Rhodopsin activation studies had been conducted using a 
similar method and it was determined that during activation of rhodopsin and β2AR TM6 
rotates and/or tilts to a more hydrophobic environment and becomes closer to TM5. 
This is the same conformation observed in rhodopsin activation. This indicates a 
possible general mechanism of activation for GPCRs, however the slower kinetics of the 
β2AR movements could possibly reflect the discrepancies one might expect to be 
present in a diffused ligand system such as the β2AR versus rhodopsin’s covalently 
bound retinal.  Also in 2001, Kobilka and Ghanouni expanded on the study published 
just a few months earlier using functionally distinct agonists. They noted that partial 
agonists and full agonists induce distinct conformations and postulated GPCRs may 
have multiple active conformations stabilized by different drugs. Finally, in an insightful 
closing remark, the authors proposed “Thus, it may be possible to identify even more 
potent agonists or agonists that can alter G-protein coupling specificity” (Ghanouni 
2001). Characterization of the receptor binding site was achieved using structurally 
related ligands known to bind to the β2AR, both catechol full agonists and the non-
catechol partial agonist salbutamol. Using molecular docking computations, it was 
determined that the non-catechol agonists were not able to fully engage the residues 
involved in catechol binding (Swaminath 2005). Specifically, that the subtle difference in 
the structure of the aromatic ring of the catechols and non-catechol salbutamol leads to 
differences in activation kinetics and downstream functions. Also, the authors 
demonstrated that agonists and partial agonists induced distinguishable active states 
and that the process of activation occurs through at least two kinetically distinguishable 
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steps. Kobilka and Swaminath concluded that agonist binding occurs through a series of 
distinct conformational intermediates as the receptor engages the different ligand 
components.  
In parallel with the β2AR dynamics studies, more information was being gained about 
the conformational changes induced by activation of rhodopsin. In addition to the 
rotation/ tilt of TM6 toward TM5 relative to TM3, light-induced conformational changes 
have also been observed in the cytoplasmic domain spanning TM1 and TM2, and the 
cytoplasmic end of TM7. This information provided more insight into receptor activation 
conformers and allowed for further comparison between rhodopsin and the β2AR (Cai 
1999a, Cai 1999b, Alterbach 2001).  
In a 2007 J. Biol. Chem. manuscript with Granier et al, the β2AR C-terminal domain 
activation dynamics are addressed. Using the most advanced fluorescent label thus far, 
FlAsH (or Fluorescein Arsenical Helix binder) the authors used intermolecular 
fluorescence resonance energy transfer (FRET) as a molecular ruler to gain insight into 
the activation induced movement of the highly flexible C-terminal tail of the β2AR. The 
method employed was fluorescent donor labeling of a relatively stationary amino acid in 
the 3rd intracellular loop, Cys265 and fluorescence acceptor labels at the tail mid-point 
(Cys351) or the last 5 amino acids in the C-terminal tail.  The tail of the Β2AR and most 
GPCRs is dissimilar to that of rhodopsin which has been shown to be highly structured. 
The C-terminus of rhodopsin has been resolved by x-ray crystallography and the 
domain is structured and compactly folded over the eighth helix and first intracellular 
loop (Granier 2007). However, in the native Β2AR, the average distance between 
Cys265 and the distal C-terminus is similar to the distance observed in rhodopsin 
28 
 
denatured with urea. There is little homology between the two receptor types and the 
tail of the β2AR is 45 amino acids longer, thus it is predicted this portion of the protein 
behaves in a different fashion than that of rhodopsin. The β2AR is activated by a 
functionally broad spectrum of diffusible ligands, ranging from conventional agonists like 
epinephrine to the partial agonist dopamine, the antagonist alprenolol, and the inverse 
agonist ICI-118. The authors determined that the fluorescence signature of different 
ligand types was unique and potentially indicative of ligand characterization in the 
absence of prior knowledge. Ligands that have been shown to induce arrestin-
dependent ERK activation, including the full activating agonists and the inverse agonist 
ICI118551, led to a decrease in FRET between the distal FlAsH site and Cys265, 
whereas other ligands had no effect or induced a small increase in FRET. This finding 
indicates the C-terminal tail takes on an extended conformation upon activation by 
these ligands, possibly facilitating interactions with non-G-protein effectors such as 
arrestins and GPCR kinases (GRKs). These results support the conclusion that the C-
terminus is moving away from the core of the receptor upon agonist binding, possibly to 
interact more efficiently with GRKs or arrestins. This may reflect a conformational 
change necessary for arrestin-dependent activation of the MAPK pathway. The study 
provided additional evidence that agonists and partial agonists induce distinct 
conformational states. From a biological standpoint, this is an elegant way to mediate 
signaling. An adaptable and efficient gatekeeper GPCR docks the ligand and responds 
in a ligand-specific manner using a variety of downstream effectors of which it has 




1.2 Downstream Signaling 
 
1.2.1 Canonical Signaling at GPCRs 
As a rich and diverse protein family comprised of about 800 genes, the GPCRs are the 
largest group of membrane receptors and make up almost 1% of the total human 
genome (Venter 2001). Because of their significant role in physiological homeostasis 
and pathophysiological processes and transducing information across the plasma 
membrane, GPCRs are highly sought-after pharmaceutical targets.  They are best 
known for their role as guanine nucleotide exchange factors (GEFs) for heterotrimeric 
guanine nucleotide binding proteins, transmitting intracellular signals by activating 
effector enzymes or ion channels.  
The family of the heptahelical GPCRs is well characterized, consisting of a wide 
branching phylogeny.  The largest class of this family is class A, the rhodopsin-like 
receptors. Over half of these are olfactory receptors; the remaining GPCRs are those 
with known endogenous ligands, and so-called orphan receptors which have no 
identified ligand currently. Despite the lack of sequence homology between classes, all 
GPCRs share the same basic structure and general signaling mechanism. A variety of 
ligands are known to activate the receptors; such as hormones, chemokines, odors, 
pheromones, and neurotransmitters. These activated receptors control many biological 
processes including growth, proliferation, differentiation, and inflammatory responses of 





1.2.2 Classical GEF activity and G proteins 
The GPCR family takes its name from the first characterized group of ubiquitous signal 
transducers known as the guanine nucleotide-binding proteins (G-proteins). Almost 
every GPCR functions as a guanine nucleotide exchange factor (GEF) for heterotrimeric 
G proteins. The G protein heterotrimer consists of three subunits α, β, and γ. Activation 
of the receptor by a ligand induces a conformational change and initiation of GEF 
activity. The receptor exchanges GDP for GTP on the Gα subunit. This causes the 
trimer to dissociate into a Gα monomer and a Gβ/γ dimer. Once dissociated, the Gα and 
Gβ/γ can proceed to activate enzymatic effectors and initiate signaling cascades. After 
this event the receptor is free to activate another G-protein, thereby leading to signal 
amplification. Many of the signaling events following receptor activation are mediated 
through second messengers such as intracellular calcium and cAMP. Gα exists as 
several isomers, and expression levels of each isomer vary by cell type. Gαs directly 
stimulates adenylate cyclase, activating the cAMP-dependent pathways. While Gαi 
inhibits the production of cAMP from adenylate cyclase, Gαq/11 stimulates the 
membrane-bound phospholipase C beta, which cleaves phosphatidylinositol 4,5-
bisphosphate (PIP2) into two second messengers inositol trisphosphate (IP3) and 
diacylglycerol (DAG). Lastly, Gα12/13 is involved in Rho GTPase signaling. The Gα 
subunit will eventually hydrolyze the GTP to GDP by inherent enzyme activity, allowing 
it to re-associate with the Gβ/γ subunits and start a new cycle.   
The α, β, and γ subunits of the G-protein heterotrimer are bound together in the 
inactivated receptor state. Upon agonist binding, the Gα subunit shifts conformation and 
the trimer dissociates into the Gα unit and the Gβ/γ dimer and are released from the 
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receptor to effect signaling changes. There are four alpha subunits (Gs, Gi, Gq, and 
G12) each with the ability to activate distinct downstream effectors, such as adenylyl 
cyclase, phosphodiesterases, phospholipase C, and ion channels. Many GPCRs couple 
to two, three, or more unrelated G-protein classes at physiological levels of expression, 
enabling a single receptor to engage multiple signaling pathways simultaneously or 
activate them differentially in a tissue-selective manner (Mahon 1993, Offermans 1994, 
Laugwitz 1996, Jin 2001, Mahon 2004). 
 
1.2.3 Signal Termination 
Heterotrimeric G-protein signaling is regulated by negative regulation on several levels. 
G-proteins may terminate their own activation due to their intrinsic GTP to GDP 
hydrolysis capability. However, this reaction proceeds at a slow rate (≈0.02 times/sec) 
and, thus, it would take ~50 seconds for any single G-protein to deactivate if other 
signaling components were not involved. Regulators of G protein signaling (RGS) 
proteins may increase the rate of GTP hydrolysis up to 1,500 times, allowing the 
receptor the essential rapid response time for biological activity. The receptor itself is 
also desensitized in two different ways; 1) heterologous desensitization occurs when a 
second-messenger dependent kinase such as PKA or PKC phosphorylates specific 
residues on the intercellular domain and is independent of ligand occupancy; 2) 
homologous desensitization occurs only at ligand-occupied receptors and is dependent 
on the binding of accessory proteins. The ligand-bound receptor has a conformational 
shift which increases the affinity of the receptor for G-protein coupled receptor kinases 
(GRKs) which phosphorylate the receptor on the third intracellular loop or C-terminal tail 
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thus providing a docking site for arrestins. The arrestins then translocate from the 
cytosol to the membrane, bind the receptor and sterically inhibit further G-protein 
interaction (Daaka 2997, Dale 2001, Kang 2015). 
 
1.2.4 Arrestins 
There are four known arrestins; isoforms 1 and 4 are primarily visual arrestins with 
expression restricted to the visual sensory tissues. Arrestin isoforms 2 (β-arrestin1) and 
3 (β-arrestin2) are ubiquitously expressed and interact with many GPCRs throughout 
the body. Although deletion of both β -arrestin isoforms is embryonically lethal, knocking 
out one or the other produces a relatively mild phenotype with no gross morphological 
differences. It is not until the organism is pharmacologically challenged that the 
differences become evident.  β-arrestin1 null mice exhibit exaggerated sensitivity to β-
adrenergic receptor agonists (Connor 1997, Bohn 1999). β-arrestin2 null mice 
demonstrate enhanced morphine-induced analgesia and attenuation of opioid tolerance  
(Bohn 2002). 
G-protein coupled receptor binding induces significant conformational changes to the 
arrestin (Shukla 2008) which then link the receptor to clathrin-dependent endocytotic 
machinery called AP-2 adaptor complex (Stoffel 1997). The Clathrin/AP-2 bound 
arrestin leads receptors to cluster in in clathrin-coated pits, which are then pinched off 
from the membrane by the motor protein dynamin. The removal or sequestration of 
receptors from the cell surface renders it less responsive to subsequent stimuli. GPCRs 
can be divided into 2 classes based on their interactions with the non-visual arrestin 
isoforms (Oakley 2000). One class (A) has a greater affinity for β-arrestin2 than β-
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arrestin1 and forms transient receptor/arrestin complexes which dissociate soon after 
internalization. This transience allows for rapid receptor recycling and return of the 
receptor to the plasma membrane. Examples of this class A type are β2 adrenergic 
receptor, μ-opioid receptor, endothelin type A receptor, dopamine D1A receptor, and 
α1β adrenergic receptor. Class B receptors (angiotensin II type 1A receptor, 
neurotensin receptor 1, vasopressin V2 receptor, thyrotropin-releasing hormone 
receptor, and substance P receptor) form more stable receptor/arrestin complexes and 
have equal affinities for β-arrestin1 and β-arrestin2. Class B receptors are also 
sequestered in endosomes which are processed more slowly or undergo degradation. 
 
1.2.4.2 Arrestin as a Signaling Scaffold 
While G-protein dependent signaling events can account for the majority of known 
GPCR effects, it is clear that GPCR signaling does not end with receptor internalization. 
Experiments have determined that GPCRs can generate signals that are independent of 
the GEF activity of the receptor by coupling to adaptor or scaffolding proteins (El Far 
2002, Wang 2002, Maurice 2011) and other GPCRs (Pin 2003), linking the protein to 
non- G-protein downstream effectors. One of the best characterized of these alternate 
signaling mechanisms is the arrestin signalsome. While arrestin’s first characterized role 
was GPCR desensitization, there is a substantial amount of evidence indicating the 
protein has a role in G-protein independent signaling from the receptor.  It is now 
appreciated that, in addition to signaling through G proteins, GPCRs can also use β-
arrestins 1 and 2 to activate cellular pathways (Lefkowitz 2005, Dewire 2007). Arrestins 
serve as adaptors not only in the context of G-protein signaling but in linking activated 
34 
 
GPCRs to other enzymatic effectors including the tyrosine kinase Src (Luttrell 1999), 
Src family member Tyrosine-protein kinase Hck (Barlic 2000), members of the MAP 
Kinase cascade (McDonald 2000, Defea 2000, Imamaura 2001), the E3 ubiquitin ligase 
Mdm2 (Shenoy 2001), phosphodiesterase enzymes (Perry 2002), and serine/threonine 
kinase Akt with protein phosphatase PP2A (Beaulieu 2005). Considering the abundance 
of arrestins binding to agonist-bound GPCRs, it is not surprising that arrestins recruit 
effector enzymes to participate in signaling and promote degradation of second 
messengers.  
When the arrestin-bound receptor is pinched off the plasma membrane in an 
endosome, it has two fates depending on the receptor class. It may be quickly recycled 
back to the membrane (class A) or persist in an endosome for minutes or even hours  
(class B) (Charest 2005, Pfleger 2006).  
There is substantial evidence that while the receptor-arrestin complex exists, the 
receptor continues to signal in this “signalsome” via the enzymatic effectors scaffolded 
by the arrestin (Alemayehu 2013, Tohgo 2002 and 2003, McGovern 2014). GPCR-
arrestin signalsomes likely function in the regulation of processes that require spatial 
localization and sustained activation of signaling proteins, such as cytoskeletal 
rearrangement during chemotaxis (Ge 2004, Zoudilova 2010).  
 
1.3 Ligand Bias  
Receptors on the cell surface act as signal transducers for information flowing between 
the interior and exterior of the cell. Signal transduction is based on the physical 
interaction of a ligand with the binding pocket of the receptor and the receptor with the 
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intercellular effectors; therefore, ligand binding must initiate conformational changes in 
the receptor that are transmitted to the interior. As discussed earlier, far from the simple 
“on/off” switches first imagined, the modern version of receptor theory envisions multiple 
active conformations each with a proclivity to couple to a downstream effector. The 
unbound receptor cycles through these active states in a conformational equilibrium 
where ligand binding perturbs this equilibrium and effects signaling changes. Agonist 
binding reduces the oscillation through the various active states, intensifying effects of 
the now limited signaling repertoire. Where a receptor may have spent 2% of its time in 
a conformation which favored Gs coupling, the perturbed conformational equilibrium 
may have shifted such that the receptor now spends 70% of the time in that 
conformation, which results in an increase in cAMP production. Ligands are often 
classified by two parameters, affinity and efficacy. Affinity is the binding coefficient of the 
ligand for the orthosteric or “natural” binding pocket and efficacy is the ability of the 
ligand to elicit a measurable response upon receptor binding. If the receptor was a 
simple switch with two states, then ligand activity or efficacy would be independent of 
the assay used to detect the response. Since it is evident that GPCRs do form multiple 
active states, parameters like efficacy must evolve as well to encompass the variety of 
effects different ligands can have on the same receptor. Bouvier and Galandrin coined 
the term “pluridimensional efficacy” to describe the ligand-dependent results of receptor 
activation (Galandrin 2006). It is well known that the β-adrenergic receptor binds 
multiple ligands and is coupled to many signaling pathways (Masri 2008). Using 
different assays to measure ligand-induced activity and a panel of known β-adrenergic 
receptor ligands, the authors demonstrate that the compounds have complex efficacy 
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profiles. Due to the ability of the receptor to couple to multiple downstream effectors 
when activated, there is no a priori reason to assume the efficacy profile would be 
identical for every ligand of the cognate receptor. For example, Bouvier found that 
compounds which are inverse agonists for adenylyl cyclase (AC) activity were agonists, 
inverse agonists, or antagonists for the MAPK pathway. Thus, the term “ligand bias” 
was introduced. Ligand bias simply means the binding of a ligand to a cognate GPCR 
promotes differential coupling of the receptor to Gα subunits or G protein-independent 
pathways such as β-arrestin signaling. It could be said that a compound which is an 
agonist for cAMP but antagonist for MAPK activation is “biased” for the cAMP or Gs 
pathway (Shenoy 2006, Azzi 2003). In the 2013 follow-up paper, Bouvier demonstrated 
a method for quantifying efficacy/ ligand bias at the β-adrenergic receptor based on four 
parameters: cAMP production, Erk(1/2) activation, calcium mobilization, and receptor 
endocytosis at the β-adrenergic receptor (Van der Westhuizen 2014). This concept can 
also be extended to drugs in clinical use, in a 2007 proof-of-principle demonstration 
Lekowitz et al determined that the FDA approved β-blocker carvedilol is a β2-adrenergic 
receptor biased-ligand, favoring recruitment and signaling through β-arrestin and acted 
as an inverse agonist for cAMP. The authors stated:  
We observed that in β2 adrenergic receptor (β2AR)-expressing HEK293 cells, 
carvedilol has inverse efficacy for stimulating Gs-dependent adenylyl cyclase but, 
nonetheless, stimulates (i) phosphorylation of the receptor's cytoplasmic tail on 
previously documented G protein-coupled receptor kinase sites; (ii) recruitment 
of β-arrestin to the β2AR; (iii) receptor internalization; and (iv) activation of 
extracellular regulated kinase 1/2 (ERK 1/2), which is maintained in the G 
protein-uncoupled mutant β2ART68F,Y132G,Y219A (β2ARTYY) and abolished 
by β-arrestin2 siRNA.  
 
Carvedilol had proven particularly effective in the treatment of heart failure (Packer 
1996, Pool-Wilson 2003), and these observations were highly relevant for biased 
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agonist drug design, but also to provide a mechanism for why carvedilol seemed have a 
therapeutic advantage over other β-blockers (Wisler 2007). 
Ligand bias has also been demonstrated for other GPCRs, including the D2 
dopaminergic receptor, the µ-opioid receptor, and the parathyroid hormone type-1 
receptor (PTH1R).  
- D2 dopaminergic receptor: Masri et al demonstrated that many clinically effective 
antipsychotics binding the D2 dopaminergic receptor are agonists for G-alpha-i activity 
but share a common molecular mechanism involving inhibition of D2(L)R/ β-arrestin 2 
mediated signaling  (Masri 2008).   
-μ-Opioid receptor (MOR):  It is thought that the potentially lethal side effects of 
morphine and related opioids-which include fatal respiratory depression are mediated 
by the μ-opioid-receptor (MOR) signaling through the β-arrestin pathway. Significant 
progress has been made in developing ligands which favor G-protein signaling over that 
of arrestin-dependent signaling at the mu opioid receptor (Manglik 2012, Manglik 2016, 
DeWire 2013). 
-PTH1R: A β-arrestin2 biased agonist bPTH(-34) of the PTH1R has been shown in vivo 
to produce an anabolic effect in bone, similar to that of the osteoporosis anabolic agent 
Forteo (Lilly). While the Forteo-bound receptor couples to G-proteins and arrestin, the 
bPTH(7-34)-bound receptor signals primarily through arrestin-dependent pathways 
(Gesty-Palmer 2006, 2009, 2013).  This bias potentially allows for activation of the 




This highlights the promise of biased ligands which has generated excitement in the 
field of GPCR research. Researchers are hoping for the development of so-called 
“designer drugs” which activate the desired response of the GPCR and suppress the 
deleterious response via pathway selection.  Should this become a pharmacological 
reality, the therapeutic advantages would be tremendous. 
 
2. Proteomics 
2.1 In vivo drug activity prediction and multiple parameters of efficacy 
"What we observe is not nature itself but nature exposed to our method of questioning."- 
Werner Heisenberg  
Current drug discovery efforts often include only one measured output for compound 
selection. However, there is a growing body of evidence that this method leaves out 
much pertinent biological information. Through proteomics and the evolution of gene 
ontology (GO) information, prediction of regulated biological processes is being 
increasingly attributed to activation or suppression of a particular cell signaling pathway. 
For instance, it is known that activation of the protein kinase C (PKC) family members 
regulate numerous cellular responses including gene expression, protein secretion, cell 
proliferation, and the inflammatory response. Conventional PKC family members are 
isoform alpha, β1, β2, and gamma, and these proteins are stimulated with the activity of 
phospholipase C (PLC). PLC activity results in the cleavage of phospholipids and the 
cleavage products of DAG and IP3. An industrial drug screen probing only for an output 
of cAMP (indicator of Gαs activity) would miss the potential utility of this compound’s 
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biological effect on PKC. As was discussed in the previous sections, a ligand’s ability to 
modulate receptor signaling is defined by the assay used to measure output and a 
greater understanding of the efficacy profile may provide better prediction of in vivo 
activity.  
To apply a systematic mathematical approach to efficacy and ligand bias, multiple 
parameters of efficacy must be measured. Bouvier and Van der Westhuizen 
demonstrated a method for quantifying efficacy/ ligand bias at the β-adrenergic receptor 
based on 4 parameters: cAMP production, Erk(1/2) activation, calcium mobilization, and 
receptor endocytosis at the β-adrenergic receptor in HEK293 cells (Van der 
Westhuizen, 2013). Using isoproterenol as the metric for full receptor activation, the 
authors demonstrated the agonism/partial agonism/ inverse agonism of the ligand 
depends on the assay being used. The ligands can then be grouped into sets 
depending on their efficacy profile. Carvedilol appears to have a profile which is quite 
distinct from isoproterenol and a high level of functional selectivity as activation of 
Erk1/2 signaling is the only significant pathway output of the four measured.  
Measurements of multiple parameters of efficacy inform the observer of known on-
target efficacy but also of unknown on-target parameters which may affect the 
screening/selection process.  
Another multi-parameter means of characterizing signaling bias is performed using 
Bioluminescence Resonance Energy Transfer (or BRET) biosensors. Bret works by 
using a fluorescent protein donor and a protein acceptor (e.g. luciferase and green 
fluorescent protein).  The proximity and orientation of the BRET pair members 
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determine if light was produced. The output of the assay is fluorescent light and BRET 
is often called a “molecular ruler” as the fluorescent donor protein and the fluorescent 
acceptor protein must come within 10-15 nanometers of each other to produce 
measurable output. These labels can be used as intra-molecular FRET (pair members 
on distal portions on the same protein) or intermolecular FRET (on different proteins) to 
determine either changes in conformation or molecular associations. Targeting the 
Angiotensin II type 1 receptor (AT1R), Namkung and Laporte used the method to 
quantify the properties of different Angiotensin II ligands to engage either Gαq (by 
measuring the interaction between Gαq and Gβ/γ) and β-arrestin2 (as an intramolecular 
conformational sensor) responses. Using dose response curves, the authors were able 
to quantify effect of each ligand on Gq and β-arrestin activation for AngII and 4 analogs. 
Confirming that the known AT1R biased agonist SII caused to receptor to preferentially 
engage β-arrestin and has no significant activation of the predominant AT1R G-protein, 
G-alpha-q.  
Applying a systematic approach such as the two described above across different 
systems would allow the classification of compounds into functionally distinct clusters. 
While we have far to go toward quantifying the pluripotency of GPCR signaling, the 
continuing evolution of efficacy characterization is likely to facilitate the design of drugs 
with increased therapeutic efficacy and reduced side effect profiles. 
2.1.1 “Unnatural” receptor activation 
 
When considering a multi-parameter efficacy profile, it is useful to think about how this 
might be applied to screening a large library of compounds for drug development. How 
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much information is necessary to adequately predict the in vivo efficacy of a potential 
biased therapeutic? There is clear evidence that efficacy is pluridimensional and ligands 
are biased, therefore drug discovery programs must at least consider the possibility of 
unpredicted “on-target” effects.  To characterize a conventional agonist or an 
antagonist, it is reasonable to compare it the native hormone or ligand. For example, the 
ability of angiotensin receptor (AT1R) agonists to promote vasoconstriction and 
aldosterone release could be predicted from studies of the natural agonist angiotensin II 
(AngII); and the effects of antagonizing ligands to lower blood pressure by examination 
of the effect of the therapeutic losartan. However, biased agonists are less predictable. 
By activating the receptor in an “unnatural way”, biased ligands favor signaling 
modalities which may typically play a very minor role in physiology. Thus, the same 
properties which provide the benefits functional selectivity implies, i.e. favoring 
activation of one signaling pathway over another, are also that which makes them less 
predictable than conventional drugs. In nature, GPCR and their ligands co-evolved in a 
dependent fashion. Thus, their relationships are “balanced”. Biased agonists, on the 
other hand, stabilize a different distribution of active receptor states. The resulting 
signals may not be qualitatively different, but are “unbalanced” compared to the native 







2.2 Model System: PTH Signaling in Bone 
2.2.1.1 Bone composition 
Bone comprises the largest proportion of the body’s connective tissue mass. Unlike 
other types of connective tissue, bone is unique in that it is mineralized and constantly 
renewed throughout life via bone remodeling. This is achieved by the coupled 
interactions of bone-depositing osteoblasts and bone resorbing osteoclasts. Osteocytes, 
which are terminally differentiated osteoblasts, comprise more than 90% of the cells 
within the matrix or on bone surfaces (Bellido 2014). The incredible strength, lightness 
and flexibility of bone can be attributed to its composite nature. The majority of bone is 
extracellular matrix, and this matrix consists of mineral, collagen, water, non-
collagenous proteins, and lipids. The mineral phase is composed of hydroxyapatite, a 
naturally occurring material [Ca10(PO4)6(OH)2] albeit with many substitutions including 
magnesium. The hydroxyapatite strengthens the collagen matrix and provides a source 
of calcium, phosphate, and magnesium. The other major portion of bone is the collagen 
fiber network. Collagen is a triple helical molecule, and these molecules connect in a 
network forming both inter- and intramolecular covalent cross links and it is this network 
which provides bone with a degree of flexibility. Noncollagenous proteins compose 10-
15% of total bone protein and are: serum derived proteins such as albumin and alpha2-
HS-glycoprotein; proteoglycans like chondroitin derivatives decorin and biglycan; 
glycosylated proteins like osteonectin, thrombospondin-2, and tetranectin; and Gla-
containing proteins such as osteocalcin.  
2.2.1.2 Bone Remodeling 
43 
 
In a healthy adult, bone remodeling is a constant balanced process which repairs and 
replaces the skeleton with new bone while maintaining mineral homeostasis. 
Proceeding at a rate of approximately 10% per year, the remodeling process involves 
multiple cell types working in tight coordination. Together, the cells that are responsible 
for bone remodeling are known as the basic multicellular unit (BMU).  The BMU is 
mainly populated with clusters of bone-resorbing osteoclasts and bone-forming 
osteoblasts. Osteoclasts are terminally differentiated myeloid cells derived from 
hematopoietic stem cells. They have distinct morphological characteristics used to 
identify them, including multinucleation, a ruffled border, and expression of tartrate-
resistant acid phosphatase and the calcitonin receptor (Teitlebaum 2003).  
The first stage of bone remodeling involves detection of an initiating remodeling signal 
by the osteoblasts. This signal can take different forms, structural damage or activation 
by parathyroid hormone (PTH). In the bone microenvironment, PTH activates the 
parathyroid hormone type-1 receptor (PTH1R), a G-protein coupled receptor on the 
surface of osteoblastic cells (Jupper 1991).  Binding of PTH to its receptor activates 
protein kinase A, protein kinase C, and increases intracellular calcium signaling in these 
cells (Swarthout 2002). Activation of these (and possibly other) signaling pathways 
induces a host of transcriptional responses that ultimately lead to secretion of molecules 
that recruit osteoclast precursors, induce osteoclast differentiation and activation, and 
establish bone resorption. The PTH-stimulated osteoblasts produce two master 
cytokines, colony stimulating factor-1 (CSF-1) and receptor activator of nuclear factor 
kappa-B ligand (RANKL) to promote osteoclast differentiation and activity (Raggett 
2010). Additionally, osteoblast expression of osteoprotegrin (a decoy receptor for 
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RANKL) is reduced, providing more of the released RANKL to activate the osteoclasts 
(Onyia 2004) and produce further bone resorption.  
Upon appropriate signaling, osteoclast precursors begin to fuse together and 
differentiate into the mature multinucleated cell. After activation, osteoclasts move to 
areas of microfracture in the bone by chemotaxis and initiate the remodeling process.  
They begin to resorb bone by forming a tight sealing zone via attachment of the 
osteoclast's plasma membrane to the underlying bone, then secreting hydrogen ions 
through the action of carbonic anhydrase. This leads to the dissolution of old bone and 
an increase in serum calcium and phosphate. Osteoblasts are fibroblast-like cells 
derived from pluripotent mesenchymal cells. A mature osteoblast is a cuboidal cell with 
a large nucleus and enlarged Golgi highly enriched in alkaline phosphatase. It produces 
type I collagen and specialized bone-matrix proteins as osteoid, the basic protein for 
further bone formation and mineralization. Osteoblasts produce alkaline phosphatase, 
the specific function of which has yet to be determined (Halter 2009). The osteoblasts 
follow the osteoclasts in the BMU and secrete and deposit osteoid and direct its 
formation and mineralization into mature bone. An active BMU consists of a leading 
front of bone-resorbing osteoclasts and a lagging edge of bone depositing osteoblasts.  
In metabolic bone diseases like osteoporosis and osteopetrosis, the tightly regulated 
process of bone remodeling becomes imbalanced and results in pathological bone 
disorders. Osteopetrosis is a rare genetic disorder characterized by abnormally dense 
bones which are prone to fracture, and results from failure of osteoclast-mediated bone 
resorption in the skeleton (https://ghr.nlm.nih.gov/condition/osteopetrosis). The disease 
can be caused by defects in multiple genes and the impaired bone resorption which 
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leads to unresorbed cartilage accumulating, collagen fibers that do not connect the 
individual bone units, and microcracks which fail to heal. Children with severe forms of 
this disease are treated by bone marrow transplantation.  The only FDA approved drug 
available for delaying the progression of the disease is interferon gamma-1b discovered 
through Dr. Lyndon Key’s work at the Medical University of South Carolina (Key, L 
1995).  
2.2.1.3 Osteoporosis 
Osteoporosis is a disease characterized by low bone mass and micro-architectural 
deterioration of bone tissue leading to enhanced bone fragility and increase in fracture 
incidence (Halter 2009). Worldwide, osteoporosis causes more than 8.9 fractures 
annually, resulting in an osteoporotic fracture every three seconds (Wright 2014). In the 
U.S., 8.2 million women and 2.0 million men age 50 and above have osteoporosis and 
51.4 million women and 35 million men have low bone mass and are at a higher risk of 
fracture (Wright 2014, Rosen 2013). While post-menopausal women are 
disproportionately affected, it is estimated that 12% of Americans over the age of fifty 
have osteoporosis (www.cdc.gov) and that 44 million Americans suffer from 
osteoporosis or osteopenia (low bone-density) (Rosen 2013).   
Osteoporosis can be defined either by the presence of a fragility fracture or by bone 
mineral density (BMD) measurement. Two factors contribute to bone strength; BMD and 
bone quality. Bone density refers to grams of mineral per volume area and bone quality 
refers to architecture, mineralization, turnover, and accumulation of damage 
(microfractures). There are two main types of bone tissue, cortical or compact bone, 
and trabecular or cancellous bone. The cortical bone forms the hard exterior of bones 
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and is much denser, stiffer, and stronger than trabecular bone. Trabecular bone forms 
the interior bone tissue webbing or trabeculae. Trabecula is softer and weaker than 
cortical bone, but it is also lighter, more flexible, and contains a high surface area to 
mass ratio. The imbalance in bone formation and resorption has effects on trabecular 
bone (loss of connectivity) and cortical bone (cortical thinning and porosity) (Eastall 
2016). The microarchitecture of bone reflects its relative strength and as the resorptive 
activity of osteoclasts outperforms the deposition of new bone by osteoblasts, the 
interior bone webbing trabeculae, are lost. This leads to a substantial reduction in the 
surface area of bone in the compartment. In defining BMD criteria for osteoporosis, the 
World Health Organization (WHO) used as the standard the BMD of young adult women 
who are at the age of peak bone mass. For each standard deviation below peak bone 
mass a woman's risk of fracture approximately doubles (Halter 2009). Women are at 
higher risk of osteoporosis due to lower peak bone mass than men and they also 
experience accelerated bone loss during menopause when systemic estrogen levels 
decrease. In men and women, the early changes associated with age-related bone loss 
are similar. However, women experience accelerated bone loss of approximately 3% to 
5% per year during menopause. Estrogen deficiency results in an increase in bone 
turnover owing to effects on all types of bone cells.  
Teriparatide/Forteo, the N-terminal 34 amino acids of parathyroid hormone (PTH(1-34)), 
is the only therapeutic proven to act proanabolically.  PTH(1-34) treatment stimulates 
bone remodeling with a net positive effect on bone microarchitecture, trabecular 
connectivity and cortical thickness (Schiller 1999).  Other therapeutics such as 
bisphosphonates (alendronate/ Fosamax) and Denosumab/ Prolia are antiresorptive 
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and act by inhibiting osteoclast activity. These antiresorptive agents work indirectly to 
build bone through osteoclast apoptosis, but are not effective at restoring bone that has 
been destroyed. There is also concern in the field about long-term use of 
bisphosphonates.  Long-term suppression of bone remodeling by bisphosphonates may 
compromise bone integrity leading to increased bone fragility. While highly effective at 
slowing bone loss, these drugs are also associated with osteonecrosis of the jaw and 
atypical femur fractures (Kennel and Drake, 2009).  
Another option in development may be the inhibition of sclerostin. Sclerostin (SOST) is 
a hormone produced solely by the osteocytes which has an antianabolic effect on bone 
and acts by inhibiting the Wnt-mediated activation of osteoblasts (Li 2005). An antibody 
against sclerostin is being investigated as an anabolic agent due to the specificity of 
sclerostin for bone and was demonstrated to form bone in a rat model of osteoporosis 
(Li 2009). 
While the net result of intermittent PTH(1-34) treatment is anabolic, due to the coupled 
nature of bone remodeling, activated osteoblasts secrete RANKL leading to the 
recruitment, differentiation, and activity of osteoclasts (Gesty-Palmer 2009).  It would 
therefore, be advantageous to develop therapeutics that can uncouple the bone 
remodeling process and selectively enhance osteoblast number, differentiation, and 
survival. 
2.2.1.4 Role of Estrogen in the pathogenesis of osteoporosis  
Before women enter menopause, the small degree of age-related bone loss and 
fracture rates of men and women are roughly equal. However, during perimenopause 
women experience a rapid decline in bone density, losing up to 5% of bone mass per 
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year (Rosen 2013).   While bone loss is systemic, the trabecular bone is more affected 
than the cortical bone because it has more surface area for bone resorption to occur. 
Therefore, osteoporotic fractures tend to occur initially in regions like the hip and wrist; 
as the bone loss proceeds, vertebral fractures become more common. The rapid bone 
loss can be attributed to increased bone resorption by osteoclasts. In menopausal 
women, the indices of bone resorption are twice as high as pre-menopausal levels, 
while the markers of bone formation are only about 50% elevated compared to 
premenopausal levels (Garnero 1996). Estrogen is the hormone which has the biggest 
impact on mineral metabolism and its production declines with entry into menopause. 
Estrogen has direct action on bone cells (Rosen 2013), and estrogen receptors are 
present on the surface of osteoblast and osteoclasts. Estrogen promotes development 
of osteoblasts from precursors as opposed to adipocytes, the other fate lineage of 
mesenchymal stem cells (MSCs) (Okasaki 1996) and increases their proliferation (Fujita 
2002). Estrogen has a suppressive effect on osteoclast activity by increasing apoptosis 
(Kameda 1997), reducing expression of RANKL, and increasing production of 
osteoprotegrin (Syed 2005).  
 
 
2.2.1.5 PTH effects in the body 
The PTHR is a class II GPCR that shares overall structural similarities with other 
peptide hormone GPCRs including those for glucagon, calcitonin and secretin 
(Kolakowski 1994, Jupper 1991). PTH1R is most highly expressed in kidney and bone.  
It has two native ligands, PTH and parathyroid hormone-related protein (PTHrP). PTH is 
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an 84-amino acid polypeptide, expressed principally in the parathyroid gland, that 
functions as the primary regulator of calcium-phosphate homeostasis.  G protein-
coupled calcium-sensing receptors on parathyroid cells negatively regulate the 
secretion of PTH, such that a fall in serum calcium increases PTH secretion while rising 
calcium levels suppress it. The peripheral actions of PTH work in concert to raise serum 
calcium, establishing a classic hormonal negative feedback loop.  In the kidney, PTH 
increases renal tubular calcium retention and phosphaturia.  It also upregulates renal 
expression of the 1-alpha-hydroxyase necessary to convert 25(OH)-vitamin D to its 
active form 1,25(OH)2-vitamin D, which in turn increases intestinal calcium absorption 
(Schmidt 1995).  PTH exerts complex effects in bone, its other major target organ.  It 
directly stimulates osteoblasts to form new bone by increasing osteoblast number and 
activity, promoting the deposition of new matrix, and accelerating the rate of 
mineralization (Martin 2016). At the same time, PTH increases the recruitment, 
differentiation, and activity of bone-resorbing osteoclasts.  Osteoclasts themselves lack 
PTH receptors, instead being regulated by soluble factors, such as receptor activator of 
NF-kappa-B ligand (RANKL) and osteoprotegrin, a RANKL decoy receptor secreted by 
osteoblasts in response to PTH. On the other hand, the effects of PTHrP are thought to 
function mainly in pre-natal physiology and are restricted to skeletal patterning and 
development. PTHrP coordinates endochondral bone formation during embryonic 
skeletal development and contributes to the regulation of bone remodeling in the post-
natal skeleton (Martin 2016). 
 
2.2.1.5.2 PTH Intracellular Signaling 
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PTH(1-34) acts as a conventional agonist inducing the full complement of signaling 
effects that are elicited by PTH. These effects are mediated by PTH1R coupling to Gs 
and Gq/11. The Gs pathway is characterized by the production of cAMP by adenylyl 
cyclase, activation of protein kinase A, and phosphorylation of many downstream 
targets including the transcription factor CREB.  The Gq/11 pathway activates 
phospholipase C (PLCβ) and subsequently induces Ca++ signaling and the activation of 
protein kinase C (PKC), Ca++/calmodulin dependent kinases, Akt, and mTOR (Bohinc 
2013, Shevtsov 2006).  PTH(1-34) also promotes β-arrestin-mediated desensitization 
and internalization of the PTH1R (Ferrari 1999, Vilardaga 2002). PTH(1-34) can 
stimulate ERK1/2 MAPK signaling by G-protein dependent or G-protein independent β-
arrestin-mediated pathways (Gesty-Palmer 2006, Azarani 1996, Takasu  1999, Mohan 
2000) or, as occurs in differentiated osteoblasts, PTH(1-34) attenuates ERK1/2 
phosphorylation and activation.  
 
2.2.1.6. Signaling Cascades Controling Osteoblast Differentiation 
Mesenchymal stem cells (MSCs) can differentiate into different types of tissues, 
including muscle, bone, and fat. Differentiation into these cell types is regulated by 
tissue-specific cytokines and transcription factors. Osteoblast (OB) differentiation 
cytokines and hormones include bone morphogenic proteins (BMPs), Hedgehogs, TGF-
β, PTH, insulin, IGF-1, and Wnt proteins. The osteoblast differentiation process can be 
divided into several stages: proliferation, matrix deposition, matrix maturation, and 
mineralization. Specific protein expression levels are used when measuring OB 
differentiation, typically alkaline phosphatase (Alp, an early marker), type 1 collagen 
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(Col1), osteopontin (OPN), and osteocalcin (OCN, a late marker).  The initial fate 
commitment of osteoblast precursors comes with the activation of osteoblast master 
transcription factor, Runt-related transcription factor 2 (Runx2). Mice lacking Runx2 fail 
to develop a mineralized skeleton, instead retaining only the cartilaginous skeleton 
(Komori 1997, Otto 1997). The activity of Runx2 can increase or decrease expression of 
OB specific genes including collagen, ALP, OPN, and OC. Runx2 also regulates the 
expression of late differentiation transcription factor Osterix (SP7). The promotor of SP7 
contains a Runx2 binding sequence. Similar to the effects of knocking out Runx2, mice 
lacking osterix are devoid of osteoblasts and fail to form a mineralized skeleton. Bone 
morphogenic proteins (BMPs) are members of the TGF-β superfamily. They were first 
discovered as the active component in bone extracts which were capable of inducing 
bone formation at ectopic locations. Many studies have demonstrated the ability of 
BMPs to induce mesenchymal stem cells to differentiate into bone, confirming their role 
in bone and cartilage formation. BMPs are important in embryogenesis and 
development, maintenance of adult bone tissue homeostasis, and play an important role 
in fracture healing (Wanga 2014). Upon activation by BMP, the BMP receptor 
phosphorylates SMADs 1/3/5. The SMADs then associate with SMAD4 where they can 
interact with transcription factors like Runx2, binding promotor regions and controlling 
osteoblast-specific gene expression and osteoblast differentiation. BMP-2 regulates 
expression of osterix, which in addition to Runx2 is regulated by MAP kinases.  
2.2.1.7 Other Osteotropic hormones and cytokines 
TGFβ: The TGF-β superfamily members are involved in the regulation of migration, 
proliferation, survival, and differentiation of many different cell types. In bone, TGF-β 
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plays a major role in skeletal homeostasis and can have a positive or negative effect on 
bone formation depending on concentration and microenvironment. TGF-β signaling 
proceeds in a manner similar to BMP signaling, however, after activating its specific 
receptors, TGF-β induces activation of SMADs2/3. Smad3 overexpression in MC3T3-E1 
cells increases bone matrix production and mineralization (Alliston 2001). Also like 
SMAD1/5, Runx2 interacts with SMAD3 and assists in regulating TGF-β induced 
transcription. Precursor molecules of TGF-β are synthesized by osteoblasts and 
deposited in the bone matrix. Upon osteoclast activation, the precursors are activated 
by secreted acids and matrix metalloproteases (Janssens 2005). Like many other 
hormones and cytokines, the role of TGF-β in bone is complex. In mesenchymal stem 
cells (MSCs), which can differentiate into osteoblasts, TGF-β favors bone formation by 
stimulating proliferation and migration in the early stages of osteoblastogenesis 
(Janssens, 2005). However, in the later stages of osteoblastogenesis, TGF-β inhibits 
MSC differentiation and mineralization of mature osteoblasts in culture. In high doses, 
TGF-β decreases production of RANKL in osteoblasts decreasing the activation and 
migration of osteoclasts (Alliston 2001, Meada 2004). In osteoclast precursors, TGF-β 
acts in a dose dependent manner, with low doses stimualting migration of osteoclast 
precursors to remodeling site. Overall, in vivo experiments indicate that TGF-βs favor 
bone resorption and destruction (Balooch 2005, Mohammed 2009, Lamora 2014). 
 
Wnt Proteins: WNTs are secreted glycoproteins which regulate stem cell pluripotency 
and development. They bind to the GPCR “Frizzled” on the surface of osteoblasts and 
along with the co-receptor lipoprotein receptor related protein (LRP) transduce the 
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signal to β-catenin, an integral E-cadherin cell-cell adhesion adaptor protein and 
transcriptional co-regulator. β-catenin is translocated to the nucleus via Rac1 and 
initiates transcription of target genes involved in osteoblast differentiation (Baron 2013, 
Rosen 2013). 
 
The 1,25(OH)2D, FGF23, and PTH Axis: Circulating 1,25(OH)2D has 3 classical tissue 
targets: bone, gastrointestinal tract, and kidney. The endocrine actions of 1,25(OH)2D 
involve concerted action with two peptide hormones, PTH, and fibroblast growth factor 
23 (FGF23) which maintain serum calcium and phosphate concentration, respectively. 
In the highly-regulated Vitamin D/ FGF23/ PTH axis, PTH is the main stimulator of 
1,25(OH)2D production in the kidney. In turn 1,25(OH)2D suppresses PTH levels directly 
via a transcriptional mechanism (renal 1α-hydroxylase downregulation) and indirectly by 
increasing serum calcium levels. Calcium acts via calcium sensing receptors (CaSR) in 
the parathyroid gland to suppress PTH release.  FGF23 acts as an endocrine hormone 
by interaction of the C-terminus with its co-receptor α-klotho (αKl) in the parathyroid 
glands, and has been postulated as a direct inhibitor of PTH synthesis (Ben Doz 2007). 
It has been estimated that 80–85 % of filtered phosphate is reabsorbed in the proximal 
tubule via sodium-phosphate co-transporters (NaPi) 2a and 2c (Shimada 2003). FGF23 
directly down-regulates the transcription, translation, and translocation of NaPi 2a and 
2c transporters leading to reduced renal phosphate reabsorption (Shimada 2004). 
FGF23 also directly down-regulates renal 1α-hydroxylase which decreases production 




Bone as a Vitamin D target tissue 
Studies performed in vitro and in vivo support the role of 1,25(OH)2D for directly acting 
on bone (Goltzman 2004, Blau 2015), there is however controversy on this topic 
(Takahashi 2013). It has been demonstrated that osteoblast differentiation can be 
stimulated in vitro by administration of 1,25(OH)2D (Raisz 1972), and that osteoblast 
production of RANKL can be suppressed by active vitamin D compounds like 
eldecalcitol (1α,25-dihydroxy-2β-(3-hydroxypropoxy) vitamin D3) (Takahashi 2013). 
However, there are other studies that have found the opposite response in regard to 
RANKL production resulting from osteoblast stimulation with 1,25(OH)2D leading to 
bone resorption (Yasuda 1998). Thus, the role of 1,25(OH)2D as a direct modulator of 
bone tissue is uncertain and complex.  Nevertheless, active vitamin D compounds such 
as calcitriol (1α,25(OH)2D3), alfacalcidol (1α-hydroxyvitamin D3, 1α (OH)D3) and 
eldecalcitol (1α,25-dihydroxy-2β-(3-hydroxypropoxy) vitamin D3) have been used as 
therapeutic drugs to treat osteoporosis in Japan, because they improve bone mineral 
density (BMD) and decrease the risk of fractures (Matsumoto 2005, 2010).  
 
Calcitonin a 32 amino acid peptide that opposes the actions of PTH on bone is 
produced by the specialized C cells in the thyroid gland. Osteoclasts express receptors 
for calcitonin and respond to it with a rapid decrease in activity (Boron 2004). However, 
patients with radical thyroidectomy (thereby loss of calcitonin peptide) show no changes 
in skeletal morphology. Its action in humans is not well established but synthetic 
calcitonin has been used to treat Paget’s disease, hypercalcemia, and osteoporosis but 
with significant side effects including flushing and nausea. However, it has been 
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demonstrated to possess analgesic properties, specifically in the case of osteoporosis-
induced vertebral fractures. These fractures are very painful and often require bed rest. 
In 13 clinical trials, where daily calcitonin injection and traditional analgesics were 
compared to treatment with analgesics alone; Calcitonin treatment significantly 
decreased pain associated with new osteoporosis-induced vertebral fractures (Knopp-
Sihota 2011). 
Vitamin A (retinol) is is an essential micronutrient which only can be derived from the 
diet. Retinol has many physiological benefits.  It promotes growth and is critical for the 
immune system, reproduction, and vision (www.niams.gov). However, hypervitaminosis 
of vitamin A can lead to pathological effects including increased risk of fracture and 
bone loss. Vitamin A is taken up from the blood stream by target cells and is converted 
to its active metabolite, retinoic acid, inside the cell. CYP26B1, a member of the family 
of oxidizing P450 enzymes (CYP26 A, B, C), specifically inactivates retinoic acid inside 
the cell. Mice lacking activity of CYP26BP1 demonstrate calvarial thinning and skull 
bone defects, and this effect has been recapitulated with excessive doses of vitamin A 
(Lind 2017). In vitro studies have demonstrated that retinol directly stimulates 
osteoclastic bone resorption, inhibits collagen synthesis, and inhibits osteoblast cell 
proliferation (Burkhardt 2014). These unfortunate consequences of vitamin A toxicity 
have been observed in human infants, specifically in Swedish children observed in the 
1950’s when high doses were thought to prevent rickets (Lind 2017). 
Interleukin-1 and tumor necrosis factor-alpha (TNFα) are known as pro-inflammatory 
cytokines. Interleukin-1 (IL-1) and TNFα have direct action on osteoblasts and 
osteoclasts. These cytokines suppress osteoprotegrin (OPG) expression while 
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simultaneously enhancing that of RANKL, leading to a marked increase in available 
RANKL and osteoclast activation. In osteoclast precursors, IL-1 induces the fusion of 
mononuclear cells leading to multinucleation and maturation. IL-1 also directly 
enhances osteoclast activity through receptors on the cell surface.  In chronic 
inflammatory diseases like rheumatoid arthritis or severe periodontitis, a pathological 
loss of bone is observed through the actions of IL-1 and TNFα. Recent progress has 






2.2.4 Biased Agonism of the Parathyroid Hormone Receptor 
The PTH type 1 receptor (PTH1R) is a class II GPCR.  Through advances in the field of 
GPCR signaling, it has become apparent that these seven-transmembrane proteins are 
capable of coupling to multiple downstream effectors including G-proteins, arrestins and 
other scaffolding proteins, and even other GCPRs (Laugwitz 1996, Angers 2002, Brady 
2002, Hall 2002). Biased agonism refers to the ability of a ligand to selectively recruit 
different intracellular signaling proteins upon receptor activation. This implies that two 
different ligands can activate the same receptor in alternate ways and elicit different 




Biased Agonists of the Parathyroid Hormone Receptor: PTH(1-34) and bPTH(7-34) 
Of the biased signaling models currently postulated and characterized, few are as 
promising as the PTH1R.  PTH, an 84 amino acid peptide secreted from the parathyroid 
gland, regulates calcium and phosphate homeostasis by its actions on kidney and bone.  
In addition to PTH, the PTH1R binds the endogenously expressed PTH related peptide 
(PTHrp) and several N-terminal PTH analogues, including PTH(1-34) or teriparatide, 
and bPTH(7-34), a β-arrestin-dependent, biased ligand.  The activation of the receptor 
by PTH or analogues thereof involves multiple intracellular enzymes, second 
messengers, and scaffolding proteins.  
 
2.2.5 Previous Studies 
 
2.2.5.1 PTH(1-34) and bPTH(7-34) Produce an Anabolic Effect in Murine Bone 
Similar to PTH(1-34), intermittent administration of bovine PTH residues 7-34 (D-Trp12, 
Tyr34), referred to hereafter as bbPTH(7-34), to mice increases osteoblast number and 
promotes bone formation (Gesty-Palmer 2009). However, while both agonists bind the 
PTH1R, they utilize different downstream signaling mediators to achieve this anabolic 
effect.  bbPTH(7-34) activates β-arrestin-dependent signaling pathways while acting as 
an inverse agonist for Gs coupled signaling (Gesty-Palmer 2006). The requirement of 
arrestin-mediated signaling was verified in β-arrestin2 null mice which lack the anabolic 
response to bPTH(7-34) (Gesty-Palmer 2009).  β-arrestins have been shown to couple 
to ERK1/2 and the non-receptor tyrosine kinase, Src (Luttrell 2006).  Unlike PTH(1-34), 
in vivo administration of bPTH(7-34) did not increase osteoclast number or markers of 
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bone resorption (Gesty-Palmer 2009) suggesting that the biased response to bPTH(7-
34) has the potential to uncouple osteoblast-mediated bone deposition from osteoclast-
mediated bone resorption in skeletal remodeling (Gesty-Palmer 2009, 2011, and 2013).   
 
2.2.5.2 PTH(1-34) and bPTH(7-34) Elicit Distinct Functional Genomic Signatures in 
vivo 
To understand how these two ligands activate the same receptor and yield different 
efficacy profiles in vivo, the transcriptomes from calvarial osteoblasts from wt or β-
arrestin2-null mice treated intermittently for eight weeks with PTH(1-34), bPTH(7-34), or 
vehicle were compared (Gesty-Palmer 2009). These studies revealed the regulation of 
gene sets that were shared and unique to each agonist. Promoter analysis of regulated 
genes by both ligands revealed an overrepresentation of predicted STAT1 and STAT5 
DNA-binding sites.  Promoter-specific luciferase reporters were utilized to measure the 
activity at promoters of STAT1/2, STAT5, and transcription factors known to respond to 
cAMP/PKA signaling (CREB), PKC/Ca++ signaling (NFAT), and ERK1/2 signaling (Elk-
1/Srf) in primary calvarial osteoblasts differentiated in culture for 10 days. Both agonists 
increased STAT1/2 and STAT5 expression and decreased Elk-1/Srf expression as 
compared to vehicle treated controls.  As expected, CREB expression only increased in 
response to PTH(1-34) stimulation (Gesty-Palmer 2013). bPTH(7-34) primarily affected 
pathways that promote osteoblast population expansion, such as cell cycle regulation, 
cellular adhesion and migration, and cell survival; whereas treatment with PTH(1-34) 
affected pathways associated with enhanced bone formation such as collagen synthesis 
and matrix mineralization (Gesty-Palmer 2013).  Further studies in cultured primary 
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calvarial osteoblasts confirmed that both ligands modestly slowed proliferation and 
promoted survival when challenged with etoposide and bPTH(7-34) more effectively 
stimulated osteoblast migration as compared to PTH(1-34)( Gesty-Palmer 2009). 
 
2.2.5.3 Profiling Bias of the PTH1R in vitro with PTH(1-34) and bPTH(7-34) leads to 
distinct efficacy profiles of cAMP, intracellular calcium influx, and Erk1/2 
activation 
 
A multi-parameter efficacy study was conducted using conventional and biased ligands 
of the PTH1R in a HEK293 cell background. This allowed systematic comparison of the 
ligand’s effects on cAMP production, intracellular calcium influx, and Erk1/2 activation 
and yielded insight into the efficacy profile of ligand bias at the PTH1R. Appleton et al 
demonstrated a distinct efficacy profile of the conventional ligand of the PTH1R (PTH(1-
34)) and the profile of the β-arrestin biased agonist (D-Trp12, Tyr34)-PTH(7-34). While 
PTH(1-34) fully activated the receptor leading to increases in the three efficacy 
parameters profiled, biased agonist (D-Trp12, Tyr34)-PTH(7-34) stimulated only Erk1/2 
activation and did not produce an increase in serum calcium or cAMP. Given the 
previous evidence that both drugs produce an anabolic effect in vivo, the effects of (D-
Trp12, Tyr34)-PTH(7-34) seemed to contradict the general conclusion that Gs activation 
is necessary for the anabolic actions of PTH (Appleton 2013). 
 
3. Phosphoproteomics- Why comprehensive coverage is necessary 
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While the previous studies have greatly expanded our understanding of the genomic 
mechanisms by which the two agonists affect bone mass, the proximal receptor-
signaling networks engaged by PTH(1-34) and bPTH(7-34) have not been elucidated.  
Many of the effects of G-protein and β-arrestin mediated signaling are elicited through 
the activation of kinases, thus we propose the use of quantitative phosphoproteomic 
experiments to more fully characterize the β-arrestin specific signaling cascade and 
distinguish the proximal signaling events that culminate in the anabolic effects of 
bPTH(7-34). The goal of Aim 1 is to establish a quantitative phosphoproteomic 
approach and to identify the phosphorylation mediated signaling network that is 
regulated by acute stimulation with PTH(1-34) in osteoblasts. This will serve as a 
baseline for comparison in Aim 2 which is focused on identifying the shared and distinct 
kinase-mediated signaling events of bPTH(7-34) as compared to PTH(1-34).  
Differential activation of kinases and signaling pathways, transcriptional activity, and 
biological processes that are revealed were validated experimentally in cell-based 
assays.   
 
The experiments proposed have the potential to advance our understanding of 
canonical PTH1R signaling and the phosphorylation-mediated mechanisms underlying 
the effects of PTH(1-34) and reveal novel mechanism(s) by which the biased ligand, 
bPTH(7-34), increases bone formation.  We anticipate we will discover signaling 
intermediates and kinases-substrate relationships, that act in conjunction with β-
arrestin2 which will further our understanding of how the differential effects of β-
arrestin2-mediated biased agonism are elicited.  With tremendous therapeutic potential, 
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biased agonism appears to be a compelling avenue of GPCR drug targeting and 
receptor theory. By influencing the proclivity of the receptor to couple with select down-
stream effectors, biased ligands have the potential to qualitatively change the response 
of a target cell to receptor activation, enabling the creation of drugs with improved 
efficacy and diminished side effects. Yielding possible new ways to manipulate GPCR 
signaling for therapeutic benefit in the treatment of osteoporosis and other pathologies 
that may be ameliorated by targeting GPCRs. 
 
3.1.2 Phosphoproteomics: other GPCR studies 
Protein phosphorylation is a highly dynamic and tightly regulated post-translational 
modification (PTM). The dysregulation of protein phosphorylation is implicated in the 
development of many diseases such as cancer. It is estimated that up to 95% of all 
proteins will be phosphorylated at some point in their lifetime. However, phosphorylation 
typically occurs at low stoichiometry and as with most PTM’s requires specific 
enrichment from milligram quantities of protein for detection and quantification. Large 
scale, quantitative phosphoproteomic studies rely on the use of high-resolution mass 
spectrometry instrumentation. The unbiased identification of phosphorylation sites that 
are regulated following stimulation with hormones/drugs/ligands or genetic alterations 
allows researchers to characterize signaling networks as opposed to isolated events 
and this provides a comprehensive overview of the effects of receptor activation. It is 
possible to perform global phosphorylation studies in tissues and primary or cultured 
cell lines. For the study of PTM’s which are sub-stoichiometric however, in vitro cell 
lines have the distinct advantage of being able to produce milligrams of starting material 
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prior to enrichment steps. Phosphoproteomic experiments performed to compare biased 
and conventional ligands of GPCRs have been performed in HEK293 cells 
overexpressing the GPCR of interest.  These results must be interpreted with caution 
due to receptor over expression and the HEK293 background.  The most 
comprehensive global phosphoproteomics study of biased GPCR signaling thus far was 
completed in HEK293 cells expressing the Angiotensin II type-1 receptor (AT1R) and 
used employed the use of SILAC (stable isotope labeling by amino acids in cell culture) 
for relative peptide quantification (Christenson 2010).  Angiotensin II was used as the 
control ligand (conventional agonist) and the biased agonist [Sar1,Ile4,Ile8]angiotensin 
II (SII), which only activates the Gαq protein-dependent signaling. The enriched 
phosphopeptides were analyzed by high resolution (LTQ-Orbitrap) MS and over 10,000 
sites of phosphorylation were identified. Upon comparison of the two phosphoproteomic 
datasets, the authors found that stimulation of AT1R with the biased agonist SII led to 
changes in phosphorylation of a subset of the sites which changed in response to 
Angiotensin II treatment. Another biased agonist study of this type was completed by 
Karaki et al at the 5-HT2A serotonin receptor, another GPCR. HEK293 cells transiently 
expressing the 5-HT2A receptor were exposed to either vehicle or the synthetic 
hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) or the 
nonhallucinogenic 5-HT2A agonist lisuride (Karaki 2014). The authors found differential 
regulation at sixteen sites of phosphorylation (out of 5,995) by the two ligands, 
importantly including serine280 located in the third intracellular loop of the 5-HT2A 
receptor, a region important for its desensitization. Karaki et al concluded:  
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“These findings suggest that hallucinogenic and nonhallucinogenic agonists 
induce different conformational states of the 5-HT2A receptor, and represent a 
striking example of functional selectivity that translates into contrasting pattern of 
mice behavior: induction of head-twitches by hallucinogenic but not by 
nonhallucinogenic agonists” (Karaki 2014). 
Phosphoproteomic studies of GPCR signaling cascades in primary cells have also been 
an area of high interest. Gunaratne et al used a label-free quantitation approach and 
characterized cAMP/vasopressin-dependent signaling pathways in native renal thick 
ascending limb (mTAL) cells stimulated with vasopressin, glucagon, parathyroid 
hormone, or calcitonin. Gunaratne and quantified 654 phosphopeptides and concluded 
that although protein kinase A plays a central role in mTAL signaling, additional kinases, 
including those that target proline-directed motifs, may be involved in vasopressin 
signaling (Gunaratne 2010).  
In breast-cancer stem cells stimulated with stromal cell-derived factor 1 (SDF-1), Yi, 
Gygi, and Wagner analyzed CXCR4–mediated signaling pathways and observed an 
impressive 11,000 phosphorylation sites in 2,500 phosphoproteins using a reductive-
dimethyl labeling approach. Resultant bioinformatic analysis identified a previously 
unidentified SDF-1/CXCR4-PKA-MAP2K2-ERK signaling pathway and demonstrated 
the feedback regulation on MEK, ERK1/2, δ-catenin, and PPP1Cα in SDF-1/CXCR4 
signaling in breast cancer stem cells. This study especially highlights the advantages of 
global phosphoproteomics studies. This unbiased mass spectrometry approach enables 
characterization of the activated/suppressed kinases, their substrates, and signaling 




The hope of global phosphoproteomics is simple, characterizing these signaling 
networks will allow for improved understanding of proximal signaling events and 
targeting of therapeutics. It is highly probable as yet undetermined signaling mediators 
will prove to be competent targets for drug design. While yielding leading information, it 
is no longer sufficient to look at isolated phosphorylation events to make biological 
conclusions. Cells transmit information by activation or suppression of signaling 
networks and this idea complements the notion of pluridimensional efficacy in that they 
both acknowledge the complexity of biological systems. Our study is unique in the field 
because we are using cultured osteoblasts which endogenously express the PTH-
receptor. Currently, most if not all, GPCR in vitro studies have been completed in 
HEK293 cells over-expressing the receptor of interest and we hope to gain a high level 
of physiological relevance from our system. Additionally, there remain many questions 
to be answered about biasing a receptor and two previous studies characterizing this 
bias have determined the biased ligand binding the receptor activates a subset of the 
conventional ligand activation (Christensen 2010, Xiao 2010). It is not known how 
pervasive this trend may be and if we have learned anything from rhodopsin, it is that 
GPCR’s continue to surprise the observers. Finally, it has long been accepted that 
activation of the osteoclasts and osteoblasts cannot be uncoupled and this makes 
metabolic bone disease intractable to many therapeutics. The biased ligand we are 
interrogating has demonstrated an anabolic effect on the skeleton when given to mice. 
Histomorphometric data indicate this occurs concomitantly with an increased in the 
numbers of osteoblasts without recruitment of osteoclasts. We seek to characterize 
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previously unknown PTH1R activated signaling networks and mediators, compare the 
networks engaged by a conventional and biased agonist, and use bioinformatic 
approaches to predict changes in biological responses to these ligands. Additionally, a 
global phosphoproteomics study has not yet been completed in osteoblasts stimulated 
with PTH.  This dataset will provide a resource for bone biologists interrogating the 
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Chapter 2: Hypothesis and Aims 
 
Our overall goal is to identify mechanisms by which the PTH receptor agonists, 
PTH(1-34) and bPTH(7-34) engage different signaling pathways to yield anabolic 
effects on bone.  The action of PTH is mediated through the PTH type-1 receptor 
(PTH1R), a class II GPCR highly expressed in kidney and bone. The N-terminal 
fragment of PTH (first 34 residues) is FDA approved for the treatment of osteoporosis. 
When given intermittently PTH(1-34) (teriparatide/Forteo), acts anabolically via 
osteoblasts to build bone. However, due to the coupled nature of osteoblasts and 
osteoclasts during bone remodeling, continuous exposure to PTH(1-34) leads to net 
bone loss. In 2009, it was demonstrated in vivo that bPTH(7-34) promoted bone 
formation independently of G-protein activation.  When intermittently administered to 
wild-type mice, bPTH(7-34) promotes bone formation and increases osteoblast number 
without production of cAMP and actually acts as an inverse agonist to Gs. While both 
ligands exert an osteoblast-mediated anabolic effect, bPTH(7-34) does so without an 
increase in osteoclast number or markers of bone resorption. The bPTH(7-34) treated 
mice had increased markers of bone formation and osteocalcin levels (circulating and 
mRNA) as compared to PTH(1-34) treated controls, and the anabolic effect of bPTH(7-
34) was completely abrogated in β-arrestin2-null mice.  A comparison of calvarial 
transcript expression in mice treated for 8 weeks with PTH(1-34), PTH(7–34), or 
vehicle, demonstrated the two agonists stimulate the expression of distinct gene sets 




Together these data support the hypothesis that there is a unique, osteogenic 
signal transduction network engaged by stimulation of the PTH1R with bPTH(7-
34).  To further test this hypothesis and identify phosphorylation-mediated signaling 
events that are unique to the ligands, a quantitative phosphoproteomic approach was 
employed.  Preliminary phosphoproteomic studies in osteoblasts stimulated ± PTH(1-
34) for 5 minutes confirmed activation of canonical Gs/cAMP/PKA and Gq/11/PKC/Ca
2+ 
mediated pathways and revealed novel sites of regulated phosphorylation of Elk/Srf, 
Osterix, and NFAT3 transcription factors. 
 
Specific Aim 1:  To identify proteins that are differentially phosphorylated upon 
stimulation with the conventional agonist PTH(1-34) using quantitative 
phosphoproteomics.  To ensure a sufficient quantity of starting material and enable 
metabolic labeling of protein with stable isotopes (SILAC), murine MC3T3-E1 
preosteoblast cells were used.  Cells, grown in SILAC media were induced to 
differentiate to osteoblasts by culturing in ascorbic acid and beta glycerol phosphate for 
10 days followed by stimulation ± 0.1 uM PTH1-34 for 5 minutes.  Experiments were 
designed with 3 biological replicates and the inclusion of a label switch.  Following 
trypsin digestion and strong cation exchange, enriched phosphopeptides were be 
analyzed by LC-MS/MS.  Peptide identification, phosphorylation site assignment, and 
quantification was performed with Maxquant.  Statistical analyses were performed with 
Perseus and other platforms as needed.  The data was interrogated for putative 
regulated kinases, regulated transcription factors, enriched signaling pathways, and 
enriched biological processes.  We expect these data to reveal novel information 
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regarding PTH(1-34)-induced signaling and provide a baseline for comparison to the 
effects elicited by bPTH(7-34) (Aim2B). 
 
Specific Aim 2A:  To identify proteins that are differentially phosphorylated upon 
stimulation with the biased agonist bPTH(7-34) using quantitative 
phosphoproteomics  
This aim was performed as described for Aim 1. 
 
Specific Aim 2B:  To compare the signaling networks engaged by both ligands 
and relate experimentally determined changes to the differences in efficacy 
profiles observed in vitro and in vivo.  
The predicted activated kinases, signaling pathways, and biological processes 
regulated by PTH(1-34) and bPTH(7-34) were compared to define the shared and 
distinct processes that are regulated by the ligands.  The identification of candidate 
activated kinases, signaling pathways, and cellular processes that are unique to 
bPTH(7-34) were validated using cell-based biological assays.  
 
Impact: This project has specific implications for human bone disease therapy and a 
wider expansion of the concept of exploiting functionally selective, biased agonism of 




Chapter 3: Characterize the phosphorylation-mediated signaling profile of MC3T3-




As our appreciation of the “pluridimensionality” of G protein-coupled receptor (GPCR) 
efficacy (Galandrin 2006) has grown, it has become increasingly important to consider 
ligand action in the context of signaling networks.  At physiological levels of expression, 
individual GPCRs may engage multiple downstream signaling pathways simultaneously, 
using both heterotrimeric G proteins and non-G protein effectors, e.g. arrestins, as 
conduits (Luttrell 2010, Kenakin 2010).  As these initial signals propagate, the potential 
for crosstalk expands exponentially, rapidly exceeding the capacity of simple pathway-
focused approaches, e.g. protein immunoblots, to capture the complexity.  Adding to the 
problem is the knowledge that ligand structure can “bias” the efficiency with which a 
GPCR activates its downstream effectors relative to the native ligand (Christopoulos 
2002, Kenakin 2007).  “Biasing” GPCR signaling by varying ligand structure holds the 
promise of novel therapeutics, but at the same time introduces the specter of 
unexpected “on-target” effects arising from activating GPCRs in “unnatural” ways 
(Luttrell 2014). Yet another concern is the impact of system factors, e.g. cell 
background-specific variations in receptor density and expression of downstream 
effectors, which can introduce wide variations in the observed response (Kenakin 2007).  
Given these challenges, an “ideal” approach to understanding GPCR signal 
transduction would involve studying GPCRs in a native context using methods capable 
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of both capturing high-dimensionality data and deconvoluting it to generate information 
about the net effect on biological pathways and processes. 
Quantitative phosphoproteomic analysis provides an avenue for elucidating transient 
phosphorylation-mediated signaling events following receptor-ligand interactions (Olsen 
2006, Roux, 2013). Dynamic post-translational modifications impact signal transduction 
by affecting protein interactions, subcellular localization, enzyme activity, and protein 
half-life.  Recent in-depth phosphoproteomic studies indicate that seventy-five percent 
of proteins are phosphorylated, the majority of which (85%) are multiply phosphorylated 
(Sharma 2014), and phosphorylation is a key post-translational mediator of cellular 
signaling necessary for growth, proliferation, motility, differentiation, survival, and the 
response to hormones and therapeutics.  While subject to its own limitations, mass 
spectrometric approaches provide the capacity to capture a global “snapshot” of 
stimulus-induced changes in the phosphoproteome that reflect the first few minutes of 
receptor activation.  Combining this information with bioinformatic approaches to 
translate regulated phosphorylation sites into consensus kinases motifs, link kinases to 
potential substrates, and identify signaling pathways and regulated biological 
processes, can produce a holistic picture of signaling at the network level, and generate 
testable hypotheses about the links between proximal signaling events and downstream 
phenotypic responses.  Indeed, proteomic studies investigating the phosphorylation 
regulated by stimulation of GPCRs are revealing unanticipated signaling intermediates, 
finding non-canonical signaling events, and enabling the prediction of activated kinases. 




Here, we apply quantitative stable isotopic labeling by amino acids in cell culture 
(SILAC)-based mass spectrometry to probe the protein phosphorylation networks 
regulated by short term exposure to hPTH(1-34), a conventional agonist of the type 1 
parathyroid hormone (PTH1R).  PTH1R signaling is complex, resulting from activation of 
diverse heterotrimeric G protein species, i.e. Gs, Gi, and Gq/11, as well as non-canonical 
arrestin-mediated signaling events (Gesty-Palmer 2006 and 2009, Appleton 2013), so to 
reduce artifacts related to receptor overexpression our experiments were performed in 
cultured differentiating osteoblastic cells expressing native levels of receptor.  In 
addition to detecting the expected contributions of Gs-cAMP and Gq/11-calcium signaling, 
our results demonstrate a robust phosphorylation network regulating small GTPases 
and cytoskeletal rearrangement, and provide insights into PTH1R-mediated signaling in 
a physiological context. 
 
3.2. Materials and Methods:   
 
3.2.1. General Considerations 
Continued advances in methodology, instrumentation, and computational proteomics 
are enabling the identification and functional assessment of differentially regulated post-
translational modifications (Olsen 2013).  For in vitro studies, SILAC is considered the 
gold standard (Olsen 2006, Ong 2002). Utilizing SILAC, changes in protein expression 
and phosphorylation can be measured, providing a comprehensive view of the dynamic 
phosphorylation events occurring following ligand-receptor stimulation.  As compared to 
isobaric tagging and label free approaches, SILAC-labeled proteins are combined in the 
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first step of the sample preparation workflow thereby reducing the effect of technical 
errors introduced when preparing multiple samples in parallel.  This yields a higher 
sensitivity to measure smaller changes in the extent of phosphorylation.   
 
On the other hand, SILAC requires metabolic incorporation of amino acids into proteins 
prior to cell stimulation, so that individual peptide tandem mass spectra can be assigned 
to their sample of origin, e.g. stimulated versus non-stimulated, when the mixed 
samples are analyzed.  Thus, the approach is not amenable to analysis of proteins 
prepared directly from tissue.  Further, comparison of the phosphoproteomes of multiple 
murine tissues has revealed the occurrence of tissue-specific sites of protein 
phosphorylation necessitating analysis in the cell type of interest (Huttlin 2010).  To 
circumvent these limitations, we chose to metabolically label MC3T3-E1 pre-osteoblast 
cells, an immortalized cell line derived from newborn mouse calvaria, to establish a 
system to investigate the receptor-proximal effects of PTH1R activation in a near native 
cell background.   
 
3.2.2. Cell Culture and Stable Isotope Labeling with Amino Acids 
MC3T3-E1 subclone 4 pre-osteoblast cells (CRL-2593, ATCC) were used as a model of 
osteoblast differentiation and function.   When grown in osteogenic media containing 
ascorbic acid and β-glycerophosphate, the cells differentiate, express markers reflecting 
different stages of osteoblast differentiation, and secrete a mineralized hydroxyapatite 
matrix (Wang 1999; Franceschi 1994, 1992a,1992b).  The presence of the PTH1R in 
these cells has been confirmed and the cAMP response to receptor stimulation is 
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readily detectable after 4 days in culture (Schiller 1999; Spurney 2003; Sudo 1983).  
This response is maintained after 10 days of culture in osteogenic media.  
 
Reagents for cell culture and SILAC labeling of MC3T3-E1 cells: 
1. Stable isotope labeled amino acids: 
 Light Arg:  Arg0 L-Arginine-HCl (Fisher Scientific: PI-89989)    
 Light Lys:  Lys0 L-Lysine-2HCl (Fisher Scientific: PI-89987)   
 Medium Arg: Arg6 (13C6 L-Arginine-HCL) (Fisher Scientific: PI-88210) 
 Medium Lys: Lys4 (4,4,5,5-D4 L-Lysine-2HCl) (Cambridge Isotopes: DLM-2640-0.5)  
 Heavy Arg: Arg10 (13C6 
15N4 L-Arginine-HCL) (Fisher Scientific: PI-89990)  
 Heavy Lys: Lys8 (13C6 
15N2 L-Lysine-2HCl) (Cambridge Isotopes: CNLM-291-0.1)  
2.  SILAC Media: For “light”, “medium”, or “heavy” SILAC media add labeled amino 
acids to  custom α-MEM media lacking arginine and lysine (Gibco®). For a final 
concentration of 0.5 mM arginine add 0.015 ml of 10 mg/ml arginine per ml media.   
3.  SILAC Growth Media: For growth media 10% dialyzed fetal calf serum (FCS) (Fisher 
 Scientific) and 1% penicillin/streptomycin were added to SILAC media.   
4. SILAC Osteogenic Media: For osteogenic differentiation media (MEMα, 10% FCS, 
 50 μg/ml  ascorbic acid and 10 mM β-glycerophosphate) were added  to  SILAC 
growth media.   
Cell culture and SILAC labeling of MC3T3-E1 cells: 
1. To enable full incorporation of isotopically labeled arginine and lysine into the cellular 
protein pool, pre-osteoblastic MC3T3-E1 cells were grown subconfluently at 37°C 
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Arg) amino acids.   
2. Efficient metabolic labeling of cellular proteins was confirmed by LC-MS/MS 
(Lanucara 2011). Once the labels were fully incorporated (≥95%), cells were seeded 
or aliquots were stored in liquid nitrogen for subsequent experiments. 
3. The SILAC-labeled cells were seeded at 1 x 104 cells per cm2 and grown to 
confluence in growth media. To obtain sufficient starting material for TiO2 enrichment 
of phosphopeptides from osteoblasts, five to ten 100 mm culture plates with 9 ml of 
media per dish for each condition of a triple SILAC experiment were used.  This 
yielded 5-7 mg of protein per treatment condition.  
4. For time course experiments at different stages of osteoblast differentiation, after 
reaching confluence cells are incubated in osteogenic media with media changes 
every other day.  As the cells differentiate, mineralized matrix accrues in the dish.  At 
day 10 of differentiation (day 13 in culture) the cells are visibly differentiated and 
bone nodules have begun to form in the dish.   
3.2.3. Receptor Stimulation and Protein Preparation 
3.2.3.1 Acute Stimulation of MC3T3-E1 cells 
1. Eighteen hours prior to stimulation, cells were serum-starved by reducing the 
concentration of dialyzed FCS to 1% v/v in osteogenic SILAC media.  Light, medium, 
or heavy labeled SILAC cells were stimulated for the desired time with 0.1 μM 
human PTH N-terminal residues 1-34 [hPTH(1-34)].  hPTH(1-34) (Tocris) to 0.1 mM 
was dissolved in MEMα medium and dispensed in cell plate at a ratio of 1:1000. 
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2. Correction for potential false positives arising from reagent-specific changes such as 
isotope effects on cellular metabolism, changes to peptide retention time, or 
metabolic inclusion of “light” amino acids (Park 2012), a label swap control was 
required in at least one biological replicate analysis. 
3. Cells were lysed immediately with freshly made urea lysis buffer [9.0 M urea, 20 mM 
HEPES (pH 8.0), 1 mM sodium orthovanadate, 2.5 mM sodium pyrophosphate, 1 
mM β-glycerol-phosphate in HPLC grade water] and lysate incubated on a rotator for 
4 hrs at 4°C.   
4. Cellular debris was removed by centrifugation at 17,000 x g for 10 minutes at 4°C.  
5. Protein concentration determined by using a Bradford assay, and ~5 mg protein from 
each treatment group was combined at 1:1:1 ratio. 
3.2.3.2 Reduction, Alkylation and Tryptic Digestion in Solution 
1. Protein sample was diluted to 2 M urea with water (~50 ml). 
2. Cysteines reduced in 1 mM of dithiothreitol for 30 minutes at room temperature. 
3. Thiols were alkylated in 5.5 mM of iodoacetamide for 15 minutes at room 
temperature in the dark. 
4. Protein was digested with trypsin (Promega) at a 1:100 (w/w) enzyme to protein ratio 
overnight at 37°C. 
5. Digestion reaction was quenched by adding 4.0 ml of 10% v/v trifluoroacetic acid 
(TFA) in water.  
6. Desalt digested peptides (15-20 mg) using a 6cc C18 Sep-Pak cartridge (Waters) 
and dry under vacuum.  Store at -80°C until further use. 
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3.2.4. Peptide Fractionation  
Prior to enrichment of post-translationally modified peptides, fractionation of the 
complex tryptic peptide mixture provides a greater separation space enabling detection 
of less abundant analytes by LC-MS/MS.  
3.2.4.1. Strong Cation Exchange Chromatography 
SCX is routinely used as an orthogonal approach to fractionate peptides into less 
complex mixtures prior to phosphopeptide enrichment and C18RP-LC-MS/MS.  The low 
to high salt gradient of the SCX chromatography allows for fractionation of peptides by 
net charge state. Negatively charged phosphopeptides are minimally retained and elute 
early within the gradient.  The separation of multiply phosphorylated peptides from 
mono-phosphorylated peptide can reduce the bias of enrichment of multi-
phosphorylated peptides by titanium dioxide. 
Materials and Buffers for SCX: 
1. Column: 6.4 mm x 30 mm (15 µm) Resource S methylsulfonate column (GE 
Healthcare). 
2. Buffer A: 5 mM KH2PO4 (pH 2.7), 30% acetonitrile.  600 ml needed per separation. 
3. Buffer B: 5 mM KH2PO4 (pH 2.7), 350 mM KCl, 30% acetonitrile. 400 ml needed per 
separation. 
Protocol for SCX:  
1. Desalted, dried peptides (15-20 mg) were brought up in 1-2 mL in SCX Buffer A. 
2. Fractionation of peptides was achieved by SCX using a gradient of 0% B for 10 min; 
0-30% B in 30 min; 30-100% B in 5 min; 100% B for 10 min at a flow rate of 1 
ml/min.   
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3. Fractions were collected every minute and chromatographic separation monitored at 
214 nm.   
4. Adjacent fractions were combined into a total of twelve, three-minute fractions.  
3.2.5. Phosphopeptide Enrichment 
Due to the relatively low concentration of modified peptides in proteolytically digested 
cell or tissue lysates, an enrichment step is necessary for robust identification and 
quantitation.  Enrichment strategies utilizing immobilized metal affinity chromatography 
(IMAC), titanium dioxide (TiO2), or a combination thereof (Ti
4+-IMAC), are capable of 
yielding up to 99% enrichment of phosphopeptides from complex mixtures (Lundby 
2013, de Graaf 2014). Coupled with increased mass accuracy and enhanced sensitivity 
of modern mass spectrometers, these enrichment techniques allow the application of 
quantitative proteomic methods to the characterization of dynamic phosphorylation 
(Erickson 2015). In our hands, the most effective material is a TiO2 bead slurry. If 
performed after SCX, the most phospho-rich portion of the SCX run is the first 40 
minutes of a 1 mL per minute flow rate, with the number of phosphorylated peptides 
slowly decreasing as the gradient changes (Villen 2008).  
Reagents and Materials for TiO2 phosphopeptide enrichment:  
1. Buffer A: 80% acetonitrile, 0.5% trifluoroacetic acid  
2. Buffer B: 3:1 (v/v) Buffer A: Lactic acid.  Elution solution: 40% acetonitrile, 5% 
NH4OH in water (~1-2ml) 
3. Low-Bind 1.5 mL microcentrifuge tubes 
4. C4 ZipTips 
5. 5 mg TiO2 beads per fraction (Titansphere, 10 µm, GL Sciences) 
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Protocol for TiO2 phosphopeptide enrichment:  
Phosphopeptides from each fraction are enriched using a slurry of 5 mg TiO2 beads, 
fresh buffers and elution solution (Larsen 2005).   
1. Peptide fractions were reconstituted in 200 μl of HPLC water and added to 1300 μl 
of buffer B.  
2. 5 mg of TiO2 beads (per tube) were washed in 200 μl buffer A and equilibrated in 
200 μl buffer B. Buffers removed after each step.  
3. Peptides were incubated with beads for 45 minutes at room temperature with mixing.  
4. Flow-through removed. Beads washed sequentially with buffers B and A.  Removing 
buffer after each step.  
5. TiO2 beads were resuspended in 50 μl of buffer A and transfered to the top of a C4 
Ziptip, which served as a frit.  
6. Buffer removed by centrifugation. 
7. Peptides eluted by placing C4 Ziptip in a clean, low-bind 1.5 ml centrifuge tube, and 
adding 50 μl of elution buffer to top of tip.  
8. Sample fractions was centrifuged at 1,000 x g for 5 minutes twice.  
9. The eluted peptide solution was immediately neutralized with 10 μl of neat formic 
acid.  
10. Samples dried under vacuum, then desalted with a C18 ZipTip. 






3.2.6. Mass Spectrometric Analysis (LC-MS/MS) 
1. Peptides were loaded onto a trap column, eluted, and separated on a 75 μm x 15 cm 
fused-silica column packed in-house with C18 reversed-phase resin (YMC-ODS-AQ; 
5-μm particles; 200-Å pore; Waters) using an acetonitrile gradient of 5-50% in 180 
min containing 0.2% formic acid on a Dionex Ultimate 3000 nano LC system at flow 
rate of 200 nl/min. The sample was introduced via nano-electrospray ionization 
(nESI) using an uncoated silica emitter (360 μm OD, 50 μm ID, with a 5 μm tip, New 
Objective) to a hybrid dual-pressure linear ion trap-orbitrap mass spectrometer 
(Orbitrap Elite, Thermo Scientific).  
2. Mass spectra acquired in data dependent mode using a TOP10 method that 
acquires one FTMS survey MS scan in the mass range of m/z 400-1800 followed by 
tandem mass spectra (MS/MS) of the ten most intense ions in the ion trap.  
3. The automatic gain control was set at target value in the Orbitrap at 106 for the 
survey MS scan at a resolution of 60,000 at m/z 400.     
4. Fragmentation was performed in the ion trap by collision-induced dissociation (CID) 
with an automatic gain control target value of 1000 ions and a minimum threshold of 
500 counts.   
3.2.7. Data Processing and Analysis 
Many peptides have multiple potential sites of phosphorylation, introducing the need to 
confidently assign the site of modification prior to downstream analysis. Large-scale 
identification of site-specific changes in phosphorylation and subsequent prediction of 
activated kinases have been enabled by algorithms that assess and score the 
assignment of the position of the modification during automated database searches 
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(Beausoleil 2006; Taus 2011; Bern 2012; Cox 2011).  Manual inspection of the 
annotated tandem mass spectra is still warranted to confirm the appropriate threshold 
parameters have been set and to verify the assignment prior to proceeding with site-
directed mutagenesis and antibody generation. Peptides with confidently assigned sites 
of phosphorylation were further examined for enrichment of kinase substrate motifs 
(Schartz 2005; Hornbeck 2015; Maddelein 2015). Freely available software platforms 
also provide the ability to readily access protein, protein interactions, and site-specific 
information stored in multiple shared data repositories (Co 2012, Horn 2014).  As the 
data quality and modification-and site-specific informatic tools and databases advance, 
the potential to assimilate and functionally interrogate post-translationally regulated 
signaling networks will improve. Together these complementary approaches and 
advances are pushing the field forward and provide robust workflows for 
phosphoproteomics that can be adapted to other post-translational modifications as 
well. 
3.2.7.1. Peptide Identification, Site-Assignment, and Quantitation  
Multiple software platforms are available for the identification and quantification of 
SILAC labeled phosphopeptides.  We chose to use MaxQuant since the output contains 
the protein residue number that is modified, sequence windows of 15 residues on either 
side of the site of modification, and the ability to easily interrogate the identified sites 
against databases of known and functionally annotated post-translational modifications.  
Additionally, hundreds of LC-MS/MS analyses can be searched simultaneously with the 
output assimilated to simplify downstream processing.  Specifically regarding SILAC-
based experiments, after the initial database search MaxQuant provides the ability to 
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look for and quantify a SILAC peptide partner that was not selected for sequencing by 
tandem mass spectrometry.  
1. The MaxQuant/Perseus platforms are freely available (version1.5.0.22 Max Planck 
Institute of Biochemistry, Dept. of Proteomics and Signal Transduction, Munich, 
Germany) (Cox 2011, 2009, and 2008).  Workshops and on-line tutorials are kindly 
made available for users. 
2. All of the raw files from multiple biological replicate experiments including label swap 
controls were searched simultaneously in MaxQuant.  Andromeda, the database 
search algorithm embedded in MaxQuant, was configured to search for mass shifts 
of interest, neutral loss ions, and diagnostic fragment ions.  Prior to searching, the 
tandem mass spectra are processed such that 12 ions per 100 m/z are retained.  To 
correct for drift in the calibration during data acquisition, a recalibration option was 
selected in which a first database search is performed at 20 ppm precursor mass 
tolerance.  Following recalibration of the m/z ratios, the search was repeated with a 
more stringent mass tolerance of 4.5 ppm for precursor ions measured in the 
Orbitrap.  The mass tolerance is 0.5 Da for fragment ions generated by CID and 
ETD and measured in the ion trap.  Cysteine carbamidomethylation was selected as 
a fixed modification and methionine oxidation and phosphorylation on serine, 
threonine, and tyrosine as variable modifications. Trypsin cleaves on the C-terminal 
side of lysine and arginine and we specify that trypsin also cleaves between lysine 
and proline. Only fully tryptic peptides are reported and two missed cleavages are 
permitted.   
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3. The tandem mass spectra are searched using a forward and reversed concatenated 
database decoy approach supplemented with protein sequences of common 
contaminants, such as porcine trypsin and human keratin.  The database and 
anticipated diagnostic ions was specified when configuring Andromeda (Cox  2011).  
4. To establish the false discovery rate for peptide identification and phosphorylation 
site assignment, a “Revert” decoy database mode is selected (Sharma 2014) and 
the results are filtered by a 1% Bonferroni false discovery rate (FDR) at the peptide 
spectral match (PSM) and site levels.  
5. Minimum Andromeda and delta scores of 40 and 6, respectively, are the default 
parameters required for identification of modified peptides. These values are 
adjusted if necessary after manual inspection of the spectral matches.  To search for 
missing SILAC partners after the initial database search the “Requantify” option was 
employed.  If biological or technical replicates were performed under the same 
chromatographic conditions, the “match between runs” feature was enabled to 
increase the number of quantified pairs that are identified.  This feature matches 
identifications in adjacent fractions and among biological replicate experiments with 
measured ratios of SILAC pairs that may have not been sequenced.   
6. In MaxQuant, the relative quantitation is achieved by comparison of the integrated 
isotopic envelope (summed centroids) from each member of the SILAC pair.  
7. The MaxQuant 1.5 output includes a variety of tab-delimited text files. The 
“Evidence” file includes the modified tryptic peptides observed, the m/z of precursor 
ion selected for sequencing, the recalibrated m/z of the precursor, charge state, and 
number of missed cleavages. The PhosphoSTY file features the “sequence window” 
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for each site of phosphorylation identified with the site of phosphorylation in the 
center and 15 amino acids on each side of the phosphosite, facilitating kinase 
substrate motif analysis.  The PhosphoSTY file also contains the residue number of 
the site of modification within the protein sequence.  The “Tables” pdf file contains a 
description of each text file generated by MaxQuant and the parameters that are 
reported in each text file.  
8. To process the data, the text files generated in MaxQuant were uploaded into the 
Perseus platform, which contains visualization tools for quality control, statistical 
tests, easily accessible databases of site-specific modifications, and functional and 
structural annotation associated with specific sites of modification [54]. The 
normalized SILAC ratios (_1,_2,_3) was added from the PhosphoSTY file to the 
expression column, potential contaminants to the categorical column, and all 
additional information into the numerical or text columns.   Normalization of the ratios 
was achieved by subtracting the median of all ratios per column of ratios (Cox 2008).  
Current databases of known sites of post-translational modifications, kinase-
substrate interactions, regulatory sites, and disease associated sites were 
downloaded into the configuration folder of Perseus from Phosphosite Plus (PSP) 
Resource (Hornbeck 2015) for annotation. 
9. Reproducibly regulated phosphosites were determined using the moderated t-
statistic function within the R LIMMA package from Bioconductor (Ritchie 2015). 
Similar to an ordinary t-statistic, in the moderated t-statistic test, the standard error is 
calculated using an empirical Bayes method, making each peptide inference more 
robust. To determine the reproducibly regulated phosphopeptides, ratios from the 
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biological replicate experiments were evaluated using a moderated t-statistic with a 
Benjamini-Hochberg correction for multiple hypothesis testing (Benjamini 1995).   
After statistical analysis, text files were re-imported into Perseus for further 
processing and analyses for GO enrichment, and other downstream analyses to 


















3.3.1. Defining the PTH Regulated Phosphoproteome in Osteoblastic Cells 
Expressing Endogenous Levels of PTH1R  
The original estimates of the relative abundance of S/T/Y phosphorylation based on 
autoradiographic measurements made in 1980 (Ser 90%, Thr 10%, and Tyr 0.05%) 
(Hunter 1980) have been recapitulated in global proteomic analyses of cells at basal 
conditions (Ser 84.5%, Thr 15.1%, and Tyr 0.04%) (Sharma 2014). Quantitatively, the 
stoichiometry of S/T/Y phosphorylation was found to be low in unstimulated cells.  
However, during highly coordinated cellular events such as mitosis, occupancy of the 
majority of S/T phosphosites rises from <20% to >60% while Y phosphorylation remains 
low (Sharma 2014). Tyrosine phosphorylation occurs much less frequently and is 
maintained at lower stoichiometric levels rising from 10% to 50% following receptor 
tyrosine kinase stimulation (Sharma 2014). The specificity of ligand-initiated events is 
achieved, in part, through the temporal regulation of phosphorylation at a subset of 
protein S/T/Y residues.   
 
3.3.1.1. Detection and Identification of Osteoblast Phosphoproteins  
The experimental workflow employed to identify phosphoproteins and phosphorylation 
sites regulated by acute stimulation with the conventional PTH1R agonist, hPTH(1-34), 
is summarized in Figure 3.1A. SILAC-labeled MC3T3-E1 cells differentiated in 
osteogenic media for 10 days were incubated in 1% FCS containing media for 18 hours 
prior to stimulation with hPTH[1-34] for varying times.  Proteolytically digested peptides 
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were separated into twelve fractions by SCX chromatography and phosphopeptides 
were enriched from each fraction using TiO2.  The resulting peptides were analyzed by 
LC-MS/MS with an Orbitrap Elite mass spectrometer.  Tandem mass spectra were 
acquired on the ten most abundant ions in each survey mass spectral scan following 
CID or a CID-ETD decision tree approach.  For peptide identification, tandem mass 
spectra from 9 SILAC experiments including technical replicates for 2 experiments (132 
LC-MS/MS analyses) were searched simultaneously against a mouse protein database 
(Uniprot; December 2013) with MaxQuant v1.5.1.0 on a 24 core, 48 GB RAM high 
performance server. Informatic identification of large numbers mass spectra is an 
evolving technical challenge and there are several species of algorithms in use today 
(e.g. Mascot, Sequest, and Andromeda), what is common to all of then is an extremely 
stringent suggested false discovery rate (FDR) parameter on peptide spectral matches 
(PSM), protein identifications, and site identification of 0.01. Even when using this 
criteria, most journals require manual evaluation of all spectra from which regulation of 
post-translational modification is proposed. Therefore, a false discovery rate (FDR) 
threshold of 0.01 was used for peptide spectral matches, protein identifications, and site 
identifications.  For modified peptides an Andromeda score greater than 40 and a 
minimum delta score of 6 was required.  The text files generated in MaxQuant were 
processed using Perseus v1.5.0.8.   Matches to the reversed database and common 
potential contaminants were removed.  From the modification-specific peptides table, 
6,621 phosphopeptides were identified (table available upon request).  These 
phosphopeptides corresponded to 2,060 protein groups, 85 of which were derived from 
multiple gene products, 1561 corresponded to a unique protein group, and 414 were 
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mapped to a unique protein.  A single titanium dioxide enrichment step yielded 44% 
phosphopeptides.  In subsequent studies we have been able to increase the enrichment 
to 95% using a double enrichment strategy.  All of the protein groups identified (3,148) 
are shown in Supplemental Table 2A (available upon request) We observed 146 protein 
kinases (GO:0004672) (Supplemental Table available upon request) and 123 
sequence-specific DNA binding transcription factors (GO:0003700) including Runx1, 
Runx1T1, and 41% sequence coverage of the osteogenic transcription factor Runx2 
(Supplemental Table 2C, available upon request). 
As very few phosphoproteomic studies have been carried out in osteoblasts, the 
phosphoSTY file was processed using the Perseus software to identify how many novel 
sites of phosphorylation were observed.  A total of 7,237 sites of phosphorylation were 
identified, 4,635 were “Class I” sites with a localization probability ≥0.75 and a minimum 
score difference of 5 (Supplemental Table 3 A-B, available upon request).  Known 
phosphorylation sites, kinase-substrate relations, known regulatory and disease-related 
sites from databases including PhosphositePlus, Uniprot, and the Human Protein 
Reference database accessible via Perseus were used for protein, site, and 
modification-specific annotation.  Five hundred and forty of the Class I sites identified 
have not been reported in Uniprot or PhosphositePlus (Supplemental Table 3C, 
available upon request).  Novel sites of phosphorylation were observed on many 
proteins that regulate osteoblast differentiation and function including transcriptional 




3.3.1.2. Identification of Phosphopeptides Regulated after 5 Minute hPTH(1-34) 
Stimulation 
The relative changes in the extent of phosphorylation were measured in MaxQuant and 
are based on the ratio of chromatographically resolved peak areas of the isotopic 
clusters for the SILAC phosphopeptide pairs.  To demonstrate the information that can 
be obtained by this quantitative approach we are reporting the phosphorylation events 
that were regulated after 5 minutes of stimulation with hPTH(1-34) in five biological 
replicate experiments including a label swap control.  To determine the regulated sites 
of phosphorylation, the normalized ratios of singly, doubly, and multiply phosphorylated 
peptides associated with a particular site were transposed from a single row in the 
phosphoSTY table into columns yielding 3 potential ratio measurements per site.  The 
ratios from the label swap experiment were inverted and all of the ratios were then log2 
transformed.  Data quality was assessed using the Perseus platform.  To ensure the 
data in each biological replicate experiment were normally distributed and properly 
normalized, the log2 transformed peptide ratios were viewed as histograms (Figure 
3.1B). To assess the reproducibility of measured ratios for each peptide between 
biological replicate experiments, the correlation between experiments was examined 
pairwise.  Four out of five experiments comparing the relative changes in 
phosphorylation after 5 minutes of stimulation yielded a Pearson correlation coefficient 
greater than 0.75 and were utilized for subsequent analyses (Figure 3.1C).  In the four 
replicates, a total of 4,720 SILAC-labeled, phosphopeptide pairs were quantified.  Of 
these, 924, 522, and 260 phosphopeptide pairs were measured in 2, 3, or all 4 
biological replicates, respectively.  Since most of the phosphopeptides were only 
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quantified in one experiment, we also extracted the monophosphorylated peptides 
observed once that exhibited >2 fold change (Supplemental Table 4, available upon 
request).  This list of 589 potentially regulated phosphorylation sites included decreased 
phosphorylation of MAPK1 Y185, which has been shown in previous studies by 
immunoblotting (Datta 2010) and increased phosphorylation at PTH1R S491, a known 
PTH-regulated site (Miedlich 2008; Tawfeek 2002; Blind 1996). 
A more rigorous method was applied to determine the sites of modification that were 
significantly regulated.  The moderated t test was performed on the log2 transformed 
ratios using the R LIMMA package from Bioconductor and the p values were corrected 
for multiple hypothesis testing with the Benjamini Hochberg (BH) method (Ritchie 2015; 
Benjamini 1995; Manning 2002). Using a BH corrected p value threshold of 0.1 and n≥2 
observations, 376 phosphosites corresponding to 224 protein groups were regulated. Of 
the regulated peptides, 361 were localized Class I sites and 16 were novel (Table 2).  
162 sites were decreasing in phosphorylation and 214 were increasing in 
phosphorylation.   To view the reproducibility of each phosphopeptide ratio measured 
within these four experiments, the –log10 p value for each peptide was plotted against 
the log2 transformed ratios (Figure 3.1D).  
Because tissue-specific sites of phosphorylation are as-yet incompletely catalogued 
(Huttlin 2010), there is no ‘gold standard’ database against which to objectively assess 
how comprehensively an experimental dataset covers the entire phosphoproteome. 
Moreover, the conditions used for phosphopeptide isolation/enrichment and analysis 
can lead to systematic underrepresentation of certain species, e.g. intrinsic membrane 
proteins and Y-phosphoproteins.  The limited dynamic range and stochastic nature in 
107 
 
sampling by the mass spectrometer also limit the depth of coverage.  The Venn diagram 
in Figure 3.2A illustrates number/overlap of phosphorylation sites observed between the 
four biological replicates we employed for subsequent analyses.  Rapid advances in 
experimental design, instrumentation, software and improvement at each step of the 
workflow, continue to reveal the breadth and complexity of the phosphoproteome.  In 
our hands, subsequent studies utilizing HpH RPLC fractionation provided additional 
quantitative measurements and increased the number of observations between 
experiments.  While these advances yield higher confidence in peptide identification and 
quantification, from a systems perspective, the bioinformatic analysis of signaling 
networks only requires that the input dataset be large/accurate enough to generate 
reliable predictions of pathway regulation. To crudely assess pathway coverage, we 
overlaid our list of observed/regulated phosphoproteins onto the Ingenuity® Systems 
canonical GCPR signaling pathway network.  As shown in Figure 3.2B, our dataset 
provided very good coverage of signaling pathways classically associated with short 
term GPCR activation. 
 
3.3.2 Ingenuity Pathway Analysis (IPA)- Software Limitations 
Using a single pathway analysis program to interrogate this type dataset is a common 
method yet it does imbue some limitations in result interpretation. The statistical 
significance of the enrich pathways and processes are based on the curated annotation 
for each protein, which is always going to exhibit some degree of inadequacy. A specific 
limitation of IPA is that the databases it references are highly populated by cancer data 

















3.2. Exploring the PTH Regulated Kinome  
Protein kinases are one of the largest families of genes in eukaryotes, with genetic 
studies estimating that these enzymes account for 2% of the total genome. In humans, 
518 genes code for kinases (Udeshi 2012) of which 510 orthologues exist in mice 
(Caenepeel 2004).  Based on the prevalence of the most frequently phosphorylated 
residues serine, threonine and tyrosine, an estimated 700,000 possible phosphorylation 
sites are available in the cellular environment (Echols 2002; Ubersax 2007).  Figure 3.3 
depicts selected MC3T3-E1 osteoblast phosphoproteins organized by molecular 
function and cellular localization to provide a sense of the distribution of basal and 
regulated phosphorylation events observed across the cellular landscape in our dataset. 
As many protein kinases are themselves phosphoproteins, quantitative phosproteomic 
datasets can provide empiric information about the phosphorylation state of functionally 
annotated regulatory sites on specific kinases, thus allowing inferences about their 
activation/inhibition. The quality of such direct observational data is dependent on 
multiple factors, including the extent of coverage in the input dataset, i.e. whether 
relevant phosphorylation sites are “seen” in the data; and the arbitrary threshold(s) 
assigned to define significant change, i.e. p value and number of observations.  A 
complementary approach, kinase substrate motif enrichment analysis using Motif-X 
Figure 3.3. Selected phosphoproteins observed in hPTH(1-34) stimulated osteoblasts. The full list of 
identified phosphoproteins (Supplemental Table available upon request) was sorted by molecular function. 
Selected proteins classified as kinases, phosphatases, transcription factors, epigenetic modulators, GPCRs, 
membrane receptors, regulators of small GTPases, and proteins with the GObp annotation ‘‘bone 
formation’’, are shown grouped according to GO cellular compartment. All proteins shown were observed 




(Schwartz 2005), which searches all observed phosphorylation sites to identify the most 
abundant consensus phosphorylation motifs, can implicate kinases that may not have 
been directly observed and begin to link specific kinases to their downstream 
substrates.  Due to the exponential growth of protein and post-translational modification 
databases, we are now able to add contextual information to substrate predictions.  
NetworKIN is a kinase prediction tool that incorporates consensus motifs with a 
probabilistic protein interaction network (STRING) for a context-specific analysis of 
kinase/substrate interactions (Horn 2014; Linding 2007 and 2008). Based on the idea 
that signaling complexes are modular in nature, the linear motif information is coupled to 
a corresponding signaling module for increased prediction accuracy. This allows for 
integration of more of the nuanced aspects of kinase substrate specificity. The 
contextual information is gathered from PhosphositePlus and PhosphoELM databases. 
 
3.2.1. Observed and Regulated Kinases in hPTH(1-34) Stimulated MC3T3-E1 
Osteoblasts   
To identify kinases regulated by acute hPTH(1-34) stimulation, a list of phosphorylated 
protein kinases was extracted using GO annotations.  Figure 3.4A depicts the kinases 
observed in 10-day cultures of differentiating MC3T3-E1 osteoblasts in a circular 
phylogenetic tree, aligned based on the homology of the kinase domains (Letunic 2011; 
Rigbolt 2011).  The identified kinases span all of the major kinase families.  The 
number, location, and direction of significantly regulated sites of phosphorylation are 
displayed in the concentric bar graph (BH adj. p value <0.1; n≥2 observations; with the 
exception of ERK2, >2 fold decrease, n=1).  Based on the observed changes in site-
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specific phosphorylation of kinases, the predicted activity of BRAF, ERK2, and EEF2K 
would be attenuated, whereas the predicted activity of ARAF and PAK2 would be 
enhanced following 5 minute PTH1R stimulation.  Increased phosphorylation of BRAF at 
S347 (homologous to human S365) is associated with inhibited kinase activity (Cheung 
2008; Zhang 2001; Guan 2000).  Consistent with reduced activity of BRAF, which lies 
upstream of ERK2, we observed decreased phosphorylation of the ERK2 peptide 
containing residues T183 and Y185.  Increased phosphorylation of ARAF at S255 
(homologous to human S257) has been shown to enhance its kinase activity (Baliuls 
2008).  Increased phosphorylation of p21 protein (Cdc42/Rac)-activated kinase 2 
(PAK2) was observed at residues S141 and T154. Phosphorylation at these sites 
increases PAK2 kinase activity (Li 2011). The only other functionally annotated, 
regulated phosphorylation site observed was on calcium/ calmodulin-dependent 
eukaryotic elongation factor 2 kinase (EEF2K) at S444.  Phosphorylation of the 
homologous site in human EEF2K decreases the half-life of the kinase (Kruiswiik 2012).  
 
3.2.2. Linking Kinases to Substrates by Substrate Motif Analysis 
The activation state of upstream kinases should be reflected in the phosphorylation of 
downstream targets bearing their consensus substrate motifs.  To confirm predicted 
regulation of kinase activity based on the observed changes in their phosphorylation 
state and identify likely downstream targets, regulated monophosphorylated peptides 
with high confidence site-assignments were evaluated for kinase substrate motif 
enrichment using Motif-X (Schwartz 2005). Motif-X enables matching of input peptide 
sequences to non-redundant output consensus motifs and provides an output file 
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indicating which peptide substrates matched to a particular sequence motif.  298 
peptides were monophosphorylated with 118 sites decreasing and 180 sites increasing 
in phosphorylation. The pre-aligned sequence windows obtained from the phospho-
S/T/Y file generated by MaxQuant were decreased to a width of 15 amino acids and 
submitted to Motif-X with a minimum of 20 occurrences, 0.000001 significance, and the 
mouse proteome used as the background. Due to the increased frequency of detection 
of phosphorylated serines with respect to threonine and tyrosine, the motif outputs were 
serine centered. Detection of regulated phosphopeptides/peptides with a site of tyrosine 
or threonine phosphorylation corresponding with the serine-centered motifs were 
manually determined and added to the putative substrate list.  As shown in Figure 3.4B, 
Motif-X analysis revealed increased phosphorylation of basophilic substrates which 
would include PKA/CAMK2, and decreased phosphorylation by proline directed kinases 
such as ERK/MAPK/CDK.  To confirm the informatic predictions, whole cell lysates from 
10-day MC3T3-E1 osteoblasts exposed to vehicle or hPTH(1-34) were immunoblotted 
using antisera recognizing the consensus motifs for PKA (RxxpS/T) or MAPK/CDK 
(PxpSP).  As shown in Figure 3.4C, robust increases in PKA consensus site 
phosphorylation and decreases in consensus MAPK/CDK consensus site 
phosphorylation occurred with 5 min stimulation.  Since activation of Gs-cAMP signaling 
is an early consequence of PTH1R activation (Appleton 2013) and phosphorylation of 3 
isoforms of the PKA regulatory subunit, Prkar1a, Prkar2a, and Prkar2b were observed 
in the phosphoprotein dataset (Supplemental Table 4, available upon request), the 
finding of increased phosphorylation among PKA consensus phosphorylation sites was 
predictable.  Similarly, the observed increase in BRAF S327 phosphorylation (Figure 
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3.4A), corresponding to a predicted decrease in ERK activity, was substantiated by the 
global decline in phosphorylation of consensus MAPK sites. 
 
3.2.3. Predicted Kinase Regulation Analysis  
 
To link kinases to their predicted substrates, we utilized KinomeExplorer 3.0 with the 
NetworKIN and NetPhorest algorithms (Horn 2014).  For this application we expanded 
the list of hPTH(1-34)-regulated, phosphorylation sites to include those sites observed 
once with >2 fold change in order to increase the number of sites for prediction of 
kinase activation and kinase substrate interactions.  To facilitate uploading data into 
NetworKIN, which encompasses a database of 200 human kinases and their substrate 
interactions, the 12 amino acid sequence windows were converted from mouse to 
human sequences using PhosphositePlus.  This yielded about 65% conversion 
efficiency.  The combined list of sequences was submitted to Motif-X with a minimum of 
20 occurrences, 1x10-5 significance, and the mouse proteome used as the background. 
Motif outputs were serine centered.  The phosphopeptide substrate windows that 
matched each sequence motif are provided in Supplemental Table 6, available upon 
request.   
The sets of sequence windows assigned to each non-redundant motif were individually 
analyzed by NetworKIN and matched to kinases in that database. The output includes a 
calculated NetworKIN score, which is a combination of the STRING network proximity 
score and Netphorest probability score. These two scores are multiplied into a “unified 
likelihood” which is the NetworKIN score (Horn 2014) and when the score for an “id” 
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kinase approaches zero so does the chances of it being the perpetrator of the 
phosphorylation.  The NetworKIN output was filtered by a minimum score of 0.22, a max 
score difference of 4, and a maximum of ten kinase predictions per site. Because of the 
redundancy and overlap of substrates with functionally-related kinases, it was not 
considered appropriate to exclusively analyze the top scoring kinase predicted for each 
site. For example, phosphorylation of a member of the RRxS motif bearing set, 
Anaphase Promoting Complex Subunit 1 (ANAPC1) at serine 355 was predicted to be 
extremely likely by both Cdk1 and Cdk2, with assigned scores of 8.5 and 9.6 
respectively. The results were then filtered for kinases observed to be present in 
MC3T3-E1 osteoblasts and the sites associated with the protein ANHAK were removed 
(Hornbeck 2014). The frequency value of each kinase per motif was calculated by 
determining the number of occurrences the kinase was predicted in the filtered motif-
specific dataset and dividing by the number of unique sites. Occurrence frequencies of 
less than 20% were discarded.  The heat map generated with NetworKIN output 
(Linding 2008) illustrates the relationship between observed consensus site motifs in 
individual protein substrates and the kinases that phosphorylate them (Figure 3.5).  
While this analysis is limited by the redundancy in consensus phosphorylation site 
motifs amongst different kinases, the data output clearly shows a high degree of 







3.3. Predicting PTH regulated signaling networks 
An advantage of “unbiased” high dimensionality datasets is that they harbor encrypted 
information about the higher order pathways and biological processes that are affected 
by experimental perturbation of a complex system, e.g. living cells.  The challenge is to 
produce a rational and biologically relevant condensation of complex data into outputs 
that predict the functional activities of the genes/proteins modulated between the control 
and test datasets. Geneset enrichment analysis (GSEA) is a statistical approach that 
compares an experimentally determined list of regulated factors, e.g. phosphoproteins 
or mRNA transcripts, to a curated database of genes/proteins involved in specific 
signaling pathways/biological processes, to determine the probability of pathway 
regulation based on the overrepresentation of observed factors in the database 
pathway/process cluster. There are multiple freely available pathway databases and 
facile calculation programs to facilitate these analyses (Kim, 2005; Maudsley 2011 and 
2013).  Because co-regulated geneset databases are themselves based on empiric 
data and not fully, or even correctly, annotated, such analyses should be considered 
exploratory in nature.  It is preferable to employ multiple tools and interrogation 
strategies to explore the experimental dataset (Maudsley 2013), and to undertake 
independent validation experiments before conclusions are drawn.   
Figure 3.4a: Substrate motif analysis of PTH(1-34) regulated protein kinases. (A) All protein 
kinases identified in differentiated MC3T3-E1 cells are displayed according to phylogenetic 
similarity of the kinase domain. Domain sequences were retrieved from KinBase, aligned in 
Clustal X, and displayed using iTOL. Phosphorylation sites regulated following 5 min stimulation 
with hPTH(1-34) are indicated by the concentric bar graph. Directionality and number of sites 
regulated are denoted by the size and color of the bar, with green indicating increased 








3.3.1. Analysis of Signaling Pathways 
Figure 3.6A depicts the output of a parametric GSEA performed using the list of 
regulated class I phosphorylation sites (Supplemental Table 5, available upon request) 
detected in hPTH(1-34)-stimulated MC3T3-E1 osteoblasts using the Ingenuity® 
Systems Pathways Analysis (IPA) tool.  As expected, many of the top-scoring 
pathways; e.g. cAMP-mediated signaling, calcium signaling, phospholipase C signaling 
(white arrows), correspond to the known heterotrimeric G protein coupling profile of 
PTH1R.  Interestingly, seven of the top ten scoring pathways relate to regulation of small 
GTPases involved in cytoskeletal rearrangement, cell motility, and signaling via focal 
adhesion complexes; e.g. integrin signaling, integrin-linked kinase (ILK) signaling, 
paxillin/p21 protein (Cdc42/Rac)-activated kinase (PAK) signaling, and regulation of 
Rho GTPases (black arrows).  IPA analysis also suggested robust crosstalk between 
PTH1R and insulin-like growth factor type 1 signaling pathways; e.g. IGF-1 signaling, 
mTor signaling, which may reflect the large number of regulated phosphorylation sites 
seen on insulin receptor substrate 1 (IRS-1; Figure 3.2).   
Figures 3.6B and 3.6C depict the top-scoring IPA network diagrams generated by 
combining the list of observed regulated phosphorylation events associated with 
classical GPCR signaling pathways (Figure 3.6A; white arrows) or small GTPase 
signaling pathways (Figure 3.6A; black arrows), respectively.  The components of the 
IPA predicted network, along with the identity and direction of regulation of observed 
factors, are shown below each network.  Since observational proteomic datasets are 
inevitably incomplete, either due to incomplete coverage of the regulated 
phosphoproteome or the simple fact that not all pathway components are regulated by 
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phosphorylation, network diagrams such as these often predict the involvement of 
unobserved pathway intermediates and provide testable hypotheses for experimental 
validation. In this analysis, ERK1/2 and AKT were predicted to act as nodal kinases in 
the downstream PTH1R signaling network, while PAK1/2 was predicted to be involved in 
cross regulation of Rac1 and ERK1/2 signaling via the PAK-interacting Cdc42/Rac 
guanine nucleotide exchange factor ARHGEF7.  ARHGEF7, also called α-Pix/COOL-1, 
is regulated via PKA-dependent phosphorylation (Klooster 2006; Chadhi 2008).  
Notably, α -PIX forms a dimeric complex with GIT1, an ADP ribosylation factor (ARF)-
GTPase activating protein (GAP) that transiently localizes PAKs to remodeling focal 
adhesions through binding to paxillin (Premont 2004), and increased GIT1 S410 
phosphorylation was experimentally observed (Figure 3.3).   
Although regulation of ERK1/2-pT183/pY185 and PAK2-pS141 were observed in one or 
two biological replicates, and regulated changes in AKT phosphorylation were not 
directly observed by mass spectrometry, targeted immunoblotting based on the IPA 
network output confirmed strong negative regulation of ERK1/2 and AKT 
phosphorylation and increased PAK2 phosphorylation (Figure 3.6D).      
 
3.3.2 From Pathways to Biological Processes 
Using Perseus, we next examined the GO biological process terms associated with the 
regulated phosphorylation sites (Supplemental Table 5, available upon request) using a 
Fisher exact test, BH FDR of 0.02, and unregulated phosphosites as background.  As 
with the IPA pathways analysis output, which heavily populated pathways related to 
regulation of small GTPases, the most strongly populated GO bp terms related to 
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cytoskeletal rearrangement and cell motility; e.g. microtubule 
polymerization/depolymerization, cell motility, Rho signal transduction, and ARF 
GTPase activity (Figure 3.6E; white arrows).  Notably, hPTH(1-34) stimulates migration 
of primary pre-osteoblasts in vitro (Gesty-Palmer 2013)  and regulation of Rho, Rac1 
and Cdc42 signaling in osteoblasts is known to affect osteoblast mechano-transduction, 
survival, and motility (Yoshida 2009; Hamamura 2012; Wan 2013).  Other commonly 
represented GO bp terms related to regulation of phosphatidylinositol 3’-kinase activity 
(PI3K) (black arrows), reflecting the observed regulation of Rac1-PAK signaling and 
regulation of AKT demonstrated in the IPA analysis. Thus, our data suggest that 
downstream of the initial cAMP-PKA regulated signaling events, the short-term 
responses of differentiating osteoblastic cells to PTH1R activation revolve around 
regulation of Rac/Rho/Cdc42 control of cytoskeletal dynamics involved in cell-matrix 



















The consequences of GPCR activation are encoded by receptor coupling to a relatively 
small number of proximal effectors, e.g. heterotrimeric G proteins, arrestins, and other 
non-G protein effectors.  Although the initial number of signaling conduits is limited, 
tremendous complexity in the both the short and long term biological response arises 
from the interplay of signal strength/duration and the cellular context in which the 
receptor is expressed.  Capturing this level of complexity in a native cell context 
requires the ability to generate high-dimensionality data that reflect, as much as 
possible, all of the downstream changes resulting from receptor activation.  Here, we 
employed SILAC-based quantitative mass spectrometry combined with bioinformatic 
pathways analysis to examine global changes in protein phosphorylation following 
short-term stimulation of endogenously expressed PTH1R with the conventional agonist 
hPTH(1-34). Our results reveal both comforting familiarities and some surprising 
insights.  Given its known activation of Gs-cAMP and Gq/11-calcium signaling pathways, 
Figure 3.6: Informatic analysis of hPTH(1-34) regulated signaling pathways and biological processes. 
(C) The top-scoring IPA network diagram generated by combining the list of observed regulated 
phosphorylation events associated with small GTPase signaling pathways. The network components, 
along with the identity and direction of regulation of observed factors are shown at the top of each 
panel. In panels B and C, black circles denote the position of AKT, ERK, and PAK within the predicted 
networks. (D) Total cell protein isolated from differentiated MC3T3-E1 treated for 5 min with 0.1 lM 
hPTH(1-34) or vehicle control (CNTL) was probed using antisera specific for activated (pT202/pY204) 
or total ERK1/2; active (pS473) or total AKT; and active (pS141) or total PAK2. Representative 
immunoblots of triplicate samples are shown. (E) Significantly populated GObp terms determined in 
Perseus. The Top 50 enriched GObp terms are shown. GObp terms related to regulation of 
cytoskeletal dynamics (white arrows) and regulation of PI3K/AKT and lipid kinase signaling (black 
arrows) are indicated. 
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it is not surprising that global phosphorylation of consensus PKA/CAMK sites rose 
dramatically in the first 5 min of stimulation.  Likewise, cAMP signaling is known to affect 
ERK1/2 activity, producing either activation or inhibition depending on cellular context 
(Lefkowitz 2002).   
In 13-day old differentiating MC3T3-E1 cells, hPTH(1-34) stimulation increased 
phosphorylation of an inhibitory site on BRAF, leading to decreased ERK1/2 activity, 
and a global fall in the phosphorylation of consensus MAPK sites.  Somewhat less 
expected were the central roles of ERK1/2 and AKT detected in the IPA pathways 
analysis, and the heavy bias toward regulation of small GTPase signaling.  Early in the 
response, ERK1/2 and AKT signaling were depressed, while signaling via ARHGEF6 (α 
-PIX) and ARHGEF7(α -PIX)-PAK2 was activated, suggesting that regulation of 
Rac1/Cdc42 signaling, dynamic cytoskeletal rearrangement, and crosstalk with focal 
adhesion/paxillin-based signaling are important contributors to PTH1R signaling in 
osteoblasts.  
Although SILAC is considered the gold standard for quantitative proteomic assessment 
of post-translational modifications (Olsen 2006; Ong 2002), the technique is not without 
limitations.  Caveats of the approach include 1) redundant sequencing of SILAC-labeled 
peptide pairs which reduces the depth of the analysis; 2) limitations in multiplexing; and, 
3) incompatibility with protein prepared directly from tissue.    
Recent studies have demonstrated the ability of alternative technologies, such as label 
free quantification, to probe deeper into the phosphoproteome (Sharma 2014) and to 
assay dynamic phosphorylation profiles following GPCR-stimulation in vitro (deGraaf 
2014) and in vivo (Olsen 2013).  Advances in instrumentation are also permitting the 
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evaluation of multiplexed approaches such as 18-plex NeuSILAC (Merrill 2014) and 10-
plex TMT isobaric labeling with phosphorylation-directed data acquisition (Paulo 2015).  
Beyond technological limitations, phosphoproteomic analysis of signal transduction on 
the time scale of a few minutes may not capture the information needed to link 
activation of signaling pathways with longer-term transcriptional regulatory events that 
determine the phenotypic response of a tissue to ligand stimulation.  To fully appreciate 
the complexity, it would be necessary to relate high-dimensionality mass spectrometric 
datasets to longer term in vitro or in vivo transcriptomic and conventional phenotypic 
data (Gesty-Palmer 2013; Maudsley 2015). 
Using informatic approaches to analyze complex datasets likewise calls for an 
appreciation of the limitations and exercise of judgement.  High-dimensionality, e.g. 
proteomic and transcriptomic, datasets are prone to both false discovery and missing 
data, depending on the filters applied to determine significance.  If very stringent criteria 
are applied, then the resulting data were highly reliable, i.e. contain a low percentage of 
false positives, but may yield datasets too small for reliable pathways analysis due to a 
high false negative rate.  While the output of pathways analysis is dependent on the 
quality of the input data, GSEA approaches are able to tolerate a relatively high degree 
of “noise”, as they rely on calculating the statistical probability that the curated pathway 
geneset was not populated by random chance (Maudsley 2013).  Datasets that are too 
small, or datasets that are too large, i.e. contain a high percentage of false positives, will 
both decrease the sensitivity of the analysis.  As a result, it is often most rewarding to 
perform pathways analysis using factor lists extracted at different levels of significance, 
to determine by trial-and-error which parameters yield the most informative results from 
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a given dataset.  Because of their exploratory nature, it is likewise preferable to employ 
multiple tools to explore the experimental dataset (Maudsley 2013), and to undertake 
independent validation experiments before drawing conclusions.  Despite these 
limitations, our results illustrate how technological advances in mass spectrometry-
based proteomics have enabled more in-depth study of endogenous GPCR signaling in 
a native cell background.  Given its ability to capture high-dimensionality data without 
pre-conceived hypotheses about function, these approaches should be of particular 
value in settings where the signaling outcomes are less predictable, e.g. 
characterization of non-canonical GPCR signaling pathways activated by arrestin 
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Chapter 4: Biasing the PTH1R 
Biased agonist bPTH(7-34) binding at the PTH1R elicits differential Erk2 
regulation and discrete signaling networks compared to binding by 
conventional agonist hPTH(1-34) 
 
4. INTRODUCTION 
Biased Agonism of G Protein Coupled Receptors (GPCR) 
The parathyroid hormone type 1 receptor (PTH1R) is a class II G protein coupled 
receptor (GPCR).  Through advances in the field of GPCR signaling, it has become 
apparent that these seven α-helical, integral membrane proteins are capable of coupling 
to multiple downstream effectors including G-proteins, arrestins and other scaffolding 
proteins, and even other GCPRs (Laugwitz 1996; Angers 2002; Brady 2002; Hall 2002). 
Once thought to possess only two-states, the “on” state as detected by tissue response 
(Stephenson 1956), and “off” as the unbound, constitutively inactive receptor state, 
research has determined GPCR signaling is much more textured and nuanced. It is now 
more accurate to describe the receptor as existing in a variety of conformations, or an 
“ensemble” of active states, each with an as yet undefined proclivity to signal through 
different cellular paths (Kenakin 2002a and 2002b). Furthermore, the ligand:receptor 
complex can be considered a distinct signaling entity, with the ligand stabilizing a subset 
of the active state ensembles of the receptor, thus each chemically distinct ligand 
creating a “new receptor” when bound to its cognate GPCR. There is no reason to 
assume that the chemically distinct ligands observed to bind to the receptor will all 
cause the receptor to bind all possible downstream effectors and elicit identical effects. 
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Biased agonism refers to the ability of a ligand to selectively recruit different intracellular 
signaling proteins upon receptor activation. This implies that two different ligands can 
activate the same receptor in alternate ways and elicit different biological effects. In 
recent years, the concept of biased agonism has gained traction in the field of G-
coupled protein receptor signaling. Also called “pluridimensional efficacy” (Galandrin 
2006) and “functional selectivity”, biased agonism exploits the GPCR’s innate ability to 
couple with multiple downstream effectors. These effectors then propagate the signal to 
a variety of pathways, leading to alterations in gene expression and cell metabolism and 
finally to systems-level biological effects.  
Few GPCR systems amenable to bias are as promising as the PTH1R. the N-terminal 
fragment of the naturally occurring parathyroid hormone (hPTH(1-34)) is the only 
anabolic osteoporosis therapeutic known to act on the bone-forming osteoblasts. 
Activation of the PTH1R by hPTH(1-34) leads to engagement of Gαs, Gαq/11, and 
βArrestin1 and 2 mediated signaling networks (Juppner 1991;  Abou-samra 1992; 
Bringhurst 1993; Pines 1994; Takasu 1998; Gesty-Palmer 2006). Other n-terminal 
fragments of PTH have been characterized and possess different profiles of bias (Table 
1). Similar to hPTH(1-34), intermittent administration of bovine PTH residues 7-34 (D-
Trp12, Tyr34), referred to hereafter as bPTH(7-34), to mice increases osteoblast 
number and promotes bone formation (Gesty-Palmer 2009). However, while both 
agonists bind the PTH1R, they utilize different downstream signaling mediators to 
achieve this anabolic effect.  bPTH(7-34) activates β-arrestin-dependent signaling 
pathways while acting as an inverse agonist for Gs coupled signaling (Gesty-Palmer 
2006). The requirement of arrestin-mediated signaling was verified in β-arrestin2 null 
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mice which lack the anabolic response to bPTH(7-34) (Gesty-Palmer 2009).  β-arrestins 
have been shown to couple to ERK1/2 and the non-receptor tyrosine kinase, Src 
(Luttrell 1999).  Unlike hPTH(1-34), in vivo administration of bPTH(7-34) did not 
increase osteoclast number or markers of bone resorption (Gesty-Palmer 2009) 
suggesting that the biased response to bPTH(7-34) has the potential to uncouple 
osteoblast-mediated bone deposition from osteoclast-mediated bone resorption in 
skeletal remodeling (Gesty-Palmer 2009, 2011, and 2013). The precise signaling 
modalities of hPTH(1-34) and bPTH(7-34) are not known and we seek to characterize 
the hypothesized discreet phosphorylation-mediated signaling networks engaged by 





Table 1.  Reported activity profiles of N-terminal fragments of PTH engaging the PTH1R.  





PTH(1-34) 2±1 Gs and Gq/11 β-Arrestin1 
and 2 
Juppner 1991;  Abou-samra 
1992; Bringhurst 1993; Pines 
1994; Takasu 1998; Gesty-
Palmer 2006 
PTH(1-31) ND Gs and Gq/11 ND Whitfield 1995, Takasu 1998, 
Sneddon 2004 
Trp1PTHrp     
(1-36) 
ND Gs only Antagonist Gesty-Palmer 2006 
PTH(3-34) 10 Gs and Gq 
antagonist 
ND Segre 1979, Nussbaum 1980, 
Takasu 1999 
hPTH(7-34) 58±16 Gs and Gq 
antagonist 
ND Hoare 2000, Sneddon 2004 
(D-Trp12, Tyr34)-
bPTH(7-34) 
25±2 Gs inverse 




Gardella 1996, Hoare 2000, 





Quantitative phosphoproteomic analysis provides an avenue for elucidating transient 
phosphorylation-mediated signaling events following receptor-ligand interactions (Olsen 
2006) (Roux 2013). A global phosphoproteomics study allows for quantifying PTM 
changes in thousands of proteins and has the potential to discover the activity of nodal 
kinases and also their downstream substrates. This unbiased approach reveals 
heretofore unpredicted signaling mediators and provides a global picture of the reaction 
of the cell when stimulated with hPTH(1-34) or bPTH(7-34). Given that both hPTH(1-34) 
or bPTH(7-34) build bone in mice and appear to do so through different signaling 
mechanisms, we performed a global phosphoproteomic study in MC3T3-E1 cells 
(mouse pre-osteoblasts) endogenously expressing the PTH receptor. The cells were 
stimulated for 5 minutes with either drug at two different time points of osteoblast 
differentiation, day 0 and day 10. Purified phosphopeptides were identified and 
quantified by LC-MS/MS.  To characterize the signaling background differences at day 0 
and day 10, a label-free quantitative protein expression study was conducted.  
Bioinformatic analyses were performed to predict active kinases and compare the 
signaling networks, molecular functions, and biological processes regulated by each 
ligand.  The results of these studies were verified by cell-based assays and 
immunoblotting. 
 
MATERIALS AND METHODS  
4.2.1. Cell culture (general) 
MC3T3-E1 preosteoblasts were maintained subconfluently at 37C and 5% CO2 in 
MEMα containing 10% fetal bovine serum (FBS) (Fisher Scientific) and 1% 
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penicillin/streptomycin antibiotic/antimycotic. For experiments in 10-day differentiating 
osteoblasts, upon reaching ~85% confluence, the cells were placed in osteogenic media 
in which 50 ug/ml ascorbic acid and 10 mM b-glycerophosphate has been added to the 
growth media. “Differentiation day 0” experiments were conducted ~3 days after the 
cells were seeded at 1x104 cells/cm2 whenever they reached ~85% confluency. 
Differentiation day 10 experiments were conducted 10 days after cells were placed in 
osteogenic media. 
 
4.2.2 Determination of changing mRNA levels over differentiation 
MC3T3-E1 cells were grown to confluence and then changed to differentiation 
medium starting at Day 3 (Differentiation day 0). Cells were harvested on Days 2, 5,10 
and 28 and RNA was isolated using Qiashredder homogenization and the RNeasy Plus 
kit (Qiagen). RNA concentration was assessed by Nanodrop and normalized to 50 
ng/uL. 100 ng of total RNA was hybridized to a custom NanoString CodeSet 
overnight.  The custom CodeSet included genes expressed throughout osteoblast 
differentiation (Table 4) according to the manufacturer's instructions using a nCounter 
Analyzer.  All probes included in the CodeSet were designed and verified by NanoString 
Technologies, Inc. The resulting data was analyzed using Nanostring analysis software. 
The six housekeeping genes were included in the CodeSet as controls (OAZ1, EIF4A2, 






4.2.3. Quantifying protein expression changes: Label-free quantitation 
4.2.3.1 Cell culture conducted as in materials and Methods 1.0. The protein 
concentration was determined using a Bradford analysis.  The cell lysate was diluted to 
2 M urea with water (40 ml). Cysteines were reduced in 1 mM of dithiothreitol for 30 
minutes at room temperature. Thiols were alkylated in 5.5 mM of iodoacetamide for 15 
min at room temperature in the dark. The pH was adjusted using 30 mM ammonium 
bicarbonate 7.8–8.7 for effective trypsin digestion. Protein was digested with trypsin 
(Sigma) at a 2:100 (w/w) enzyme to protein ratio overnight at 37°C. The digestion 
reaction was quenched by adding a small volume of 10% v/v trifluoroacetic acid (TFA) 
in water until a pH of 2-3 was obtained. Digested peptides (15–20 mg) were desalted 
using a 6 cc C18 Sep-Pak cartridge (Waters) and dried under vacuum. Samples were 
stored at -80C until further use. 
 
4.2.4. LC MS/MS Analysis  
Peptides (5 µg) were dissolved in solvent A and loaded on a trap column (C18 pepMap 
100, 300 µm x 5 mm) (Thermo) and separated on a 75 µm x 20 cm analytical column, 
packed in house (C18-Reprosil-AQ Pur RP 3 µm particles, Dr. Maisch, GmbH) heated 
to 50°C.  A gradient from 5% B to 50% B in 180 min (Solvent A: 0.2% formic acid in 2% 
acetonitrile; Solvent B: 2% formic acid in 98% acetonitrile) on a LC Packings U3000 
nano LC system was utilized at a flow rate of 200 nl/min. The effluent was introduced 
via nano-electrospray ionization (nESI) using an uncoated silica emitter (360 μm OD, 50 
μm ID, with a 5 μm tip, New Objective) to a hybrid dual-pressure linear ion trap-orbitrap 
mass spectrometer (Orbitrap Elite, Thermo Scientific). Mass spectra were acquired in 
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data dependent mode with one FTMS survey scan, mass range of m/z 400-1700 Th, 
followed by collisional dissociation of the ten most intense ions in the ion trap. The 
automatic gain control target value in the Orbitrap was 10E6 ions for the survey MS 
scan, and the resolution 60,000 at m/z 400 Th. Ions with a +1 charge were excluded 
from selection. Dynamic exclusion was enabled with a repeat count of 1, a duration of 
30 seconds, exclusion list size of 50, and exclusion duration of 180 sec.  Lock mass 
was not enabled.  To obtain the tandem mass spectrum at the apex of the 
chromatographic peak, rather than the first time the peptide ion was detected, 
chromatography mode was used with an expected peak width of 30 seconds and a 
minimum threshold of 1000.  
 
4.2.5 Database Searching for Label-Free Quantitation of Protein Expression 
Tandem mass spectra were searched using the newest release of the MaxQuant 
algorithm (Cox 2011) against the most recent release of the mouse Uniprot protein 
database and a reversed decoy database.  The false discovery rate was set at 0.01 at 
the protein, peptide, and acetyl site levels.  Fully tryptic peptides were required including 
cleavage between lysine and proline.  Three missed cleavages and three modifications 
were permitted and a minimum of 7 residues required per peptide.  A minimum score 
(40) and delta score (6) were required for the identification of modified peptides.  The 
first search was performed with a 20 ppm mass tolerance, after recalibration a 4.5 ppm 
tolerance was used for the main search.  Match between runs was enabled with a 0.7 




4.2.6. Identification of differentially expressed proteins  
For changes in protein expression, the MaxLFQ label free quantification algorithm was 
utilized which normalizes the LC-MS/MS analyses for pairwise comparisons of log2 
transformed protein intensities between different groups (Cox 2014).  Systematic 
analyses with known amounts of protein standards spiked into a comples peptide 
mixture demonstrated the Welch’s two-sided t test with a p val <0.05 cutoff yielded the 
most accurate data with the least false positives (Ramus 2016).  Protein quantification 
was based on measurements of at least two peptides per protein excluding modified 
peptides and unmodified counterparts.   
 
4.3. Phosphoproteomics 
4.3.1. SILAC Cell Culture and labeling  
Reagents: 
1) SILAC Media: For ‘‘light’’, ‘‘medium’’, or ‘‘heavy’’ SILAC media add labeled amino 
acids to custom MEMa media lacking arginine and lysine (Gibco). For a final 
concentration of 0.5 mM arginine and a final concentration of 0.4 mM. lysine. 
2)  SILAC Growth Media: 10% dialyzed fetal calf serum (FCS) (Fisher Scientific) and 
1% penicillin/streptomycin were added to SILAC media. The FCS is dialyzed to 
eliminate a source of unlabeled lysine or arginine. 







For SILAC cell culture, MC3T3-E1 preosteoblasts were grown for at least five doublings 
subconfluently in custom MEMα media containing 10% dialyzed fetal calf serum (dFBS), 
1% antibiotic/antimycotic and only ‘light’’, ‘‘medium’’, or ‘‘heavy’’ isotopes of 
lysine(0.4mM) and arginine(0.5mM). The SILAC isotopes were as follows:  light 
([12C614N2] Lys, [12C614N4] Arg), medium ([2H4] Lys, [13C6] Arg), or heavy 
([13C615N2] Lys, [13C615N4] Arg) amino acids (Cambridge Isotope Labs). Efficient 
metabolic labeling of cellular proteins was confirmed by LC–MS/MS. After label 
incorporation confirmation, the cells are aliquoted and stored in liquid nitrogen. This 
allows for all experiments to be performed on similar MC3T3-E1 passage numbers. In 




Because the phosphoproteome of a cell is ~1% of the total proteome, a large amount of 
starting material is needed for phospho-SILAC experiments. Differentiation day 0 (D0) 
experiments were performed on 6-8 x150 mm plates (5 mg total protein) per condition, 
for a total of 18-24 x150 mm plates and 15 mg of starting protein material. 
Differentiation day 10 (D10) experiments required 10 x100 mm plates per condition (5 
mg protein) for a total of 15 mg protein starting material.  
 
Drug treatment: Eighteen hours prior to stimulation, cells are serum-starved by reducing 
the concentration of dialyzed FCS to 1% v/v in SILAC media. then treated for 5 minutes 
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with either hPTH(1-34) (0.1 μm) or bPTH(7-34) (1.0 μm) at 37°C and 5%CO2.  hPTH(1-
34) was purchased from Tocris and solubilized in water. (D-Trp12, Tyr34)-bPTH(7-34) 
was purchased from BAChem and solubilized in water. 
 
4 3.2.1 Cell lysis and protein preparation  
After drug treatment, SILAC cells were immediately placed on ice, rinsed 2x with ice 
cold PBS to remove any residual serum proteins, and lysed in freshly made urea buffer 
[9.0 M urea, 20 mM HEPES (pH 8.0), 1 mM sodium orthovanadate, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerol-phosphate in HPLC grade water].  The lysate was 
incubated on a rotator for 4 hour at 4°C. To remove cellular debris, lysate was then 
centrifuged at 14,000 x g for 10 minutes. Lysate was frozen overnight. Protein 
concentration determined by using a Bradford assay, and equal amounts of protein (~5 
mg) from each treatment group were combined at 1:1:1 ratio.  
 
4 3.2.2 Reduction, alkylation and tryptic digestion in solution 
Protein sample diluted to 2 M urea with water (40 ml). Cysteines reduced in 1 mM of 
dithiothreitol for 30 min at room temperature. Thiols alkylated in 5.5 mM of 
iodoacetamide for 15 min at room temperature in the dark. The pH was adjusted using 
30 mM ammonium bicarbonate 7.8–8.7 for effective trypsin digestion. Protein digested 
with trypsin (Sigma) at a 2:100 (w/w) enzyme to protein ratio overnight at 37°C. The 
digestion was quenched by adding a small volume of 10% v/v trifluoroacetic acid (TFA) 
in water until a pH of 2-3 was obtained. Digested peptides (15–20 mg) were desalted 
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using a 6 cc C18 Sep-Pak cartridge (Waters), dried under vacuum and stored at -80C 
until further use.  
 
4 3.2.3. Peptide fractionation by strong cation exchange chromatography (SCX) 
Peptides were fractioned on a 6.4 mm x 30 mm (15 μm) Resource S methylsulfonate 
column (GE Healthcare) which has a 20 mg capacity.  Buffer A was composed of 5 mM 
KH2PO4 (pH 2.7) in 30% acetonitrile. Typically, 600 ml is required per separation. Buffer 
B was 5 mM KH2PO4 (pH 2.7), 350 mM KCl, 30% acetonitrile. Typically, 400 ml is 
required per separation.  Desalted, dried peptides (15–20 mg) were solubilized in 1–2 
ml of SCX Buffer A. Peptides were separated using a gradient of 0% B for 10 min; 0–
30% B in 30 min; 30–100% B in 5 min; 100% B for 10 min at a flow rate of 1 ml/min. 
Chromatographic separation was monitored the at 214 nm and fractions collected every 
minute starting with the unretained flow-through peak. Adjacent fractions were 
combined to yield twelve final fractions for LC–MS/MS analyses. 
 
4 3.2.4 TiO2 phosphopeptide enrichment: 
Phosphopeptides from each fraction were enriched using a slurry of 5 mg TiO2 beads 
(Titansphere, 10 lm, GL Sciences) per fraction, fresh buffers and elution solution 
(Larsen 2005). Enrichment protocol performed as in Chapter 3, except two rounds of 
sequential enrichment were performed on each fraction.  
            
4 3.2.5. Mass spectrometric analysis (LC–MS/MS) 
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Peptides were loaded onto a trap column (C18 pepMap 100, 300 µm x 5 mm) (Thermo), 
eluted, and separated on a 75 um x 15 cm fused-silica column packed in-house with 
C18 reversed-phase resin (YMC-ODS-AQ; 5-um particles; 200-Å pore; Waters or a 75 
µm x 20 cm analytical column, (C18-Reprosil-AQ Pur RP 3 µm particles, Dr. Maisch, 
GmbH) heated to 50°C with a gradient from 5% B to 50% B in 180 min (Solvent A: 0.2% 
formic acid in 2% acetonitrile; Solvent B: 2% formic acid in 98% acetonitrile) on a U3000 
nano LC system at a flow rate of 200 nl/min.  
The sample was introduced via nano-electrospray ionization (nESI) with an uncoated 
silica emitter (360 um OD, 50 um ID, with a 5um tip, New Objective) to a hybrid dual-
pressure linear ion trap-orbitrap mass spectrometer (Orbitrap Elite, Thermo Scientific). 
Mass spectra were acquired in data dependent mode using a TOP10 method collecting 
one FTMS survey MS scan within a mass range of m/z 400–1800 followed by 
acquisition of tandem mass spectra (MS/MS) of the ten most intense ions in the survey 
scan. The automatic gain control target value in the Orbitrap was 10E6 for the survey 
MS scan at a resolution of 60,000 at m/z 400. Peptides were fragmented in the ion trap 
by collision-induced dissociation (CID) with an automatic gain control target value of 
1000 ions and a minimum threshold of 500 counts. 
 
4.3.3 Phosphoproteomics Data processing and analysis 
4.3.3.1 Peptide identification, site-assignment, and quantitation  
The MaxQuant/Perseus platforms are freely available (version1.5.2.8) Max Planck 
Institute of Biochemistry, Dept. of Proteomics and Signal Transduction, Munich, 
Germany) (Cox 2008) . 
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All the raw files from multiple biological replicate experiments including label swap 
controls were searched simultaneously using MaxQuant v1.5.2.8 on a 24 core, 48 GB 
RAM high performance server. Andromeda, the database search algorithm embedded 
in MaxQuant, was configured to search the murine database of interest (Uniprot; 
December 2013), and for neutral loss and diagnostic fragment ions. Prior to searching, 
the tandem mass spectra were processed such that 8 ions per 100 m/z were retained. 
To correct for drift in the calibration during data acquisition, a recalibration option was 
selected in which the first database search was performed at 20 ppm precursor mass 
tolerance. Following recalibration of the m/z ratios, the search was repeated with a more 
stringent mass tolerance of 4.5 ppm for precursor ions measured in the Orbitrap mass 
analyzer. The mass tolerance was 0.5 Da for fragment ions generated by CID 
measured in the ion trap. Cysteine carbamidomethylation was selected as a fixed 
modification. Methionine oxidation and phosphorylation on serine, threonine, and 
tyrosine were included as variable modifications. Tryptic peptides were reported with a 
maximum of two missed cleavages. The tandem mass spectra were searched against a 
concatenated forward and reversed database supplemented with protein sequences of 
common contaminants. To establish the false discovery rate for peptide identification 
and phosphorylation site assignment, a ‘‘Revert’’ decoy database mode was selected 
[9] and the results were filtered by a 1% false discovery rate (FDR) at the peptide 
spectral match (PSM) and site levels.  Minimum Andromeda and delta scores of 40 and 
6, respectively, were the default parameters required for identification of modified 
peptides. These values are adjusted if necessary after manual inspection of the spectral 
matches. For relative quantification, the peak areas of both the heavy and light SILAC-
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labeled phosphopeptides must be measured.  To search for missing SILAC partners 
after the initial database search the ‘‘Requantify’’ option in MaxQuant was employed. To 
avoid quantification of ambiguous site assignments the ‘‘match between runs’’ feature 
was not enabled. Initial data processing was performed in Perseus, including the 
removal of potential contaminants and matches to the reversed database, log2 
transformation of experimental ratios, normalization by subtraction of the median ratio 
for each experiment, protein and site level annotation, extraction of a sequence window 
(phosphorylation site flanked by adjacent amino acids determined from sequence 
information), and visualization of the data for quality control parameters such as 
reproducibility and normalization.  For the hPTH(1-34) experiments reproducibly 
regulated phosphosites were determined using the moderated t-statistic function within 
the LIMMA package (Ritchie 2015). Ratios from the biological replicate experiments 
were evaluated using a moderated t-test with a Benjamini–Hochberg correction for 
multiple hypothesis testing (Udeshi 2014). For bPTH(7-34), which elicited a less robust 
signal, the threshold of change was determined as the experimental ratio ≥ 2.5 times 
the mean absolute deviation observed at least twice (Olsen 2013). 
 
 
4.3.4 Western Blotting  
Total cell protein isolated from proliferating or differentiated MC3T3-E1 treated for 5 min 
with 0.1 μM PTH(1-34), 1.0 μM bPTH(7-34), or vehicle control (CNTL) and quantitated 
using a Bradford assay. Ten ug of proteins from each condition were separated on a 4-
20% polyacrylamide gel for 120 minutes at 120V and 100 mAMPs. The separated 
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proteins were then transferred to nitrocellulose and blocked for an hour with milk.   The 
nitrocellulose was probed using antibodies specific for activated (pT202/pY204) or total 
ERK1/2; active (pS473) or total AKT; known PKA substrate Creb(pS133) or total Creb; 
MAPK substrate motif containing phosphoproteins (PxpSP); PKA substrate containing 
phosphoproteins (RRxpS); or inhibited Cdk1 (pY15); and GAPDH. Antibodies were 
purchased from Cell Signaling Technologies.   
 
4.3.5. MTT proliferation and Etoposide resistance assays (Roche) 
4.3.5.1 Proliferation 
MC3T3-E1 cells were seeded at 1,000 cells per well in 96-well plates and treated with 
0.1 uM hPTH(1-34), 1.0 uM bPTH(7-34), or vehicle control (CNTL) for 1, 3, 4, 5, and 6 
days. Cells treated for 4, 5, and 6 days were re-treated with fresh drug on day 3. After 
the timepoint was reached, cells were labeled for 4 hours with MTT. The yellow 
tetrazolium MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) is 
reduced by metabolically active cells, in part by the action of dehydrogenase enzymes, 
to generate reducing equivalents such as NADH and NADPH. The resulting intracellular 
purple formazan can be solubilized and quantified by spectrophotometric means 
(550nm/660nm). After labeling, cells were placed in solubilization buffer overnight and 
quantified by spectrophotometry. 
 
4.3.5.2 Etoposide resistance 
Cells were seeded at 3,000 cells per well in a 96-well plate and treated with 0.1 uM 
hPTH(1-34), 1.0uM bPTH(7-34), or vehicle control (CNTL) for 24 hours. Then 100 uM 
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etoposide was added to the cell media and incubated for 24 hours. Cells were then 
labeled for 4 hours with MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium 
bromide), solubilized overnight, and quantified the next day.  
 
4.4 Results  
4.4.1 MC3T3-E1 cells are pre-osteoblasts differentiating in vitro - mRNA 
MC3T3-E1 cells are an established model of osteoblast differentiation in vitro. Derived 
from newborn mouse calvaria, this spontaneously immortalized cell line will form bone 
nodules on the dish while expressing the PTH receptor and other essential markers of 
osteoblasts. The morphology of the cells changes in a significant manner as the cells 
approach differentiation. Early stage pre-osteoblasts transition from a fibroblast-like, 
proliferating, motile cell to differentiating cells with a “cobblestone” appearance. To 
confirm osteogenic differentiation, the mRNA transcript expression levels of bone 
markers in MC3T3-E1 cells at day 0, 3, 7, and 26 of differentiation were measured.  As 
anticipated, essential bone-specific proteins, PTH1R, RUNX2, and SP7 (osterix), 
steadily increasing over the measured period (Figure 4.1). 
 
4.4.2. Differential protein expression before and after 10 days of osteogenic 
differentiation   
Label-free quantitative mass spectrometry was performed on MC3T3-E1 cells at day 0 
and day 10 of differentiation to assess the effect of cell background on the PTH1R -
mediated signaling profile.  The threshold of change was set using a two-sided Welch t-
test, with a p≤0.05. From the 3,783 proteins identified, 707 were changing in expression 
156 
 
(Figure 4.2); with 452 proteins significantly increased at day 0 and 256 proteins 
significantly increased at day 10 (19% regulated). In figure 4.3, immunoblot results 
demonstrate that expression of β-arrestin is significantly different between days 0 and 
10 of differentiation, with expression levels being considerably higher at day 0. The 
changing proteins included 138 protein kinases and 84 DNA-binding transcription 
factors (Figures 4.4A and B). Selected proteins related to specific pathways of interest 







4.4.4 Evidence of different kinase-mediated signaling with hPTH(1-34) and 
bPTH(7-34) 
To probe for potential differences in kinase activity and the role of osteoblast 
differen≥tiation state on the downstream signaling elicited by the two PTH1R agonists, 
protein lysates from cells stimulated for 5 minutes with hPTH(1-34), bPTH(7-34), or 
vehicle at days 0 and 10 were probed for changes in phosphorylation. As a positive 
control, hPTH(1-34) dependent activation of PKA was confirmed by increased 
phosphorylation at CREB S133, a known PKA substrate that is often used proxy for 
PKA activation. The basal level of phosphorylation of Akt at an activating site, S473, 
was reduced by hPTH(1-34) at both days and bPTH(7-34) elicited no significant effect 
on Akt phosphorylation. The most notable differences were in the differential regulation 
of Erk1/2 phosphorylation between drug treatments at day 0, with hPTH(1-34) causing a 
decrease in phosphorylation from basal and bPTH(7-34) causing an increase from 
basal phosphorylation levels.  Western blots and densitometry are shown in Figure 4.2.  
Based on these results, the phosphoproteomes of proliferating pre-osteoblasts and 
differentiating osteoblasts acutely stimulated with the two agonists of the PTH1R were 







4.4.5 Defining the hPTH(1-34) and bPTH(7-34) regulated phosphoproteome in 
osteoblastic cells expressing endogenous levels of PTH1R at day 0 and day 10 of 
differentiation 
 
4.4.5.1 Detection and identification of osteoblast phosphoproteins  
The experimental workflow employed to identify phosphoproteins and phosphorylation 
sites regulated by acute stimulation with the conventional PTH1R agonist, hPTH(1-34) 
or biased agonist bPTH(7-34), is summarized in Fig. 5. From the modification-specific 
peptides table, 9,322 phosphopeptides were identified (Table available upon request). 
These phosphopeptides corresponded to 4,093 protein groups, 435 of which were 
derived from multiple gene products, 8,747 (unique groups column) corresponded to a 
unique protein group, and 1,576 were mapped to a unique protein. All of the protein 
groups identified (4,093) are shown in a supplemental table available upon request. 
Double titanium dioxide enrichment yielded 87% (9322/10519) phosphopeptides. We 
observed 148 protein kinases (GO:0004672) (Supplemental Table available upon 
request) and 121 sequence-specific DNA binding transcription factors (GO:0003700) 
including 33.5% sequence coverage of the osteogenic transcription factor Twist1 
(Supplemental Table available upon request). A total of 10,485 sites of phosphorylation 
were identified, 6,551 were ‘‘Class I’’ sites with a localization probability ≥0.75 and a 
minimum score difference of 5 (see Supplemental Table available upon request).  
 
Known phosphorylation sites, kinase-substrate relations, known regulatory and disease-
related sites from databases including PhosphositePlus, Uniprot, and the Human 
Protein Reference database accessible via Perseus were used for protein, site, and 
modification-specific annotation. 4,873 of the Class I sites identified have not been 
reported in Uniprot or PhosphositePlus (Supplemental Table available upon request). 
Novel sites of phosphorylation were observed on many proteins that regulate function 
including transcriptional regulators such as SP7 or Osterix (4 new) and the catalytic 





Quantitated Site Overlap 
To assess coverage overlap of quantified phospho-sites, the Pangloss Venn diagram 
program was used with input being all sites with a quantified phosphopeptide ratio in 
each condition. It was determined that there was a high degree of overlap in the sites 
quantified in both treatment conditions at day 0 (67%) and at day 10 (62%). This 
provides information that differences seen in the signaling network analysis of these 













































4.4.5.2. Identification of phosphopeptides regulated after 5 min hPTH(1-34)  or 
bPTH(7-34) stimulation (regulated phosphosites from all four conditions 
displayed in Table 3) 
 
The relative changes in the extent of phosphorylation were measured in MaxQuant and 
are based on the ratio of chromatographically resolved peak areas of the isotopic 
clusters for the SILAC phosphopeptide pairs. To demonstrate the information that can 
be obtained by this quantitative approach we are reporting the phosphorylation events 
that were regulated after 5 min of stimulation with either hPTH(1-34) or bPTH(7-34) in 
three biological replicates (per drug) at Day 0 of differentiation and three biological 
replicates per drug at day 10 of differentiation including a label swap control at both 
days. To determine the regulated sites of phosphorylation, the normalized ratios of 
singly, doubly, and multiply phosphorylated peptides associated with a site were 
transposed from a single row in the phosphoSTY table into columns yielding 3 potential 
ratio measurements per site. The ratios from the label swap experiment were inverted 
and all the ratios were then log2 transformed. A summary of the workflow can be seen 
in figure 4.6A. Data quality was assessed using the Perseus platform and PTX-QC. To 
assess normalization of the treated/untreated peptide ratios, the distribution of log2 
transformed ratios is visualized as a histogram in figure 4.7. The hPTH(1-34) regulated 
sites of phosphorylation were determined using the moderated t-test on the log2 
transformed ratios in the LIMMA package of Bioconductor R and the p values were 
corrected for multiple hypothesis testing with the Benjamini–Hochberg (BH) method  
(Benjamini 1995, Ritchie 2015). Using BH corrected p value threshold of 0.01, 149   
phosphosites corresponding to 98 protein groups were regulated at day 0 of 
differentiation and   188 phosphosites corresponding to 133 protein groups were 
regulated at day 10 of differentiation (figure 4.6B). 
 
bPTH(7-34) regulated sites of phosphorylation were determined using 2.5 x’s the mean 
absolute deviation (2.5xMAD) threshold applied to log2 transformed ratios for each site 
seen at least twice. This method yielded 120 phosphosites corresponding to 91 protein 
groups were regulated at day 0 of differentiation and 87 phosphosites corresponding to 
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48 protein groups were regulated at day 10 of differentiation. The Venn diagrams in Fig. 
6 illustrates number/overlap of phosphorylation sites observed between the four 
experimental conditions utilized for subsequent analyses, first compared by 
differentiation day(A) and then by drug (B). From Venn diagram A, we can conclude the 
phosphorylation signaling network engaged by hPTH(1-34) is more conserved between 
days 0 and 10 (site overlap 21%) than that of bPTH(7-34) with a site overlap between 
day 0 and day 10 of 6%. From Venn diagram B, we can conclude the signaling 
networks engaged by each drug at day 0 (overlap 11%) or at day 10 (Overlap 8%) show 
little conservation between the drugs; thus introducing the idea the networks are distinct 
and bPTH(7-34) does not simply activate a subset of the hPTH(1-34) phosphorylation-
mediated signaling network.  
 
4.4.6. Exploring the hPTH(1-34) and bPTH(7-34) regulated kinomes 
The activation state of upstream kinases should be reflected in the phosphorylation of 
downstream targets bearing their consensus substrate motifs. To confirm predicted 
regulation of kinase activity based on the observed changes in their phosphorylation 
state and identify likely downstream targets, regulated peptides (3x mean absolute 
deviation threshold of change), with high confidence site-assignments (localization 
probability > 0.75) were evaluated for kinase substrate motif enrichment using Motif-X 
(Baker 2011).   
MOTIFS  Increasing Decreasing 
Day 0  bPTH(7-34) 411 563 
hPTH(1-34) 405 439 
Day 10  bPTH(7-34) 455 1065 
hPTH(1-34) 483 633 
 
4.4.6.1 Motif-X Analysis 
The pre-aligned sequence windows obtained from the phospho-S/T/Y file generated by 
MaxQuant were decreased to a width of 15 amino acids and submitted to Motif-X to test 
for enrichment against a background of the mouse proteome. A minimum of 20 
occurrences and p value threshold of 0.000001 were required. An insufficient number of 
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regulated phosphoTyr and phosphoThr residues limited the analysis to peptides 
containing regulated phosphoSer. As shown in Fig. 6, At day 0, the hPTH(1-34) 
stimulated set Motif-X analysis revealed increased phosphorylation of basophilic 
kinases which would include PKA/CAMK2, and decreased phosphorylation by proline 
directed kinases such as ERK/MAPK/CDK. However, the day 0 bPTH(7-34) changing 
phospho-sequences revealed a more specific (PxpSP) proline directed motif as the 
dominant motif increasing in phosphorylation with treatment, and the slightly more 
general proline-directed motif of pSP as the dominant decreasing motif. This would 
imply that stimulation by hPTH(1-34) activates a different kinase network than bPTH(7-
34) after 5 minutes of treatment, and in in fact the dominant decreasing 7-34 motif being 
quite similar to the dominant increasing 7-34 motif indicates the possibility of differential 
kinase regulation at day 0. At day 10, both drugs Motif-X analysis look very similar and it 
appears the differential kinase regulation effect is not present after 10 days of 
differentiation.  
 
4.4.6.2 Immunoblots provide orthogonal validation for MS data 
Whole cell lysate from cells treated at day 0 of differentiation with either hPTH(1-34) or 
bPTH(7-34) were probed with antibodies for putative MAPK substrates (PxpSP), PKA 
substrates (RRxS), or CDK1-pY15. A decrease in the phosphorylation of putative MAPK 
substrates bearing the PxpSP motif in the hPTH(1-34) condition confirms the previous 
immunoblot on the activation sites of Erk1/2 and the analysis from Motif-X. The bPTH(7-
34) treated condition did not show a robust increase in phosphorylated MAPK motifs, 
but this may be because of the increased phosphorylation of the CDK1 inhibitory site 
(which has the same motif) or that possibly 7-34 activation of the receptor leads to  
activation of a small pool of subcellularly localized Erk1/2 which is not detected on the 
motif blot. Phosphorylation of CDK1 on tyrosine 15 inhibits kinase activation, 
phosphorylation on threonine14 of the kinase provides secondary regulation. 
Dephosphorylation of this site on CDK1 is essential for cells to enter mitosis from G2.  
The immunoblot of CDK1-phospho Tyr15 indicated both hPTH(1-34) and bPTH(7-34) 5 









 4.4.6.3 Conditional Motif Heatmap (Figure 4.8) 
To illustrate the motif-substrate relationship further, in figure 4.8 regulated sites of 
phosphorylation for each treatment condition were divided into sets of motifs as 
appropriate: Proline-directed, Basophilic, acidophilic, and other. While statistics were 
not applied, there is a general trend it is possible to see that the proline-directed motif 
substrates of the hPTH(1-34) treated conditions substrates as decreasing in 
phosphorylation and the bPTH(7-34) treatment conditions as increasing in 
phosphorylation. It is common for multiple kinases to phosphorylate a specific site, 
depending on the cellular conditions. Comparison of the list of regulated sites with 
known kinase-substrate relations from Phosphosite plus indicated several sites where 
there are known substrates of different kinases.  
 
4.4.6.4 Kinase activation heatmap- Networkin and Phoxtracks (Figure 4.10) 
Networkin is a kinase-substrate (K-S) relationship predicting algorithm. By composing a 
score weighted with known kinase substrate motifs and the STRING database of 
protein-protein interactions, Networkin is able to make predictive associations of K-S 
relationships. Phoxtracks compiles data from observed K-S relations in Uniprot, 
Phosphosite plus, ELM and Swissprot.  
 
NetworKIN and Phoxtracks analysis of phosphorylated substrate peptides changing with 
treatment predicts kinases involved with GPCR signaling and cytoskeletal regulation. 
Kinase activation analysis performed on regulated (3x mean absolute deviation) 
phosphopeptides in each condition were separated into increasing and decreasing sets 
and matched to kinases in NetworKIN. NetworKIN output was filtered by score minimum 
of 0.22, maximum score difference of 4, and maximum of 2 predictions per site. 
Networkin predictions and Phoxtrack analysis produce complementary data sets, with 
only 10% overlap observed out of a combined 450 K-S relationships from both 
programs. The redundant relationships were removed in favor of retaining the known 
Phoxtracks information. The number of unique regulated sites assigned to each kinase 
was divided by the total number of predictions for that condition and a fractional score 
was created, with 0.38 corresponding to 38% of a total set being assigned to a 
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particular kinase and negative scores being assigned to the sites which were 
decreasing in phosphorylation. The resultant analysis compliments the previous Motif-X 
results in that the top indicated kinase for the D0 bPTH(7-34) treated increasing 
phosphorylation sites was indicated to be MAPK1/Erk2, and for the D0 hPTH(1-34) 
increasing sites PKA was highly indicated. For the decreasing sites of phosphorylation, 
the dominant indicated kinase for D0 bPTH(7-34) and D0 hPTH(1-34) was Pak1. Erk1/2 
were also strongly predicted for the D0 hPTH(1-34) decreasing sites. Black squares are 
where no value was indicated. Kinases indicated in less than 5% of total assigned sites 
were eliminated. 
 
4.4.6.5 Phoxtracks Kinase activation prediction with the Kolmogorov–Smirnov 
test 
Figure 4.11 
The Kolmogorov–Smirnov test is a nonparametric test of the equality of continuous, 
one-dimensional probability distributions that can be used to compare a sample with a 
reference probability distribution. Phoxtracks employs this statistical analysis to 
determine kinase activation. The 3xMAD regulated data sets from each condition were 
analyzed in Phoxtracks. These results provide orthogonal validation of the bioinformatic 












4.4.7 Ingenuity Pathway Analysis of regulated phosphoproteins 
Informatic analysis of Day 0 and Day 10 hPTH(1-34) and bPTH(7-34)  regulated 
signaling pathways and biological processes. Ingenuity Pathways Analysis 
(www.ingenuity.com) was performed using the list regulated phosphorylation sites 
detected in hPTH(1-34) or (7-34) stimulated MC3T3-E1 osteoblasts. Significantly 
regulated pathways were defined as ≥3 genes per group, p < 0.05 enrichment 
compared to a standard murine background database. Pathways related to cell survival, 
gene transcription, canonical GPCR signaling, cytoskeletal, and bone specific pathways 
are indicated. The -log(p-value) is displayed as the height of the bar. Directionality of the 
effect on the pathway cannot be determined from the bar height which is related to 
probability the path is affected in some way. Survival and transcription pathways appear 
to be dominated by the effects of bPTH(7-34), while the hPTH(1-34) begins to 
predominate in the GPCR, cytoskeletal, and bone. However many of the hPTH(1-34) 











4.4.7.1 hPTH(1-34) and bPTH(7-34) confer etoposide resistance 
To assess the accuracy of the bioinformatic predictions (IPA) of drug regulation of cell 
survival and apoptosis from the phosphorylation data, an etoposide resistance assay 
was performed. Cells were pre-treated with hPTH(1-34) or bPTH(7-34) for 24 hours and 
then etoposide was added for a final concentration of 100uM and incubated for 24 
hours. Cells were then labeled with MTT for four hours then solubilized overnight in 
detergent. Pretreatment with both drugs conferred significant etoposide resistance as 
measured by incorporation of the NADH-dependent fluorescent label MTT which is 
directly proportional to the number of live cells. The control cells which were only treated 
with PBS or ligand as compared to 100uM etoposide treated demonstrate the degree of 
cell death achieved. Figure 4.15 
 
4.4.7.2 hPTH(1-34) and bPTH(7-34) increase cell proliferation  
To validate the IPA predictions that both drugs would affect cell proliferation. An MTT 
labeling assay was performed and the cell proliferation was measured after 1,3,4,5, and 
5 days of incubation with ligand. The cells were re-drugged on day 3 to accommodate 
potential loss of ligand to cell metabolism. At days 3,4, and 5 the bPTH(7-34) treated 
cells demonstrated a significant increase in cell number. hPTH(1-34) treated cells also 
demonstrated a modest increase in cell number at day 1, 3, and 4, but this effect was 













Here, we have investigated the murine osteoblast phosphoproteome at 2 different days 
of osteoblastic cell development, as stimulated with 2 different ligands. We had two 
main aims, the first being to characterize the signaling profiles of a conventional 
(hPTH(1-34)) or biased (bPTH(7-34)) agonist of the PTH type-1 receptor that was 
endogenously expressed in osteoblasts. The second aim was to assess the effect of 
cell background on the signaling profile generated from stimulating the MC3T3-E1 cells. 
The focus of this study was the regulation of the phosphoproteome following acute 
stimulation with a conventional agonist of the parathyroid hormone type 1 receptor 
(PTH1R) and a β-Arrestin dependent, biased agonist which activates the same receptor 
on the surface of osteoblasts. The first global phosphoproteomics study published in 
osteoblastic MC3T3-E1 cells, the expression levels and phosphorylation status of 
thousands of proteins have been accurately quantified in an endogenously expressing 
GPCR system. Following observed morphological changes in differentiating MC3T3-E1 
cells, we confirmed that the signaling background in the proliferating stage and 
differentiating stage of the cell are quite different and this has an impact on signaling 
networks engaged by drug stimulation. Notably including decreasing expression levels 
of β-arrestin over time. Given the biased ligand, bPTH(7-34) signaling efficacy is 
dependent on the presence of β-arrestin we expect to observe more unique bPTH(7-34) 






Our phosphoproteomics analysis revealed that while β-Arrestin biased agonist (D-Trp12, 
Tyr34)-bPTH(7-34) and conventional agonist hPTH(1-34) bind and activate the PTH1R, 
they elicit different downstream signaling effects which are highly dependent on cell 
background. In the proliferating cells, we see differential activation of nodal kinase 
Erk1/2, a hPTH(1-34) and bPTH(7-34) induced increase in phosphorylation at the 
inhibitory site of Cdk1, and a myriad of potential kinase substrates with motifs specific to 
the drug condition. Previous studies conducted in HEK293 cells over-expressing the 
PTH receptor have also observed differential effects of the two ligands on Erk1/2. 
(Appleton 2013). However the current study is unique in that we observed a significant 
increase in apparent Erk1/2 activity as a result of biased ligand stimulation in an cell 
system endogenously expressing the PTH receptor. While this effect has not been 
recapitulated in primary osteoblasts, which are a mixture of mouse calvarial cells, this 
study demonstrates that two ligands can bind the same endogenously expressed 
receptor and elicit different signaling outcomes (Gesty-Palmer 2006). . 
The increase of phosphorylation on the inhibitory site of CDK1 at day 0 by bPTH(7-34) 
and hPTH(1-34) stimulation was not anticipated or observed at day 10 experiments. In 
immunoblots of day 10 whole cell lysate, CDK1-Y15 was observed with a high level of 
phosphorylation in all conditions, with basal and drug treated not significantly different. 
In vertebrates, this site inhibits kinase activity and an additional phosphorylation at T14 
augments the effect. Removal of the phosphorylation is necessary for Cdk1 (a 
conserved regulator of the eukaryotic cell cycle) activity, a critical event in the 




Paradoxically, this indicator of cell cycle arrest exists while the cell assays demonstrate 
treatment with bPTH(7-34) significantly increases the number of cells present after 4 
and 5 days of sub-confluent culture. The anabolic effects of bPTH(7-34) can not be 
solely attributed to anti-apoptotic effects in this study because the absolute value of the 
MTT absorbance assay increased over time, not just the percentage of cells alive from 
the original seeding. This effect on proliferation was not observed in primary osteoblasts 
and in fact treatment with bPTH(7-34) appears to slow proliferation and progression of 
those cells through the cell cycle (Gesty-Palmer 2013).  
hPTH(1-34) and bPTH(7-34) provide a protective effect on cells exposed to large doses 
of etoposide. The pro-survival effect of hPTH(1-34) is thought to be the dominating 
factor which increases osteoblast number in response to intermittent treatment 
(Krishnan 2003, Sharma 2013). A large body of work has previously described this 
effect and thought to originate from PKA dependent activation of the transcription factor 
cAMP response element binding protein (Creb). Activation of Creb leads to the 
transcription of anti-apoptotic genes BCL-2 and P21, and the inactivation of pro-
apoptotic genes such as Bad and the apoptosis inducer Cell Cycle Apoptosis Regulator 
Protein (CARP-1)(Chen 2002, Schnoke 2009). The anti-apoptotic mechanism of 
bPTH(7-34) in this study is yet unclear but the activation of mitogenic, pro-survival, 
kinase Erk1/2 is likely involved.  
 
As MAP kinases and CDKs tend to have the same PxSP phosphorylation motif 
(phosphositePlus.com), it is possible the opposing effects of activating Erk1/2 and 
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inhibiting Cdk1 precipitated the lack of gross changes with treatment observed in the 
MAPK/CDK phosphorylated substrate immunoblot (PxSP) (Fig.7). 
 
bPTH(7-34) is a known inverse agonist for PTH1R with respect to cAMP,  which has 
been demonstrated in these cells and the phosphoproteomics results support this 
conclusion. We see the dominant motif in the decreasing set of phosphosites from the 
bPTH(7-34) is a putative PKA substrate motif (RR/KxS) (and the immunoblot of the 
whole cell lysate confirmed this effect) and the Kolmogorov-Smirnov kinase activation 
analysis determined that PKA was likely inhibited based on the independent list of all 
changing phosphosites. While the anabolic effects of hPTH(1-34) have been attributed 
exclusively to the actions of Gαs (Sinha 2016), the actions of  bPTH(7-34) do not 
support this theory. When given intermittently in vivo, both ligands demonstrate an 
anabolic effect on bone, with the effects of bPTH(7-34) being dependent on the 
presence of β-Arrestin2. Subsequent gene microarray analysis indicated that while both 
drugs build bone in mice, they appear to do so by different mechanisms. 9- week old 
male Sprague-Dawley mice were subjected 8-week intermittent treatment with hPTH(1-
34) or bPTH(7-34) or vehicle hPTH(1-34). The resultant Affymetrix data was analyzed 
by Ingenuity Pathway analysis. The output of that analysis demonstrated the hPTH(1-
34) lead to changes in expression of genes related to Wnt, BMP, skeletal patterning, 
and matrix biosynthesis. Whereas, bPTH(7-34) resulted alteration in pathways and 




Figure 4.17 presents a summary of the proposed mechanism, through engagement of 
the PTH1R with a conventional and biased ligand, different signaling profiles were 
observed.  Where previous studies have indicated biased agonists may simple activate 
a subset of what the conventional agonist can do, the current study supports the 
hypothesis that biased ligands can activate signaling profiles unique from that of the 
conventional agonist. hPTH(1-34) engagement of the PTH1R activates Gαs and Gαq 
signaling networks, leading to activation of PKA (phospho-substrate motif RRxpS) and 
PKC(phospho-substrate motif RRxpS) and inhibition of ERK1/2. Further bioinformatic 
analysis of the phosphorylated substrates bearing the RRXpS motif indicated PKA 
playing a much larger role than PKC in downstream signaling events (figure 4.10 and 
4.11). Both ligands resulted in increased phosphorylation on an inhibitory site of CDK1 
and this was confirmed by immunoblotting. Dephosphorylation of this site is necessary 
for entry into the G2 phase of the cell cycle.  The relationship between the indicated 
CDK1-mediated arrest of cell cycle and the in vitro assay observations that both drugs 
lead to increased proliferation and etoposide resistance is not yet clear. 
 
In the past twenty years, it has become apparent that ligand structure is an important 
determinant of not only which receptor is activated, but how the receptor is activated. 
This MS-based phosphoproteomics method has allowed us to characterize acute 
signaling network changes resulting from stimulation of the PTH type-1 receptor in 
osteoblastic cells with two different drugs. Bioinformatic analysis of these large datasets 
has determined the activation profiles of each drug look quite different at the level of 
signaling pathways affected. While exhibiting a notable degree of overlap, bPTH(7-34) 
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has a more significant effect on pathways related to survival and transcription and 
hPTH(1-34) dominates G-protein driven and bone pathways. The analysis begins to 
converge however when we examine the data at the level of biological process, and 
both ligands promote survival and motility (Figure 4.13). These observations highlight 
the need for studies of the actions of biased agonists. While endogenous GPCR ligand 
co-evolved alongside their cognate receptors, biased ligands activate the receptor in an 
“unnatural” way, making their in vivo actions difficult to predict. 
 
This data can be utilized in a variety of ways in different fields. As the first GPCR biased 
agonist/ conventional agonist global comparison study using endogenous receptor 
expression levels, this analysis method may be applied to other bias-amenable 
systems. This may allow for the discernment of a conserved arrestin signaling profile to 
aid in development of biased therapeutics and enhanced prediction of in vivo effects.  
We have also demonstrated discovery of over 4,000 previously unobserved sites of 
phosphorylation, and identified new mediators of PTH signaling in bone. These study 
results will be available in data repositories for researchers in the bone field to mine and 
develop further hypotheses. 
Finally, we propose these results serve as a proof-of-principle that it is possible to 
uncouple bone remodeling, inciting activation of the osteoblasts without subsequent 
activation of the osteoblasts, which is the limiting factor of hPTH(1-34). The effects of 
long-term osteoclast suppression as indicated by treatment with bisphosphonates can 
lead to more fragile bones, and the development of therapeutics which effect primarily 
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the osteoblasts without direct osteoclast suppression would be of great benefit to the 
millions of Americans suffering from osteoporosis. 
 
 
4.5.2 Placing results in the broader context of bone biology, comparing ligands 
While phosphorylation-mediated signaling profiles can be determined in vitro, and 
unique features identified; translating ligand bias into potential therapeutics requires 
demonstration of efficacy in vivo. This is among the most difficult in drug development 
and is especially challenging for arrestin pathway-selective ligands with unknown 
physiological relevance.  
 
4.5.2.1 Main Findings 
The results of this study demonstrate three main findings. The first is that two different 
ligands can activate the same G-protein coupled receptor (GPCR) at similar points of 
development and induce differential signaling effects. While the PTH1R is known to bind 
PTH and parathyroid-related peptide (PTHrP), the role of physiological levels of PTHrP 
in the adult skeleton is as yet unclear (Vilardaga, 2008). We observed that 5 minute 
treatment of sub-confluent (differentiation day 0) MC3T3-E1 preosteoblasts with 
hPTH(1-34) lead to a decrease in basal phosphorylation of extracellular signal-regulated 
kinase 1/2 (Erk1/2) and resultant decrease in phosphorylation of putative Erk 
substrates, activation of protein kinase A (PKA) and an increase in phosphorylation of 
putative PKA substrates. However, 5 minute treatment on MC-3T3 cells differentiation 
day 0 with (D-Trp12, Tyr34)-bPTH(7-34) resulted in an increase in Erk phosphorylation 
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and activity as evidence by the increased phosphorylation of known and putative Erk 
substrate proteins and decreased PKA activity as evidence by the reduced 
phosphorylation of known and putative PKA substrates. The known substrates were 
subjected to a kinase activation analysis based on the Kolmogorov-Smirnov test of non-
parametric distributions and the results confirm the proteomic and immunoblot data 
(Figure 4.11). It should be noted with respect to consensus motifs that several kinases 
can have the same basic motifs and other factors come into play for determining the 
upstream kinase (phosphositeplus.com). This is especially important to keep in mind 
when considering the top two motifs for day 0 bPTH(7-34) which were similar in the 
increasing and decreasing phosphorylation peptide sets. For the proline directed motifs, 
a possible reason for this may be the opposing activity of Erk1/2 and Cdk1 with bPTH(7-
34) treatment, the Erk consensus motif is PxSP and the less specific SP motif is 
associated with Cdk1 (phosphositeplus.com).  The activating phosphorylation of Erk1/2 
(T183/Y185) and inhibitory phosphorylation of Cdk1 (Y15) were confirmed by 
immunoblot. When analyzing the motifs in this condition with the arginine at the -2 and -
3 positions, again this is another common kinase motif and could be attributed to 
different proteins enzymatic activity. Thus, when extracting information from motif 
analysis it is useful to consider to motifs as indicative of certain groups of kinase than an 
individual. However, we can say just from figure 4.8 that it is likely that the RRxS for the 
decreasing phosphorylation set can be attributed to PKA activity inhibition, and this 
proposal can be strengthened by the results of the Kolmogorov-Smirnov kinase 
activation analysis in figure 4.11B. This analysis by Phoxtracks is based on known 
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kinase-substrate interactions pulled from several curated databases and gives a more 
specific result.  
Additionally, while a relatively high degree of observed phosphorylation site overlap was 
determined between the two drug treatments on differentiation day 0 (67%) the overlap 
of phosphorylation regulated in each treatment condition was only 14%, indicating it is 
unlikely that the signaling differences we observed can be attributed to lack of coverage.  
The second main finding is that cell background affects bias agonist efficacy. We 
determined that the bias agonist could exert unique signaling effects explained in the 
previous sections (first finding) only at day 0 of differentiation as opposed to 10 days of 
differentiation. From the phosphoproteomics experiments, we were able to observe  
from the Motif-X analysis that the dominant kinase substrate motifs for bPTH(7-34) at 
day 0 were distinct from that of hPTH(1-34) at day 0; and this effect was lost at day 10 
when the two concensus motifs were similar (figure 4.8). These findings were also 
demonstrated by immunoblot in figure 4.2.  
Further characterization of the cell background was completed when days 0 and 10 of 
MC3T3-E1 differentiation were analyzed by label-free LC-MS/MS for changes in protein 
expression. Of the 3,757 proteins observed in both conditions, 436 had increased 
expression at day 0 relative to day 10 and 246 had increased expression at day 10 
relative to day 0 as determined by Welch t-test with a 0.05 p-value (figure 4.3). The 
changing proteins included 138 protein kinases and 84 DNA-binding transcription 
factors (Figures 4.4A and B). Selected proteins related to specific pathways of interest 
were extracted and log2 expression level average is displayed in figure 4.3B, changes 
in expression of proteins like Grk2 (gene name ADRBK1) and Gαs (GNAS) would 
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almost certainly affect the signaling repertoire of both ligands. Lastly, and possibly most 
important was the finding that the expression of β-arrestin decreases with differentiation, 
this was shown by immunoblot for 4.3C and is present in the table of significantly 
changing proteins (Table 3). Given that previous research has demonstrated the 
anabolic effects of bPTH(7-34) are dependent on the presence of β-arrestin in mice, it is 
very likely this lack of β-arrestin at day contributes to the ligand’s inability to illicit a 
unique signal.  
The third main result of this study were the confirmatory results of the cell based 
assays, specifically in the context of previous studies (Gesty-Palmer, 2013). Our 
informatic analysis determined that hPTH(1-34) and bPTH(7-34) affected signaling 
pathways and processes related to cell cycle,  survival, and migration. When challenged 
with etoposide as displayed in figure 4.15, continuous treatment with either hPTH(1-34) 
or bPTH(7-34) confered apoptosis resistance, with significantly improved survival rates 
compared to vehicle treated. The effects of both ligands on cell proliferation were also 
assessed over days 3, 4, and 5 of continuous treatment in figure 4.16. bPTH(7-34) 
significantly increased the number of cells after 3, 4, and 5 days of continuous exposure 
with the results of hPTH(1-34) treatment being inconclusive.  
Taken together, the results of this phosphoproteomic study indicate a possible 
mechanism for the anabolic effects of bPTH(7-34) in bone. bPTH(7-34) increases the 
available pool of active osteoblasts in two ways: by conferring resistance to apoptosis 
and by increasing proliferation of the bone-depositing cells.  
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Our results confirm what is published about the anabolic mechanism with hPTH(1-34), 
that the ligand increases the number of osteoblasts by  conferring apoptosis resistance 
and increasing differentiation of osteoblast precursors (Gesty-Palmer 2009, 2013). 
 
Ligands in vivo 
The anabolic effects of PTH have been largely attributed to the actions of Gαs signaling. 
This includes the PKA-dependent transcript expression of osteocalcin (Bglap), MMP13, 
and Tnfsf11 (Boguslawski 2000, Selvamurugan 1998, Lee 1999). It has also been 
demonstrated that a constituatively active mutant of the PTH1R which predominantly 
activates G-s mediated signaling significantly increases trabecular bone mass (Shipani 
1995). Additionally, in the osteoblast lineage, the α subunit of the Gs heterotrimer is 
required for normal skeletal development during embryogenesis (Wu 2008 and 2016, 
Chen 2011). However, it has recently been demonstrated that in the post-natal skeleton 
of mice with a conditional knockout of Gs there is still an anabolic response to hPTH(1-
34) administration. The mice are severely osteoporatic and although there was no 
increase in trabecular bone volume or cortical thickness, osteoblast numbers and bone 
formation rate still increased along the trabecular surface. (Sinha 2016) This data 
indicates the involvement of other downstream mediators in the anabolic effect of PTH.  
 We propose the ability of the Gs knockout mice to form bone in response to PTH 
administration may be due to the effects of β-arrestin mediated signaling. In a previous 
in vivo study, while no gross skeletal differences were observed the β-arrestin knockout 
KO mice demonstrated increased markers of bone turnover and osteoclast coupling 
(Gesty-Palmer 2009). Compared to WT mice, β-arrestin2−/− mice exhibit significantly 
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higher basal rates of bone turnover. Additionally the β-arrestin2−/− exhibited decreased 
numbers of trabeculea but increased thickness, thus indicating the likely involvement of 
β-arrestin2 in bone metabolism.  
In vivo, biased agonists likely exhibit mixed agonism/ antagonism effects. In the 
extracellular mileui both endogenous and exogenous binders of the PTH1R will be in 
competition. However, we can not entirely attribute the anabolic effect of bPTH(7-34) to 
PTH antagonism. While hypoparathyroidism (insufficient PTH production) is associated 
with abnormal calcium and skeletal homeostasis, increased trabecular bone formation 
has not been observed (Cusano 2016). In the 2013 hPTH(1-34) and bPTH(7-34) 
genomic study by Gesty-Palmer, informatic analysis of the regulated genes indicated 
the bPTH(7-34) treatment affected processes such as  cell cycle, survival, and 
migration. These processes could work in concert to produce the observed anabolic 
effect of bPTH(7-34) in mice. This indicates bPTH(7-34) treatment enhances the bone 
formation process by increasing the migration of osteoblasts to the remodeling site and 
increasing survival of the osteoblastic pool cells that may be destined for apoptosis.  
Given that osteoblasts have 3 fates: terminal differentiation into osteocytes, 
differentiation into bone lining cells or apoptosis, this effect on cell survival is likely very 
significant. It has been observed that bPTH(7-34) treatment in vivo increased mineral 
apposition rate on trabeculae of treated animals, indicating an increase in osteoblast 
activity on the bone surface (Gesty-Palmer 2009).  
The results of the previous in vivo studies of bPTH(7-34) versus hPTH(1-34) treatment 
in mice are in agreement with the results of the experiments contained in this 
dissertation. Our phosphoproteomic results indicate bPTH(7-34) binding the the 
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endogenously expressed PTH1R leads to engagement of unique phosphorylation-
mediated signaling networks resulting in resistance to apoptosis and an increase in 
proliferation, and immunoblots confimed the increased phosphorylation of essential cell 
cycle mediator CDK1 on the inhibitory site. We observed thousands of sites of 
phosphorylation on hundreds of proteins in MC3T3-E1 cells after 5 minutes of treatment 
with hPTH(1-34) or bPTH(7-34), many of which were novel sites on previously unknown 
mediators of PTH signaling. While this result is limited by the in vitro experimental 
system and the available analytical technology to date, it provides compelling evidence 
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Chapter 5: Conclusions and future directions 
 
5.1 Summary 
The overarching goal of this dissertation project was to use global phosphoproteomics 
to discover and characterize biased ligand signaling at the PTH receptor. “Biased” 
ligands preferentially engage signaling with one downstream effector over another and 
are usually referred to by their cognate GPCRs. The potential of biased therapeutics is 
the development of drugs that activate beneficial signaling pathways while antagonizing 
deleterious ones. Development in receptor theory and our understanding of GPCR’s 
over the last 20 years indicates receptors are not the simple “on/off” switches they were 
first imagined to be (Galadrin 2006, Kenakin 2009). Rather they are dynamic proteins, 
cycling through an ensemble of conformations called a “dynamic equilibrium”. Ligand 
binding is thought to stabilize one or more of these conformations that will influence 
downstream signaling. Furthermore, it is thought that biased ligands stabilize a 
conformation of the receptor which is typically in very low occurrence naturally and this 
can create unexpected signaling events (Kenakin and Luttrell 2011). 
This is highly relevant to many current GPCR-targeted therapeutic strategies, especially 
the β-adrenergic, µ-opioid, and type-1 parathyroid hormone receptors (PTH1R). This 
project focuses on the PTH1R and specifically on comparing current osteoporosis 
therapeutic hPTH(1-34) to biased agonist (D-Trp12, Tyr34)-bPTH(7-34). hPTH(1-34), also 
called teriparatide with the brand name Forteo (Lilly), is the only osteoporosis 
therapeutic proven to act anabolically through actions on the osteoblast, but it only has 
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a 2-year therapeutic treatment window due to increasing activity of the osteoclasts over 
time (Riek 2011) (https://www.fda.gov/downloads/drugs/drugsafety/ucm088604.pdf). 
 
5.2 Hypothesis  
Our hypothesis is that there is a unique, phosphorylation mediated, osteogenic signal 
transduction network engaged by stimulation of the PTH1R with β-Arrestin biased 
agonist (D-Trp12, Tyr34)-bPTH(7-34) (hereafter called bPTH(7-34)). The evidence 
supporting this hypothesis is robust- gene microarray studies (Gesty-Palmer 2013), 
mouse bone studies with histomorphometry (Gesty-Palmer 2009), and observed bias of 
the ligand (bPTH(7-34)) in other cell  systems (Appleton 2013, Gesty-Palmer 2006).  
We felt like we had a good grasp of what happened at the gene level and the bone of 
animals treated with the drug, but the proximal signaling mediators were as yet 
uncharacterized. When in skilled hands, quantitative phosphoproteomics can yield 
information the expression levels and modification status of thousands of proteins 
(Geiger 2012).  
 
5.3 Aim 1 
At the start of this project in 2012, Dr. Ball had acquired an Orbitrap Elite mass 
spectrometer through a NIH shared instrumentation grant.  This was the first Orbitrap 
mass spectrometer in South Carolina and it provided the resolving power and sensitivity 
to perform SILAC-based quantitative experiments to measure changes in the extent of 
post-translational modifications (Li 2007, Wisniewski 2007). So, to begin this ambitious 
project our first aim was optimize cell culture conditions and establish a pipeline to 
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perform global phosphoproteomic analysis using hPTH(1-34). hPTH(1-34) is the first 34 
amino acids of the naturally occurring parathyroid hormone and is an FDA approved 
anabolic agent for treatment of osteoporosis. It is known to bind and activate the 
PTH1R, engendering receptor coupling to several downstream signaling mediators: 
Gαs, Gαq, and the cytosolic adaptor protein β-arrestin2 (Juppner 1991, Abou-Samra 
1992, Bringhurst 1993, Pines 1994, Takasu 1999, Gesty-Palmer 2006). Many of the 
signaling effects of hPTH(1-34) receptor engagement are known but there was (and is) 
still a great deal to be learned about parathyroid hormone signaling. Additionally, we 
needed a control ligand to which to compare the biased ligand (bPTH(7-34)) for method 
validation and to discern the possible distinct signaling profiles elicited by the two 
different ligand classes.  This made hPTH(1-34) an ideal candidate to use for the 
flagship phosphoproteomics study. Upon completion and analysis of the results this 
study, we determined the 5 minute stimulation of the PTH1R with hPTH(1-34) in MC3T3-
E1 10-day differentiated osteoblasts lead to regulation of 376 sites of phosphorylation 
on 223 unique proteins. Data quality were analyzed for reproducibility and 
normalization, and lab members attended a week-long workshop to learn how to use 
computation proteomics software amenable to phosphoproteomic analysis. 
Bioinformatic analysis of these regulated sites determined activation of PKA, PKC, and 
cytoskeletal regulating kinase Pak, along with suppression of basal Erk1/2 activity which 
was known in the literature. This allowed for confirmation that the method was valid, 
which was highly relevant to the analysis of the hundreds of kinase substrates we had 
identified as regulated including 146 kinases and 123 DNA sequence specific 
transcription factors.  
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Using Ingenuity Pathway Analysis (IPA), it was determined that these regulated 
signaling networks controlled cellular processes such as differentiation, growth, 
proliferation, and cell migration, along with a confirmation that these were GPCR-
mediated events. The results of this study were published in the January 2016 issue of 
Methods, with the title “Exploring G protein-coupled receptor signaling networks using 
SILAC-based phosphoproteomics.” Also, the methodology established during this 
project is now offered to investigators by the MUSC Mass Spectrometry Facility. 
 
5.4 Aim 2 
Our next aim (2) was to compare phosphorylation-mediated signaling networks 
engaged by stimulation of the PTH1R with hPTH(1-34) or bPTH(7-34). This was a much 
larger aim and included analysis of hPTH(1-34) and bPTH(7-34) in proliferating MC3T3-
E1 pre-osteoblasts (Day 0) and 10-day differentiating osteoblasts (Day 10). The 
combined analysis resulted in 276 high-resolution mass spectrometry raw data files and 
over 10 million individual mass spectra. From these spectra we identified over 10,000 
unique sites of phosphorylation, ~5,000 of which had not yet been observed. Resultant 
analysis indicated that both drugs activated unique signaling cascades after five-minute 
treatment.  
 
The comparison of phosphoproteomic profiles at day 0 and day 10 indicated the biased 
ligand initiated a distinct signaling profile at day 0 only. At this earlier timepoint, 
differential Erk1/2 activation was confirmed (increasing with bPTH(7-34) treatment, 
decreasing with hPTH(1-34) treatment) and elaborated upon. Cyclin-dependent kinase 
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1 (CDK1) also demonstrated changes in phosphorylation with treatment by hPTH(1-34) 
and  bPTH(7-34), increasing phosphorylation on the inhibitory site tyrosine 15. 
Dephosphorylation of this site is necessary for cell entry to G2, it is possible this site 
may somehow be involved in apoptosis resistance. Based on IPA analysis, the ligands 
engage different signaling networks with hPTH(1-34) activating pathways involved with 
canonical GPCR signaling and bone pathways such as Wnt signaling and bPTH(7-34) 
activating pathways more related to cell survival and transcription. However, at the level 
of biological processes the two signaling networks converge both promoting cell 
survival, migration, and proliferation. Effects of both ligands on survival and proliferation 
were confirmed using a MTT cell labeling assay.  
 
In summary, the information we have obtained supports the hypothesis that bPTH(7-34) 
engagement of the PTH1R activates a unique, osteogenic, phosphorylation mediated 
signaling network. We have concluded that cell background (as expected) has a 
significant effect on ligand efficacy. The differential signaling effects we observed in 
proliferating MC3T3-E1 cells were not present after 10 days of differentiation in our 
hands. Additionally, we can conclude that it is the ligand:receptor complex which 
defines the quality of the signal produced; we have studies two different ligands which 
bind the orthosteric pocket of the PTH1R and elicit different effects. Lastly, this study 
has demonstrated the utility of predictive bioinformatic algorithms  for biological 
processes, as the predicted actions of increased proliferation and apoptosis resistance 




Research in primary osteoblasts with these two drugs has resulted in similar findings 
with a few notable differences. The work of Diane Gesty-Palmer concluded that 
bPTH(7-34)  promotes bone formation independent of G protein activation, there are 
distinct β-arrestin and G protein-dependent pathways for parathyroid hormone receptor-
stimulated ERK1/2 activation,  and both drugs build bone in mice. However, the Erk 
activation by bPTH(7-34) which was observed by Gesty-Palmer was after 30 minute 
stimulation not 5 minutes, and in primary cells bPTH(7-34) administration slows 
osteoblast proliferation. More research in required to determine the exact mechanism by 
which bPTH(7-34) acts anabolically in vivo.  
 
5.5 Data Utility 
This information comprises a large dataset and can be mined by researchers in different 
fields. For the field of biased agonism, it presents possible leads on developing drug 
screening for biased ligands and also illustrates how activation of different signaling 
networks can converge on similar biological effects. Also, this is the first study of its kind 
(comparing a conventional and biased ligand of a GPCR) using endogenous levels of 
receptor expression to compare 2 ligands and the method itself will likely have utility to 
studies of biased agonism and GPCR research. Not only the cell culture and sample 
preparation condition but the bioinformatic data treatment. When analyzing “Big Data” 
the quality control and extraction of biological meaning from the sea of background is 
often the bottleneck to conclusions. Our analysis demonstrates an accurate and 
reproducible method for performing this type of study. For the field of bone metabolism, 
the implications of this study are significant because the prevailing thought is that bone 
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remodeling cannot be uncoupled i.e. the actions of the bone building osteoblasts will 
always followed by actions of the bone-resorbing osteoclasts, and our study does not 
support that hypothesis. Because bPTH(7-34) in an inverse agonist for Gs, the Gs-
dependent production of RANKL by the osteoblast does not occur when stimulated with 
the biased agonist, thus osteoclasts are not recruited to the site (Gesty-Palmer 2009).  
Lastly, to the field of osteoporosis research, the first line treatment for osteoporosis is 
bisphosphonates which act by inhibiting the activity of osteoclasts. While these drugs 
are highly effective at reducing bone loss, they do not grow new bone and the long-term 
effects of osteoclast suppression can be devastating. Some of the risks of 
bisphosphonate treatment are atypical femur fractures and osteonecrosis of the jaw. 
hPTH(1-34) is the only drug which acts anabolically on the osteoblasts. It is only given 
to patients refractory to other treatments and has a short treatment window (24 months), 
after which the action of the osteoclast supersedes the benefits of increased osteoblast 
activity. The results of this study present the possibility of developing drugs which do not 
suppress or stimulate osteoclast activity, but act primary through stimulation of the 
osteoblasts. 
 
5.6 Future directions 
One of the main limitations of SILAC technology is the need for metabolic incorporation 
of the isotopically labeled amino acids in the cells. While SILAC-labeled mice are 
available, the costs preclude the use of SILAC for analysis of a limited source of primary 
cell cultures and tissue-based studies. Mass spectrometry-based label-free quantitation 
has advanced rapidly in recent years, and while data processing should be done with 
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extreme caution by an experienced, peptide-based MS user, label-free quantitation 
(LFQ) with spiked in internal standards has the potential to overcome some of the 
limitations of SILAC labeling. An LFQ study in primary osteoblasts with these two drugs 
might provide insight into some of the differences we see between primary cells and 
MC3T3-E1s. Also, the preverbal elephant in the room is other post-translational 
modifications. Phosphorylation and O-GlcNAc modification occur on the same type of 
residues (serine, threonine, and tyrosine) and O-GlcNAc modification is also observed 
on many proteins we observed as phosphorylated in bone, such as RUNX2 (Nagel 
2014). Also because of the nature of this study, regulated tyrosine phosphorylation was 
not included in the analysis, which when completed would provide an additional level of 
information. 
Additionally, there is significant cross-talk between PTH and IGF-1 signaling, we 
observed in previous immunoblots (not shown) that pre-treatment of MC3T3-E1 cells 
with hPTH(1-34) inhibited IGF-1 and insulin stimulated phosphorylation of cytosolic 
adaptor protein IRS-1 and the bioinformatic analysis of this data  indicated cross-talk 
between PTH and IGF-1 signaling. The growing field aimed at understanding glucose 
homeostasis and the impact of diabetes and obesity on the integrity of bone will also 
likely benefit from the publication of this study. Further interrogation of this dataset will 
likely reveal many unique aspects of PTH signaling in osteoblastic cells. 
In conclusion, the attainment of large proteomic datasets “Big Data” is now a reality and 
while generation and processing of that data is far from trivial, a robust and thorough 
analysis can provide a wealth of information. GPCR signaling is far more textured and 
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nuanced than previously thought, and expanding our concept of efficacy for rational 
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66 S 2.11 0.55 0.97 NaN 1.21 0.09 1.00 yes 3 + 
Aak1 621 S -0.29 -0.29 -0.90 -0.68 -0.54 0.05 0.94 yes 2 + 
Aebp2 383 S 2.00 1.95 NaN NaN 1.98 0.01 1.00 yes 3 + 
Agfg1 177 T -3.15 -2.88 NaN NaN -3.01 0.00 1.00 yes 3 + 
Agfg1 177 T -3.31 -3.19 -2.95 -1.89 -2.84 0.00 1.00 yes 3 + 
Agfg1 181 S -3.31 -3.14 -2.95 -1.89 -2.82 0.00 1.00 yes 4 + 
Ahnak 5510 S -2.99 -2.51 NaN NaN -2.75 0.01 0.89 yes 2 + 
Ahnak 5099 S -2.68 -2.76 NaN NaN -2.72 0.00 0.99 yes 3 + 
Ahnak 5512 S -3.21 -2.67 -1.50 -2.89 -2.57 0.01 1.00 yes 3 + 
Ahnak 5504 S -3.05 -2.66 -1.50 -2.89 -2.53 0.01 1.00 yes 3 + 
Ahnak 5512 S -2.47 -2.08 -2.65 NaN -2.40 0.00 1.00 yes 3 + 
Ahnak 5510 S -2.41 -2.09 -1.98 NaN -2.16 0.00 0.89 yes 2 + 
Ahnak 4890 S -0.58 -0.78 -0.35 NaN -0.57 0.05 1.00 yes 2 + 
Ahnak 5504 S 0.61 0.60 0.63 0.17 0.50 0.04 1.00 yes 3 + 
Ahnak 5553 S 0.86 0.67 NaN NaN 0.77 0.05 0.99 yes 3 + 
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Ahnak 5557 S 0.86 0.76 NaN NaN 0.81 0.04 0.94 yes 3 + 
Ahnak 2438 S NaN 1.35 1.49 NaN 1.42 0.02 1.00 yes 2 + 
Ahnak 2566 S 2.49 3.76 2.95 NaN 3.07 0.01 1.00 yes 2 + 
Ahnak 2371 S NaN 2.26 4.44 NaN 3.35 0.05 1.00 yes 3 + 
Ahnak 5017 S 4.23 5.52 4.55 NaN 4.77 0.00 1.00 yes 3 + 
Ahnak 2887 S NaN 4.42 5.68 NaN 5.05 0.01 1.00 yes 3 + 
Ahnak2 286 S NaN -0.63 -0.55 NaN -0.59 0.08 1.00 yes 2 
 
Ahnak2 503 S 0.96 0.82 0.33 NaN 0.70 0.06 1.00 yes 3 
 
Ahnak2 1458 S -0.56 -0.48 -0.21 NaN -0.42 0.10 1.00 yes 3 + 
Akap12 598 S NaN -0.60 NaN -0.85 -0.73 0.06 1.00 yes 2 + 
Akap13 1892 S -1.23 -1.35 -1.30 NaN -1.29 0.00 1.00 yes 3 + 
Akap13 1895 S -1.23 -1.35 -1.30 NaN -1.29 0.00 1.00 yes 3 + 
Ap3d1 760 S -2.34 -2.24 -1.46 -1.36 -1.85 0.01 1.00 yes 3 + 
Ap3d1 760 S 1.32 2.37 2.18 4.12 2.50 0.02 1.00 yes 3 + 
Ap3d1 754 S 2.61 3.67 4.11 4.12 3.63 0.00 0.99 yes 2 + 
Apbb2 334 S NaN 1.61 0.75 NaN 1.18 0.08 1.00 yes 2 + 
Araf 255 S -2.69 -3.75 NaN NaN -3.22 0.02 0.99 yes 2 + 
Arfgap3 331 S NaN -0.83 -1.02 NaN -0.92 0.03 1.00 yes 3 + 
Arfgef2 621 S 0.91 NaN 0.82 NaN 0.87 0.03 0.93 yes 3 + 
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Arhgap17 698 S 3.29 3.91 3.33 3.38 3.48 0.00 0.99 yes 4 + 
Arhgap21 875 S 1.39 1.28 NaN NaN 1.34 0.02 0.97 yes 3 + 
Arhgap21 1656 S NaN 1.63 NaN 1.52 1.58 0.01 1.00 yes 3 + 
Arhgef11 1324 S NaN 3.33 2.68 NaN 3.01 0.01 1.00 yes 2 + 
Arhgef17 953 S -0.66 -0.49 NaN NaN -0.57 0.09 0.95 yes 3 + 
Arhgef17 142 S NaN 1.78 1.72 NaN 1.75 0.01 1.00 yes 2 + 
Arhgef2 122 S -0.69 -0.95 NaN -1.02 -0.89 0.02 0.92 yes 3 + 
Arhgef6 679 S 2.74 3.30 2.30 2.71 2.76 0.00 1.00 yes 3 + 
Arhgef6 639 S 3.04 3.44 3.16 2.35 3.00 0.00 1.00 yes 3 + 
Arhgef7 621 S NaN 2.40 1.49 NaN 1.95 0.03 1.00 yes 2 + 
Arhgef7 665 S 4.14 4.12 4.04 NaN 4.10 0.00 1.00 yes 3 
 
Asap1 819 S -1.11 -1.63 NaN -0.66 -1.13 0.03 1.00 yes 2 + 
Asap1 823 S -1.11 -1.63 NaN -0.66 -1.13 0.03 1.00 yes 2 + 
Atg16l1 269 S 3.40 3.59 3.48 2.91 3.34 0.00 1.00 yes 2 + 
Bad 112 S 1.06 1.21 0.64 NaN 0.97 0.02 1.00 yes 2 + 
Bag3 136 S -1.88 -1.57 NaN NaN -1.72 0.01 0.65 no 2 + 
Bag3 201 S NaN NaN 2.67 2.09 2.38 0.01 0.62 no 3 + 
Bag3 270 S -1.80 -2.19 -1.96 NaN -1.98 0.00 1.00 yes 3 + 
Bag3 274 S -1.80 -2.19 -1.96 NaN -1.98 0.00 1.00 yes 3 + 
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Bag3 138 S -1.37 -1.56 -1.81 NaN -1.58 0.00 0.99 yes 3 + 
Bmp2k 929 S NaN -0.52 -1.03 NaN -0.78 0.09 0.50 no 3 + 
Bmp2k 927 S NaN -0.52 -1.03 NaN -0.78 0.09 0.79 yes 3 + 
Bnip2 114 S 0.57 1.02 0.49 NaN 0.69 0.05 1.00 yes 2 + 
Braf 347 S 0.43 0.56 NaN 0.38 0.45 0.05 0.77 yes 3 + 
Cad 1343 S 3.49 4.96 3.75 3.27 3.87 0.00 1.00 yes 2 + 
Cald1 465 S NaN -0.49 NaN -0.70 -0.59 0.09 0.96 yes 2 
 
Cald1 149 S 0.58 0.52 0.67 NaN 0.59 0.03 1.00 yes 3 
 
Cald1 248 S -1.14 -1.24 -1.71 NaN -1.36 0.01 1.00 yes 2 + 
Camk2d 330 S 1.57 2.17 NaN NaN 1.87 0.02 0.95 yes 3 + 
Camkk2 99 S 2.16 2.60 NaN NaN 2.38 0.01 1.00 yes 3 + 
Carhsp1 31 S NaN 1.62 1.06 NaN 1.34 0.03 1.00 yes 3 + 
Carhsp1 33 S NaN 1.62 1.06 NaN 1.34 0.03 1.00 yes 3 + 
Casp7 16 S NaN -1.30 NaN -0.79 -1.04 0.05 0.95 yes 3 + 
Cast 11 S -0.32 -1.65 -1.38 -1.39 -1.18 0.03 1.00 yes 3 + 
Cast 290 T NaN -0.90 -0.79 NaN -0.85 0.04 0.90 yes 3 + 
Cbx5 93 S NaN NaN 2.95 2.06 2.51 0.02 0.99 yes 2 + 
Cc2d1b 377 S 2.45 3.55 NaN NaN 3.00 0.02 1.00 yes 3 + 
Ccdc6 360 S NaN 0.72 0.96 NaN 0.84 0.05 0.67 no 3 + 
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Cd44 318 S 3.73 4.75 3.95 3.74 4.04 0.00 1.00 yes 4 + 
Cdc42bpa 1347 S 1.82 2.19 NaN 1.68 1.90 0.00 1.00 yes 3 + 
Cdc42ep1 34 T NaN 3.32 2.99 NaN 3.16 0.00 1.00 yes 2 + 
Cdk14 95 S 0.80 0.65 0.49 NaN 0.65 0.03 1.00 yes 3 + 
Cdk17 180 S 0.83 1.28 0.35 NaN 0.82 0.07 1.00 yes 2 + 
Cep170 1155 S NaN -0.63 NaN -0.81 -0.72 0.06 1.00 yes 3 + 
Cep170 950 S 3.76 4.36 3.82 NaN 3.98 0.00 1.00 yes 2 + 
Cgnl1 298 S NaN 1.82 1.33 NaN 1.57 0.02 0.99 yes 2 + 
Clasp1 647 S NaN 2.92 NaN 2.61 2.77 0.00 0.72 no 3 + 
Clasp1 750 S -0.68 -0.99 NaN NaN -0.84 0.05 0.78 yes 3 + 
Clasp1 646 S NaN 2.75 NaN 2.61 2.68 0.00 1.00 yes 3 + 
Clasp2 178 S -0.41 -0.33 -0.33 -0.40 -0.37 0.03 1.00 yes 3 + 
Clip1 309 S NaN -1.03 NaN -1.01 -1.02 0.03 0.75 no 3 + 
Clip1 311 S -0.73 -0.61 NaN -0.56 -0.63 0.02 0.83 yes 3 + 
Clip1 347 S NaN 4.84 4.92 NaN 4.88 0.00 1.00 yes 2 + 
Clip2 939 S NaN 2.88 3.07 NaN 2.98 0.00 1.00 yes 2 + 
Crtc2 70 S -0.87 -1.32 NaN -1.06 -1.08 0.01 1.00 yes 3 + 
Ctnnb1 552 S 2.61 3.31 2.56 NaN 2.83 0.00 1.00 yes 2 + 
Ctnnd1 268 S -1.46 -1.10 -1.08 -1.19 -1.21 0.00 1.00 yes 2 + 
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Ctnnd1 252 S -1.38 -0.90 -1.15 -1.31 -1.18 0.00 1.00 yes 3 + 
Ctnnd1 268 S NaN -1.17 -1.06 NaN -1.12 0.02 1.00 yes 2 + 
Ctnnd1 269 S NaN -1.17 -1.06 NaN -1.12 0.02 1.00 yes 2 + 
Ctnnd1 230 S -1.14 -0.95 -0.99 -1.01 -1.02 0.00 1.00 yes 3 + 
Cul4a 10 S 4.06 4.50 NaN NaN 4.28 0.00 1.00 yes 3 + 
Ddhd2 348 S NaN 4.00 3.30 NaN 3.65 0.01 1.00 yes 3 + 
Ddx21 244 S 0.55 NaN 0.28 0.79 0.54 0.07 0.93 yes 3 + 
Ddx21 245 S 0.55 NaN NaN 0.99 0.77 0.08 0.93 yes 3 + 
Dennd1a 349 S 1.61 2.21 NaN 1.93 1.92 0.00 1.00 yes 3 + 
Dennd4c 1096 S 0.68 0.53 NaN NaN 0.60 0.08 1.00 yes 3 + 
Dennd5a 1079 T -1.01 -1.23 -0.57 NaN -0.93 0.03 0.98 yes 4 + 
Dennd5a 1085 S -1.01 -1.23 -0.57 -0.31 -0.78 0.04 0.97 yes 4 + 
Dock1 1758 S 2.54 3.39 2.49 3.03 2.86 0.00 0.92 yes 3 + 
Dok1 269 S 1.16 0.67 NaN NaN 0.91 0.06 1.00 yes 3 + 
Dpysl3 101 S NaN -0.71 -0.54 NaN -0.62 0.08 1.00 yes 3 + 
Eef2k 70 S NaN -2.66 -2.79 -2.05 -2.50 0.00 1.00 yes 2 + 
Eef2k 73 S NaN -2.62 -2.79 -2.05 -2.49 0.00 1.00 yes 3 + 
Eef2k 444 S -1.51 -2.41 NaN NaN -1.96 0.03 0.99 yes 3 + 
Eef2k 73 S -1.81 -1.77 NaN NaN -1.79 0.01 1.00 yes 3 + 
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Eef2k 391 S -1.01 -0.56 NaN NaN -0.79 0.08 1.00 yes 3 + 
Efhd2 76 S -2.92 -2.51 NaN NaN -2.71 0.01 0.89 yes 3 + 
Eif4ebp1 69 T -0.81 -0.97 NaN NaN -0.89 0.03 1.00 yes 4 + 
Eif4ebp1 64 S -0.81 -0.97 NaN NaN -0.89 0.03 1.00 yes 3 + 
Eif4g2 394 S -1.51 -1.26 NaN NaN -1.39 0.02 0.85 yes 4 + 
Emg1 16 S 1.63 1.68 NaN NaN 1.66 0.01 1.00 yes 3 + 
Epb4.1l1 534 S -0.90 -0.62 NaN NaN -0.76 0.06 1.00 yes 2 + 
Fam129a 601 S 0.67 0.99 1.18 0.78 0.90 0.01 1.00 yes 3 + 
Fam21 388 S -0.60 -0.48 -0.23 NaN -0.44 0.09 1.00 yes 3 + 
Farp1 427 S -1.12 -0.71 -1.65 -0.60 -1.02 0.03 1.00 yes 3 + 
Farp2 374 T NaN 1.77 2.49 NaN 2.13 0.02 0.50 no 2 
 
Farp2 375 S 1.30 1.58 1.36 NaN 1.41 0.00 0.91 yes 3 + 
Fbxo6 276 S 0.73 0.79 NaN NaN 0.76 0.05 1.00 yes 3 + 
Filip1l 551 S NaN 1.33 0.71 NaN 1.02 0.07 1.00 yes 2 + 
Flna 2144 S 1.58 1.53 1.44 NaN 1.52 0.00 1.00 yes 3 + 
Fnbp1 491 S NaN 1.36 1.22 NaN 1.29 0.02 1.00 yes 3 + 
Fxyd1 83 S 0.54 0.97 NaN NaN 0.75 0.08 0.93 yes 3 + 
Gapvd1 454 S NaN 1.81 1.90 NaN 1.85 0.01 0.70 no 3 + 
Gapvd1 881 S 0.82 0.50 0.37 NaN 0.57 0.06 1.00 yes 2 + 
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Gas2l1 489 S -0.58 NaN NaN -0.74 -0.66 0.07 1.00 yes 3 + 
Gas2l1 482 S -0.58 NaN NaN -0.74 -0.66 0.07 1.00 yes 3 + 
Gas2l1 493 S -0.58 NaN NaN -0.74 -0.66 0.07 1.00 yes 2 + 
Git1 410 S 0.65 0.90 NaN NaN 0.77 0.05 0.98 yes 3 + 
Golga5 116 S 0.84 1.05 0.82 NaN 0.90 0.01 1.00 yes 3 + 
Golgb1 189 S 3.52 3.91 3.48 NaN 3.64 0.00 1.00 yes 3 + 
Gpr107 537 S 1.80 NaN NaN 2.32 2.06 0.01 1.00 yes 2 + 
Grb10 432 S -0.85 NaN -1.15 NaN -1.00 0.03 0.96 yes 3 + 
Grb10 430 S NaN -0.52 -0.94 NaN -0.73 0.09 0.98 yes 3 + 
Hdac6 59 S NaN 3.96 2.82 NaN 3.39 0.02 1.00 yes 3 + 
Irs1 346 T -1.48 NaN NaN -1.57 -1.52 0.01 0.85 yes 3 
 
Irs1 340 S NaN -2.38 -2.19 -1.57 -2.05 0.01 1.00 yes 2 + 
Irs1 1095 S -1.92 NaN -1.76 -2.00 -1.89 0.00 1.00 yes 2 + 
Irs1 343 S NaN -2.38 -2.19 -0.44 -1.67 0.07 1.00 yes 2 + 
Irs1 632 S -1.25 -1.89 NaN NaN -1.57 0.03 1.00 yes 2 + 
Irs1 318 S NaN -0.99 NaN -1.13 -1.06 0.03 1.00 yes 3 + 
Irs1 441 T -0.43 -0.69 -0.23 -0.23 -0.40 0.08 1.00 yes 3 + 
Irs1 1135 S NaN 0.87 0.51 NaN 0.69 0.09 0.96 yes 3 + 
Irs1 1212 S 0.92 0.83 0.41 NaN 0.72 0.04 1.00 yes 3 + 
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Irs1 325 S 0.90 1.13 1.11 1.38 1.13 0.00 0.85 yes 3 + 
Irs1 324 S NaN 1.13 1.12 1.38 1.21 0.01 0.86 yes 3 
 
Itpr3 934 S 1.71 NaN 1.71 NaN 1.71 0.01 1.00 yes 3 + 
Jcad 980 S NaN NaN 1.23 0.93 1.08 0.03 0.99 yes 3 + 
Kank2 248 S NaN -1.11 -1.16 NaN -1.14 0.02 0.50 no 3 
 
Kank2 246 S NaN -1.10 -1.16 -0.57 -0.94 0.03 0.85 yes 3 + 
Kank2 174 S NaN -0.62 -0.84 NaN -0.73 0.06 0.82 yes 3 + 
Kank2 178 T NaN -0.62 -0.84 -0.37 -0.61 0.05 1.00 yes 3 + 
Kif13b 1388 S -1.67 -1.65 -1.36 NaN -1.56 0.00 0.96 yes 3 + 
Kif13b 1390 S -1.67 -1.07 NaN NaN -1.37 0.03 0.94 yes 3 + 
Kif13b 1409 S -1.33 NaN NaN -1.13 -1.23 0.02 1.00 yes 3 + 
Kif21a 842 S 2.64 2.70 NaN NaN 2.67 0.00 0.96 yes 3 + 
Larp1 299 S -0.71 -1.07 NaN NaN -0.89 0.05 0.95 yes 3 + 
Larp1 302 S -0.71 -1.07 NaN -0.53 -0.77 0.03 1.00 yes 3 + 
Lima1 225 S 0.86 1.29 0.88 NaN 1.01 0.02 1.00 yes 3 + 
Lima1 230 S 0.93 1.37 NaN NaN 1.15 0.03 0.93 yes 3 + 
Lmna 573 S 0.63 0.44 0.26 NaN 0.44 0.09 1.00 yes 3 + 
Lmo7 850 T -1.25 -1.72 NaN NaN -1.49 0.02 1.00 yes 3 
 




Lmo7 1516 S 2.13 1.97 1.38 1.40 1.72 0.00 1.00 yes 3 + 
Lmo7 1514 S 2.26 1.99 NaN NaN 2.12 0.01 0.86 yes 3 + 
Lrrc16a 1295 S -1.48 -2.34 NaN NaN -1.91 0.03 1.00 yes 2 + 
Luzp1 261 S 1.43 NaN 1.49 NaN 1.46 0.01 1.00 yes 2 + 
Map1a 2637 S NaN -0.68 -0.52 NaN -0.60 0.08 1.00 yes 4 
 
Map3k7 412 S NaN -0.69 NaN -0.80 -0.75 0.05 1.00 yes 2 + 
Map3k7 412 S NaN NaN 0.91 0.80 0.86 0.04 1.00 yes 2 + 
Map4k4 869 S 3.18 3.80 3.03 NaN 3.34 0.00 1.00 yes 2 + 
Map7d1 115 S NaN 1.63 1.94 NaN 1.79 0.01 1.00 yes 2 + 
Mapkap1 318 S 0.82 0.77 NaN NaN 0.80 0.04 0.99 yes 2 + 
Marcks 156 S -0.52 -0.51 -1.27 -1.14 -0.86 0.03 1.00 yes 2 + 
Marcks 152 S -0.43 -0.51 -1.27 -1.14 -0.84 0.03 1.00 yes 2 + 
Marcks 163 S -0.34 -0.68 -1.27 NaN -0.76 0.09 1.00 yes 2 + 
Marcks 138 S NaN -0.97 -0.41 -0.67 -0.68 0.05 0.99 yes 2 + 
Mark2 409 S NaN 3.14 NaN 3.68 3.41 0.01 0.98 yes 2 + 
Matr3 188 S 1.57 1.77 2.21 NaN 1.85 0.01 1.00 yes 4 + 
Mcm2 27 S -0.90 -0.81 -1.05 -0.76 -0.88 0.00 1.00 yes 3 + 
Mcm2 27 S NaN 1.24 1.60 1.67 1.50 0.01 1.00 yes 3 + 
Mcm2 21 S 1.56 1.28 1.60 1.67 1.53 0.00 1.00 yes 3 + 
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Mcm2 21 S NaN 2.03 1.71 NaN 1.87 0.01 1.00 yes 3 + 
Mllt4 1157 S -1.12 NaN -0.92 NaN -1.02 0.03 1.00 yes 4 + 
Mllt4 1158 S -1.12 NaN -0.92 NaN -1.02 0.03 1.00 yes 4 + 
Mllt4 1158 S -0.81 -0.79 -0.69 NaN -0.76 0.02 1.00 yes 4 + 
Mllt4 1167 S -0.81 -0.78 -0.69 NaN -0.76 0.02 1.00 yes 2 + 
Mllt4 1157 S NaN -0.71 -0.69 NaN -0.70 0.05 1.00 yes 4 + 
Mllt4 1092 S -0.38 -0.27 -0.46 NaN -0.37 0.09 1.00 yes 3 + 
Mllt4 1167 S NaN 1.28 1.48 1.32 1.36 0.00 1.00 yes 2 + 
Mprip 1015 S 0.58 0.42 NaN 0.37 0.46 0.05 1.00 yes 2 + 
Mtss1 276 S NaN 1.21 1.75 NaN 1.48 0.03 0.98 yes 2 + 
Mtss1l 209 S 1.83 2.14 NaN 1.93 1.97 0.00 1.00 yes 3 + 
Myh10 1956 S NaN 2.12 0.98 NaN 1.55 0.07 1.00 yes 2 + 
Myh10 1952 S NaN 2.12 0.98 NaN 1.55 0.07 1.00 yes 3 + 
Myl12b 20 S -0.35 -0.73 NaN -0.51 -0.53 0.06 1.00 yes 3 + 
Mylk 355 S -0.45 -0.65 -0.83 -0.31 -0.56 0.03 1.00 yes 3 + 
Mylk 1795 S NaN 4.03 2.86 NaN 3.45 0.02 1.00 yes 2 + 
Myo10 1141 S NaN 2.90 2.80 NaN 2.85 0.00 1.00 yes 2 + 
Myo18a 728 S NaN -0.89 NaN -0.87 -0.88 0.03 1.00 yes 3 + 
Myo18a 1966 S -0.48 -0.42 -0.04 -0.54 -0.37 0.10 1.00 yes 3 + 
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Myo18a 1970 S -0.48 -0.42 -0.04 -0.54 -0.37 0.10 1.00 yes 3 + 
Myo18a 1966 S 1.32 1.68 NaN NaN 1.50 0.02 1.00 yes 3 + 
Myo9a 1243 S NaN 1.57 1.32 NaN 1.44 0.02 1.00 yes 2 + 
Myo9b 1336 S 2.96 4.33 4.04 NaN 3.78 0.00 1.00 yes 2 + 
Ncbp1 22 S 1.51 1.44 2.10 NaN 1.69 0.01 0.97 yes 3 + 
Nck1 21 S 1.97 2.51 2.43 NaN 2.30 0.00 1.00 yes 3 + 
Ndrg1 330 S NaN -1.14 NaN -1.63 -1.39 0.03 1.00 yes 3 + 
Ndrg1 328 T NaN -1.14 NaN -1.11 -1.12 0.02 1.00 yes 3 + 
Ndrg1 326 S NaN -1.14 NaN -0.86 -1.00 0.03 0.98 yes 2 + 
Ndrg1 2 S 1.24 1.54 0.85 1.14 1.19 0.01 1.00 yes 3 + 
Nf1 2524 S 1.62 1.56 NaN NaN 1.59 0.01 1.00 yes 2 + 
Nfatc4 272 S 2.26 2.18 
 
NaN 2.24 0.00 1.00 yes 2 + 
Nfatc4 334 S 2.86 2.66 2.29 2.99 2.70 0.00 0.99 yes 2 + 
Numa1 1951 S 2.96 4.35 2.62 4.58 3.63 0.00 1.00 yes 3 + 
Osbpl11 186 S -1.72 NaN NaN -2.21 -1.97 0.02 1.00 yes 2 + 
Osbpl11 194 S 1.76 2.46 NaN NaN 2.11 0.02 1.00 yes 3 + 
Osbpl3 546 S 1.87 2.04 NaN NaN 1.95 0.01 0.82 yes 3 + 
Palm 145 T -4.05 -2.63 -3.26 NaN -3.32 0.01 1.00 yes 3 + 
Palm 141 T -4.05 -2.63 -3.26 NaN -3.32 0.01 1.00 yes 3 + 
226 
 
Pank2 42 S NaN 1.06 1.49 NaN 1.28 0.03 1.00 yes 2 + 
Pank2 42 S NaN 2.54 2.23 2.60 2.46 0.00 1.00 yes 2 + 
Pank2 43 S NaN 2.69 2.23 2.60 2.51 0.00 1.00 yes 2 + 
Parva 19 S -0.74 -0.59 NaN NaN -0.66 0.07 0.99 yes 3 + 
Patl1 179 S NaN -2.02 NaN -1.82 -1.92 0.01 1.00 yes 2 + 
Patl1 184 S -1.77 -2.02 NaN -1.82 -1.87 0.00 1.00 yes 2 + 
Pbrm1 60 S 1.80 0.90 2.22 NaN 1.64 0.03 1.00 yes 3 + 
Pcbp2 185 S -0.86 -0.65 NaN NaN -0.75 0.05 1.00 yes 4 + 
Pde8a 452 S 1.34 1.77 1.09 NaN 1.40 0.01 1.00 yes 2 + 
Pea15 94 S 1.23 0.94 0.91 NaN 1.03 0.01 1.00 yes 3 + 
Pgm3 64 S 0.33 0.39 0.18 0.35 0.31 0.06 1.00 yes 2 + 
Phactr4 258 S -1.05 -0.71 NaN NaN -0.88 0.05 0.95 yes 3 + 
Phlda3 117 S NaN 4.15 2.31 2.30 2.92 0.02 1.00 yes 2 + 
Phldb1 565 S NaN 0.95 NaN 1.11 1.03 0.03 1.00 yes 3 + 
Phldb2 975 S -0.72 NaN -1.06 NaN -0.89 0.05 0.98 yes 3 + 
Phldb2 1021 S NaN -0.79 -0.97 NaN -0.88 0.04 1.00 yes 2 + 
Phldb2 973 S -0.71 -0.65 NaN NaN -0.68 0.06 0.75 yes 3 + 
Phldb2 510 S 1.81 1.90 1.45 NaN 1.72 0.00 1.00 yes 2 + 
Pi4ka 198 S 2.07 1.50 1.57 NaN 1.71 0.01 1.00 yes 2 + 
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Pi4kb 496 S 1.02 1.68 NaN NaN 1.35 0.04 1.00 yes 3 + 
Pid1 200 S NaN 1.73 NaN 1.05 1.39 0.04 1.00 yes 2 + 
Pid1 188 S 1.78 1.56 NaN NaN 1.67 0.01 0.85 yes 2 + 
Pitpnm1 664 S NaN NaN 1.77 2.69 2.23 0.02 0.83 no 3 
 
Pitpnm1 665 T NaN NaN 1.77 2.69 2.23 0.02 0.80 yes 3 
 
Plec 21 S -0.46 -0.41 -0.85 -0.35 -0.52 0.04 1.00 yes 2 + 
Plec 4241 S 0.57 0.62 0.23 0.20 0.41 0.07 1.00 yes 3 + 
Plec 4487 T NaN 0.77 NaN 0.86 0.82 0.04 0.94 yes 2 + 
Plekhg1 164 S NaN NaN 2.44 2.26 2.35 0.01 1.00 yes 2 + 
Plekhg1 163 S NaN NaN 2.44 2.26 2.35 0.01 1.00 yes 2 + 
Plekhg3 472 S 1.95 2.12 2.02 NaN 2.03 0.00 1.00 yes 3 + 
Plxdc2 456 S 1.20 2.01 NaN NaN 1.61 0.04 1.00 yes 3 + 
Ppfibp1 500 S -0.70 -0.47 -0.47 -0.18 -0.45 0.05 0.81 yes 3 + 
Ppip5k2 57 S NaN 4.52 5.01 NaN 4.77 0.00 1.00 yes 2 + 
Ppp1r9b 192 S NaN -1.20 -0.89 -0.32 -0.81 0.07 0.90 yes 3 + 
Ppp2r5d 565 S 2.10 2.00 0.86 1.55 1.63 0.01 1.00 yes 3 + 
Prkar2b 112 S -0.68 -0.44 NaN -0.68 -0.60 0.03 1.00 yes 2 + 
Prkd2 197 S 0.58 0.59 NaN NaN 0.59 0.08 1.00 yes 3 + 
Prrc2a 1078 S 1.12 0.80 NaN NaN 0.96 0.04 0.84 yes 3 + 
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Prrc2a 449 S 2.48 3.47 3.61 NaN 3.18 0.00 1.00 yes 2 + 
Prrc2c 2625 T NaN -1.57 -2.02 -1.62 -1.74 0.00 1.00 yes 3 + 
Prrc2c 899 S 1.62 1.97 NaN 1.48 1.69 0.00 0.80 yes 4 + 
Psd3 348 S NaN -2.54 NaN -1.27 -1.91 0.05 1.00 yes 3 + 
Psmd11 14 S 3.25 2.72 NaN NaN 2.98 0.01 1.00 yes 3 + 
Ptpn14 620 S NaN -1.46 NaN -0.74 -1.10 0.07 1.00 yes 3 + 
Ptpn14 646 S 0.73 0.94 NaN NaN 0.83 0.04 1.00 yes 2 + 
Ptrf 171 S 2.61 3.23 2.82 NaN 2.89 0.00 1.00 yes 2 + 
Ptrf 169 S 2.95 3.57 2.77 NaN 3.10 0.00 0.94 yes 2 + 
Ptrf 302 S 3.94 4.32 4.04 2.83 3.78 0.00 1.00 yes 3 + 
Pum1 615 S 1.13 1.23 0.76 NaN 1.04 0.02 1.00 yes 2 + 
Pum2 587 S NaN 2.17 2.00 NaN 2.08 0.01 1.00 yes 2 + 
Pxn 306 S NaN -1.25 -1.02 NaN -1.13 0.02 0.91 yes 3 + 
Pxn 83 S -0.66 -0.93 -0.56 -0.32 -0.62 0.03 1.00 yes 2 + 
Rab12 20 S -1.81 -2.03 NaN -1.72 -1.85 0.00 1.00 yes 3 + 
Ralgps2 315 S NaN 1.50 2.00 NaN 1.75 0.02 0.76 no 3 
 
Ralgps2 315 S NaN 2.89 NaN 2.61 2.75 0.00 0.76 no 3 
 
Ralgps2 296 S NaN -2.52 NaN -2.17 -2.35 0.01 0.85 yes 3 + 
Ralgps2 308 S NaN -2.52 NaN -2.17 -2.35 0.01 1.00 yes 3 + 
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Ralgps2 316 S NaN 2.89 NaN 2.61 2.75 0.00 0.83 yes 3 + 
Ralgps2 336 S NaN 2.89 NaN 2.61 2.75 0.00 1.00 yes 3 + 
Rapgef2 931 S NaN 0.99 1.49 NaN 1.24 0.03 0.89 yes 3 + 
Rbm14 618 S 3.09 3.02 2.31 NaN 2.80 0.00 1.00 yes 2 + 
Ripk2 284 S 1.73 2.33 2.46 NaN 2.18 0.00 0.99 yes 2 + 
Rmdn3 46 S 0.61 0.61 0.75 NaN 0.66 0.02 1.00 yes 3 + 
Rnf214 356 S -1.39 -1.34 NaN NaN -1.36 0.02 0.99 yes 3 + 
Rrm2 20 S -0.92 -1.02 -1.57 -1.09 -1.15 0.01 1.00 yes 3 + 
Scarf2 672 S -1.08 -0.95 -0.73 NaN -0.92 0.02 1.00 yes 3 + 
Sdpr 293 S -1.37 NaN NaN -1.12 -1.25 0.02 1.00 yes 2 + 
Sdpr 288 S -0.96 -0.17 -0.47 -0.62 -0.55 0.06 0.99 yes 3 + 
Sdpr 293 S -0.85 -0.22 -0.52 -0.58 -0.54 0.04 1.00 yes 2 + 
Sec16a 1028 S -0.73 -1.00 -0.75 NaN -0.83 0.02 1.00 yes 3 + 
Sec16a 1030 S NaN -0.90 NaN -0.72 -0.81 0.05 0.99 yes 3 + 
Sec16a 1028 S -0.91 -0.63 -0.20 -0.24 -0.50 0.09 1.00 yes 3 + 
Sec22b 137 S NaN 4.11 4.41 3.45 3.99 0.00 1.00 yes 3 + 
Septin-7 407 T 0.25 0.42 0.47 NaN 0.38 0.09 1.00 yes 3 + 
Septin-9 67 S -0.96 -1.47 NaN NaN -1.22 0.04 1.00 yes 3 + 




Serbp1 203 S 4.00 3.17 NaN NaN 3.59 0.01 0.50 no 2 + 
Sh3kbp1 399 S NaN -1.60 -1.63 NaN -1.62 0.01 1.00 yes 3 + 
Sh3kbp1 550 S -0.67 -0.34 -1.02 -1.65 -0.92 0.05 1.00 yes 3 + 
Sh3pxd2a 776 T 0.98 NaN 0.92 NaN 0.95 0.03 1.00 yes 3 + 
Sh3pxd2a 769 S 1.12 1.40 0.79 NaN 1.10 0.02 1.00 yes 2 + 
Sh3pxd2b 551 S NaN -1.26 -1.17 NaN -1.22 0.02 0.76 yes 3 + 
Sh3pxd2b 499 S 2.24 2.74 NaN NaN 2.49 0.01 0.92 yes 3 + 
Sh3pxd2b 528 S 4.31 4.71 3.91 NaN 4.31 0.00 1.00 yes 3 + 
Sik3 579 S 1.34 1.39 0.85 NaN 1.19 0.01 1.00 yes 2 + 
Skt 937 S NaN -2.17 -1.14 -0.97 -1.43 0.03 1.00 yes 3 + 
Slain2 392 S 2.79 3.31 1.62 NaN 2.57 0.02 1.00 yes 2 + 
Slc7a2 662 S NaN 2.89 2.05 NaN 2.47 0.02 1.00 yes 2 + 
Snrk 128 S NaN 1.35 1.16 NaN 1.25 0.02 0.99 yes 3 + 
Sntb1 86 S NaN -1.23 NaN -0.86 -1.05 0.04 1.00 yes 2 + 
Sntb2 213 S -1.31 NaN -0.74 NaN -1.03 0.06 0.92 yes 3 + 
Snx1 187 S NaN 2.32 1.64 NaN 1.98 0.02 1.00 yes 2 + 
Sorbs2 389 S NaN -0.73 -1.29 NaN -1.01 0.06 0.99 yes 3 + 
Sorbs2 392 S NaN -0.73 -1.29 NaN -1.01 0.06 1.00 yes 2 + 
Sorbs2 86 S -0.63 -0.59 -0.67 NaN -0.63 0.02 1.00 yes 3 + 
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Sorbs2 403 S 1.29 1.83 1.30 NaN 1.47 0.01 1.00 yes 3 + 
Spag9 38 S -1.62 -2.20 -2.81 NaN -2.21 0.01 1.00 yes 3 + 
Spag9 52 T -1.94 -2.00 NaN NaN -1.97 0.01 1.00 yes 3 + 
Spats2 382 S 2.88 4.27 NaN NaN 3.58 0.02 0.77 yes 4 
 
Spats2 385 S NaN 4.48 4.65 NaN 4.57 0.00 0.91 yes 4 + 
Specc1l 385 S NaN 1.75 1.00 NaN 1.38 0.05 0.99 yes 2 + 
Srrm2 1243 S 0.57 0.49 0.29 0.22 0.39 0.05 1.00 yes 3 + 
Srrm2 1243 S 0.46 0.64 0.41 0.17 0.42 0.05 1.00 yes 3 + 
Srrm2 1247 S 0.46 0.69 0.41 0.17 0.43 0.06 1.00 yes 2 + 
Stambpl1 76 S -1.08 -1.24 NaN -0.92 -1.08 0.01 1.00 yes 2 + 
Steap4 67 Y NaN NaN 1.38 1.47 1.43 0.01 1.00 yes 2 
 
Steap4 68 S NaN NaN 1.38 1.47 1.43 0.01 1.00 yes 2 
 
Steap4 72 S NaN NaN 1.38 1.47 1.43 0.01 1.00 yes 2 
 
Stk3 398 S 4.83 4.64 NaN NaN 4.74 0.00 1.00 yes 3 + 
Stmn1 16 S 1.51 1.59 1.44 NaN 1.52 0.00 1.00 yes 2 + 
Stxbp5 109 S 0.34 0.75 0.36 NaN 0.48 0.09 1.00 yes 2 + 
Stxbp5 83 S 1.61 1.76 1.52 NaN 1.63 0.00 1.00 yes 3 + 
Svil 323 T -0.60 -0.31 -0.46 -0.21 -0.40 0.05 0.92 yes 4 
 
Svil 453 S 3.00 3.38 2.66 2.96 3.00 0.00 1.00 yes 2 + 
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Sympk 494 S NaN 2.58 3.72 2.43 2.91 0.01 1.00 yes 3 + 
Synpo 1023 S -3.27 NaN NaN -2.29 -2.78 0.02 1.00 yes 2 + 
Synpo 1018 S -3.27 NaN NaN -2.29 -2.78 0.02 1.00 yes 3 + 
Synpo 988 S NaN -2.40 NaN -1.85 -2.13 0.01 1.00 yes 3 + 
Synpo 1091 S 1.70 2.20 1.98 1.35 1.81 0.00 1.00 yes 2 + 
Tab1 7 S 1.42 1.88 NaN 1.77 1.69 0.00 1.00 yes 3 + 
Tab2 524 S 2.93 3.16 2.47 NaN 2.85 0.00 1.00 yes 3 + 
Tbc1d10b 673 S 1.00 1.54 1.35 NaN 1.30 0.01 1.00 yes 4 + 
Tbc1d12 205 S 0.40 1.21 1.15 0.71 0.87 0.02 1.00 yes 3 + 
Tcof1 1191 S 0.53 0.45 0.36 0.47 0.45 0.02 1.00 yes 3 + 
Tjap1 527 S 0.95 NaN NaN 0.51 0.73 0.09 1.00 yes 2 + 
Tjp1 912 S -1.03 -0.73 -1.03 NaN -0.93 0.01 1.00 yes 3 + 
Tjp1 617 S -0.62 -0.58 NaN NaN -0.60 0.08 1.00 yes 2 + 
Tnks1bp1 796 S 1.13 1.49 1.29 NaN 1.30 0.01 1.00 yes 3 + 
Tnks1bp1 429 S 2.31 2.81 1.52 1.96 2.15 0.00 1.00 yes 2 + 
Tnks1bp1 887 S 2.79 2.74 NaN NaN 2.76 0.00 0.99 yes 2 + 
Tns1 204 S NaN -0.63 -0.68 NaN -0.66 0.06 0.99 yes 2 + 
Tns3 769 S 1.12 1.43 0.39 1.27 1.05 0.02 1.00 yes 2 + 
Tpd52l2 146 S 1.04 0.74 0.28 NaN 0.69 0.08 1.00 yes 2 + 
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Tpr 2149 S -1.38 -1.15 -1.07 NaN -1.20 0.01 1.00 yes 3 + 
Trio 2462 S -1.82 -2.40 NaN NaN -2.11 0.02 1.00 yes 3 + 
Trio 2458 S -1.82 -2.40 NaN NaN -2.11 0.02 1.00 yes 3 + 
Triobp 157 S NaN 3.37 2.39 NaN 2.88 0.02 1.00 yes 3 + 
Triobp 169 S NaN 3.38 2.39 NaN 2.88 0.02 0.80 yes 4 + 
Triobp 170 S NaN 3.38 2.39 NaN 2.88 0.02 0.88 yes 3 + 
Unk 381 S NaN 4.59 3.46 NaN 4.03 0.01 1.00 yes 3 + 
Vim 39 S 2.92 2.65 2.20 2.28 2.51 0.00 1.00 yes 3 + 
Vim 73 S NaN 3.93 2.94 NaN 3.44 0.01 0.99 yes 2 + 
Wdr20b 331 S NaN 0.71 0.96 NaN 0.83 0.05 1.00 yes 3 + 
Wdr20b 329 S NaN 0.79 0.96 NaN 0.87 0.04 0.98 yes 2 + 
Wdr91 253 S NaN NaN -0.95 -0.86 -0.90 0.03 0.71 no 3 + 
Wipf2 235 S NaN -2.47 -1.45 NaN -1.96 0.03 1.00 yes 3 + 
Wnk1 2032 S 3.16 2.80 2.61 3.30 2.97 0.00 1.00 yes 3 + 
Zc3h11a 236 S 4.00 3.20 NaN NaN 3.60 0.01 1.00 yes 3 + 
Zc3h14 662 S 2.31 2.73 NaN NaN 2.52 0.01 1.00 yes 3 
 
Zcchc24 93 S NaN NaN -0.97 -0.88 -0.92 0.03 1.00 yes 3 + 
Zfp800 318 S 2.21 3.01 4.25 NaN 3.15 0.02 1.00 yes 3 + 




TABLE 3: Phosphosites Regulated by 5 min PTH(1-34) or bPTH(7-34) at Days 0 or 10 of Osteogenic Differentiation. 
Mean Log2 ratios of treated/untreated SILAC-encoded cells.  PTH(1-34) regulated sites were determined using a 
moderated t test with a Benjamini Hochberg corrected p value for multiple hypothesis testing (adj p val >0.01 considered 
regulated).  Less stringent criteria were applied to bPTH(7-34) stimulated cells.  bPTH regulated sites were determined 
using a 2.5x median absolute deviation from the mean. Phosphosite localization probability >0.75.   
   MC3T3-E1 cells  
Day 0 of Differentiation 
MC3T3-E1 cells 




















































66 S 0.38    0.83 +    +  
8030462
N17Rik 
66 S 0.57      0.41 + +  
8030462
N17Rik 
69 S 0.55      0.40 + +  
Ablim1 355 S       0.48 + +  
Ablim1 359 S       0.48 + +  
Ablim1 478 S 3.44 +        +  
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Acin1 823 S 4.09 +     1.44  +  
Aebp2 383 S     1.97 + 1.77  +  
Agfg1 177 T -3.05 + -0.35 + -3.15 + -3.21  +  
Agfg1 177 T     -2.98 + -2.68  +  
Agfg1 179 S -2.55 +   -2.95 + -2.99  +  
Agfg1 181 S -2.89 +   -3.13 + -3.10  +  
Agps 78 S 0.38  0.00 +      +  
Ahnak 136 S 0.52  0.79 + 0.11     + + 
Ahnak 818 S     3.20 + 2.47  + + 
Ahnak 2438 S     1.43 + 1.04  + + 
Ahnak 2566 S     2.99 + 3.31  + + 
Ahnak 2887 S     5.05 + 4.11  + + 
Ahnak 5017 S     4.83 + 4.93  + + 
Ahnak 5098 S -1.86 +        + + 
Ahnak 5099 S -2.30 +   -2.68 + -2.56  + + 
Ahnak 5502 T       -1.67 + + + 
Ahnak 5504 S -2.89 + -0.40 + -2.73 + -1.57 + + + 
Ahnak 5504 S 0.02    0.63 +    + + 
Ahnak 5510 S -3.16 + -0.35 + -2.77 + -1.68 + + + 
Ahnak 5510 S -2.78 +   -2.19 + -1.58 + + + 
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Ahnak 5512 S -2.93 +   -2.42 + -2.57  + + 
Ahnak 5512 S -2.89 +   -3.10 + -2.99  + + 
Ahnak 5522 S     0.39  -0.49 + + + 
Ahnak 5536 S       -0.45 + + + 
Ahnak 5563 S       -2.43 + + + 
Ahnak 5567 T       -2.23 + + + 
Ahnak2 841 S 0.47  -0.65 + 0.92 + 0.69  +  
Akap13 1892 S     -1.24 +    + + 
Akap13 1895 S     -1.28 + -1.74  + + 
Ap3d1 754 S 2.90 +   3.46 + 3.76  +  
Ap3d1 760 S -1.48 +   -2.04 + -2.34  +  
Ap3d1 760 S 3.21 +   1.53  1.03  +  
Apbb1ip 532 S 2.96 +   3.52 + 4.00  +  
Araf 255 S -2.56 +   -3.46 + -0.43  + + 
Arfgap3 331 S     -0.93  -0.71 + + + 
Arhgap
17 
698 S 3.44 +   3.49 + 3.83  +  
Arhgap
21 
879 S 1.26 +   1.35 + 1.18  +  
Arhgap
21 





1660 S     1.66 + 1.90  +  
Arhgap
28 
590 S 3.42 + 0.53 + 2.82 + 3.38  +  
Arhgap
31 
1163 S     1.94 + 1.93  +  
Arhgap
5 
1219 S     -0.08  0.63 + +  
Arhgef1
1 
1324 S 2.81 +   2.98 + 2.93  +  
Arhgef1
7 
142 S     1.72 + 1.52  + + 
Arhgef6 663 S 2.90 +   3.25 + 3.33  +  
Arhgef6 703 S 2.56 +   2.78 + 3.00  +  
Arhgef7 544 S 3.48 +   3.20  3.95  +  
Arpp19 67 S -1.47 +     -0.35  +  
Atg16l1 269 S     3.44 +    + + 
Atg16l1 287 S 2.05    2.01 + 1.99  + + 
Bad 112 S     0.99 + 1.35  +  
Bag3 136 S     -1.77 + -1.28  +  
Bag3 138 S -1.20    -1.64 + -1.28  +  
Bag3 270 S -1.42 +   -1.98 + -1.62  +  
Bag3 274 S -1.42 +   -1.98 + -1.62  +  
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Bag3 289 S     -2.73 + -2.94  +  
Bag3 291 T     -2.96 + -3.02  +  
Bag3 380 S -0.88 +        +  
Bag3 390 S -0.84 +     -0.40  +  
Bmp2k 927 S     -0.78  -0.71 + + + 
Bod1l 656 S 2.16 + 0.84 +      + + 
Btf3 129 S     3.04 + 3.38  +  
Cad 1343 S 4.32 +   4.09 + 4.73  +  
Cald1 248 S -0.99 +   -1.33 +    + + 
Cald1 257 S 0.86    1.25 + 0.98  + + 
Cald1 394 S -0.04  0.43 +      +  
Camk2d 330 S     1.87 +    + + 
Camkk1 458 S 3.51 +        + + 
Canx 553 S -0.06  -0.51 + 0.02  -0.92  +  
Canx 563 S -0.06  -0.51 + 0.03  -0.92  +  
Canx 582 S -0.04  -0.50 + 0.03     +  
Carhsp1 31 S 0.85  -0.50 + 1.34  1.30  +  
Carhsp1 33 S 0.85  -0.50 + 1.34     +  
Cast 11 S -0.97 +   -1.39 + -1.36  +  
Cast 81 S       1.05 + +  
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Cast 290 T     -0.86  -0.72 + +  
Cbx5 93 S 2.67 + 0.51 +      + + 
Cc2d1b 377 S 2.37 +   2.99 + 3.35  +  
Ccny 301 S -0.31  -0.45 +   -0.41  +  
Ccs 267 S 3.16 +        +  
Cd44 320 S     4.13 + 4.22  +  
Cdc42b
pa 
1451 S     1.98 + 2.13  +  
Cdc42e
p1 
34 T     3.10 + 3.20  + + 
Cdc42e
p3 
144 S     1.48 + 1.64  + + 
Cdk1 14 T       0.59 + +  
Cdk1 15 Y 0.25  0.47 +      +  
Cdk1 15 Y       0.59 + +  
Cdk14 78 S     0.40  0.62 + +  
Cdk14 95 S 0.77  0.58 + 0.62     +  
Cep170 950 S     3.85 + 3.75  +  
Cep170
b 
421 S 1.47 +     1.44  +  
Cgnl1 298 S     1.56 + 1.86  +  
Clasp1 646 S 3.06 +        +  
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Clasp1 1044 S -2.20 +        +  
Clasp1 1046 S -2.21 +        +  
Clip1 311 S     -0.62 +    +  
Clip1 353 S 3.47 +   4.78 + 4.73  +  
Clip2 939 S     2.97 + 3.39  +  
Cmtr1 27 S 0.30  0.65 +      + + 
Col6a1 465 S 0.52  2.32 +   -1.25 + + + 
Csnk1d 382 S -1.97 +        +  
Ctnna1 655 S       -0.51 + +  
Ctnna1 658 T       -0.51 + +  
Ctnnb1 552 S 2.63 +   2.83 + 3.07  +  
Ctnnd1 230 S -1.11    -1.02 + -1.18  +  
Ctnnd1 252 S -1.38 + -0.46 + -1.15 + -1.18  +  
Ctnnd1 268 S -1.30 +   -1.23 + -1.13  +  
Ctnnd1 268 S     -1.12 + -1.16  +  
Ctnnd1 269 S     -1.12 + -1.16  +  
Cul4a 10 S     4.32 + 4.38  +  
Dclk1 332 S -0.26  -0.36 + -0.11  0.66  +  
Dcp1a 543 S -0.63 +   -0.53     + + 
Ddhd2 348 S     3.59 + 3.93  +  
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Ddx21 247 T       -0.48 + +  
Dennd4
c 
971 S   0.49 +      + + 
Dock1 1758 S 3.77 +   3.08 + 1.88 + + + 
Dock7 1398 S -1.43 +        +  
Dync1li
1 
510 S   0.43 +   0.37  +  
Dync1li
1 
512 T 1.17  0.63 +      +  
Dync1li
1 
515 T 0.36  0.43 +      +  
Dync1li
1 
516 S   0.74 +   0.54  +  
Dync1li
1 
516 S 0.84  0.44 +      +  
Eef2k 70 S     -2.74 + -2.29  +  
Eef2k 73 S     -2.72 + -2.39  +  
Eef2k 73 S     -1.79 + -1.34  +  
Efhd2 74 S -2.32 +        +  
Efhd2 76 S -2.23 +   -2.73 + -2.63  +  
Eif4g1 1182 S 0.26    0.33  0.62 + +  
Eif4g2 507 T -1.35 +        +  




Emg1 16 S 1.39 + 0.58 + 1.81 + 1.71  +  
Eml3 177 S -1.00  -0.61 + 0.10     + + 
Enah 620 S 3.97 +     5.81  +  
Epb4.1l
3 
63 S   -0.37 + -0.55  -0.70  +  
Eps8 424 S 2.73 + 0.61 +      +  
Erc1 17 S -2.00 +     -2.13  +  
Erc1 21 S -2.02 +     -2.16  +  
Erk2 185 Y -0.10  0.66 +   -1.36  +  
Etl4 1244 S     -1.75  -1.15 + +  
Etl4 1306 S   0.41 +      +  
Evl 329 S 1.36    1.90 + 1.30  +  
Fam129
a 
601 S 0.80    0.96 + 0.90  + + 
Fam160
a2 
811 S   -0.59 +      +  
Fam188
b 
308 S       1.71 + +  
Farp1 427 S     -0.89 + -1.01  + + 
Farp2 375 S     1.37 + 0.54  + + 
Flna 2144 S 1.16 +   1.71 + 1.63  +  
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Fnbp1 491 S     1.32 + 1.35  +  
Foxk1 402 S -0.28  -0.55 + -0.16     + + 
Foxk1 406 S -0.25  -0.45 +      + + 
Fxyd1 83 S     0.92 +    + + 
Gas2 225 S 0.19  0.47 + -0.27     +  
Gas2 231 S 0.17  0.47 + -0.27     +  
Golga5 116 S     0.91 + 1.21  + + 
Golgb1 2614 S 3.09 +   3.51 + 3.36  +  
Hdac6 59 S     3.40 + 3.89  +  
Hist1h1
c 
37 S 1.61 +        +  
Irs1 302 S   0.54 +   0.56 + +  
Irs1 307 S       0.57 + +  
Irs1 318 S       0.56 + +  
Irs1 324 S     1.13 + 1.61  +  
Irs1 325 S 1.30 + 0.41 + 1.13 + 1.61  +  
Irs1 325 S -0.76  0.57 +      +  
Irs1 340 S -1.71 + -0.63 +   0.40  +  
Irs1 340 S   -0.39 + -2.30 + -2.12  +  
Irs1 343 S -1.56 +   -0.95  -0.42  +  
Irs1 343 S -0.55  0.59 + -2.30 + -2.12  +  
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Irs1 410 S     2.86 + 2.52  +  
Irs1 1094 S 1.35 +        +  
Irs1 1095 S -1.91 +   -1.84 + -0.43  +  
Itpkb 42 S -0.02  0.57 +      + + 
Itpr3 934 S     1.73 +    + + 
Kank2 246 S     -1.14 + -1.18  +  
Kif13b 1388 S     -1.53 + -1.86  + + 
Kif13b 1409 S     -1.46 +    + + 
Kif13b 1653 T -1.52 +        + + 
Kif13b 1794 S 4.54 +        + + 
Kif13b 1795 S 4.54 +        + + 
Kif21a 842 S 2.46 +   2.63 + 3.05  +  
Kifap3 60 S   0.41 +      +  
Larp1 138 S 3.26 +        +  
Larp1 299 S     -0.93 + -0.77  +  
Larp1 302 S -0.93 +   -0.93 + -0.77  +  
Lcmt1 46 S 2.39 + 0.99 +      +  
Lima1 225 S 1.12 +   1.01 + 1.34  + + 
Lmna 22 S 0.03      0.37 + + + 
Lmna 629 S 0.10  0.46 +      + + 
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Lmo7 850 T     -1.47  -1.48 + +  
Lmo7 1012 S       -0.57 + +  
Lmo7 1014 S       -0.51 + +  
Lmo7 1191 S 1.14 +   0.65  0.65  +  
Lmo7 1514 S 1.48 +   2.13 + 1.76  +  
Lmo7 1516 S 1.58 +   1.87 + 1.22 + +  
Lmo7 1609 S -0.77 +   -0.54  -0.67  +  
Lmo7 1611 S -0.64    -0.60  -0.53 + +  
Lmod1 511 S -2.48 +        +  
Lrch3 48 S 2.71 + 1.11 +      +  
Lrch3 208 S -2.33  -0.51 +      +  
Lrrfip1 84 S -1.09  -0.42 +      + + 
Luzp1 261 S     1.44 +    + + 
Macf1 6920 S 3.00 + 0.88 +      +  
Map3k2 153 S     1.47 + 1.44  +  
Map3k3 166 S 1.17 + 0.50 +      +  
Map3k3 176 S 1.17 + 0.50 +      +  
Map3k7 412 S -1.28 +     -0.67 + +  
Map3k7 412 S 0.93 +        +  
Map4 901 S -1.15 + -0.44 +      +  
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Map4 914 S -0.73 +        +  
Map4 1046 S -0.88 +   -0.77 +    +  
Map4k4 882 S 4.07 + -0.39 + 3.35 + 3.96  +  
Map7d1 115 S 1.26 +   1.71 + 1.93  +  
Map7d1 115 S 0.57  -0.62 +      +  
Marcks 163 S -1.07 +   -0.74     + + 
Mark2 40 S 1.86 +        +  
Mark2 409 S     2.74 + 3.25  +  
Mark2 453 S -1.22 +        +  
Matr3 188 S 1.69 + 0.58 + 1.83 + 1.67  +  
Mcm2 21 S 1.07    1.45 + 1.12 + +  
Mcm2 26 S       1.04 + +  
Mcm2 27 S 1.22    1.39 + 0.59  +  
Mef2a 235 S -0.42  -0.37 +      +  
Mier1 18 S 0.36  0.38 +      +  
mKIAA0
704 
546 S     2.00 + 2.18  +  
mKIAA1
608 
349 S     2.01 + 2.13  +  
Mllt4 1157 S -1.25 + -0.57 + -1.02     +  
Mllt4 1157 S -0.75 +   -0.69  -0.86  +  
247 
 
Mllt4 1158 S -1.25 + -0.57 + -1.02     +  
Mllt4 1158 S -0.71    -0.77 + -0.66  +  
Mllt4 1167 S 1.07 +   1.37 + 1.23  +  
Mllt4 1167 S -0.77 +   -0.76 + -0.76  +  
Mtss1 276 S     1.43 + 1.23  +  
Mtss1l 209 S     2.09 + 0.66  +  
Mylk 1804 S     3.49 + 3.60  +  
Myo10 1141 S     2.85 + 2.37  +  
Myo18a 1966 S     1.53 + 1.73  + + 
Myo9a 1243 S     1.44 + 1.59  +  
Myo9b 1336 S     3.81 + 4.14  + + 
Ncapd2 1323 S -1.53 +     -1.02  + + 
Ncbp1 21 T 1.98 + 0.68 +      + + 
Ncbp1 22 S   0.73 + 1.72 + 1.59  + + 
Nck1 21 S 2.35 +   2.32 + 2.45  +  
Ndrg1 2 S     1.19 + 1.01  +  
Ndrg1 326 S       -0.97 + +  
Ndrg1 328 T       -1.07 + +  
Ndrg1 330 S -1.63 +        +  
Necap2 181 S     -1.44 + -1.18  +  
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Necap2 186 S -1.09 +        +  
Nf1 2524 S     1.69 + 1.19  +  
Nfatc4 272 S     2.22 + 2.15  +  
Nfatc4 334 S 2.19 +   2.66 + 2.87  +  
Nfia 272 S   0.86 +      +  
Nfia 279 S   0.86 +      +  
Nhsl1 1075 S 2.93 +     1.46  +  
Nipbl 274 S 0.24  0.61 +      + + 
Nop56 554 S 2.27 + 0.70 + 2.32 + 2.28  + + 
Nop58 509 S -0.35    -0.09  -0.78 + + + 
Nsfl1c 175 S 0.87 +        +  
Nucb1 368 S 0.40  -0.45 + -0.03     +  
Nufip2 231 S 0.76 +        + + 
Numa1 1951 S 3.91 + 1.04 + 3.43 + 4.43  + + 
Osbpl11 192 S -1.59 +        +  
Osbpl11 200 S 2.04 +   2.16 + 2.41  +  
Pacs1 500 T       -2.89 + +  
Pak2 197 S -1.06 +     -0.48  + + 
Pak4 97 S -1.80 +        +  
Pak4 104 S -1.80 +        + + 
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Palld 173 S 0.78  0.49 +      +  
Palm 141 T     -3.33 + -2.92  +  
Palm 145 T     -3.33 + -2.92  +  
Pank2 42 S     2.35 + 2.44  +  
Pank2 43 S     2.40 + 2.60  +  
Parva 14 S -0.33    -0.63 + -0.37  +  
Parva 19 S -0.38    -0.63 +    +  
Patl1 179 S     -1.73 + -1.63  + + 
Patl1 184 S     -1.73 + -1.63  + + 
Pcm1 380 S 2.69 +        +  
Pcm1 384 S 2.69 +        +  
Pde8a 452 S 1.18 +   1.40 + 1.32  + + 
Pds5b 1356 S 0.57      0.75 + + + 
Pdxdc1 687 T -0.09  0.44 +      +  
Pdxdc1 691 T -0.09  0.45 +      +  
Pgrmc1 161 S 0.02  -0.42 + -0.01  -0.43  +  
Phlda3 117 S 3.81 +   3.22  4.08  + + 
Phldb1 656 S 1.59 +     2.53  +  
Phldb2 510 S 1.56 +   1.71 + 1.89  +  
Phldb2 555 S 0.74    1.22 + 0.89 + +  
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Phldb2 579 S     3.56 + 4.14  +  
Pi4ka 198 S     1.74 + 1.15  +  
Pid1 188 S     1.65 + 1.92  +  
Pkn2 571 S -0.22      0.41 + +  
Plec 4032 T -0.82  -1.06 + 0.55  0.95  +  
Plec 4615 S -1.62 +     1.45  +  
Plekha5 538 S -1.60 +        +  
Plekhg3 472 S     2.03 + 2.09  +  
Plxdc2 456 S 1.78 +   1.61  1.10 + +  
Ppip5k2 1179 S     4.65 + 4.06  +  
Ppp1r12
a 
693 S 0.34  -0.40 +   -0.85  +  
Ppp1r9b 192 S     -1.07  -0.80 + + + 
Ppp2r5d 565 S 2.31 + -0.50 + 1.65  1.77  +  
Prkd3 213 S 1.17    1.26 + 1.37  +  
Prrc2a 399 S 3.32 +   3.18 + 3.74  +  
Prrc2c 2625 T     -1.67 + -0.88 + +  
Psmd11 14 S     2.94 + 2.40  +  
Ptpn13 240 S -0.10  0.64 +      +  
Ptrf 169 S 2.47 +   3.11 + 1.76 + + + 
Ptrf 171 S     2.84 + 2.57  + + 
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Ptrf 302 S 3.00 +   4.05 + 4.07  + + 
Pum1 615 S 0.91    1.11 + 1.33  +  
Pum2 587 S     2.00 + 1.63  +  
Pxn 83 S -0.10    -0.75 + 0.35  +  
Pxn 340 S     -1.14 + -0.80  +  
Rab12 68 S -1.67 +   -2.01 + -1.87  +  
Ralgps2 296 S -1.27      -1.47 + +  
Ralgps2 308 S -0.71      -1.47 + +  
Raph1 1011 S     4.37 + 4.03  + + 
Raph1 1168 T 0.27  0.57 +      + + 
Rbm14 618 S     2.80 + 2.88  + + 
Rbm17 169 S 2.78 + 0.39 +   3.28  + + 
Rbms2 33 S -1.28 +        +  
Rgl3 568 S -0.33  -1.33 +   -0.60  + + 
Ripk2 284 S     2.17 + 2.36  +  
Rnf214 511 S     -1.35 +    + + 
Rps6 235 S 2.75 +     1.80  +  
Rps6 235 S       2.07 + +  
Rps6 236 S 1.11  0.54 + 0.91  1.67 + +  
Rps6 236 S 2.15  0.82 +   1.18 + +  
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Rps6 240 S 2.75 +     1.19 + +  
Rps6 240 S   0.72 +   0.44  +  
Rps6 244 S   0.74 +   0.58  +  
Rrm2 20 S -1.47 +   -1.16 +    +  
Rtkn 93 S 2.27 +        +  
Rundc1 499 S 2.85 +        + + 
Scarf2 672 S     -0.91 + -1.56  +  
Sec16a 1028 S -0.69 +   -0.84 + -1.07  +  
Sec22b 137 S 4.54 +   3.99 + 3.81  +  
Septin-9 67 S -1.79 +   -1.33 + -1.56  +  
Septin-9 71 S -1.82 +     -1.83  +  
Septin-9 125 T -2.60 +     -3.62  +  
Setd1a 1174 T   1.06 +   0.41  + + 
Setd1a 1176 S   1.06 +   0.41  + + 
Sh3kbp
1 
436 S     -1.62 + -1.76  +  
Sh3kbp
1 
587 S -0.78 +   -0.67     +  
Sh3pxd
2a 
377 S -1.50 +        +  
Sh3pxd
2a 





991 S   -0.42 +   -0.56  +  
Sh3pxd
2b 
499 S     2.48 + 2.88  +  
Sh3pxd
2b 
528 S 2.82 +   4.31 + 4.62  +  
Sh3pxd
2b 
551 S     -1.21 + -0.65  +  
Six1 169 S -2.28 +        +  
Slain2 392 S 2.46    2.97 + 3.36  +  
Slc16a1 69 S 0.32  -0.61 +   -0.59  +  
Slc7a2 662 S     2.48 + 2.94  +  
Smarca
d1 
79 S 1.86    3.56 + 4.59  + + 
Smtn 439 S 0.24  0.71 +      +  
Smtn 440 T 0.05  0.64 +      +  
Sntb1 86 S -0.91    -1.30 +    + + 
Snx1 139 S     2.00 + 1.67  +  
Snx7 8 S 0.76  1.13 +      + + 
Sorbs2 27 S -1.45 + -0.93 +      +  
Sorbs2 27 S -1.45 + -0.93 +      +  
Sorbs2 86 S     -0.62 + -1.15  +  
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Sorbs2 352 T 0.17  -0.41 + 0.00     +  
Sorbs2 403 S 1.20 +   1.51 + 0.76 + +  
Spag9 203 S     -2.19 + -2.46  +  
Spag9 217 T     -1.97 + -2.07  +  
Spast 266 S -1.30 +     -1.68  + + 
Spats2 382 S     3.65 + 4.39  +  
Spats2 385 S     4.56 + 4.64  + + 
Specc1l 385 S 0.95 +   1.32  1.55  + + 
Specc1l 888 S 2.78 +        + + 
Srp14 45 S 2.93 +   2.43  3.45  +  
Srrm2 952 S -0.27      0.52 + +  
Srrm2 1243 S 0.65    0.57  0.73 + +  
Srrm2 1247 S 0.76    0.54  0.77 + +  
Stambpl
1 
76 S -1.16 +   -1.16 + -1.25  +  
Stk3 398 S     4.74 + 4.30  + + 
Stmn1 16 S 1.48 + 0.35 + 1.52 + 1.77  +  
Stox1 391 S -1.96  -5.80 +   0.90  +  
Stxbp5 83 S     1.70 + 1.86  +  
Svil 453 S  2.24 +   3.02 + 1.91 + +  
Svil 607 S       2.52 + +  
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Svil 627 S 3.27    4.50 + 5.00  +  
Sympk 494 S 2.00 + 1.22 + 3.07 + 2.68  +  
Synpo 488 S     -2.35 + -3.38  +  
Synpo 512 S -1.04    -1.44 + -1.16  +  
Synpo 988 S -2.13 +   -1.85  -2.94  +  
Synpo 1018 S -1.15 +        +  
Synpo 1023 S -1.34 +        +  
Synpo 1091 S 2.07 +   1.97 + 1.94  +  
Synpo2 895 S -0.23  -0.63 +   0.56  +  
Tab1 7 S     1.63 + 1.97  +  
Tab2 524 S     2.75 + 2.87  +  
Tanc1 60 S   -0.69 +   -0.40  +  
Tanc1 63 S   -0.69 +      +  
Tbc1d1
0b 
673 S     1.32 + 1.61  + + 
Tenm4 226 S     -0.02  -0.52 + + + 
Tfeb 108 S -1.61      -0.59 + +  
Tfeb 113 S -1.02 +     -0.44 + +  
Tfeb 113 S -1.61      -0.59 + +  
Tfeb 121 S -1.13 +     -0.44 + +  
Tfeb 121 S -1.61      -0.59 + +  
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Tjap1 537 S 0.87 +        +  
Tjp1 617 S -0.67    -0.63 + -0.70  +  
Tjp1 912 S -1.36 +   -0.89 + -1.22  + + 
Tmem2
45 
12 S -0.15  -0.81 +      +  
Tmem2
45 
16 S -0.15  -0.81 +      +  
Tnks1b
p1 
429 S 2.57 +   2.39 + 2.85  +  
Tnks1b
p1 
796 S 1.55 +   1.33 + 1.48  +  
Tnks1b
p1 
887 S     2.83 + 2.77  +  
Tns3 769 S 0.98    1.17 + 0.96 + + + 
Toe1 349 S 1.28 + 0.81 +      + + 
Tpd52l2 146 S -0.97  -0.95 + 0.72  1.06 + +  
Tpr 2149 S -0.27  0.92 + -1.19 +    +  
Trim28 473 S 0.82  0.42 + -0.25  0.46  +  
Trio 2458 S     -2.13 + -2.90  +  
Trio 2462 S     -2.13 + -2.90  +  
Triobp 1545 S     2.92 + 3.10  +  
Triobp 1557 S     2.93 + 3.11  +  
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Triobp 1558 S     2.93 + 3.11  +  
Trps1 851 S 1.98 + 0.75 +   2.74  +  
Tsc22d4 165 S -1.74 +        +  
Tulp3 65 S     3.48 + 3.77  +  
Ube2o 510 S     5.36 + 5.39  + + 
Unk 381 S     4.02 + 4.76  +  
Vasp 235 S 5.23 + -0.81 +   4.69  + + 
Vim 39 S     2.59 + 1.42 + +  
Vim 72 S 2.32 + 0.52 +      +  
Vim 73 S 3.15 +   3.57 + 3.50  +  
Wdr20 432 S 0.87 +   0.76  0.68 + + + 
Wipf1 330 S 4.00 +        + + 
Wipf1 340 S -0.88  0.41 +      + + 
Wnk1 2032 S     2.86 + 2.88  +  
Ybx3 259 S 3.36 +   3.31 + 1.63 + +  
Zc3h11a 236 S 2.97 + 1.47 + 3.61 + 3.26  +  
Zc3h4 1221 S       -0.76 + +  
Zc3h4 1227 S -0.23    0.01  -0.76 + +  
Zfp609 1007 S -1.06 +        +  
Zfp800 318 S     3.15 + 2.75  +  
258 
 
Zfyve19 219 S     2.69 + 2.94  +  
Zyx 144 S     1.97 +    +  
Zyx 336 S 0.40  0.49 +      +  
 
 
TABLE 4: Time Course of Transcript Expression During Osteogenic Differentiation of MC3T3-E1 Preosteoblasts.  
Data obtained using Nanostring nCounter.  Positive and negative controls are listed after the gene list.  Bone-specific 
transcripts are at the end of the table. 
Gene Name Normalized Means  Fold of Day 2 
 Day 2 Day 5 Day 10 Day 28  Day 5 Day 10 Day 28 
ADAM17 1263 1400 489 1187  1.108 -2.583 -1.064 
ALK-1 10 7 9 10  -1.429 -1.111 1 
ALK-2 (Acvr 1) 1665 1158 658 1167  -1.438 -2.53 -1.427 
ALK-3 (BMR1A) 5029 4584 2846 3893  -1.097 -1.767 -1.292 
ALK-4 (Acvr 1B) 235 206 113 384  -1.141 -2.08 1.634 
ALK-5 (TGFbR 
I) 
2071 2117 1662 3606  1.022 -1.246 1.741 
ALK-6 
(BMPR1B) 
8 8 10 13  1 1.25 1.625 
ALK-7 (Acvr1C) 20 16 30 25  -1.25 1.5 1.25 
259 
 
AMH 5 7 5 10  1.4 1 2 
APRIL 25 21 54 73  -1.19 2.16 2.92 
Activin AB 16 12 17 16  -1.333 1.063 1 
Activin RIIA 
(Acvr2a) 
516 489 344 558  -1.055 -1.5 1.081 
Alpl 28 57 131 346  2.036 4.679 12.357 
Arg-1 10 6 11 11  -1.667 1.1 1.1 
Arginase 6 5 4 9  -1.2 1.5 
 
1.5 
BAMBI 104 146 209 280  1.404 2.01 2.692 
BMPR-II 1515 1247 339 1101  -1.215 -4.469 -1.376 
Bad 190 174 284 231  -1.092 1.495 1.216 
Bax 4490 5318 4080 3239  1.184 -1.1 -1.386 
Bcl2 201 172 127 247  -1.169 -1.583 1.229 
Bcl2l1 662 462 213 438  -1.433 -3.108 -1.511 
Bcl2l11 275 323 227 408  1.175 -1.211 1.484 
Bcl6 236 288 237 1026  1.22 1.004 4.347 
Bglap 8 7 24 48  -1.143 3 6 
Bmp-1 2064 1010 1200 2272  -2.044 -1.72 1.101 




C-fos 274 266 162 165  -1.03 -1.691 -1.661 
C1qa 26 27 21 33  1.038 -1.238 1.269 
C1qb 17 15 15 25  -1.133 -1.133 1.471 
C3ar1 24 23 46 44  -1.043 1.917 1.833 
C5ar1 32 16 32 52  -2 1 1.625 
CCL2 360 261 98 90  -1.379 -3.673 -4 
CCR5 9 6 7 9  -1.5 -1.286 1 
CD105 
(Endoglin) 
14 13 8 16  -1.077 -1.75 1.143 
CD109 2503 3894 1485 2624  1.556 -1.686 1.048 
CD11b 7 6 8 7  -1.167 1.143 1 
CD16 4 4 4 6  1 1 1.5 
CD163 21 13 10 10  -1.615 -2.1 -2.1 
CD206 3 9 10 18  3 3.333 6 
CD32 17 17 28 33  1 1.647 1.941 
CD40lg 24 22 22 45  -1.091 -1.091 1.875 
CD46 13 12 14 19  -1.083 1.077 1.462 
CD55 27 29 16 41  1.074 -1.688 1.519 
CD56 (NCAM) 5504 2794 785 2940  -1.97 -7.011 -1.872 
261 
 
CD59 32 22 40 62  -1.455 1.25 1.938 
CD86 6 5 5 8  -1.2 -1.2 1.333 
CEBPb 4125 2413 2057 4156  -1.709 -2.005 1.008 
CSF1 12959 3800 985 7066  -3.41 -13.156 -1.834 
CSF2 10 10 9 12  1 -1.111 1.2 
CSF3 16 12 15 19  -1.333 -1.067 1.188 
CXCL1 7 9 9 19  1.286 1.286 2.714 
CXCL10 21 20 25 25  -1.05 1.19 1.19 
CXCL13 5 7 9 13  1.4 1.8 2.6 
CXCL2 4 4 9 9  1 2.25 2.25 
CXCL9 10 11 12 14  1.1 1.2 1.4 
CXCR5 9 7 9 9  -1.286 1 1 
Calcr 10 7 8 15  -1.429 -1.25 1.5 
Cd 44 20563 22066 8280 8030  1.073 -2.483 -2.561 
Cd 47 5072 4025 2649 6426  -1.26 -1.915 1.267 
Cd 9 9510 18856 39273 31930  1.983 4.13 3.358 
Cdh1 19 11 9 14  -1.727 -2.111 -1.357 
Chordin 122 95 278 384  -1.284 2.279 3.148 
Col1A2 88133 89213 62542 182055  1.012 -1.409 2.066 
262 
 
Col1a1 441455 473793 190991 497408  1.073 -2.311 1.127 
Cpt1a 2400 1172 750 693  -2.048 -3.2 -3.463 
Crim1 1919 939 272 411  -2.044 -7.055 -4.669 
Ctla4 24 20 34 33  -1.2 1.417 1.375 
Ctnnb1 14007 17384 16643 25936  1.241 1.188 1.852 
Ctsk 2799 3514 11613 13049  1.255 4.149 4.662 
CxCl11 8 13 11 14  1.625 1.375 1.75 
DMP-1 23 31 156 2440  1.348 6.783 106.087 
Dcstamp 27 20 36 38  -1.35 1.333 1.407 
Decorin 3220 5113 22780 16448  1.588 7.075 5.108 
Dermatopontin 26 24 1143 400  -1.083 43.962 15.385 
EGF 17 24 47 112  1.412 2.765 6.588 
EOMES 35 41 25 39  1.171 -1.4 1.114 
Elastase 
(ELANE) 
22 15 28 31  -1.467 1.273 1.409 
Emr1(F4/80) 11 7 8 9  -1.571 -1.375 -1.222 
Erbin 5151 2854 1138 2631  -1.805 -4.526 -1.958 
Ets1 1136 702 292 684  -1.618 -3.89 -1.661 
FKBP51 643 576 162 293  -1.116 -3.969 -2.195 
263 
 
FLT3L 126 112 208 333  -1.125 1.651 2.643 
Factor B 8 11 13 38  1.375 1.625 4.75 
Fgf2 131 89 76 104  -1.472 -1.724 -1.26 
Fizz1 17 19 19 25  1.118 1.118 1.471 
Follistatin 4001 2144 3091 3470  -1.866 -1.294 -1.153 
FoxP3 21 22 21 27  1.048 1 1.286 
Fstl3 181 56 42 79  -3.232 -4.31 -2.291 
Fstl4 12 12 19 24  1 1.583 2 
Furin (PACE) 3549 2891 1467 2024  -1.228 -2.419 -1.753 
G6pd2 2042 2209 665 583  1.082 -3.071 -3.503 
GDF1 18 14 22 40  -1.286 1.222 2.222 
GDF15 (MIC-1) 236 66 89 163  -3.576 -2.652 -1.448 
GDF2 (BMP9) 16 12 19 17  -1.333 1.188 1.063 
GDF3 (Vgr-2) 8 7 6 10  -1.143 -1.333 1.25 
GDNFR alpha-2 2512 2375 1373 731  -1.058 -1.83 -3.436 
GDNFR alpha-3 12 11 14 17  -1.091 1.167 1.417 
GFR alpha-1 12 13 13 23  1.083 1.083 1.917 
GP49A 28 22 29 49  -1.273 1.036 1.75 
Gfra4 6 5 7 12  -1.2 1.167 2 
264 
 
Gprasp1 134 141 81 187  1.052 -1.654 1.396 
Gprasp2 6 7 6 7  1.167 1 1.167 
Gr1 7 7 10 7  1 1.429 1 
Gremlin 1455 864 1812 2934  -1.684 1.245 2.016 
GzmB 6 5 12 14  -1.2 2 2.333 
HAVCR2 20 16 15 22  -1.25 -1.333 1.1 
Hk2 1281 1095 442 1924  -1.17 -2.898 1.502 
Hmgb1 7219 8621 3743 3735  1.194 -1.929 -1.933 
Hmox1 2224 1166 1211 5257  -1.907 -1.836 2.364 
IFNG 26 16 15 19  -1.625 -1.733 -1.368 
IL-10 18 13 11 14  -1.385 -1.636 -1.286 
IL-12a 10 35 102 379  3.5 10.2 37.9 
IL-13 23 16 30 30  -1.438 1.304 1.304 
IL-15 10 5 10 6  -2 1 -1.667 
IL-15Ra 83 73 82 100  -1.137 -1.012 1.205 
IL-17a 11 12 14 19  1.091 1.273 1.727 
IL-1B 20 20 35 28  1 1.75 1.4 
IL-2 5 6 9 13  1.2 1.8 2.6 
IL-21r 4 4 5 13  1 1.25 3.25 
265 
 
IL-2RB 54 42 61 125  -1.286 1.13 2.315 
IL-2Rg 15 13 15 30  -1.154 1 2 
IL-4 20 16 32 27  -1.25 1.6 1.35 
IL-4Ralpha 613 366 326 424  -1.675 -1.88 -1.446 
IL-6 65 57 45 44  -1.14 -1.444 -1.477 
IL-7 800 436 104 91  -1.835 -7.692 -8.791 
IL-7Ra 14 16 14 19  1.143 1 1.357 
IL18r1 10 14 24 15  1.4 2.4 1.5 
IL1RL1 1048 1026 1073 187  -1.021 1.024 -5.604 
IL2ra 13 13 11 16  1 -1.182 1.231 
IL9R 7 8 9 15  1.143 1.286 2.143 
Ibsp 34 2552 40862 141485  75.059 1201.824 4161.324 
Ift122 838 625 513 879  -1.341 -1.634 1.049 
Ift139 883 1136 560 1187  1.287 -1.577 1.344 
Ift140 609 746 419 529  1.225 -1.453 -1.151 
Ift172 434 360 247 724  -1.206 -1.757 1.668 
Ift88 107 107 113 198  1 1.056 1.85 
Igsf1 26 18 30 31  -1.444 1.154 1.192 
Irf-5 1013 338 124 145  -2.997 -8.169 -6.986 
266 
 
LRRC32 22 35 44 97  1.591 2 4.409 
Lag3 36 45 42 56  1.25 1.167 1.556 
Ldha 38675 39035 36675 36620  1.009 -1.055 -1.056 
Lef1 282 288 280 492  1.021 -1.007 1.745 
Lefty 82 82 86 95  1 1.049 1.159 
MCP-1 10 12 14 20  1.2 1.4 2 
MIS RII (Amhr2) 29 40 155 566  1.379 5.345 19.517 
MMP2 32306 31357 26362 21332  -1.03 -1.225 -1.514 
MMP9 34 33 24 34  -1.03 -1.417 1 
MT1-MMP 
(MMP14) 
7672 6308 7620 10827  -1.216 -1.007 1.411 
MT3-MMP 
(MMP16) 
353 355 116 346  1.006 -3.043 -1.02 
Mmp1 23 15 31 33  -1.533 1.348 1.435 
Msx2 714 445 114 117  -1.604 -6.263 -6.103 
ND4 1859 1873 2646 4606  1.008 1.423 2.478 
NGF 953 689 184 267  -1.383 -5.179 -3.569 
Nanog 89 57 62 60  -1.561 -1.435 -1.483 
Nfatc1 637 560 277 635  -1.138 -2.3 -1.003 
Nfkb 1642 1590 701 991  -1.033 -2.342 -1.657 
267 
 
Nicalin 3583 3471 1153 1211  -1.032 -3.108 -2.959 
Noggin 49 22 46 251  -2.227 -1.065 5.122 
Nox1 13 8 19 17  -1.625 1.462 1.308 
Ocstamp 8 8 10 15  1 1.25 1.875 
PDGFA 2159 3483 5100 4173  1.613 2.362 1.933 
PGAM1 8370 7063 7728 8060  -1.185 -1.083 -1.038 
PGE2 847 1069 840 662  1.262 -1.008 -1.279 
POSTN 52675 53353 15246 11572  1.013 -3.455 -4.552 
PPARG 16 18 16 22  1.125 1 1.375 
PTPRC 18 18 38 31  1 2.111 1.722 
Pcx 636 1305 366 931  2.052 -1.738 1.464 
Pdcd1 18 9 23 32  -2 1.278 1.778 
Pdlim7 6471 2873 1780 2074  -2.252 -3.635 -3.12 
Pfkl 3195 1986 1597 2703  -1.609 -2.001 -1.182 
Pgd 2156 2120 941 1126  -1.017 -2.291 -1.915 
Pilrb1 18 13 23 34  -1.385 1.278 1.889 
Plasmin 
(Plasminogen) 
7 9 12 13  1.286 1.714 1.857 
Pou5f1 25 16 28 32  -1.563 1.12 1.28 
268 
 
Ppargc1a 8 7 10 9  -1.143 1.25 1.125 
Prdm1 5 6 7 15  1.2 1.4 3 
Prf1 14 12 13 15  -1.167 -1.077 1.071 
Ptgs2 1363 436 279 831  -3.126 -4.885 -1.64 
Pth1r 3632 6239 12823 26419  1.718 3.531 7.274 
RGM-A 219 307 149 374  1.402 -1.47 1.708 
RGM-B 1061 983 480 973  -1.079 -2.21 -1.09 
RGM-C 17 14 24 23  -1.214 1.412 1.353 
Rorc 20 18 41 41  -1.111 2.05 2.05 
Runx2 1464 2708 2232 6633  1.85 1.525 4.531 
SCF 1231 1089 201 229  -1.13 -6.124 -5.376 
SDF-1 27671 6394 774 749  -4.328 -35.751 -36.944 
SOCS1 413 750 419 510  1.816 1.015 1.235 
SOST 6 4 5 14  -1.5 -1.2 2.333 
SPON-1 13 14 14 15  1.077 1.077 1.154 
Shh 5 3 7 8  -1.667 1.4 1.6 
Slc2a1 1041 850 395 1507  -1.225 -2.635 1.448 
Slc2a4 27 20 35 38  -1.35 1.296 1.407 
Sox9 1665 1788 957 2042  1.074 -1.74 1.226 
269 
 
Sp7 1743 2677 2751 8109  1.536 1.578 4.652 
Sparc 20990 14982 38310 31653  -1.401 1.825 1.508 
Sphk1 284 289 1220 479  1.018 4.296 1.687 
Spp1 19540 17195 53771 151722  -1.136 2.752 7.765 
Stat1 1142 1517 523 745  1.328 -2.184 -1.533 
TFAM 1517 1580 1233 2073  1.042 -1.23 1.367 
TGF-B1 1273 1836 2542 7485  1.442 1.997 5.88 
TGF-beta 2 1112 404 190 272  -2.752 -5.853 -4.088 
TGF-beta 3 5163 1916 1265 1067  -2.695 -4.081 -4.839 
TGFBRIII 613 735 222 433  1.199 -2.761 -1.416 
TGFb R II 5198 5591 2589 3446  1.076 -2.008 -1.508 
TNF 14 15 22 29  1.071 1.571 2.071 
TNFRSF4 36 42 26 66  1.167 -1.385 1.833 
Tbx21 8 6 10 15  -1.333 1.25 1.875 
Tcf7 88 580 5139 4478  6.591 58.398 50.886 
Tdgf1 (Cripto) 8 10 7 15  1.25 -1.143 1.875 
Tnfrsf11a 18 25 24 34  1.389 1.333 1.889 
Tnfrsf11b 1165 933 2072 757  -1.249 1.779 -1.539 
Tnfsf11 20 14 27 25  -1.429 1.35 1.25 
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Tnfsf13b 14 15 17 45  1.071 1.214 3.214 
VEGF 2225 533 536 3636  -4.174 -4.151 1.634 
VHL 562 537 745 1013  -1.047 1.326 1.802 
Ym1 35 34 53 67  -1.029 1.514 1.914 
a-SMA 67704 31712 16456 15981  -2.135 -4.114 -4.237 
atf4 15985 8095 13266 20318  -1.975 -1.205 1.271 
axin2 70 304 208 136  4.343 2.971 1.943 
bmp4 2957 2086 1874 2847  -1.418 -1.578 -1.039 
col10a1 4 6 5 2474  1.5 1.25 618.5 
col2a1 20657 3109 296 768  -6.644 -69.787 -26.897 
dkk1 23 14 26 36  -1.643 1.13 1.565 
dspp 12 14 15 18  1.167 1.25 1.5 
fgf23 35 36 25 52  1.029 -1.4 1.486 
fgf4 24 23 31 32  -1.043 1.292 1.333 
fgf8 12 12 11 13  1 -1.091 1.083 
foxo1 240 178 89 442  -1.348 -2.697 1.842 
gata3 62 22 16 30  -2.818 -3.875 -2.067 
gli1 36 47 29 63  1.306 -1.241 1.75 
iNOS 29 26 66 71  -1.115 2.276 2.448 
271 
 
ihh 8 9 10 19  1.125 1.25 2.375 
lilrb4 5 3 5 13  -1.667 1 2.6 
msx1 81 105 97 84  1.296 1.198 1.037 
ptch1 219 244 92 291  1.114 -2.38 1.329 
pthlh 59 45 30 61  -1.311 -1.967 1.034 
serpinb9 382 317 269 256  -1.205 -1.42 -1.492 
smad 3 2700 1390 1057 2598  -1.942 -2.554 -1.039 
sprouty2 255 191 119 139  -1.335 -2.143 -1.835 
sprouty4 55 47 64 107  -1.17 1.164 1.945 
wnt5a 234 170 82 684  -1.376 -2.854 2.923 
wnt7a 14 17 20 24  1.214 1.429 1.714 
Eif4a2 9934 8006 16252 32897  -1.241 1.636 3.312 
GusB 1388 1586 988 674  1.143 -1.405 -2.059 
Oaz1 23266 28360 30508 22574  1.219 1.311 -1.031 
Stk36 32 42 21 34  1.313 -1.524 1.063 
Tceb1 5763 5128 3932 3708  -1.124 -1.466 -1.554 
Tubb4a 9 9 17 12  1 1.889 1.333 
NEG_A 35 31 38 41  -1.129 1.086 1.171 
NEG_B 10 11 12 11  1.1 1.2 1.1 
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NEG_C 8 14 8 7  1.75 1 -1.143 
NEG_D 9 7 8 11  -1.286 -1.125 1.222 
NEG_E 36 42 45 49  1.167 1.25 1.361 
NEG_F 19 19 25 20  1 1.316 1.053 
NEG_G 16 19 8 14  1.188 -2 -1.143 
NEG_H 42 52 18 36  1.238 -2.333 -1.167 
POS_A 30172 30937 35668 32729  1.025 1.182 1.085 
POS_B 8651 9089 10210 9389  1.051 1.18 1.085 
POS_C 2225 2336 2623 2433  1.05 1.179 1.093 
POS_D 626 668 733 672  1.067 1.171 1.073 
POS_E 117 115 119 120  -1.017 1.017 1.026 
POS_F 74 84 83 74  1.135 1.122 1 
                
Bone genes                
PTPRC 18 18 38 31  1 2.111 1.722 
Runx2 1464 2708 2232 6633  1.85 1.525 4.531 
Bmp2 16 15 25 21  -1.067 1.563 1.313 
Bglap 8 7 24 48  -1.143 3 6 
Spp1 19540 17195 53771 151722  -1.136 2.752 7.765 
273 
 
Col1a1 441455 473793 190991 497408  1.073 -2.311 1.127 
Mmp1 23 15 31 33  -1.533 1.348 1.435 
Ibsp 34 2552 40862 141485  75.059 1201.824 4161.324 
Alpl 28 57 131 346  2.036 4.679 12.357 
Tnfsf11 20 14 27 25  -1.429 1.35 1.25 
Sp7 1743 2677 2751 8109  1.536 1.578 4.652 
Ctsk 2799 3514 11613 13049  1.255 4.149 4.662 
POSTN 52675 53353 15246 11572  1.013 -3.455 -4.552 
Pth1r 3632 6239 12823 26419  1.718 3.531 7.274 
bmp4 2957 2086 1874 2847  -1.418 -1.578 -1.039 
col10a1 4 6 5 2474  1.5 1.25 618.5 
col2a1 20657 3109 296 768  -6.644 -69.787 -26.897 
Tnfrsf11b 1165 933 2072 757  -1.249 1.779 -1.539 
Col1A2 88133 89213 62542 182055  1.012 -1.409 2.066 
Tnfrsf11b 1165 933 2072 757  -1.249 1.779 -1.539 
MT1-MMP 
(MMP14) 
7672 6308 7620 10827  -1.216 -1.007 1.411 
Msx2 714 445 114 117  -1.604 -6.263 -6.103 
Pdlim7 6471 2873 1780 2074  -2.252 -3.635 -3.12 
274 
 
Sox9 1665 1788 957 2042  1.074 -1.74 1.226 
Sp7 1743 2677 2751 8109  1.536 1.578 4.652 
Sparc 20990 14982 38310 31653  -1.401 1.825 1.508 
 
 
TABLE 5: Differential Protein Expression in MC3T3-E1 Cells at Days 0 and 10 of Osteogenic Differentiation. 
Sorted by gene names.  Data were obtained using label free proteomics (MaxLFQ).  Differentially expressed proteins 
were determined using a two sided Welch t-test with a p val <0.05. 
 

















Ester hydrolase C11orf54 homolog  -0.13  21.39 21.52 5.08 
Uncharacterized protein C17orf59 
homolog 
 NaN    22.48 3.14 
Uncharacterized protein C1orf198 
homolog 
 -0.16  22.70 22.85 39.98 
Uncharacterized protein C1orf50 
homolog 
 0.43  20.60 20.17 12.16 




Uncharacterized protein C7orf50 
homolog 
 NaN    17.34 1.97 
Uncharacterized protein FLJ45252 
homolog 
 -0.44 + 24.30 24.73 122.03 
UPF0449 protein C19orf25 homolog  -0.03  20.92 20.94 48.85 
UPF0489 protein C5orf22 homolog  NaN    19.23 2.01 
UPF0554 protein C2orf43 homolog  NaN    20.75 7.04 
UPF0600 protein C5orf51 homolog  0.20  22.47 22.26 11.90 
UPF0668 protein C10orf76 homolog  0.55  21.28 20.73 5.34 




NaN    20.69 6.58 
UPF0585 protein C16orf13 homolog 0610011F06Ri
k 
-1.56 + 20.39 21.95 25.47 
UPF0587 protein C1orf123 homolog 0610037L13Ri
k 
0.35  23.44 23.08 4.72 
Septin-10 10-Sep NaN    20.53 3.88 





0.09  24.39 24.30 97.52 
Protein virilizer homolog 1110037F02Ri
k 
1.48  19.96 18.48 11.97 
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15 kDa selenoprotein 15-Sep -0.18  22.11 22.29 93.12 




-0.70  20.02 20.72 13.21 
 1810009N02Ri
k 
-2.23  20.23 22.46 107.57 
Mitochondrial amidoxime reducing 
component 2 
2-Mar 1.86  20.66 18.80 2.34 
Septin-2 2-Sep 0.49 + 27.83 27.33 323.31 
 2210016F16Ri
k 
NaN    19.96 3.17 
LisH domain and HEAT repeat-
containing protein KIAA1468 
2310035C23Ri
k 
0.20  21.62 21.43 85.95 
 2410002F23Ri
k 
-0.17  19.28 19.45 8.37 
Protein C8orf37 homolog 2610301B20Ri
k 
0.18  18.68 18.50 83.37 
UPF0568 protein C14orf166 homolog 2700060E02Ri
k 
-0.59 + 25.54 26.13 323.31 
Selenoprotein H 2700094K13Ri
k 
NaN    21.25 22.42 
 2810408M09Ri
k 
0.30  20.46 20.16 4.23 






NaN    22.24 4.05 
Septin-5 5-Sep -0.94 + 24.23 25.17 38.23 
Protein Njmu-R1 5730455P16Ri
k 
-0.64  20.09 20.73 29.57 
Septin-6 6-Sep NaN  21.07   3.52 
Septin-7 7-Sep -0.07  27.28 27.36 272.02 
Septin-8 8-Sep 0.09  24.63 24.54 103.28 
Septin-8 8-Sep NaN    20.04 3.28 
Septin-9 9-Sep -0.64 + 25.55 26.19 250.91 




0.53 + 23.21 22.68 30.40 
UPF0505 protein C16orf62 homolog 9030624J02Ri
k 
-0.36  21.98 22.35 7.36 
 A630010A05Ri
k 
NaN    18.56 1.46 
Aladin Aaas 0.83  20.52 19.70 6.95 
Acetoacetyl-CoA synthetase Aacs -0.69  23.59 24.28 44.88 
AP2-associated protein kinase 1 Aak1 -0.23  24.33 24.56 192.68 
 Aamp NaN    23.41 70.40 
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Alanine--tRNA ligase, cytoplasmic Aars 0.85 + 27.48 26.62 323.31 
Alanine--tRNA ligase, mitochondrial Aars2 0.29  17.93 17.65 3.07 
Protein AATF Aatf 1.05  21.63 20.58 35.25 
Multidrug resistance protein 1A Abcb1b 2.33 + 20.49 18.15 70.69 
Multidrug resistance-associated protein 
1 
Abcc1 1.00  20.96 19.96 45.82 
ATP-binding cassette sub-family D 
member 3 
Abcd3 NaN    21.00 10.73 
ATP-binding cassette sub-family E 
member 1 
Abce1 0.04  25.22 25.18 218.87 
ATP-binding cassette sub-family F 
member 1 
Abcf1 0.16  24.07 23.90 151.74 
ATP-binding cassette sub-family F 
member 2 
Abcf2 0.53 + 23.90 23.37 32.20 
ATP-binding cassette sub-family F 
member 3 
Abcf3 -0.11  22.78 22.89 83.46 
ATP-binding cassette sub-family G 
member 2 
Abcg2 NaN  19.36   2.88 
Alpha/beta hydrolase domain-
containing protein 11 
Abhd11 0.02  20.39 20.37 4.12 




containing protein 14B 
Abhd14b -0.72 + 23.47 24.19 158.65 
Abhydrolase domain-containing protein 
4 
Abhd4 NaN    17.31 3.05 
Abl interactor 1 Abi1 -0.15  23.55 23.70 60.44 
Abl interactor 2 Abi2 -0.53  20.41 20.94 5.87 
Actin-binding LIM protein 1 Ablim1 1.10  22.71 21.61 51.27 
Active breakpoint cluster region-related 
protein 
Abr -1.55  20.84 22.39 107.56 
Costars family protein ABRACL Abracl 0.30  25.65 25.35 49.59 
3-ketoacyl-CoA thiolase A, peroxisomal Acaa1a -1.04 + 24.82 25.86 323.31 
3-ketoacyl-CoA thiolase, mitochondrial Acaa2 -1.80 + 22.85 24.64 239.66 
Acetyl-CoA carboxylase 1 Acaca 0.06  22.48 22.43 37.37 
Acyl-CoA dehydrogenase family 
member 10 
Acad10 NaN  12.72   2.06 
Isobutyryl-CoA dehydrogenase, 
mitochondrial 
Acad8 0.30  21.06 20.76 16.58 
Acyl-CoA dehydrogenase family 
member 9, mitochondrial 
Acad9 -0.10  22.58 22.69 19.68 
Long-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
Acadl -0.40 + 24.22 24.63 109.12 
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Medium-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
Acadm -0.59 + 23.54 24.14 82.54 
Short-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
Acads -0.58 + 23.35 23.94 123.59 
Short/branched chain specific acyl-CoA 
dehydrogenase, mitochondrial 
Acadsb 0.12  24.61 24.49 212.94 
Very long-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
Acadvl 0.28  24.19 23.91 117.31 
Arf-GAP with coiled-coil, ANK repeat 
and PH domain-containing protein 2 
Acap2 -1.38 + 21.44 22.82 147.83 
Acetyl-CoA acetyltransferase, 
mitochondrial 
Acat1 -0.27 + 25.92 26.19 323.31 
Acetyl-CoA acetyltransferase, cytosolic Acat2 -1.07 + 24.64 25.71 95.64 
Golgi resident protein GCP60 Acbd3 -0.73 + 23.86 24.59 87.57 
Apoptotic chromatin condensation 
inducer in the nucleus 
Acin1 0.04  22.75 22.72 166.76 
 Acin1 NaN    23.14 31.55 
ATP-citrate synthase Acly 0.42 + 26.69 26.26 323.31 
Aconitate hydratase aco1 -1.55 + 25.11 26.66 280.08 
Aconitate hydratase, mitochondrial Aco2 -0.23  26.62 26.85 323.31 
Acyl-coenzyme A thioesterase 1 Acot1 NaN    20.88 1.89 
Acyl-coenzyme A thioesterase 11 Acot11 NaN    20.16 2.33 
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Acyl-coenzyme A thioesterase 2, 
mitochondrial 
Acot2 0.34  23.93 23.59 123.61 
Cytosolic acyl coenzyme A thioester 
hydrolase 
Acot7 -0.28  22.98 23.26 23.45 
Acyl-coenzyme A thioesterase 9, 
mitochondrial 
Acot9 0.12  23.89 23.76 94.46 
Peroxisomal acyl-coenzyme A oxidase 
1 
Acox1 0.97 + 22.20 21.24 5.93 
Acyl-coenzyme A oxidase Acox3 NaN  18.36   4.34 
Low molecular weight phosphotyrosine 
protein phosphatase 
Acp1 -0.02  23.56 23.59 54.31 
Lysosomal acid phosphatase Acp2 -0.73  21.23 21.96 13.94 
Acyl-CoA synthetase family member 2, 
mitochondrial 
Acsf2 -0.19  23.56 23.75 42.15 
Acyl-CoA synthetase family member 3, 
mitochondrial 
Acsf3 0.54  20.44 19.90 4.33 
Long-chain-fatty-acid--CoA ligase 1 Acsl1 -0.14  21.09 21.23 8.62 
Long-chain-fatty-acid--CoA ligase 3 Acsl3 0.04  19.16 19.13 5.60 
Long-chain-fatty-acid--CoA ligase 4 Acsl4 NaN  19.94   1.83 
Beta-actin-like protein 2 Actbl2 0.06  29.79 29.73 8.18 
 Actg1 0.48  29.49 29.01 323.31 
Actin, gamma-enteric smooth muscle Actg2 NaN    21.68 4.20 
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Actin-like protein 6A Actl6a 0.27  23.47 23.20 105.97 
Alpha-actinin-1 Actn1 -0.11  29.20 29.31 323.31 
Alpha-actinin-2 Actn2 NaN  23.17   1.50 
Alpha-actinin-4 Actn4 -0.39 + 28.33 28.71 323.31 
 Actn4 NaN  16.67   2.91 
Actin-related protein 10 Actr10 -0.22  21.84 22.06 24.47 
Alpha-centractin Actr1a -0.05  26.49 26.55 154.09 
Beta-centractin Actr1b 0.45  24.45 24.00 38.93 
Actin-related protein 2 Actr2 -0.57 + 26.61 27.18 323.31 
Actin-related protein 3 Actr3 0.11  26.58 26.47 323.31 
Aminoacylase-1 Acy1 -0.52 + 21.13 21.65 76.08 
Acylphosphatase Acyp1 -2.02  21.27 23.29 72.63 
Adenosine deaminase Ada NaN  19.98   2.79 
A disintegrin and metalloproteinase 
with thrombospondin motifs 4 
Adamts4 NaN    19.29 10.31 
ADAMTS-like protein 4 Adamtsl4 -0.01  19.23 19.24 10.21 
AarF domain-containing protein kinase 
4 
Adck4 NaN    17.66 10.78 
Alpha-adducin Add1 1.04  23.62 22.58 47.00 
Gamma-adducin Add3 -0.64 + 20.77 21.41 28.78 
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Alcohol dehydrogenase 1 Adh1 NaN    21.12 6.04 
S-(hydroxymethyl)glutathione 
dehydrogenase 
Adh5 0.22  23.61 23.39 22.86 
Alcohol dehydrogenase class 4 
mu/sigma chain 
Adh7 -0.16  24.92 25.08 188.00 
1,2-dihydroxy-3-keto-5-
methylthiopentene dioxygenase 
Adi1 0.06  20.91 20.85 4.87 
Adenosine kinase Adk -1.63 + 23.81 25.44 182.08 
Adenosine kinase Adk -0.69  18.82 19.51 3.06 
Activity-dependent neuroprotector 
homeobox protein 
Adnp 0.02  22.60 22.57 14.52 
2-aminoethanethiol dioxygenase Ado -0.34  21.46 21.80 4.21 
ADP-dependent glucokinase Adpgk 0.10  22.11 22.00 28.36 
[Protein ADP-ribosylarginine] 
hydrolase 
Adprh -0.20  24.51 24.72 236.99 
Poly(ADP-ribose) glycohydrolase ARH3 Adprhl2 -0.15  22.05 22.19 97.01 
Manganese-dependent ADP-
ribose/CDP-alcohol diphosphatase 
Adprm -0.15  20.47 20.62 4.25 
Beta-adrenergic receptor kinase 1 Adrbk1 -2.33 + 18.70 21.03 10.06 
Adenylosuccinate lyase Adsl -0.25  25.04 25.30 170.96 
Adenylosuccinate synthetase isozyme 
2 
Adss 0.92 + 24.42 23.50 152.47 
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Adipocyte enhancer-binding protein 1 Aebp1 -5.96 + 20.16 26.12 295.06 
Zinc finger protein AEBP2 Aebp2 -0.46  16.18 16.64 30.84 
Actin filament-associated protein 1 Afap1 0.83 + 21.95 21.13 29.15 
Arf-GAP with GTPase, ANK repeat and 
PH domain-containing protein 3 
Agap3 1.30  21.42 20.12 3.94 
Arf-GAP domain and FG repeat-
containing protein 1 
Agfg1 0.94  22.46 21.52 70.34 
Arf-GAP domain and FG repeat-
containing protein 2 
Agfg2 -0.02  20.37 20.39 1.44 
 Agl -0.83  20.90 21.74 15.56 
Protein argonaute-2 Ago2 -0.18  22.63 22.82 38.54 
1-acyl-sn-glycerol-3-phosphate 
acyltransferase 
Agpat1 0.28  19.32 19.04 5.60 
Alkyldihydroxyacetonephosphate 
synthase, peroxisomal 
Agps 0.95  22.45 21.49 60.69 
Adenosylhomocysteinase Ahcy 0.51 + 26.32 25.81 129.68 
Putative adenosylhomocysteinase 2 Ahcyl1 0.07  24.10 24.03 15.98 
Adenosylhomocysteinase Ahcyl2 NaN    18.24 1.41 
AT-hook DNA-binding motif-containing 
protein 1 
Ahdc1 0.02  19.70 19.67 7.17 
 Ahnak 0.33 + 31.63 31.29 323.31 
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 Ahnak2 -0.52  23.65 24.17 16.73 
 Ahnak2 NaN    21.85 37.06 
 Ahnak2 -0.17  26.57 26.74 323.31 
Activator of 90 kDa heat shock protein 
ATPase homolog 1 
Ahsa1 0.75 + 24.98 24.22 42.69 
Activator of 90 kDa heat shock protein 
ATPase homolog 2 
Ahsa2 NaN    21.84 9.42 
Axin interactor, dorsalization-
associated protein 
Aida 0.28  21.50 21.22 49.38 
Apoptosis-inducing factor 1, 
mitochondrial 
Aifm1 -0.12  22.38 22.50 30.16 
 Aim1 0.69 + 21.42 20.73 54.55 
Aminoacyl tRNA synthase complex-
interacting multifunctional protein 1 
Aimp1 -0.02  25.05 25.07 149.35 
Aminoacyl tRNA synthase complex-
interacting multifunctional protein 2 
Aimp2 0.80  23.25 22.45 69.37 
 Aimp2 0.01  24.03 24.02 146.81 
AH receptor-interacting protein Aip 0.23  22.61 22.38 14.85 
Adenylate kinase isoenzyme 1 Ak1 -0.61 + 26.14 26.75 146.30 
Adenylate kinase 2, mitochondrial Ak2 0.18  22.40 22.22 70.37 
GTP:AMP phosphotransferase AK3, 
mitochondrial 
Ak3 -0.76 + 23.03 23.79 40.54 
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Adenylate kinase isoenzyme 5 Ak5 -1.09 + 19.80 20.88 3.23 
A-kinase anchor protein 12 Akap12 1.38  24.19 22.81 147.76 
 Akap13 NaN    22.11 5.52 
A-kinase anchor protein 8 Akap8 -0.32  20.59 20.91 18.54 
A-kinase anchor protein 9 Akap9 -0.45  21.49 21.94 32.12 
Alcohol dehydrogenase [NADP(+)] Akr1a1 -0.47 + 26.40 26.86 323.31 
 Akr1b10 -2.00  21.29 23.28 235.12 
Aldose reductase Akr1b3 -0.11  26.19 26.30 80.06 
Aldose reductase-related protein 1 Akr1b7 NaN    23.34 3.75 
Aldose reductase-related protein 2 Akr1b8 -2.93 + 20.80 23.74 75.82 
1,5-anhydro-D-fructose reductase Akr1e2 -1.60 + 20.78 22.39 19.58 
Aflatoxin B1 aldehyde reductase 
member 2 
Akr7a2 -0.50  23.59 24.10 102.08 
RAC-alpha serine/threonine-protein 
kinase 
Akt1 1.43 + 24.02 22.59 79.90 
RAC-beta serine/threonine-protein 
kinase 
Akt2 0.53  21.44 20.91 2.34 
Delta-aminolevulinic acid dehydratase Alad 0.34  23.50 23.16 162.43 
5-aminolevulinate synthase Alas2 NaN    22.55 1.56 
Aldehyde dehydrogenase family 16 
member A1 





Aldh18a1 0.85 + 27.52 26.68 323.31 
Mitochondrial 10-formyltetrahydrofolate 
dehydrogenase 
Aldh1l2 0.65 + 27.27 26.62 323.31 
Aldehyde dehydrogenase, 
mitochondrial 
Aldh2 0.23 + 28.03 27.80 323.31 
Aldehyde dehydrogenase Aldh3a1 -0.73 + 21.40 22.13 41.47 
Aldehyde dehydrogenase Aldh3a2 -0.80  19.89 20.68 7.15 
Delta-1-pyrroline-5-carboxylate 
dehydrogenase, mitochondrial 




Aldh6a1 -1.08  20.97 22.05 48.25 
Alpha-aminoadipic semialdehyde 
dehydrogenase 
Aldh7a1 -0.99 + 24.37 25.36 223.03 
4-trimethylaminobutyraldehyde 
dehydrogenase 
Aldh9a1 -0.18  23.59 23.77 76.31 
Fructose-bisphosphate aldolase Aldoa -0.78 + 28.48 29.26 323.31 
Alpha-1,3/1,6-mannosyltransferase 
ALG2 
Alg2 -0.47  23.43 23.90 139.94 
Alpha-ketoglutarate-dependent 
dioxygenase alkB homolog 3 
Alkbh3 NaN    21.57 4.28 
RNA demethylase ALKBH5 Alkbh5 -0.75  20.42 21.17 13.68 
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Homeobox protein aristaless-like 4 Alx4 NaN    18.30 4.64 
THO complex subunit 4 Alyref -0.80 + 24.88 25.68 308.98 
Alpha-methylacyl-CoA racemase Amacr -1.93 + 21.92 23.85 47.47 
Putative N-acetylglucosamine-6-
phosphate deacetylase 
Amdhd2 -0.14  22.95 23.10 50.58 
AMP deaminase 2 Ampd2 -0.90  21.78 22.68 106.03 
Anaphase-promoting complex subunit 
1 
Anapc1 -0.13  22.39 22.52 28.87 
Anaphase-promoting complex subunit 
2 
Anapc2 -0.32  19.95 20.27 4.59 
Anaphase-promoting complex subunit 
4 
Anapc4 1.01  22.66 21.65 42.87 
Anaphase-promoting complex subunit 
5 
Anapc5 0.20  20.25 20.05 11.79 
Anaphase-promoting complex subunit 
7 
Anapc7 NaN    18.43 26.15 
Angiopoietin-related protein 2 Angptl2 -3.10 + 20.07 23.17 250.00 
Progressive ankylosis protein Ank -3.04 + 18.89 21.94 33.39 
Ankyrin-2 Ank2 0.79  21.68 20.89 5.64 
Ankyrin-3 Ank3 1.83  21.73 19.90 13.70 
Rabankyrin-5 Ankfy1 -0.40 + 24.03 24.43 150.73 
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 Ankhd1 0.75  22.00 21.25 30.08 
Ankyrin repeat and MYND domain-
containing protein 2 
Ankmy2 NaN    18.24 1.56 
Ankyrin repeat domain-containing 
protein 13A 
Ankrd13a NaN  21.86   2.62 
Ankyrin repeat domain-containing 
protein 17 
Ankrd17 NaN    18.68 19.83 
Serine/threonine-protein phosphatase 6 
regulatory ankyrin repeat subunit B 
Ankrd44 0.35  21.36 21.01 14.09 
Ankyrin repeat and SAM domain-
containing protein 1A 
Anks1 0.68  19.96 19.28 11.00 
Ankyrin repeat and zinc finger domain-
containing protein 1 
Ankzf1 -0.10  20.70 20.80 9.25 
Actin-binding protein anillin Anln NaN  20.12   4.10 
Acidic leucine-rich nuclear 
phosphoprotein 32 family member A 
Anp32a 0.01  23.04 23.03 23.90 
Acidic leucine-rich nuclear 
phosphoprotein 32 family member B 
Anp32b 0.61 + 25.21 24.60 69.13 
Acidic leucine-rich nuclear 
phosphoprotein 32 family member E 
Anp32e 0.42  24.32 23.91 20.01 
Aminopeptidase N Anpep -1.98 + 21.55 23.54 185.80 
Anthrax toxin receptor 1 Antxr1 0.57  19.24 18.66 16.59 
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Annexin Anxa1 -0.36  29.50 29.86 323.31 
Annexin A11 Anxa11 0.10  23.47 23.37 64.94 
Annexin Anxa2 0.49 + 30.51 30.02 323.31 
Annexin Anxa3 0.77 + 25.71 24.93 155.85 
Annexin Anxa4 -0.65 + 27.47 28.12 323.31 
Annexin A5 Anxa5 -0.57 + 29.47 30.04 323.31 
Annexin Anxa6 NaN    18.12 52.22 
Annexin Anxa6 0.00  29.06 29.06 323.31 
Annexin Anxa7 -0.85 + 24.71 25.56 192.79 
Annexin A8 Anxa8 -0.64 + 25.41 26.05 323.31 
Aldehyde oxidase 1 Aox1 NaN    19.90 2.06 
AP complex subunit beta Ap1b1 -0.30  24.28 24.57 64.40 
AP-1 complex subunit gamma-1 Ap1g1 -0.02  23.68 23.70 158.48 
AP-1 complex subunit mu-1 Ap1m1 -0.36  22.40 22.76 18.33 
AP-1 complex subunit sigma-1A Ap1s1 1.58  21.35 19.77 89.65 
AP-2 complex subunit alpha-1 Ap2a1 -0.52 + 24.51 25.03 204.92 
AP-2 complex subunit alpha-2 Ap2a2 0.32 + 25.97 25.65 166.02 
AP complex subunit beta Ap2b1 0.38 + 26.74 26.36 323.31 
AP-2 complex subunit mu Ap2m1 -0.12  23.89 24.01 79.89 
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AP-2 complex subunit sigma Ap2s1 0.27  22.76 22.49 8.60 
AP-3 complex subunit beta-1 Ap3b1 -0.63  23.21 23.84 239.54 
AP-3 complex subunit delta-1 Ap3d1 -0.08  23.61 23.68 231.19 
AP-3 complex subunit mu-1 Ap3m1 -0.54  23.35 23.89 152.36 
AP-3 complex subunit sigma-1 Ap3s1 -0.66  22.26 22.91 31.85 
AP complex subunit beta Ap4b1 NaN    13.66 3.05 
AP-4 complex subunit epsilon-1 Ap4e1 NaN    20.01 20.47 
Apoptotic protease-activating factor 1 Apaf1 0.26  20.68 20.42 6.21 
Amyloid beta A4 precursor protein-
binding family A member 3 
Apba3 -0.84  19.44 20.28 3.21 
Acylamino-acid-releasing enzyme Apeh -1.32 + 22.90 24.22 54.69 
DNA-(apurinic or apyrimidinic site) 
lyase 
Apex1 0.41  23.66 23.25 85.74 
Apoptosis inhibitor 5 Api5 -0.56  24.81 25.36 270.21 
Methylthioribulose-1-phosphate 
dehydratase 
Apip -0.48  23.35 23.82 23.44 
NAD(P)H-hydrate epimerase Apoa1bp -0.89 + 23.62 24.51 44.35 
MICOS complex subunit Mic27 Apool NaN  20.70   3.39 
DCC-interacting protein 13-alpha Appl1 -1.34 + 21.57 22.91 125.43 
DCC-interacting protein 13-beta Appl2 -0.94  20.38 21.32 21.24 
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Adenine phosphoribosyltransferase Aprt -0.34  24.96 25.30 67.89 
Intron-binding protein aquarius Aqr 0.13  22.56 22.43 55.67 
Serine/threonine-protein kinase A-Raf Araf -0.98  20.57 21.55 10.86 
Arf-GAP with Rho-GAP domain, ANK 
repeat and PH domain-containing 
protein 1 
Arap1 0.49 + 22.75 22.26 52.18 
Coatomer subunit delta Arcn1 -0.75 + 26.23 26.98 323.31 
ADP-ribosylation factor 1 Arf3 -0.08  27.51 27.59 244.14 
ADP-ribosylation factor 4 Arf4 -1.54 + 23.89 25.43 168.12 
ADP-ribosylation factor 5 Arf5 0.60  23.13 22.53 9.85 
ADP-ribosylation factor 6 Arf6 0.60 + 22.73 22.13 10.03 
ADP-ribosylation factor GTPase-
activating protein 1 
Arfgap1 -0.83 + 23.90 24.73 323.31 
ADP-ribosylation factor GTPase-
activating protein 2 
Arfgap2 -0.99 + 23.13 24.12 323.31 
ADP-ribosylation factor GTPase-
activating protein 3 
Arfgap3 -2.24 + 23.25 25.48 204.47 
Brefeldin A-inhibited guanine 
nucleotide-exchange protein 1 
Arfgef1 NaN    17.99 21.97 
Brefeldin A-inhibited guanine 
nucleotide-exchange protein 2 
Arfgef2 -0.44  21.80 22.24 10.10 
 Arfip1 NaN    18.22 2.35 
293 
 
 Arfip1 -0.55  24.14 24.68 177.80 
Arfaptin-2 Arfip2 NaN    20.28 11.52 
Rho GTPase-activating protein 1 Arhgap1 -0.20  25.94 26.13 80.74 
Rho GTPase-activating protein 17 Arhgap17 -0.77  19.75 20.52 20.41 
Rho GTPase-activating protein 28 Arhgap28 NaN  19.70   4.60 
Rho GTPase-activating protein 35 Arhgap35 1.22  22.22 21.00 112.34 
Rho GTPase-activating protein 5 Arhgap5 0.13  21.30 21.17 51.26 
Rho GDP-dissociation inhibitor 1 Arhgdia 0.06  28.86 28.80 323.31 
Rho GDP-dissociation inhibitor 2 Arhgdib 0.14  27.28 27.14 323.31 
Rho guanine nucleotide exchange 
factor 1 
Arhgef1 -0.04  23.29 23.33 204.15 
Rho guanine nucleotide exchange 
factor 10 
Arhgef10 -0.12  20.39 20.51 38.32 
 Arhgef11 NaN    19.97 26.55 
Rho guanine nucleotide exchange 
factor 2 
Arhgef2 1.20 + 23.41 22.21 77.67 
Rho guanine nucleotide exchange 
factor 25 
Arhgef25 0.48  22.71 22.23 53.07 
Rho guanine nucleotide exchange 
factor 40 
Arhgef40 0.34  18.65 18.31 3.70 




Rho guanine nucleotide exchange 
factor 7 
Arhgef7 -0.64  20.88 21.52 23.57 
AT-rich interactive domain-containing 
protein 1A 
Arid1a 0.15  20.07 19.92 8.91 
 Arid1b -0.38  19.68 20.06 57.47 
 Arid2 NaN    19.27 39.66 
E3 ubiquitin-protein ligase ARIH1 Arih1 0.84  20.74 19.90 11.24 
E3 ubiquitin-protein ligase ARIH2 Arih2 -0.79  19.48 20.27 42.94 
ADP-ribosylation factor-like protein 1 Arl1 -0.72 + 22.97 23.69 315.85 
ADP-ribosylation factor-like protein 2 Arl2 -0.96  21.23 22.19 23.06 
ADP-ribosylation factor-like protein 3 Arl3 -0.54  23.54 24.07 28.43 
PRA1 family protein 3 Arl6ip5 -1.60 + 20.38 21.98 215.12 
ADP-ribosylation factor-like protein 8A Arl8a NaN    20.70 15.45 
ADP-ribosylation factor-like protein 8B Arl8b 1.00  22.00 21.00 5.08 
Armadillo repeat-containing protein 1 Armc1 -0.39  20.86 21.25 34.15 
Armadillo repeat-containing protein 6 Armc6 -0.64  21.38 22.02 27.67 
Armadillo repeat-containing protein 8 Armc8 -0.39  20.26 20.65 4.21 
Actin-related protein 2/3 complex 
subunit 1A 
Arpc1a NaN    20.82 1.65 
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Actin-related protein 2/3 complex 
subunit 1B 
Arpc1b -0.85 + 25.47 26.32 215.37 
Actin-related protein 2/3 complex 
subunit 2 
Arpc2 0.02  26.83 26.81 220.21 
Actin-related protein 2/3 complex 
subunit 3 
Arpc3 -0.29  25.09 25.38 217.24 
Actin-related protein 2/3 complex 
subunit 4 
Arpc4 0.08  26.97 26.90 115.33 
Actin-related protein 2/3 complex 
subunit 5 
Arpc5 -1.26 + 24.82 26.08 110.31 
Actin-related protein 2/3 complex 
subunit 5 
Arpc5 NaN      1.55 
Actin-related protein 2/3 complex 
subunit 5 
Arpc5l -0.17  22.74 22.91 52.73 
Arpin Arpin NaN    22.20 263.46 
cAMP-regulated phosphoprotein 19 Arpp19 0.24  22.42 22.18 21.25 
Beta-arrestin-1 Arrb1 -0.46  19.84 20.30 16.74 
Arylsulfatase A Arsa -1.50 + 22.70 24.20 48.84 
Arylsulfatase B Arsb -0.12  21.81 21.92 6.51 
Arsenite methyltransferase As3mt NaN    21.70 6.73 
Acid ceramidase Asah1 -1.19 + 25.20 26.39 204.20 
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Arf-GAP with SH3 domain, ANK repeat 
and PH domain-containing protein 1 
Asap1 -0.16  22.19 22.35 323.31 
Arf-GAP with SH3 domain, ANK repeat 
and PH domain-containing protein 2 
Asap2 NaN    17.65 22.04 
Activating signal cointegrator 1 
complex subunit 2 
Ascc2 0.04  20.80 20.76 22.99 
Activating signal cointegrator 1 
complex subunit 3 
Ascc3 0.15  21.03 20.88 23.91 
Set1/Ash2 histone methyltransferase 
complex subunit ASH2 
Ash2l NaN  19.99   3.95 
Argininosuccinate lyase Asl -1.30 + 22.24 23.53 60.35 
ATPase Asna1 Asna1 -1.35 + 23.32 24.67 124.91 
Asparagine synthetase [glutamine-
hydrolyzing] 
Asns 1.38 + 27.63 26.25 134.02 
Aspartyl/asparaginyl beta-hydroxylase Asph 0.39  23.28 22.89 98.52 
Asporin Aspn -8.18 + 20.25 28.43 323.31 
Tether containing UBX domain for 
GLUT4 
Aspscr1 -0.51  20.94 21.45 55.83 
Argininosuccinate synthase Ass1 -0.65  21.93 22.58 26.87 
Protein asunder homolog Asun -0.35  19.22 19.58 8.64 
ATPase family AAA domain-containing 
protein 1 
Atad1 0.15  19.83 19.68 14.55 
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 Atf7 -0.63  20.44 21.07 11.17 
Activating transcription factor 7-
interacting protein 1 
Atf7ip -0.01  19.11 19.13 25.71 
Autophagy-related protein 16-1 Atg16l1 -0.62  19.64 20.26 6.80 
Autophagy-related protein 16-2 Atg16l2 NaN    25.23 1.78 
Ubiquitin-like-conjugating enzyme 
ATG3 
Atg3 0.35  22.44 22.09 7.82 
Cysteine protease ATG4B Atg4b 0.21  21.63 21.41 120.55 
Autophagy protein 5 Atg5 NaN  20.78   4.99 
Ubiquitin-like modifier-activating 
enzyme ATG7 
Atg7 -0.87 + 21.99 22.86 51.22 
 Atg9a NaN    20.57 3.02 
Acid trehalase-like protein 1 Athl1 -1.71  20.65 22.36 37.93 
Bifunctional purine biosynthesis 
protein PURH 
Atic 0.29 + 27.26 26.97 323.31 
Atlastin-3 Atl3 -0.09  22.72 22.81 89.77 
Atrophin-1 Atn1 NaN    19.38 7.68 
Copper transport protein ATOX1 Atox1 0.21  24.68 24.47 5.48 
Sodium/potassium-transporting 
ATPase subunit alpha-1 
Atp1a1 0.84  23.19 22.35 323.31 




transporting ATPase 1 
Atp2b1 1.31  21.36 20.05 14.00 
ATP synthase subunit alpha, 
mitochondrial 
Atp5a1 0.05  29.36 29.31 323.31 
ATP synthase subunit beta, 
mitochondrial 
Atp5b -0.13  29.98 30.11 323.31 
ATP synthase subunit gamma Atp5c1 -0.15  24.98 25.13 48.01 
ATP synthase subunit delta, 
mitochondrial 
Atp5d 0.66  23.38 22.73 86.02 
ATP synthase F(0) complex subunit B1, 
mitochondrial 
Atp5f1 -0.35  22.65 23.00 13.47 
ATP synthase-coupling factor 6, 
mitochondrial 
Atp5j 0.09  24.28 24.20 8.18 
ATP synthase subunit f, mitochondrial Atp5j2 NaN    23.21 8.15 
ATP synthase subunit e, mitochondrial Atp5k NaN    19.68 56.40 
ATP synthase subunit g, mitochondrial Atp5l 0.92  22.16 21.24 1.89 
ATP synthase subunit O, mitochondrial Atp5o -0.01  26.11 26.11 140.78 
V-type proton ATPase subunit a Atp6v0a1 -0.69  20.76 21.46 54.10 
V-type proton ATPase 116 kDa subunit 
a isoform 2 
Atp6v0a2 -0.28  19.45 19.73 1.69 
V-type proton ATPase subunit d 1 Atp6v0d1 -0.41  22.61 23.02 25.91 




V-type proton ATPase subunit B, brain 
isoform 
Atp6v1b2 -1.12 + 24.19 25.30 238.92 
V-type proton ATPase subunit C 1 Atp6v1c1 -0.97 + 22.15 23.12 80.84 
V-type proton ATPase subunit D Atp6v1d -0.88  22.72 23.60 37.69 
V-type proton ATPase subunit E 1 Atp6v1e1 -1.28 + 24.00 25.28 170.41 
V-type proton ATPase subunit F Atp6v1f -0.36  21.27 21.64 119.46 
V-type proton ATPase subunit G 1 Atp6v1g1 -0.48  23.42 23.90 164.65 
V-type proton ATPase subunit H Atp6v1h -0.54  22.27 22.80 40.12 
Transcriptional regulator ATRX Atrx -0.27  21.79 22.07 40.14 
Ataxin-10 Atxn10 -0.51  23.81 24.32 114.46 
Ataxin-2 Atxn2 -0.24  21.70 21.95 61.04 
Ataxin-2-like protein Atxn2l 1.14  24.11 22.97 40.82 
Cell death regulator Aven Aven NaN    16.50 13.65 
Beta-2-microglobulin B2m -0.60  23.08 23.68 3.57 
Beta-1,3-glucosyltransferase B3galtl NaN    19.25 1.43 
BRISC and BRCA1-A complex member 
1 
Babam1 -0.16  21.57 21.73 51.08 
BAG family molecular chaperone 
regulator 1 
Bag1 -0.56 + 23.80 24.36 323.31 
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BAG family molecular chaperone 
regulator 2 
Bag2 0.02  22.48 22.46 38.31 
BAG family molecular chaperone 
regulator 3 
Bag3 0.01  24.09 24.08 293.77 
BAG family molecular chaperone 
regulator 5 
Bag5 -1.19  20.76 21.95 58.89 
Large proline-rich protein BAG6 Bag6 -0.13  24.65 24.78 187.06 
Brain-specific angiogenesis inhibitor 1-
associated protein 2 
Baiap2 -0.50  23.21 23.71 79.44 
Barrier-to-autointegration factor Banf1 0.27  23.62 23.35 51.07 
Brain acid soluble protein 1 Basp1 2.82 + 23.07 20.25 263.33 
Apoptosis regulator BAX Bax 0.15  25.03 24.88 295.03 
B-cell receptor-associated protein 31 Bcap31 -0.26  22.15 22.42 7.64 
Breast cancer anti-estrogen resistance 
protein 1 
Bcar1 0.80  21.60 20.80 48.90 
Pre-mRNA-splicing factor SPF27 Bcas2 -0.78  21.08 21.86 4.64 
Breast carcinoma-amplified sequence 3 
homolog 
Bcas3 -0.65  18.61 19.25 92.56 
Branched-chain-amino-acid 
aminotransferase 
Bcat1 0.84  22.88 22.04 75.73 
Branched-chain-amino-acid 
aminotransferase 
Bcat2 -0.38 + 23.09 23.47 45.21 
301 
 
BRCA2 and CDKN1A-interacting 
protein 
Bccip 0.17  21.83 21.65 10.97 
[3-methyl-2-oxobutanoate 
dehydrogenase [lipoamide]] kinase, 
mitochondrial 
Bckdk -0.04  20.04 20.08 6.72 
B-cell CLL/lymphoma 7 protein family 
member C 
Bcl7c NaN    20.52 4.46 
Bcl-2-associated transcription factor 1 Bclaf1 0.28  22.46 22.18 4.37 
Beclin-1 Becn1 NaN    20.06 7.52 
Biglycan Bgn -6.02 + 22.46 28.48 323.31 
 Bgn NaN    22.05 12.63 
Protein bicaudal C homolog 1 Bicc1 0.34  20.00 19.66 42.90 
Protein bicaudal D homolog 2 Bicd2 NaN    19.72 36.00 
BH3-interacting domain death agonist Bid -0.10  24.01 24.12 144.94 
Myc box-dependent-interacting protein 
1 
Bin1 -0.22  24.41 24.63 226.74 
Baculoviral IAP repeat-containing 
protein 6 
Birc6 -0.72  22.65 23.37 157.42 
Bleomycin hydrolase Blmh -0.60 + 25.64 26.24 72.96 
Biogenesis of lysosome-related 
organelles complex 1 subunit 1 
Bloc1s1 NaN    20.19 4.85 
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Biogenesis of lysosome-related 
organelles complex 1 subunit 2 
Bloc1s2 NaN    19.59 6.49 
Biogenesis of lysosome-related 
organelles complex 1 subunit 6 
Bloc1s6 0.63  21.21 20.58 43.61 
Biliverdin reductase A Blvra 0.11  24.29 24.18 60.45 
Flavin reductase (NADPH) Blvrb -0.50 + 24.64 25.13 102.44 
 Bms1 -0.54  19.49 20.03 144.17 
 Bod1l 0.58  15.54 14.96 100.00 
BolA-like protein 1 Bola1 0.22  21.83 21.61 31.24 
Ribosome biogenesis protein BOP1 Bop1 0.89  23.25 22.36 18.45 
Valacyclovir hydrolase Bphl -0.58  21.04 21.62 11.11 
3(2),5-bisphosphate nucleotidase 1 Bpnt1 -0.17  23.78 23.95 269.83 
BRCA1-associated ATM activator 1 Brat1 -0.01  20.83 20.83 33.18 
Lys-63-specific deubiquitinase BRCC36 Brcc3 0.14  21.81 21.67 25.22 
Bromodomain-containing protein 3 Brd3 NaN    14.08 1.49 
Bromodomain-containing protein 4 Brd4 -0.12  20.25 20.38 15.95 
BRCA1-A complex subunit BRE Bre 0.34  22.94 22.60 5.01 
Ribosome biogenesis protein BRX1 
homolog 
Brix1 1.80  23.70 21.91 54.59 
BRO1 domain-containing protein BROX Brox 0.25  23.51 23.26 24.50 
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Basigin Bsg NaN  19.43   4.20 
 Btaf1 -0.34  21.87 22.21 155.97 
Transcription factor BTF3 Btf3 0.12  25.94 25.82 232.35 
Transcription factor BTF3 Btf3l4 0.13  24.16 24.03 48.93 
Mitotic checkpoint protein BUB3 Bub3 0.15  24.04 23.89 111.97 
Protein BUD31 homolog Bud31 -0.59  19.95 20.54 8.73 
Bystin Bysl -0.02  20.37 20.38 15.87 
Basic leucine zipper and W2 domain-
containing protein 1 
Bzw1 0.80 + 24.18 23.38 109.32 
Basic leucine zipper and W2 domain-
containing protein 2 
Bzw2 0.83  22.41 21.58 116.31 
Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial 
C1qbp -0.56  23.80 24.36 93.97 
Carbonic anhydrase 5B, mitochondrial Ca5b -0.85  20.67 21.52 3.76 
Calcium-binding protein 39 Cab39 -0.04  22.76 22.80 69.36 
Calcium-binding protein 39-like Cab39l NaN  17.00   1.95 
Voltage-dependent P/Q-type calcium 
channel subunit alpha-1A 
Cacna1a 0.97  20.47 19.50 32.04 
Cactin Cactin NaN    19.47 5.89 
Calcyclin-binding protein Cacybp 0.22  25.75 25.53 302.10 
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CAD protein Cad 0.31 + 26.38 26.07 323.31 
 Cald1 0.72 + 29.17 28.45 323.31 
Calmodulin Calm1 -0.03  28.86 28.89 323.31 
Calreticulin Calr -0.99 + 26.69 27.68 323.31 
Calumenin Calu 1.71 + 27.56 25.86 323.31 
 Calu 0.24  25.54 25.30 87.86 
Calcium/calmodulin-dependent protein 
kinase type 1 
Camk1 0.35  23.40 23.05 31.75 
Calcium/calmodulin-dependent protein 
kinase type II subunit delta 
Camk2d -0.91 + 24.06 24.97 215.82 
Calcium/calmodulin-dependent protein 
kinase type II subunit gamma 
Camk2g -0.19  21.13 21.32 63.36 
Calcium/calmodulin-dependent protein 
kinase kinase 2 
Camkk2 -1.05  18.56 19.62 12.47 
Cullin-associated NEDD8-dissociated 
protein 1 
Cand1 0.30  27.70 27.40 323.31 
Cullin-associated NEDD8-dissociated 
protein 2 
Cand2 0.25  23.07 22.81 140.26 
Calnexin Canx 0.81  23.89 23.08 26.73 
Adenylyl cyclase-associated protein Cap1 -0.55 + 27.85 28.39 323.31 
Adenylyl cyclase-associated protein Cap2 2.32  22.47 20.15 5.56 
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Macrophage-capping protein Capg -1.40 + 26.60 27.99 323.31 
Calpain-1 catalytic subunit Capn1 0.17  23.89 23.72 79.38 
Calpain-2 catalytic subunit Capn2 -0.18  25.52 25.70 323.31 
Calpain-6 Capn6 -0.49 + 22.43 22.92 39.49 
Calpain small subunit 1 Capns1 -0.73 + 25.84 26.57 323.31 
Caprin-1 Caprin1 0.30  26.07 25.77 173.13 
F-actin-capping protein subunit alpha-1 Capza1 0.47  25.51 25.04 168.12 
F-actin-capping protein subunit alpha-2 Capza2 -0.27 + 26.89 27.16 293.17 
F-actin-capping protein subunit beta Capzb -0.83 + 25.49 26.31 197.99 
Calcium-regulated heat stable protein 1 Carhsp1 0.59  24.10 23.51 11.95 
ATP-dependent (S)-NAD(P)H-hydrate 
dehydratase 
Carkd 0.00  22.52 22.52 11.28 
Histone-arginine methyltransferase 
CARM1 
Carm1 -0.93  22.31 23.23 29.56 
Cysteine--tRNA ligase, cytoplasmic Cars 0.65 + 24.46 23.82 186.07 
Protein CASC3 Casc3 NaN  18.35   1.52 
Caskin-2 Caskin2 NaN    19.73 5.55 
Caspase-3 Casp3 NaN    20.27 4.42 
Caspase-6 Casp6 NaN  20.15   4.27 
Caspase-7 Casp7 1.58 + 20.60 19.02 109.81 
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Caspase-8 Casp8 -0.37  20.87 21.24 9.51 
Calpastatin Cast 0.29 + 25.11 24.82 323.31 
Catalase Cat 0.25  24.45 24.20 114.53 
Caveolin-1 Cav1 2.10 + 24.25 22.15 7.73 
Core-binding factor subunit beta Cbfb -0.19  22.68 22.87 9.97 
Carbonyl reductase [NADPH] 2 Cbr2 -0.72 + 23.99 24.71 228.39 
Carbonyl reductase [NADPH] 3 Cbr3 -0.52 + 24.37 24.90 183.98 
Carbonyl reductase family member 4 Cbr4 NaN    21.12 4.17 
COBW domain-containing protein 1 Cbwd1 -0.30  21.55 21.85 20.67 
Chromobox protein homolog 1 Cbx1 -1.10 + 20.76 21.87 179.64 
Chromobox protein homolog 3 Cbx3 -0.67 + 25.78 26.45 192.01 
Chromobox protein homolog 8 Cbx8 NaN    19.26 29.62 
Coiled-coil and C2 domain-containing 
protein 1A 
Cc2d1a NaN    18.63 2.98 
Coiled-coil and C2 domain-containing 
protein 1B 
Cc2d1b -1.18  19.86 21.04 7.82 
Cell division cycle and apoptosis 
regulator protein 1 
Ccar1 -0.29  22.67 22.96 43.24 
Cell cycle and apoptosis regulator 
protein 2 
Ccar2 -0.36  22.32 22.68 34.67 




Coiled-coil domain-containing protein 
132 
Ccdc132 -0.20  18.72 18.92 13.45 
Coiled-coil domain-containing protein 
167 
Ccdc167 NaN    21.70 2.41 
Coiled-coil domain-containing protein 
22 
Ccdc22 -0.31  23.08 23.38 121.57 
Coiled-coil domain-containing protein 
47 
Ccdc47 -0.24  19.46 19.70 23.75 
Coiled-coil domain-containing protein 
50 
Ccdc50 0.46  20.74 20.28 4.65 
WASH complex subunit CCDC53 Ccdc53 0.16  21.37 21.22 8.88 
Coiled-coil domain-containing protein 
58 
Ccdc58 0.23  20.05 19.82 10.63 
Coiled-coil domain-containing protein 6 Ccdc6 -0.94 + 22.18 23.11 214.00 
Coiled-coil domain-containing protein 
80 
Ccdc80 NaN  20.34   9.87 
Girdin Ccdc88a -0.91 + 19.33 20.24 56.47 
Coiled-coil domain-containing protein 
91 
Ccdc91 0.12  19.17 19.05 26.75 
Coiled-coil domain-containing protein 
93 
Ccdc93 -0.78 + 21.81 22.59 72.02 
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G1/S-specific cyclin-D2 Ccnd2 0.84  21.75 20.91 18.46 
G1/S-specific cyclin-D3 Ccnd3 NaN    19.35 4.64 
Copper chaperone for superoxide 
dismutase 
Ccs NaN    19.52 6.39 
T-complex protein 1 subunit beta Cct2 0.25  28.28 28.03 323.31 
T-complex protein 1 subunit gamma Cct3 -0.31 + 27.51 27.82 323.31 
T-complex protein 1 subunit delta Cct4 0.01  27.90 27.89 323.31 
T-complex protein 1 subunit epsilon Cct5 -0.19  27.81 28.00 323.31 
T-complex protein 1 subunit zeta Cct6a 0.30  27.76 27.46 323.31 
T-complex protein 1 subunit eta Cct7 0.03  26.70 26.67 323.31 
T-complex protein 1 subunit theta Cct8 0.08  27.80 27.72 323.31 
Vacuolar fusion protein CCZ1 homolog Ccz1 NaN    19.51 2.12 
CD109 antigen Cd109 0.74  24.06 23.32 167.31 
CD2-associated protein Cd2ap -1.42 + 22.24 23.67 122.97 
CD2 antigen cytoplasmic tail-binding 
protein 2 
Cd2bp2 1.38  20.75 19.37 6.81 
CD44 antigen Cd44 3.18  25.92 22.74 40.68 
Leukocyte surface antigen CD47 Cd47 0.30  20.76 20.46 15.31 
Tetraspanin Cd63 -2.55  20.65 23.20 43.38 
CD99 antigen Cd99 -1.93  20.64 22.58 16.49 
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Codanin-1 Cdan1 -0.24  21.27 21.51 18.02 
Cell division cycle protein 123 homolog Cdc123 NaN  19.50   3.95 
Cell division cycle protein 16 homolog Cdc16 -1.37  20.85 22.21 70.45 
Cell division cycle protein 23 homolog Cdc23 -0.27  21.33 21.61 15.73 
Anaphase-promoting complex subunit 
CDC26 
Cdc26 0.13  19.48 19.35 31.04 
Hsp90 co-chaperone Cdc37 Cdc37 0.20  24.94 24.74 323.31 
Hsp90 co-chaperone Cdc37-like 1 Cdc37l1 0.41  20.62 20.21 1.60 
Cell division control protein 42 
homolog 
Cdc42 1.47 + 24.95 23.48 107.15 
Non-specific serine/threonine protein 
kinase 
Cdc42bpa -0.17  23.04 23.22 47.42 
Non-specific serine/threonine protein 
kinase 
Cdc42bpb 0.08  22.15 22.07 37.64 
Cdc42 effector protein 1 Cdc42ep1 -0.91  21.27 22.18 17.56 
Cdc42 effector protein 3 Cdc42ep3 NaN    21.76 91.70 
Cell division cycle 5-like protein Cdc5l -0.59  23.68 24.28 144.52 
Parafibromin Cdc73 -0.02  20.38 20.40 12.65 
Cadherin-11 Cdh11 0.55  22.98 22.43 60.15 
Cadherin-2 Cdh2 NaN  21.26   14.06 
Cyclin-dependent kinase 1 Cdk1 0.43  23.28 22.86 27.87 
310 
 
Cyclin-dependent kinase 11B Cdk11b NaN    19.94 1.62 
Cyclin-dependent kinase 13 Cdk13 0.27  18.22 17.94 5.22 
Cyclin-dependent kinase 14 Cdk14 NaN  21.94   7.57 
Cyclin-dependent kinase 2 Cdk2 0.81  20.58 19.77 2.27 
Cyclin-dependent kinase 2-associated 
protein 1 
Cdk2ap1 -0.50  19.90 20.40 30.91 
Cyclin-dependent kinase 4 Cdk4 0.64  23.39 22.76 17.13 
Cyclin-dependent-like kinase 5 Cdk5 -0.95 + 21.46 22.41 16.87 
CDK5 regulatory subunit-associated 
protein 3 
Cdk5rap3 -1.68 + 21.04 22.72 134.02 
Cyclin-dependent kinase 6 Cdk6 -0.28  23.85 24.13 82.17 
Cyclin-dependent kinase 7 Cdk7 0.94  20.81 19.87 5.67 
Cyclin-dependent kinase inhibitor 1B Cdkn1b 0.37  21.16 20.79 308.91 
CDKN2A-interacting protein Cdkn2aip 0.34  21.53 21.19 12.42 
Cyclin-dependent kinase 4 inhibitor C Cdkn2c NaN    20.23 18.22 
Cerebellar degeneration-related protein 
2-like 
Cdr2l -1.06 + 19.92 20.97 6.13 
Corneodesmosin Cdsn NaN    17.17 40.16 
Protein CDV3 Cdv3 0.43  25.10 24.67 45.84 
CCAAT/enhancer-binding protein zeta Cebpz 0.68  22.87 22.19 20.00 
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CUGBP Elav-like family member 1 Celf1 0.00  22.48 22.48 21.75 
Centrosomal protein of 170 kDa Cep170 -0.83  22.22 23.05 120.17 
Centrosomal protein of 97 kDa Cep97 NaN    19.01 1.90 
Centrin-2 Cetn2 NaN    21.17 27.70 
Cilia- and flagella-associated protein 20 Cfap20 -0.18  19.70 19.87 10.52 
Cilia- and flagella-associated protein 36 Cfap36 0.07  21.47 21.40 60.25 
Craniofacial development protein 1 Cfdp1 -0.71 + 22.26 22.98 34.28 
Cofilin-1 Cfl1 -0.18  29.04 29.21 323.31 
Cofilin-2 Cfl2 -0.25  23.14 23.39 150.06 
Cingulin-like protein 1 Cgnl1 0.41  18.38 17.97 44.79 
Cell growth regulator with EF hand 
domain protein 1 
Cgref1 NaN    21.25 124.87 
Chromosome alignment-maintaining 
phosphoprotein 1 
Champ1 NaN  18.79   6.56 
MICOS complex subunit Mic19 Chchd3 0.22  21.82 21.60 3.98 
MICOS complex subunit Mic25 Chchd6 -0.08  18.82 18.90 3.82 
Chromodomain-helicase-DNA-binding 
protein 1 
Chd1 0.09  23.43 23.34 5.06 
Chromodomain-helicase-DNA-binding 
protein 2 
Chd2 NaN    17.97 2.41 






Chd8 NaN    17.49 9.07 
Chitinase domain-containing protein 1 Chid1 -2.10  19.70 21.80 5.19 
Rab proteins geranylgeranyltransferase 
component A 1 
Chm NaN    19.59 3.83 
Charged multivesicular body protein 2a Chmp2a -0.08  19.30 19.39 78.10 
Charged multivesicular body protein 3 Chmp3 -0.59 + 22.45 23.04 32.67 
Charged multivesicular body protein 4b Chmp4b 0.30  23.97 23.67 187.27 
Charged multivesicular body protein 5 Chmp5 -0.72  22.98 23.69 105.51 
Cysteine and histidine-rich domain-
containing protein 1 
Chordc1 2.71 + 22.91 20.20 5.06 
Carbohydrate sulfotransferase 12 Chst12 NaN    18.77 2.38 
Chromosome transmission fidelity 
protein 18 homolog 
Chtf18 NaN  20.40   4.37 
Chromosome transmission fidelity 
protein 8 homolog isoform 2 
Chtf8 NaN    18.15 2.13 
Chromatin target of PRMT1 protein Chtop 0.69  20.54 19.84 67.01 
Anamorsin Ciapin1 -0.19  22.17 22.36 16.57 
Cold-inducible RNA-binding protein Cirbp -0.99  20.83 21.82 18.31 
Cirhin Cirh1a 0.04  21.31 21.27 5.43 
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Citron Rho-interacting kinase Cit 1.48  22.57 21.09 2.22 
Cytoskeleton-associated protein 2 Ckap2 NaN  21.51   1.45 
Cytoskeleton-associated protein 4 Ckap4 0.08  26.63 26.55 323.31 
Cytoskeleton-associated protein 5 Ckap5 -0.75  21.85 22.60 105.78 
CLIP-associating protein 1 Clasp1 0.40  23.15 22.74 78.43 
CLIP-associating protein 2 Clasp2 -0.37  20.87 21.24 18.56 
CLIP-associating protein 2 Clasp2 -0.92  19.35 20.27 16.10 
Chloride channel protein Clcn7 2.03  20.01 17.98 6.39 
Chloride intracellular channel protein Clic1 0.25  27.31 27.05 182.66 
Chloride intracellular channel protein Clic4 0.00  25.27 25.27 47.76 
Clathrin interactor 1 Clint1 -0.96 + 23.43 24.39 208.76 
CAP-Gly domain-containing linker 
protein 1 
Clip1 -0.72  22.21 22.93 110.40 
Methylosome subunit pICln Clns1a -0.08  22.21 22.29 28.98 
ATP-dependent Clp protease 
proteolytic subunit 
Clpp -0.62 + 22.12 22.74 61.11 
ATP-dependent Clp protease ATP-
binding subunit clpX-like, 
mitochondrial 
Clpx 0.85 + 21.17 20.31 7.13 
Clathrin light chain A Clta -2.66 + 23.54 26.20 166.75 
Clathrin heavy chain Cltc -0.22 + 29.65 29.87 323.31 
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Clustered mitochondria protein 
homolog 
Cluh 1.13  20.83 19.70 8.00 
Citrate lyase subunit beta-like protein, 
mitochondrial 
Clybl -1.46 + 21.63 23.09 81.12 
N-acylneuraminate cytidylyltransferase Cmas NaN    21.22 8.07 
UMP-CMP kinase Cmpk1 -0.71 + 25.26 25.97 79.62 
Cap-specific mRNA (nucleoside-2-O-)-
methyltransferase 1 
Cmtr1 -0.42  20.83 21.24 6.30 
Cytosolic non-specific dipeptidase Cndp2 -0.20  23.20 23.40 53.72 
Calponin Cnn2 -0.54 + 27.54 28.08 313.92 
Calponin-3 Cnn3 -0.39  27.38 27.78 323.31 
CCR4-NOT transcription complex 
subunit 1 
Cnot1 0.18  23.35 23.16 224.74 
CCR4-NOT transcription complex 
subunit 10 
Cnot10 0.19  22.13 21.94 64.29 
 Cnot11 0.09  21.48 21.39 36.29 
CCR4-NOT transcription complex 
subunit 2 
Cnot2 -0.27  21.88 22.15 36.54 
CCR4-NOT transcription complex 
subunit 3 
Cnot3 NaN    20.06 4.97 
Protein canopy homolog 2 Cnpy2 -0.09  24.56 24.65 88.28 
Protein canopy homolog 3 Cnpy3 NaN  21.82   110.96 
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Protein canopy homolog 4 Cnpy4 -0.60 + 21.86 22.46 251.14 
CB1 cannabinoid receptor-interacting 
protein 1 
Cnrip1 NaN    22.03 3.48 
Bifunctional coenzyme A synthase Coasy -1.38 + 21.72 23.11 52.23 
Protein cordon-bleu Cobl 0.50  20.24 19.74 6.33 
Conserved oligomeric Golgi complex 
subunit 2 
Cog2 -0.28  21.44 21.72 23.42 
Conserved oligomeric Golgi complex 
subunit 3 
Cog3 -1.28 + 21.03 22.30 186.45 
Conserved oligomeric Golgi complex 
subunit 4 
Cog4 -0.29  20.75 21.04 22.86 
Conserved oligomeric Golgi complex 
subunit 5 
Cog5 -1.02  21.57 22.58 22.91 
Conserved oligomeric Golgi complex 
subunit 7 
Cog7 -0.82 + 21.89 22.71 86.24 
Conserved oligomeric Golgi complex 
subunit 8 
Cog8 0.12  20.18 20.06 5.16 
Collagen alpha-1(XI) chain Col11a1 -1.64 + 19.90 21.55 33.07 
Collagen alpha-2(XI) chain Col11a2 NaN    18.78 3.97 
Collagen alpha-1(XII) chain Col12a1 -0.43  29.06 29.49 323.31 
Collagen alpha-1(XV) chain Col15a1 -1.40  20.44 21.85 16.22 
Collagen alpha-1(XVI) chain Col16a1 NaN    19.01 58.72 
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Collagen alpha-1(I) chain Col1a1 0.54 + 29.97 29.43 323.31 
Collagen alpha-2(I) chain Col1a2 4.27 + 29.90 25.63 323.31 
Collagen alpha-1(II) chain Col2a1 0.01  19.95 19.94 6.60 
Collagen alpha-1(III) chain Col3a1 0.80  24.50 23.70 323.31 
Collagen type IV alpha-3-binding 
protein 
Col4a3bp -1.09  19.43 20.51 35.33 
Collagen alpha-1(V) chain Col5a1 0.40 + 25.11 24.71 306.78 
Collagen alpha-2(V) chain Col5a2 0.14  24.73 24.59 251.05 
Collagen alpha-1(VI) chain Col6a1 0.05  25.58 25.53 323.31 
Collagen alpha-2(VI) chain Col6a2 -0.22  24.61 24.83 237.70 
 Col6a2 NaN    18.42 14.04 
 Col6a3 0.15  28.27 28.12 323.31 
 Col6a3 NaN  22.13   35.35 
Collectin-12 Colec12 -1.03  21.62 22.65 66.56 
Procollagen galactosyltransferase 1 Colgalt1 0.83 + 24.26 23.43 37.77 
COMM domain-containing protein 1 Commd1 -0.54  20.77 21.31 34.48 
COMM domain-containing protein 10 Commd10 NaN    20.42 7.07 
COMM domain-containing protein 2 Commd2 -0.40  21.32 21.72 8.06 
COMM domain-containing protein 3 Commd3 -0.36  22.10 22.46 75.86 
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COMM domain-containing protein 5 Commd5 0.19  21.43 21.24 43.16 
COMM domain-containing protein 7 Commd7 -0.03  20.84 20.86 9.29 
COMM domain-containing protein 9 Commd9 -0.34  23.38 23.72 71.50 
Catechol O-methyltransferase Comt -0.66  22.78 23.44 30.53 
Coatomer subunit alpha Copa -0.83 + 27.45 28.28 323.31 
Coatomer subunit beta Copb1 -0.61 + 26.54 27.14 296.92 
Coatomer subunit beta Copb2 -0.47 + 26.55 27.02 291.71 
Coatomer subunit epsilon Cope -0.83 + 25.94 26.77 245.88 
Coatomer subunit gamma-1 Copg1 -0.60 + 26.90 27.50 323.31 
Coatomer subunit gamma-2 Copg2 -0.85 + 24.16 25.01 221.22 
COP9 signalosome complex subunit 2 Cops2 0.01  25.07 25.06 124.12 
COP9 signalosome complex subunit 3 Cops3 -0.31  24.13 24.44 277.94 
COP9 signalosome complex subunit 4 Cops4 -0.11  25.46 25.57 224.84 
COP9 signalosome complex subunit 5 Cops5 -0.52  23.18 23.70 73.32 
COP9 signalosome complex subunit 6 Cops6 0.31  24.05 23.74 97.20 
COP9 signalosome complex subunit 7a Cops7a -1.08 + 23.36 24.43 106.25 
COP9 signalosome complex subunit 7b Cops7b 0.13  19.81 19.68 33.11 
COP9 signalosome complex subunit 8 Cops8 -0.77 + 23.96 24.72 129.17 
Coatomer subunit zeta-1 Copz1 -0.93 + 23.38 24.31 60.03 
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Coatomer subunit zeta-2 Copz2 -0.68 + 23.60 24.28 323.31 
Ubiquinone biosynthesis 
monooxygenase COQ6, mitochondrial 
Coq6 NaN  19.78   5.40 
Coronin Coro1b -1.05 + 24.52 25.57 61.35 
Coronin Coro1c 0.13  24.91 24.78 182.64 
Coronin-7 Coro7 -0.89  20.41 21.30 16.05 
Coactosin-like protein Cotl1 -0.03  21.39 21.42 7.70 
Cytochrome c oxidase subunit 4 
isoform 1, mitochondrial 
Cox4i1 1.08  22.97 21.89 33.18 
Cytochrome c oxidase subunit 5A, 
mitochondrial 
Cox5a 0.11  24.38 24.28 42.94 
Cytochrome c oxidase subunit 6A, 
mitochondrial 
Cox6a1 -0.51  22.37 22.88 7.69 
Cytochrome c oxidase subunit 6B1 Cox6b1 0.01  19.60 19.59 3.25 
Cytochrome c oxidase subunit 6C Cox6c 0.42  22.48 22.06 2.83 
Cytochrome c oxidase subunit 7A2, 
mitochondrial 
Cox7a2 0.28  21.35 21.06 16.50 
Carboxypeptidase E Cpe NaN    20.26 6.57 
Copine-1 Cpne1 -0.58 + 24.65 25.23 80.00 






Cpox -0.18  20.48 20.66 11.09 
Serine/threonine-protein phosphatase 
CPPED1 
Cpped1 -1.24 + 21.83 23.07 37.76 
Carboxypeptidase Q Cpq -1.63 + 24.47 26.10 188.53 
Cleavage and polyadenylation 
specificity factor subunit 1 
Cpsf1 -0.13  21.66 21.79 18.99 
Cleavage and polyadenylation 
specificity factor subunit 2 
Cpsf2 -0.88  21.15 22.04 125.75 
Cleavage and polyadenylation 
specificity factor subunit 3 
Cpsf3 0.49  21.46 20.98 5.34 
Cleavage and polyadenylation 
specificity factor subunit 4 
Cpsf4 -0.03  18.80 18.83 42.25 
Cleavage and polyadenylation 
specificity factor subunit 6 
Cpsf6 0.06  22.84 22.78 107.16 
Cleavage and polyadenylation 
specificity factor subunit 7 
Cpsf7 0.33  22.41 22.08 58.42 
Carnitine O-palmitoyltransferase 1, liver 
isoform 
Cpt1a NaN  20.20   37.73 
Carnitine O-palmitoyltransferase 2, 
mitochondrial 
Cpt2 -0.46  22.25 22.71 81.32 
Cellular retinoic acid-binding protein 2 Crabp2 -1.51  21.51 23.02 26.44 
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Death domain-containing protein 
CRADD 
Cradd -1.78  19.85 21.64 22.50 
CREB-binding protein Crebbp -0.52  19.35 19.87 38.57 
Protein CREG1 Creg1 NaN    22.79 6.43 
Cysteine-rich with EGF-like domain 
protein 2 
Creld2 0.64  19.70 19.05 4.39 
Cysteine-rich protein 2 Crip2 -0.20  26.42 26.62 165.93 
 Crk 0.19  24.16 23.96 160.83 
Crk-like protein Crkl 0.49 + 22.92 22.43 48.01 
Cytokine receptor-like factor 3 Crlf3 -0.06  21.28 21.34 53.17 
Crooked neck-like protein 1 Crnkl1 -0.44  20.60 21.04 108.53 
Peroxisomal carnitine O-
octanoyltransferase 
Crot 1.27  21.48 20.22 11.12 
Cartilage-associated protein Crtap -0.47  23.64 24.12 41.28 
CREB-regulated transcription 
coactivator 3 
Crtc3 NaN  18.79   1.79 
Lambda-crystallin homolog Cryl1 -1.30  18.43 19.73 19.07 
Quinone oxidoreductase Cryz -1.26 + 22.65 23.90 10.46 
Quinone oxidoreductase-like protein 1 Cryzl1 -0.23  23.16 23.38 57.88 
Citrate synthase, mitochondrial Cs -0.38  26.46 26.83 209.19 
Cysteine sulfinic acid decarboxylase Csad -2.30 + 22.01 24.32 28.62 
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Cold shock domain-containing protein 
E1 
Csde1 0.59  23.58 22.99 323.31 
Exportin-2 Cse1l 0.25  28.37 28.12 323.31 
Non-specific protein-tyrosine kinase Csk 1.18 + 23.08 21.90 87.73 
Casein kinase I isoform alpha Csnk1a1 NaN  19.97   2.57 
Casein kinase II subunit alpha Csnk2a1 0.51  25.08 24.57 118.21 
Casein kinase II subunit alpha Csnk2a2 0.00  22.98 22.98 65.01 
Casein kinase II subunit beta Csnk2b -0.52  21.79 22.32 32.82 
Chondroitin sulfate proteoglycan 4 Cspg4 -2.20  22.46 24.66 323.31 
Cysteine and glycine-rich protein 1 Csrp1 1.80 + 26.27 24.48 66.66 
Cysteine and glycine-rich protein 2 Csrp2 0.83 + 25.63 24.81 66.86 
Cystatin-B Cstb -0.73 + 25.07 25.80 284.98 
Cleavage stimulation factor subunit 1 Cstf1 0.11  23.10 23.00 122.29 
Cleavage stimulation factor subunit 2 Cstf2 0.09  22.09 22.01 41.48 
Cleavage stimulation factor subunit 2 
tau variant 
Cstf2t -0.99  21.77 22.76 201.52 
Cleavage stimulation factor subunit 3 Cstf3 -0.32  22.19 22.51 115.40 
C-terminal-binding protein 1 Ctbp1 -0.77  23.46 24.24 28.08 
C-terminal-binding protein 2 Ctbp2 -0.34  21.85 22.18 9.64 
Di-N-acetylchitobiase Ctbs NaN    19.89 3.92 
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CST complex subunit CTC1 Ctc1 0.30  20.79 20.49 4.22 
Transcriptional repressor CTCF Ctcf -2.69  17.37 20.06 198.85 
Cystathionine gamma-lyase Cth NaN  19.64   5.96 
Catenin alpha-1 Ctnna1 0.28 + 26.39 26.10 323.31 
Catenin alpha-2 Ctnna2 0.03  23.63 23.59 46.49 
Catenin beta-1 Ctnnb1 0.65 + 25.45 24.80 323.31 
Beta-catenin-like protein 1 Ctnnbl1 -0.18  22.78 22.96 43.64 
Catenin delta-1 Ctnnd1 0.43 + 25.73 25.30 323.31 
CTP synthase 1 Ctps1 1.18 + 24.81 23.63 159.05 
CTP synthase 2 Ctps2 -0.82 + 21.75 22.57 23.28 
Carboxypeptidase Ctsa -2.25 + 23.13 25.38 153.69 
Cathepsin B Ctsb -1.15 + 24.66 25.80 139.33 
Cathepsin D Ctsd -1.83 + 26.36 28.19 202.25 
Pro-cathepsin H Ctsh NaN    19.59 2.80 
Cathepsin L1 Ctsl NaN    20.97 8.00 
Cathepsin Z Ctsz NaN    22.92 26.02 
Src substrate cortactin Cttn 0.17  25.26 25.09 170.97 
CTTNBP2 N-terminal-like protein Cttnbp2nl 0.08  20.25 20.17 13.38 
Cytoplasmic tRNA 2-thiolation protein 1 Ctu1 NaN    20.44 1.83 
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Cytoplasmic tRNA 2-thiolation protein 2 Ctu2 NaN    20.56 6.11 
Cullin-1 Cul1 -0.41  22.30 22.71 305.96 
Cullin-2 Cul2 0.88  22.64 21.76 27.38 
Cullin-4A Cul4a -0.37  22.00 22.37 12.18 
Cullin-4B Cul4b -0.63  22.06 22.68 139.66 
Cullin-5 Cul5 0.14  22.36 22.22 13.70 
Cullin-7 Cul7 -0.15  22.43 22.58 109.28 
Protein CutA Cuta -0.49  23.11 23.59 5.71 
Homeobox protein cut-like Cux1 0.03  22.01 21.98 13.03 
Spliceosome-associated protein 
CWC15 homolog 
Cwc15 0.53  21.55 21.02 12.13 
Pre-mRNA-splicing factor CWC22 
homolog 
Cwc22 0.28  20.22 19.94 55.68 
Peptidyl-prolyl cis-trans isomerase 
CWC27 homolog 
Cwc27 -0.94  20.24 21.18 124.75 
Cytochrome b5 Cyb5a 0.89  23.50 22.62 161.65 
Cytochrome b5 type B Cyb5b 1.32 + 24.10 22.79 38.83 
NADH-cytochrome b5 reductase 1 Cyb5r1 NaN  20.45   4.70 
NADH-cytochrome b5 reductase Cyb5r3 0.61  25.59 24.98 112.64 
Cytochrome c, somatic Cycs 1.82  21.02 19.19 5.12 
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Cytoplasmic FMR1-interacting protein 1 Cyfip1 0.48  24.86 24.38 158.41 
Cysteine and histidine-rich protein 1 Cyhr1 NaN    16.51 1.59 
Cysteine and histidine-rich protein 1 Cyhr1 NaN    17.78 2.40 
Ubiquitin carboxyl-terminal hydrolase 
CYLD 
Cyld NaN    18.57 2.63 
Lanosterol 14-alpha demethylase Cyp51a1 1.27  21.80 20.52 24.95 
Cytohesin-3 Cyth3 NaN    18.40 3.49 
ES1 protein homolog, mitochondrial D10Jhu81e 0.16  23.36 23.20 10.42 
Protein FAM91A1 D15Ertd621e -0.14  22.72 22.86 175.39 
Pumilio domain-containing protein 
KIAA0020 
D19Bwg1357e NaN  19.68   4.75 
Disheveled-associated activator of 
morphogenesis 2 
Daam2 -0.37  19.62 19.99 40.06 
Disabled homolog 2 Dab2 -0.61  21.79 22.41 24.78 
Disabled homolog 2-interacting protein Dab2ip NaN    23.78 1.54 




Dak -0.09  22.69 22.78 160.36 
28S ribosomal protein S29, 
mitochondrial 
Dap3 -0.37  20.37 20.74 30.76 
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Aspartate--tRNA ligase, cytoplasmic Dars 0.21  26.85 26.64 323.31 
Death domain-associated protein 6 Daxx 0.52  19.74 19.21 2.01 
DAZ-associated protein 1 Dazap1 -0.49  23.72 24.21 163.71 
Acyl-CoA-binding protein Dbi -0.20  27.24 27.44 210.04 
Drebrin Dbn1 0.73  23.63 22.89 191.75 
Drebrin-like protein Dbnl -0.59 + 24.47 25.06 301.46 
 Dcaf4 NaN  12.43   2.82 
DDB1- and CUL4-associated factor 7 Dcaf7 0.08  21.85 21.78 6.34 
DDB1- and CUL4-associated factor 8 Dcaf8 0.32  21.27 20.95 54.82 
Dephospho-CoA kinase domain-
containing protein 
Dcakd 0.50  21.25 20.75 5.46 
Serine/threonine-protein kinase DCLK1 Dclk1 2.07 + 24.94 22.87 162.58 
Decorin Dcn -5.41  20.72 26.13 173.16 
mRNA-decapping enzyme 1A Dcp1a 0.10  21.18 21.08 6.19 
m7GpppX diphosphatase Dcps -0.29  23.23 23.52 70.54 
Dynactin subunit 1 Dctn1 -0.25  25.48 25.73 323.31 
Dynactin subunit 2 Dctn2 -0.14  26.19 26.33 323.31 
Dynactin subunit 4 Dctn4 0.17  23.68 23.50 65.06 
dCTP pyrophosphatase 1 Dctpp1 -1.98  17.12 19.10 6.40 
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DCN1-like protein Dcun1d1 NaN    21.88 55.85 
L-xylulose reductase Dcxr -1.83 + 22.25 24.09 129.96 
DET1- and DDB1-associated protein 1 Dda1 -1.32 + 16.63 17.95 10.75 
N(G),N(G)-dimethylarginine 
dimethylaminohydrolase 1 
Ddah1 -0.21  24.01 24.22 13.08 
N(G),N(G)-dimethylarginine 
dimethylaminohydrolase 2 
Ddah2 0.55  24.52 23.97 141.68 
DNA damage-binding protein 1 Ddb1 0.31 + 26.40 26.09 177.24 
Phospholipase DDHD2 Ddhd2 NaN  21.91   4.20 
Protein DDI1 homolog 2 Ddi2 -0.41  22.73 23.15 68.36 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase 48 kDa 
subunit 
Ddost 0.66 + 24.64 23.98 190.96 
D-dopachrome decarboxylase Ddt NaN    25.12 97.85 
ATP-dependent RNA helicase DDX1 Ddx1 -0.25  25.81 26.06 241.87 
Probable ATP-dependent RNA helicase 
DDX10 
Ddx10 -1.58  17.15 18.73 3.67 
Probable ATP-dependent RNA helicase 
DDX17 
Ddx17 -0.29  24.99 25.28 269.50 
ATP-dependent RNA helicase DDX18 Ddx18 0.06  21.32 21.26 61.89 
ATP-dependent RNA helicase DDX19A Ddx19a 1.25  22.88 21.63 97.71 
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 Ddx19b NaN    19.30 5.27 
Probable ATP-dependent RNA helicase 
DDX20 
Ddx20 0.23  21.63 21.40 7.80 
Nucleolar RNA helicase 2 Ddx21 0.27  24.42 24.15 150.02 
 Ddx23 -2.83 + 19.75 22.57 23.99 
ATP-dependent RNA helicase DDX24 Ddx24 NaN    19.58 5.29 
Probable ATP-dependent RNA helicase 
DDX27 
Ddx27 0.70 + 21.92 21.21 72.20 
ATP-dependent RNA helicase DDX39A Ddx39 0.42  23.13 22.71 74.94 
Spliceosome RNA helicase Ddx39b Ddx39b 0.20  27.11 26.91 257.84 
ATP-dependent RNA helicase DDX3X Ddx3x -0.10  24.85 24.95 133.21 
ATP-dependent RNA helicase DDX3Y Ddx3y -0.14  26.89 27.03 323.31 
Probable ATP-dependent RNA helicase 
DDX41 
Ddx41 -0.75  17.31 18.07 6.32 
ATP-dependent RNA helicase DDX42 Ddx42 -0.27  21.05 21.32 89.49 
Probable ATP-dependent RNA helicase 
DDX46 
Ddx46 -0.22  22.45 22.66 113.66 
Probable ATP-dependent RNA helicase 
DDX47 
Ddx47 0.18  21.41 21.23 14.80 
Probable ATP-dependent RNA helicase 
DDX5 
Ddx5 0.15  27.21 27.07 314.30 
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ATP-dependent RNA helicase DDX50 Ddx50 -0.18  21.70 21.87 16.24 
ATP-dependent RNA helicase DDX51 Ddx51 0.06  20.02 19.97 14.91 
ATP-dependent RNA helicase DDX54 Ddx54 -0.02  20.02 20.04 16.15 
ATP-dependent RNA helicase DDX55 Ddx55 NaN    19.44 5.40 
Probable ATP-dependent RNA helicase 
DDX56 
Ddx56 0.46  20.15 19.69 12.88 
Probable ATP-dependent RNA helicase 
DDX58 
Ddx58 0.91  22.68 21.76 46.29 
Probable ATP-dependent RNA helicase 
DDX6 
Ddx6 -0.04  25.49 25.53 233.53 
2,4-dienoyl-CoA reductase, 
mitochondrial 
Decr1 0.02  25.30 25.28 108.02 
Peroxisomal 2,4-dienoyl-CoA reductase Decr2 0.03  19.37 19.34 76.04 
Differentially expressed in FDCP 6 Def6 -1.75 + 18.92 20.67 91.25 
Protein DEK Dek -0.72  23.41 24.14 49.05 
DENN domain-containing protein 1A Dennd1a NaN    19.29 1.53 
DENN domain-containing protein 4C Dennd4c -1.06  19.29 20.35 7.39 
Deoxyribose-phosphate aldolase Dera NaN  22.16   8.93 
Non-syndromic hearing impairment 
protein 5 homolog 
Dfna5 0.73  19.19 18.45 9.79 
Protein DGCR14 Dgcr14 0.40  18.27 17.87 54.50 
329 
 
Dihydrofolate reductase Dhfr 0.60  23.96 23.36 32.43 
Deoxyhypusine synthase Dhps NaN    17.96 9.33 
Dehydrogenase/reductase SDR family 
member 1 
Dhrs1 NaN    22.35 41.58 
Dehydrogenase/reductase SDR family 
member 4 
Dhrs4 -0.10  21.02 21.12 4.62 
Dehydrogenase/reductase SDR family 
member 7B 
Dhrs7b NaN  19.55   2.04 
Pre-mRNA-splicing factor ATP-
dependent RNA helicase DHX15 
Dhx15 -0.32  25.74 26.06 323.31 
ATP-dependent RNA helicase Dhx29 Dhx29 0.31  20.96 20.65 13.45 
Putative ATP-dependent RNA helicase 
DHX30 
Dhx30 -0.06  19.93 19.99 11.46 
ATP-dependent RNA helicase DHX36 Dhx36 -1.05  20.59 21.64 13.41 
Putative ATP-dependent RNA helicase 
DHX57 
Dhx57 -0.37  20.52 20.89 117.04 
ATP-dependent RNA helicase DHX8 Dhx8 NaN    19.85 3.21 
ATP-dependent RNA helicase A Dhx9 0.33  26.31 25.98 307.07 
Protein diaphanous homolog 1 Diap1 -1.03  21.46 22.48 72.46 
Protein diaphanous homolog 2 Diap2 0.00  21.72 21.71 47.66 
Death-inducer obliterator 1 Dido1 -0.79  19.62 20.41 12.31 
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Disco-interacting protein 2 homolog B Dip2b 0.44  21.66 21.22 39.90 
Exosome complex exonuclease RRP44 Dis3 1.09  22.29 21.20 20.53 
DIS3-like exonuclease 2 Dis3l2 NaN    19.79 9.01 
H/ACA ribonucleoprotein complex 
subunit 4 
Dkc1 -0.06  23.74 23.80 246.31 
Dickkopf-related protein 3 Dkk3 -0.15  18.22 18.38 40.81 
Dihydrolipoyllysine-residue 
acetyltransferase component of 
pyruvate dehydrogenase complex, 
mitochondrial 
Dlat 0.45  24.73 24.29 125.08 
Dihydrolipoyl dehydrogenase, 
mitochondrial 
Dld -0.07  24.76 24.84 136.83 
Disks large homolog 1 Dlg1 0.25  23.06 22.81 51.08 
Disks large-associated protein 4 Dlgap4 NaN    19.98 8.22 
Dihydrolipoyllysine-residue 
succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, 
mitochondrial 
Dlst 0.25  24.08 23.83 72.85 
DmX-like protein 1 Dmxl1 NaN    17.67 2.52 
DnaJ homolog subfamily A member 1 Dnaja1 -0.08  23.98 24.06 198.79 
DnaJ homolog subfamily A member 2 Dnaja2 1.03 + 24.82 23.79 37.72 
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DnaJ homolog subfamily A member 3, 
mitochondrial 
Dnaja3 0.24  21.17 20.93 39.71 
DnaJ homolog subfamily B member 1 Dnajb1 2.02  21.89 19.88 12.18 
DnaJ homolog subfamily B member 11 Dnajb11 0.87  23.40 22.53 15.59 
DnaJ homolog subfamily B member 4 Dnajb4 -0.13  22.65 22.77 39.08 
DnaJ homolog subfamily C member 10 Dnajc10 -0.72 + 22.41 23.13 56.87 
 Dnajc13 0.89  23.96 23.07 108.05 
DnaJ homolog subfamily C member 2 Dnajc2 0.08  21.93 21.84 15.92 
DnaJ homolog subfamily C member 3 Dnajc3 -0.47  22.44 22.91 159.28 
DnaJ homolog subfamily C member 7 Dnajc7 0.18  21.89 21.71 14.03 
DnaJ homolog subfamily C member 8 Dnajc8 0.38  22.33 21.95 19.76 
DnaJ homolog subfamily C member 9 Dnajc9 0.83  20.76 19.93 10.89 
Dynamin-1 Dnm1 -1.35 + 25.63 26.98 323.31 
Dynamin-1-like protein Dnm1l 0.08  25.83 25.76 323.31 
Dynamin-2 Dnm2 0.01  24.32 24.31 130.68 
Dynamin-3 Dnm3 0.72  22.90 22.18 21.32 
DNA (cytosine-5)-methyltransferase Dnmt1 0.59  21.45 20.86 14.35 
DNA (cytosine-5)-methyltransferase 3A Dnmt3a -0.56 + 18.09 18.65 61.38 





Dnph1 0.87 + 23.29 22.42 39.86 
Deoxynucleotidyltransferase terminal-
interacting protein 2 
Dnttip2 0.41  21.15 20.74 9.34 
Dedicator of cytokinesis protein 1 Dock1 -0.30  21.90 22.20 18.11 
Dedicator of cytokinesis protein 11 Dock11 NaN    18.84 6.72 
Dedicator of cytokinesis protein 4 Dock4 NaN  26.42   4.43 
Dedicator of cytokinesis protein 7 Dock7 -1.33  21.87 23.20 122.54 
Protein dopey-2 Dopey2 NaN    19.32 5.96 
Zinc finger protein ubi-d4 Dpf2 0.25  22.29 22.04 47.63 
Diphthine synthase Dph5 NaN  20.25   2.16 
Diphthine--ammonia ligase Dph6 NaN    20.12 19.28 
Dolichol-phosphate 
mannosyltransferase subunit 1 
Dpm1 NaN    21.78 4.14 
Dipeptidyl peptidase 3 Dpp3 0.34 + 25.78 25.44 323.31 
Dipeptidyl peptidase 2 Dpp7 -2.45 + 20.42 22.87 108.96 
Dipeptidyl peptidase 9 Dpp9 0.13  21.77 21.64 35.23 
Protein dpy-30 homolog Dpy30 -0.10  22.99 23.09 204.50 
Dihydropyrimidinase-related protein 2 Dpysl2 -0.77 + 27.88 28.65 323.31 
Dihydropyrimidinase-related protein 3 Dpysl3 0.03  26.45 26.41 323.31 
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Protein Dr1 Dr1 -0.11  20.80 20.91 4.07 
Dr1-associated corepressor Drap1 NaN    21.29 30.62 
Developmentally-regulated GTP-
binding protein 1 
Drg1 -0.25  23.66 23.91 206.42 
Developmentally-regulated GTP-
binding protein 2 
Drg2 0.12  23.32 23.20 51.66 
Down syndrome critical region protein 
3 homolog 
Dscr3 NaN    21.36 5.42 
Dystonin Dst -0.98  19.09 20.07 2.48 
Destrin Dstn 0.38  25.77 25.40 142.31 
D-tyrosyl-tRNA(Tyr) deacylase 1 Dtd1 -1.11  19.50 20.61 23.51 
Probable D-tyrosyl-tRNA(Tyr) 
deacylase 2 
Dtd2 0.04  21.55 21.51 9.99 
E3 ubiquitin-protein ligase DTX3L Dtx3l NaN    20.27 54.84 
Thymidylate kinase Dtymk 1.60  22.27 20.67 22.58 
tRNA-dihydrouridine(47) synthase 
[NAD(P)(+)]-like 
Dus3l 0.00  21.43 21.43 31.62 
Dual specificity protein phosphatase 3 Dusp3 NaN    22.18 17.48 
 Dut 1.28 + 20.71 19.44 26.88 
Segment polarity protein dishevelled 
homolog DVL-2 
Dvl2 -0.22  21.02 21.24 2.37 
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Ubiquitin-like protein 4A DXS254E -0.84  21.89 22.73 5.73 
Cytoplasmic dynein 1 heavy chain 1 Dync1h1 0.00  28.78 28.79 323.31 
Cytoplasmic dynein 1 intermediate 
chain 2 
Dync1i2 0.08  24.60 24.52 167.14 
Cytoplasmic dynein 1 light intermediate 
chain 1 
Dync1li1 0.33  24.37 24.04 167.27 
Cytoplasmic dynein 1 light intermediate 
chain 2 
Dync1li2 -0.02  23.30 23.32 191.41 
Cytoplasmic dynein 2 heavy chain 1 Dync2h1 1.46  23.81 22.35 1.54 
Dynein light chain 1, cytoplasmic Dynll1 1.79 + 25.02 23.23 22.97 
Dynein light chain roadblock-type 1 Dynlrb1 -0.01  25.33 25.34 73.61 
Dynein light chain Tctex-type 1 Dynlt1 -0.18  23.03 23.21 195.37 
Dysferlin Dysf -0.32  19.93 20.24 15.53 
Probable rRNA-processing protein 
EBP2 
Ebna1bp2 NaN  21.16   18.19 
Endothelin-converting enzyme 1 Ece1 0.01  19.99 19.97 3.39 
Delta(3,5)-Delta(2,4)-dienoyl-CoA 
isomerase, mitochondrial 
Ech1 -0.66 + 21.92 22.58 42.97 
Ethylmalonyl-CoA decarboxylase Echdc1 -1.09  21.41 22.51 17.45 
Enoyl-CoA hydratase domain-
containing protein 2, mitochondrial 
Echdc2 0.59  21.31 20.72 17.20 
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Enoyl-CoA hydratase, mitochondrial Echs1 0.01  24.26 24.25 37.30 
Enoyl-CoA delta isomerase 1, 
mitochondrial 
Eci1 -0.31 + 25.17 25.48 223.51 
Enoyl-CoA delta isomerase 2, 
mitochondrial 
Eci2 -0.48  21.06 21.55 23.75 
Proteasome-associated protein ECM29 
homolog 
Ecm29 -0.17  24.68 24.86 323.31 
Enhancer of mRNA-decapping protein 3 Edc3 0.13  20.54 20.40 4.51 
Enhancer of mRNA-decapping protein 4 Edc4 -0.25  24.25 24.50 323.31 
alpha-1,2-Mannosidase Edem3 -0.09  19.92 20.01 2.15 
Endothelial differentiation-related 
factor 1 
Edf1 -0.11  22.73 22.85 9.73 
EGF-like repeat and discoidin I-like 
domain-containing protein 3 
Edil3 NaN    19.94 9.88 
Early endosome antigen 1 Eea1 -0.46  23.97 24.42 323.31 
Elongation factor 1-alpha Eef1a1 0.02  30.64 30.62 323.31 
Elongation factor 1-beta Eef1b2 -0.46 + 25.81 26.27 117.88 
Elongation factor 1-delta Eef1d -0.06  23.98 24.03 24.15 
Elongation factor 1-delta Eef1d -0.22  27.84 28.06 323.31 
Eukaryotic translation elongation factor 
1 epsilon-1 
Eef1e1 0.76  22.31 21.55 8.67 
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Elongation factor 1-gamma Eef1g -0.09  28.33 28.43 212.46 
Elongation factor 2 Eef2 -0.46 + 29.72 30.18 323.31 
Eukaryotic elongation factor 2 kinase Eef2k -0.56  20.66 21.22 6.53 
Selenocysteine-specific elongation 
factor 
Eefsec -0.32  21.80 22.12 68.25 
EF-hand domain-containing protein D1 Efhd1 NaN    22.40 21.06 
EF-hand domain-containing protein D2 Efhd2 -0.56  19.80 20.37 33.32 
Elongation factor Tu GTP-binding 
domain-containing protein 1 
Eftud1 0.58  21.99 21.41 8.25 
116 kDa U5 small nuclear 
ribonucleoprotein component 
Eftud2 -0.05  25.57 25.62 323.31 
Alpha-enolase EG433182 -0.89 + 29.38 30.28 323.31 
EH domain-binding protein 1 Ehbp1 -0.31  20.08 20.39 38.31 
EH domain-binding protein 1-like 
protein 1 
Ehbp1l1 0.20  29.64 29.44 38.26 
EH domain-containing protein 1 Ehd1 0.45 + 26.60 26.15 283.10 
EH domain-containing protein 2 Ehd2 0.22 + 26.12 25.90 323.31 
EH domain-containing protein 3 Ehd3 -3.17 + 21.00 24.17 78.28 
EH domain-containing protein 4 Ehd4 0.25  23.02 22.77 43.01 
Eukaryotic translation initiation factor 1 Eif1 0.63 + 26.42 25.79 12.96 




Eukaryotic translation initiation factor 
1A, X-chromosomal 
Eif1ax 0.25  24.31 24.06 125.53 
Eukaryotic translation initiation factor 
1b 
Eif1b -0.18  21.88 22.06 22.05 
Eukaryotic translation initiation factor 
2A 
Eif2a 0.06  24.37 24.31 108.08 
Interferon-induced, double-stranded 
RNA-activated protein kinase 
Eif2ak2 0.42  22.00 21.58 83.16 
Translation initiation factor eIF-2B 
subunit alpha 
Eif2b1 -0.45  20.64 21.09 40.02 
Translation initiation factor eIF-2B 
subunit beta 
Eif2b2 -0.38  21.68 22.06 20.33 
 Eif2b3 -0.83 + 20.95 21.78 55.51 
Translation initiation factor eIF-2B 
subunit delta 
Eif2b4 -0.43  22.23 22.66 93.88 
Translation initiation factor eIF-2B 
subunit epsilon 
Eif2b5 0.10  22.45 22.35 127.64 
Eukaryotic translation initiation factor 
2D 
Eif2d 0.22  21.25 21.03 11.46 
Eukaryotic translation initiation factor 2 
subunit 1 
Eif2s1 0.35  26.30 25.95 323.31 




Eukaryotic translation initiation factor 2 
subunit 3, X-linked 
Eif2s3x 0.41  26.45 26.04 140.55 
Eukaryotic translation initiation factor 2 
subunit 3, Y-linked 
Eif2s3y NaN  22.61   5.48 
Eukaryotic translation initiation factor 3 
subunit A 
Eif3a -0.11  26.87 26.98 323.31 
Eukaryotic translation initiation factor 3 
subunit B 
Eif3b -0.37  25.68 26.05 323.31 
Eukaryotic translation initiation factor 3 
subunit C 
Eif3c 0.22 + 25.76 25.54 323.31 
Eukaryotic translation initiation factor 3 
subunit D 
Eif3d -0.51 + 24.46 24.96 181.00 
Eukaryotic translation initiation factor 3 
subunit E 
Eif3e 0.01  25.14 25.14 304.68 
Eukaryotic translation initiation factor 3 
subunit F 
Eif3f -0.66 + 25.73 26.39 323.31 
Eukaryotic translation initiation factor 3 
subunit G 
Eif3g 0.29  24.15 23.86 12.17 
Eukaryotic translation initiation factor 3 
subunit H 
Eif3h -0.23  24.97 25.19 126.05 
Eukaryotic translation initiation factor 3 
subunit I 
Eif3i 0.43  25.03 24.60 58.61 
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Eukaryotic translation initiation factor 3 
subunit J-A 
Eif3j1 -0.53  23.58 24.11 166.62 
Eukaryotic translation initiation factor 3 
subunit K 
Eif3k 0.27  23.59 23.32 183.60 
Eukaryotic translation initiation factor 3 
subunit L 
Eif3l 0.24  25.75 25.51 323.31 
Eukaryotic translation initiation factor 3 
subunit M 
Eif3m -0.22  25.00 25.22 311.86 
Eukaryotic initiation factor 4A-I Eif4a1 -0.15  29.13 29.28 323.31 
Eukaryotic initiation factor 4A-II Eif4a2 -2.19 + 21.97 24.16 174.20 
Eukaryotic initiation factor 4A-III Eif4a3 -0.17  25.60 25.77 278.83 
Eukaryotic translation initiation factor 
4B 
Eif4b -0.63  24.94 25.57 104.41 
Eukaryotic translation initiation factor 
4E 
Eif4e 0.42  23.09 22.67 47.37 
Eukaryotic translation initiation factor 
4E type 2 
Eif4e2 -1.35 + 20.98 22.33 6.30 
Eukaryotic translation initiation factor 
4E transporter 
Eif4enif1 -0.16  18.65 18.81 8.89 
Eukaryotic translation initiation factor 4 
gamma 1 
Eif4g1 -0.19  25.84 26.02 323.31 
Eukaryotic translation initiation factor 4 
gamma 2 
Eif4g2 -0.29  23.33 23.61 168.15 
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Eukaryotic translation initiation factor 4 
gamma 3 
Eif4g3 -0.77  20.64 21.41 23.81 
Eukaryotic translation initiation factor 
4H 
Eif4h 0.17  25.95 25.77 160.22 
Eukaryotic translation initiation factor 5 Eif5 0.35  22.73 22.38 59.79 
Eukaryotic translation initiation factor 
5A 
Eif5a 0.84 + 27.35 26.50 208.12 
Eukaryotic translation initiation factor 
5B 
Eif5b 0.09  24.64 24.54 192.96 
Eukaryotic translation initiation factor 6 Eif6 0.79 + 24.77 23.97 40.11 
Zinc phosphodiesterase ELAC protein 
2 
Elac2 1.44  22.65 21.21 33.36 
ELAV-like protein Elavl1 -0.09  26.41 26.49 203.66 
Engulfment and cell motility protein 2 Elmo2 0.34  21.76 21.43 20.91 
Elongator complex protein 2 Elp2 -0.33  21.30 21.63 121.01 
Elongator complex protein 3 Elp3 -1.91  21.09 23.00 12.64 
Elongator complex protein 4 Elp4 0.22  21.12 20.91 31.86 
Elongator complex protein 5 Elp5 NaN    19.72 8.79 
ER membrane protein complex subunit 
1 
Emc1 1.68  21.64 19.96 11.30 
ER membrane protein complex subunit 
2 
Emc2 -0.45  22.30 22.75 241.63 
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ER membrane protein complex subunit 
8 
Emc8 0.14  22.01 21.87 10.74 
Emerin Emd 0.72  20.17 19.45 54.17 
EMILIN-1 Emilin1 -1.71 + 25.41 27.12 323.31 
Echinoderm microtubule-associated 
protein-like 2 
Eml2 -0.52  19.97 20.49 14.38 
Echinoderm microtubule-associated 
protein-like 3 
Eml3 -0.50 + 20.16 20.66 11.83 
Echinoderm microtubule-associated 
protein-like 4 
Eml4 -0.07  22.16 22.22 54.51 
Protein enabled homolog Enah -1.85  21.30 23.15 62.54 
Beta-enolase Eno3 -1.05 + 23.76 24.81 69.21 
Enolase-phosphatase E1 Enoph1 0.92  22.55 21.63 4.19 
Alpha-endosulfine Ensa NaN    18.61 11.60 
Transcription and mRNA export factor 
ENY2 
Eny2 0.90  23.24 22.35 24.68 
Histone acetyltransferase p300 Ep300 NaN    17.66 2.31 
E1A-binding protein p400 Ep400 -0.98  17.92 18.89 25.41 
 Ep400 NaN    17.54 2.88 
Band 4.1-like protein 1 Epb4.1l1 0.03  20.65 20.62 8.84 
Band 4.1-like protein 2 Epb4.1l2 0.06  26.25 26.19 305.49 
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Band 4.1-like protein 3 Epb41l3 1.89 + 24.29 22.40 127.22 
Mammalian ependymin-related protein 
1 
Epdr1 -1.58  22.11 23.69 85.64 
Ephrin type-A receptor 2 Epha2 NaN  19.31   3.92 
Ephrin type-B receptor 3 Ephb3 0.73  19.78 19.05 5.32 
Epoxide hydrolase 1 Ephx1 0.75  25.04 24.29 93.77 
EPM2A-interacting protein 1 Epm2aip1 -0.10  22.77 22.88 73.41 
Epsin-1 Epn1 -0.06  22.10 22.16 28.11 
Epsin-2 Epn2 -2.13  18.04 20.17 44.00 
Bifunctional glutamate/proline--tRNA 
ligase 
Eprs 0.12  27.60 27.48 323.31 
Epidermal growth factor receptor 
substrate 15 
Eps15 1.39  22.98 21.58 110.62 
Epidermal growth factor receptor 
substrate 15-like 1 
Eps15l1 0.75 + 23.20 22.45 240.14 
Epidermal growth factor receptor 
kinase substrate 8 
Eps8 0.09  24.02 23.93 31.61 
Epidermal growth factor receptor 
kinase substrate 8-like protein 2 
Eps8l2 NaN    20.92 3.70 
Endoplasmic reticulum aminopeptidase 
1 
Erap1 1.81  22.98 21.17 13.05 





Erc1 0.05  23.34 23.28 79.15 
TFIIH basal transcription factor 
complex helicase XPB subunit 
Ercc3 NaN    21.29 12.42 
DNA repair endonuclease XPF Ercc4 NaN    18.93 2.28 
Endoplasmic reticulum-Golgi 
intermediate compartment protein 1 
Ergic1 1.26  23.77 22.51 52.20 
Endoplasmic reticulum-Golgi 
intermediate compartment protein 2 
Ergic2 -0.04  19.46 19.50 9.66 
Enhancer of rudimentary homolog Erh -0.83  25.11 25.94 145.22 
Erlin-2 Erlin2 0.68  22.53 21.85 42.18 
ERO1-like protein alpha Ero1l -0.27  23.02 23.29 51.25 
Endoplasmic reticulum resident protein 
29 
Erp29 -0.78 + 23.35 24.13 72.73 
Endoplasmic reticulum resident protein 
44 
Erp44 -0.41 + 25.18 25.59 142.12 
S-formylglutathione hydrolase Esd 0.62 + 26.91 26.29 153.60 
Steroid hormone receptor ERR1 Esrra NaN    13.70 4.87 
Extended synaptotagmin-1 Esyt1 0.56  23.78 23.21 144.27 
Extended synaptotagmin-2 Esyt2 1.21  21.47 20.26 21.75 
Eukaryotic peptide chain release factor 
subunit 1 
Etf1 -0.28  24.12 24.40 144.18 
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Electron transfer flavoprotein subunit 
alpha, mitochondrial 
Etfa -0.01  26.49 26.50 162.43 
Electron transfer flavoprotein subunit 
beta 
Etfb 0.01  24.80 24.78 30.80 
Sickle tail protein Etl4 0.58  22.33 21.76 68.79 
Transcription factor ETV6 Etv6 NaN  19.34   5.01 
RNA-binding protein EWS Ewsr1 -0.01  23.19 23.20 55.73 
Exocyst complex component 1 Exoc1 -2.58  20.04 22.63 67.07 
Exocyst complex component 2 Exoc2 -0.42  19.35 19.77 6.50 
Exocyst complex component 3 Exoc3 NaN    19.64 5.06 
Exocyst complex component 3-like 
protein 4 
Exoc3l4 0.04  20.16 20.13 22.25 
Exocyst complex component 4 Exoc4 0.58  23.48 22.90 73.81 
Exocyst complex component 5 Exoc5 0.41  20.99 20.58 78.53 
Exocyst complex component 6B Exoc6b 0.03  21.32 21.29 14.59 
Exocyst complex component 7 Exoc7 -0.55  21.12 21.67 47.57 
Exocyst complex component 8 Exoc8 -0.81  20.58 21.39 10.05 
Exosome component 10 Exosc10 0.80 + 19.45 18.65 5.65 
Exosome complex component RRP4 Exosc2 -0.15  21.12 21.27 11.63 
Exosome complex component RRP41 Exosc4 -0.17  21.00 21.17 7.78 
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Exosome complex exonuclease RRP42 Exosc7 NaN    19.77 3.05 
Eyes absent homolog Eya3 -0.30  19.73 20.04 6.06 
Eyes absent homolog Eya4 1.19 + 21.95 20.77 41.80 
Ezrin Ezr 0.48  24.72 24.24 305.52 
Coagulation factor XIII A chain F13a1 NaN    23.12 51.03 
Fatty acid-binding protein, heart Fabp3 NaN    19.33 1.74 
Fatty acid-binding protein, epidermal Fabp5 -0.04  25.73 25.77 70.04 
FAS-associated death domain protein Fadd -1.94 + 18.84 20.78 194.53 
Fatty acid desaturase 1 Fads1 NaN  20.54   5.51 
FAS-associated factor 1 Faf1 0.19  21.49 21.30 17.41 
FAS-associated factor 2 Faf2 0.69  20.11 19.41 7.85 
Fumarylacetoacetase Fah -1.22  22.24 23.46 70.89 
Acylpyruvase FAHD1, mitochondrial Fahd1 -0.28  21.57 21.86 22.13 
Filamin-interacting protein FAM101B Fam101b NaN    20.35 3.30 
Protein FAM107B Fam107b NaN  21.65   27.06 
Protein Noxp20 Fam114a1 -0.66 + 25.65 26.31 323.31 
Protein FAM114A2 Fam114a2 -0.63 + 21.63 22.26 51.92 
Protein FAM117B Fam117b NaN  17.24   43.58 
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Constitutive coactivator of PPAR-
gamma-like protein 1 
FAM120A -0.42  23.60 24.02 201.15 
Protein Niban Fam129a 0.39 + 25.75 25.36 318.45 
Niban-like protein 1 Fam129b -0.34  26.05 26.39 323.31 
FTS and Hook-interacting protein Fam160a2 NaN    16.24 4.25 
Protein FAM160B1 Fam160b1 -1.35  21.77 23.12 20.85 
Protein FAM162A Fam162a 0.39  21.07 20.68 8.29 
BRISC complex subunit Abro1 Fam175b -0.11  21.24 21.35 24.30 
Protein FAM192A Fam192a -1.16  18.78 19.94 275.58 
Protein FAM195B Fam195b -0.14  21.01 21.15 53.37 
WASH complex subunit FAM21 Fam21 0.18  22.16 21.97 322.08 
Protein FAM3C Fam3c -2.38  20.08 22.45 18.26 
Protein FAM45A Fam45a 0.59  21.84 21.25 20.43 
Protein FAM49B Fam49b 0.46  22.60 22.14 137.40 
Protein FAM50A Fam50a NaN    22.65 9.88 
Protein FAM65A Fam65a NaN    17.26 14.01 
Mitotic spindle-associated MMXD 
complex subunit MIP18 
Fam96b -0.12  19.75 19.87 12.55 
Protein FAM98A Fam98a 0.08  22.01 21.93 26.73 
Protein FAM98B Fam98b -0.63  22.47 23.10 49.45 
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 Fam98b -1.11  19.93 21.04 86.95 
FERM, RhoGEF and pleckstrin domain-
containing protein 1 
Farp1 2.00  23.05 21.05 15.27 
FERM, RhoGEF and pleckstrin domain-
containing protein 2 
Farp2 0.54  22.76 22.23 51.32 
Phenylalanine--tRNA ligase alpha 
subunit 
Farsa 0.02  24.83 24.81 222.00 
Phenylalanine--tRNA ligase beta 
subunit 
Farsb 0.04  23.51 23.47 79.60 
Fatty acid synthase Fasn 0.14  27.92 27.78 323.31 
 Fat1 NaN  19.81   3.11 
40S ribosomal protein S30 Fau 0.30  24.79 24.49 6.03 
rRNA 2-O-methyltransferase fibrillarin Fbl -0.32  25.44 25.76 40.07 
Fibulin-2 Fbln2 -0.68 + 26.99 27.67 199.60 
F-box/LRR-repeat protein 15 Fbxl15 NaN    20.54 5.68 
F-box/LRR-repeat protein 8 Fbxl8 0.44  19.26 18.82 4.70 
F-box only protein 22 Fbxo22 0.32  20.37 20.06 5.11 
F-box only protein 3 Fbxo3 0.79  18.68 17.89 16.70 
F-box only protein 30 Fbxo30 1.38  20.59 19.21 9.88 
F-box only protein 7 Fbxo7 NaN    19.88 11.91 
F-box/WD repeat-containing protein 8 Fbxw8 0.18  20.94 20.76 11.91 
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IgG receptor FcRn large subunit p51 Fcgrt 0.95  19.76 18.81 2.68 
F-BAR and double SH3 domains 
protein 1 
Fchsd1 NaN    19.46 5.58 
F-BAR and double SH3 domains 
protein 2 
Fchsd2 -0.70 + 18.18 18.89 14.58 
Squalene synthase Fdft1 NaN  19.73   2.34 
Farnesyl pyrophosphate synthase Fdps 0.25  26.85 26.59 245.83 
NADPH:adrenodoxin oxidoreductase, 
mitochondrial 
Fdxr 0.07  22.35 22.28 51.57 
Ferrochelatase Fech -0.91  21.47 22.38 75.09 
Flap endonuclease 1 Fen1 1.34  22.04 20.70 143.46 
Tyrosine-protein kinase Fer Fer 0.61  20.81 20.20 16.98 
Fermitin family homolog 2 Fermt2 -0.15  25.53 25.69 249.26 
Fasciculation and elongation protein 
zeta-2 
Fez2 -0.07  20.20 20.27 27.60 
 Fgfr1 NaN    16.21 3.67 
FGGY carbohydrate kinase domain-
containing protein 
Fggy NaN    17.46 1.54 
Fumarate hydratase, mitochondrial Fh -0.12  26.03 26.14 323.31 
FH1/FH2 domain-containing protein 1 Fhod1 -0.56  21.74 22.30 195.93 




Mitochondrial fission 1 protein Fis1 -0.02  22.09 22.11 108.03 
Flt3-interacting zinc finger protein 1 Fiz1 -0.68  17.31 17.99 26.66 
Peptidyl-prolyl cis-trans isomerase 
FKBP10 
Fkbp10 -2.00 + 24.98 26.98 207.41 
Peptidyl-prolyl cis-trans isomerase 
FKBP11 
Fkbp11 0.16  22.01 21.85 17.85 
Peptidyl-prolyl cis-trans isomerase 
FKBP14 
Fkbp14 NaN    21.73 68.22 
FK506-binding protein 15 Fkbp15 0.63  22.58 21.95 35.09 
Peptidyl-prolyl cis-trans isomerase Fkbp1a -0.89 + 24.55 25.44 120.87 
Peptidyl-prolyl cis-trans isomerase Fkbp2 1.38  23.15 21.77 3.84 
Peptidyl-prolyl cis-trans isomerase Fkbp3 -0.32  24.23 24.56 82.50 
Peptidyl-prolyl cis-trans isomerase 
FKBP4 
Fkbp4 0.44  25.58 25.14 135.31 
Peptidyl-prolyl cis-trans isomerase 
FKBP5 
Fkbp5 -0.30  19.77 20.06 14.57 
Peptidyl-prolyl cis-trans isomerase 
FKBP7 
Fkbp7 -1.88 + 22.05 23.93 12.97 
Peptidyl-prolyl cis-trans isomerase 
FKBP8 
Fkbp8 -0.24  20.58 20.82 49.92 




Protein flightless-1 homolog Flii -0.14  24.56 24.70 243.44 
Filamin-A Flna 0.80 + 31.27 30.47 323.31 
 Flna NaN  24.17   5.73 
Filamin-B Flnb 0.50 + 29.40 28.90 323.31 
Filamin-C Flnc 0.86 + 28.53 27.67 323.31 
Flotillin-1 Flot1 -0.29  22.82 23.11 105.54 
Flotillin-2 Flot2 1.07 + 23.34 22.27 17.05 
Formin-1 Fmn1 NaN    19.22 3.93 
Formin-like protein 2 Fmnl2 -0.29  22.23 22.53 8.24 
Formin-like protein 3 Fmnl3 NaN    20.30 4.76 
Fibromodulin Fmod -6.14 + 23.75 29.90 308.15 
 Fmod NaN    21.54 6.34 
Fragile X mental retardation protein 1 
homolog 
Fmr1 0.28  22.79 22.51 45.46 
Fibronectin Fn1 NaN  21.78   4.92 
 Fn1 NaN    19.32 10.93 
Ketosamine-3-kinase Fn3krp NaN    21.48 9.47 
Formin-binding protein 1-like Fnbp1l NaN    24.35 6.94 
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Formin-binding protein 4 Fnbp4 -0.79  20.56 21.35 4.08 
Fibronectin type III domain-containing 
protein 3B 
Fndc3b NaN  19.29   13.36 
Protein 
farnesyltransferase/geranylgeranyltran
sferase type-1 subunit alpha 
Fnta -0.52  22.21 22.72 281.37 
Focadhesin Focad NaN    20.05 6.17 
Forkhead box protein K1 Foxk1 0.20  22.17 21.98 13.85 
Forkhead box protein K2 Foxk2 NaN    17.57 4.00 
Forkhead box protein O3 Foxo3 -0.15  20.43 20.58 27.92 
Forkhead box protein P4 Foxp4 -1.06  19.37 20.43 6.05 
FERM domain-containing protein 8 Frmd8 -0.48  20.67 21.15 5.23 
Fascin Fscn1 0.86 + 28.06 27.21 323.31 
Follistatin-related protein 1 Fstl1 0.91  21.84 20.92 21.44 
Ferritin heavy chain Fth1 1.07  20.46 19.38 7.73 
Ferritin Ftl1 0.41  24.09 23.68 71.16 
Alpha-ketoglutarate-dependent 
dioxygenase FTO 
Fto -0.09  22.14 22.23 119.27 
pre-rRNA processing protein FTSJ3 Ftsj3 -0.25  21.72 21.98 110.86 
Far upstream element-binding protein 1 Fubp1 0.30  24.97 24.66 160.29 
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 Fubp3 -0.51  23.86 24.37 106.66 
Tissue alpha-L-fucosidase Fuca1 NaN    20.39 11.42 
 Fuk 0.04  20.14 20.09 10.40 
RNA-binding protein FUS Fus -0.24  25.53 25.77 95.23 
Alpha-(1,3)-fucosyltransferase 11 Fut11 -0.36  21.38 21.73 6.20 
Fragile X mental retardation syndrome-
related protein 1 
Fxr1 0.06  23.17 23.11 57.89 
Fragile X mental retardation syndrome-
related protein 2 
Fxr2 -0.79  21.44 22.23 83.47 
FYVE and coiled-coil domain-
containing protein 1 
Fyco1 -1.21 + 19.57 20.78 34.77 
Ras GTPase-activating protein-binding 
protein 1 
G3bp1 0.11  26.22 26.11 135.22 
Ras GTPase-activating protein-binding 
protein 2 
G3bp2 0.15  22.92 22.77 59.72 
Glucose-6-phosphate 1-dehydrogenase G6pdx NaN  19.86   3.23 
Glucose-6-phosphate 1-dehydrogenase G6pdx 0.07  25.93 25.85 323.31 
Lysosomal alpha-glucosidase Gaa -1.82 + 25.05 26.87 323.31 
GRB2-associated-binding protein 1 Gab1 0.33  20.36 20.03 5.60 
Gamma-aminobutyric acid receptor-
associated protein 
Gabarap 0.44 + 22.28 21.84 4.24 
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GA-binding protein alpha chain Gabpa NaN    21.28 5.68 
Cyclin-G-associated kinase Gak -0.22  20.44 20.66 16.42 
UDP-glucose 4-epimerase Gale -0.94  21.96 22.91 124.19 
Galactokinase Galk1 -1.14 + 25.52 26.66 184.24 
N-acetylgalactosamine kinase Galk2 -1.31 + 21.90 23.21 56.62 
Aldose 1-epimerase Galm 0.38  22.57 22.19 116.22 
N-acetylgalactosamine-6-sulfatase Galns NaN    22.22 7.45 
Polypeptide N-
acetylgalactosaminyltransferase 
Galnt2 NaN    18.48 9.66 
Guanidinoacetate N-methyltransferase Gamt -1.45  22.43 23.88 13.27 
Gigaxonin Gan 2.02  19.14 17.12 92.04 
Neutral alpha-glucosidase AB Ganab 0.21 + 27.76 27.55 323.31 
Neutral alpha-glucosidase C Ganc NaN    22.59 8.13 
Glyceraldehyde-3-phosphate 
dehydrogenase 
GAPDH -0.73 + 30.43 31.16 323.31 
GTPase-activating protein and VPS9 
domain-containing protein 1 
Gapvd1 0.56  20.48 19.93 5.54 
Glycine--tRNA ligase Gars 0.58 + 27.94 27.36 323.31 
Trifunctional purine biosynthetic 
protein adenosine-3 
Gart 0.31 + 25.54 25.24 323.31 
Growth arrest-specific protein 2 Gas2 -1.07  20.97 22.04 35.16 
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GAS2-like protein 1 Gas2l1 0.50  19.95 19.45 19.25 
Transcriptional repressor p66 alpha Gatad2a -0.16  20.32 20.47 33.81 
Transcriptional repressor p66-beta Gatad2b -0.24  22.62 22.86 56.04 
GATS-like protein 3 Gatsl3 1.64 + 21.05 19.41 7.48 
Glucosylceramidase Gba -1.54 + 22.38 23.93 43.27 
Protein NipSnap homolog 2 Gbas -0.59  21.10 21.68 9.21 
1,4-alpha-glucan-branching enzyme Gbe1 -0.74  21.16 21.90 20.53 
 Gbf1 -0.44  24.35 24.79 323.31 
2-amino-3-ketobutyrate coenzyme A 
ligase, mitochondrial 
Gcat 0.15  21.72 21.57 135.46 
GRIP and coiled-coil domain-containing 
protein 2 
Gcc2 -0.44  21.15 21.59 18.91 
Glutaryl-CoA dehydrogenase, 
mitochondrial 
Gcdh 0.10  22.18 22.09 21.83 
Glutamate--cysteine ligase catalytic 
subunit 
Gclc -0.29  20.97 21.26 15.97 
Glutamate--cysteine ligase regulatory 
subunit 
Gclm -1.00 + 21.26 22.26 23.04 
 Gcn1l1 -0.53 + 25.48 26.01 323.31 
Rab GDP dissociation inhibitor alpha Gdi1 -0.23  24.80 25.03 121.85 
Rab GDP dissociation inhibitor beta Gdi2 -0.17  28.16 28.33 323.31 
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Gem-associated protein 5 Gemin5 1.03  21.49 20.45 19.96 
Golgi to ER traffic protein 4 homolog Get4 -0.05  20.45 20.50 35.53 
FAD-linked sulfhydryl oxidase ALR Gfer NaN  18.71   2.42 
Elongation factor G, mitochondrial Gfm1 1.27  22.19 20.92 6.89 
Glutamine--fructose-6-phosphate 
aminotransferase [isomerizing] 1 
Gfpt1 -0.17 + 25.69 25.86 323.31 
GDNF family receptor alpha-2 Gfra2 NaN  19.48   31.17 
ADP-ribosylation factor-binding protein 
GGA1 
Gga1 -0.96  21.89 22.85 47.19 
ADP-ribosylation factor-binding protein 
GGA2 
Gga2 -2.25 + 18.79 21.04 26.48 
ADP-ribosylation factor-binding protein 
GGA3 
Gga3 NaN    15.51 2.52 
Vitamin K-dependent gamma-
carboxylase 
Ggcx NaN  19.85   10.61 
Gamma-glutamyl hydrolase Ggh -1.15  21.33 22.49 13.45 
Glucose-induced degradation protein 8 
homolog 
Gid8 0.48  23.46 22.98 71.77 
PERQ amino acid-rich with GYF 
domain-containing protein 2 
Gigyf2 -1.61  21.24 22.86 323.31 
PDZ domain-containing protein GIPC1 Gipc1 0.47  19.78 19.31 173.85 
ARF GTPase-activating protein GIT1 Git1 -0.62 + 22.20 22.82 19.59 
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ARF GTPase-activating protein GIT2 Git2 -1.11 + 20.97 22.08 34.07 
Beta-galactosidase Glb1 -1.95 + 23.79 25.73 133.27 
Nucleoporin GLE1 Gle1 NaN    18.50 4.90 
Golgi apparatus protein 1 Glg1 0.22  21.87 21.65 28.10 
Golgi-associated plant pathogenesis-
related protein 1 
Glipr2 2.36 + 24.17 21.81 62.11 
Glomulin Glmn 0.71  19.75 19.04 2.96 
Glycosylated lysosomal membrane 
protein 
Glmp NaN    20.00 8.66 
Lactoylglutathione lyase Glo1 -0.95  23.94 24.89 64.07 
Glyoxalase domain-containing protein 
4 
Glod4 -0.58 + 25.32 25.90 278.31 
Glutaredoxin-1 Glrx NaN    22.07 28.19 
Glutaredoxin-3 Glrx3 -0.08  24.90 24.98 88.44 
Glutaminase kidney isoform, 
mitochondrial 
Gls 0.53 + 24.31 23.77 182.79 
Glutamate dehydrogenase 1, 
mitochondrial 
Glud1 -0.31  26.85 27.15 238.19 
Putative oxidoreductase GLYR1 Glyr1 -0.40  21.82 22.22 49.04 
60S ribosomal protein L11 Gm10036 -0.04  27.06 27.10 152.82 




ATP synthase subunit d, mitochondrial Gm10250 0.31  22.99 22.68 28.68 
V-type proton ATPase 16 kDa 
proteolipid subunit 
Gm15487 NaN    21.16 7.35 
 Gm15800 -1.39  18.00 19.39 18.02 
Nucleoside diphosphate kinase Gm20390 -0.25  28.79 29.04 238.31 
Signal recognition particle receptor 
subunit beta 
Gm20425 NaN  20.20   25.17 
Alanyl-tRNA editing protein Aarsd1 Gm27029 -0.91  20.16 21.07 90.61 
RNA-binding protein 12 Gm28036 -0.58  18.43 19.02 7.30 
60S ribosomal protein L29 Gm5218 NaN  22.30   2.59 
Heterogeneous nuclear 
ribonucleoprotein A3 
Gm6793 0.22  28.75 28.54 323.31 
40S ribosomal protein S7 Gm9493 -0.11  27.59 27.70 315.14 
Elongation factor Tu Gm9755 0.57 + 24.91 24.34 121.99 
Proteasomal ubiquitin receptor ADRM1 Gm9774 -0.66  21.84 22.50 28.36 
GDP-mannose 4,6 dehydratase Gmds 0.31  22.96 22.65 68.18 
Glia maturation factor beta Gmfb 0.05  20.01 19.97 105.59 
Mannose-1-phosphate 
guanyltransferase alpha 
Gmppa -0.49  23.50 24.00 71.44 




GMP reductase 1 Gmpr 0.69 + 23.68 23.00 2.38 
GMP reductase 2 Gmpr2 0.02  20.54 20.53 4.72 
GMP synthase [glutamine-hydrolyzing] Gmps 0.20  24.38 24.18 40.89 
Guanine nucleotide-binding protein 
subunit alpha-11 
Gna11 0.60 + 23.70 23.10 60.25 
Guanine nucleotide-binding protein 
subunit alpha-13 
Gna13 NaN    19.48 3.20 
Guanine nucleotide-binding protein G(i) 
subunit alpha-2 
Gnai2 1.04  24.58 23.54 103.97 
Guanine nucleotide-binding protein 
G(k) subunit alpha 
Gnai3 2.19 + 22.93 20.74 5.41 
Guanine nucleotide-binding protein 
G(o) subunit alpha 
Gnao1 0.16  22.69 22.53 40.35 
Guanine nucleotide-binding protein 
G(q) subunit alpha 
Gnaq 0.35  21.76 21.41 26.29 
Guanine nucleotide-binding protein 
G(s) subunit alpha isoforms short 
Gnas 0.42 + 24.83 24.40 32.47 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-1 
Gnb1 0.45 + 25.09 24.64 55.28 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-2 
Gnb2 -1.33 + 24.86 26.18 36.69 
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Guanine nucleotide-binding protein 
subunit beta-2-like 1 




Gne -0.57  22.06 22.63 34.03 
Guanine nucleotide-binding protein-like 
1 
Gnl1 -1.10 + 22.10 23.20 141.28 
Nucleolar GTP-binding protein 2 Gnl2 -0.05  17.82 17.88 2.71 
Guanine nucleotide-binding protein-like 
3 
Gnl3 0.21  22.49 22.27 70.18 
Glucosamine-6-phosphate isomerase Gnpda1 -2.48  21.39 23.87 129.96 
Glucosamine-6-phosphate isomerase Gnpda2 NaN    21.74 4.66 
Glucosamine 6-phosphate N-
acetyltransferase 
Gnpnat1 0.95 + 23.37 22.42 62.56 
N-acetylglucosamine-6-sulfatase Gns -1.60 + 24.60 26.20 83.82 
Golgin subfamily A member 1 Golga1 NaN    17.67 6.34 
Golgin subfamily A member 2 Golga2 0.22  22.80 22.58 47.68 
Golgin subfamily A member 3 Golga3 -1.07  22.27 23.34 228.61 
Golgin subfamily A member 4 Golga4 -0.07  20.78 20.84 9.07 
Golgin subfamily A member 5 Golga5 -0.21  20.74 20.95 126.39 
 Golgb1 -0.69  22.20 22.89 242.47 
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Golgi integral membrane protein 4 Golim4 0.30  21.82 21.52 14.99 
Golgi phosphoprotein 3 Golph3 -2.56 + 20.61 23.17 154.03 
Golgi phosphoprotein 3-like Golph3l NaN    17.17 2.81 
Vesicle transport protein GOT1B Golt1b 1.68  21.60 19.93 8.33 
Golgi-associated PDZ and coiled-coil 
motif-containing protein 
Gopc -0.14  19.78 19.92 34.70 
RAB6-interacting golgin Gorab NaN    21.01 7.45 
Golgi reassembly-stacking protein 1 Gorasp1 NaN    20.99 8.48 
Golgi reassembly-stacking protein 2 Gorasp2 -1.93 + 22.86 24.79 100.14 
Golgi SNAP receptor complex member 
1 
Gosr1 NaN    19.64 3.28 
Golgi SNAP receptor complex member 
2 
Gosr2 0.12  22.37 22.25 80.61 
Aspartate aminotransferase, 
cytoplasmic 
Got1 0.14  26.23 26.09 198.42 
Aspartate aminotransferase, 
mitochondrial 
Got2 0.09  25.77 25.68 242.81 
Glycerol-3-phosphate acyltransferase 
1, mitochondrial 
Gpam NaN  18.69   1.79 
Glypican-1 Gpc1 0.14  25.61 25.47 109.29 
Glypican-4 Gpc4 1.29 + 23.68 22.39 201.72 
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Glypican-6 Gpc6 1.39 + 22.36 20.98 9.21 
Glycerol-3-phosphate dehydrogenase Gpd2 1.06  21.25 20.19 18.57 
Glucose-6-phosphate isomerase Gpi -1.75 + 26.50 28.25 323.31 
COP9 signalosome complex subunit 1 Gps1 -1.07  23.81 24.88 92.88 
G-protein-signaling modulator 1 Gpsm1 -0.09  22.93 23.02 13.90 
G-protein-signaling modulator 2 Gpsm2 -1.38  20.46 21.83 46.16 
Alanine aminotransferase 2 Gpt2 NaN  20.39   5.98 
Glutathione peroxidase 1 Gpx1 -1.32 + 23.88 25.20 101.91 
Glutathione peroxidase Gpx7 -0.35  24.33 24.68 37.01 
Growth factor receptor-bound protein 
10 
Grb10 2.03  23.00 20.97 57.65 
Growth factor receptor-bound protein 2 Grb2 -0.14  22.78 22.92 13.02 
Protein C10 Grcc10 0.03  23.69 23.66 95.39 
Glyoxylate reductase/hydroxypyruvate 
reductase 
Grhpr -2.14 + 23.09 25.23 198.74 
GRIP1-associated protein 1 Gripap1 NaN    19.53 3.00 
GrpE protein homolog 1, mitochondrial Grpel1 0.44  22.62 22.18 65.03 
G-rich sequence factor 1 Grsf1 0.18  20.50 20.32 4.16 
Glutamate-rich WD repeat-containing 
protein 1 
Grwd1 NaN    21.37 10.75 
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Gasdermin-D Gsdmdc1 -0.46 + 21.31 21.77 6.39 
Glycogen synthase kinase-3 beta Gsk3b 0.40  22.20 21.81 12.90 
Gelsolin Gsn -1.15 + 28.26 29.41 323.31 
Eukaryotic peptide chain release factor 
GTP-binding subunit ERF3A 
Gspt1 1.25  24.14 22.89 105.18 
Glutathione reductase, mitochondrial Gsr -0.25  23.85 24.09 114.88 
Glutathione synthetase Gss -1.32  22.51 23.83 81.08 
Glutathione S-transferase Mu 1 Gstm1 -1.80 + 25.64 27.44 323.31 
Glutathione S-transferase Mu 2 Gstm2 -0.76 + 27.06 27.82 297.90 
Glutathione S-transferase Mu 5 Gstm5 -1.07 + 21.61 22.68 123.12 
Glutathione S-transferase omega-1 Gsto1 0.05  24.52 24.47 84.09 
Glutathione S-transferase P 1 Gstp1 -0.41 + 28.48 28.89 323.31 
 Gstt3 NaN    19.34 4.03 
Maleylacetoacetate isomerase Gstz1 -0.25  22.43 22.69 57.61 
Transcription initiation factor IIB Gtf2b -0.22  20.47 20.69 5.34 
General transcription factor IIE subunit 
1 
Gtf2e1 -0.36  22.18 22.54 23.35 
General transcription factor IIE subunit 
2 
Gtf2e2 0.79  21.49 20.70 104.00 
General transcription factor IIF subunit 
1 
Gtf2f1 0.46  21.80 21.34 129.79 
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General transcription factor II-I Gtf2i -0.13  22.54 22.67 117.71 
General transcription factor 3C 
polypeptide 1 
Gtf3c1 -1.15  19.91 21.06 7.70 
General transcription factor 3C 
polypeptide 2 
Gtf3c2 NaN    21.65 29.67 
 Gtf3c3 NaN    18.83 55.81 
General transcription factor 3C 
polypeptide 4 
Gtf3c4 -0.55  20.02 20.58 96.35 
General transcription factor 3C 
polypeptide 5 
Gtf3c5 -0.67  18.95 19.62 2.90 
GTP-binding protein 1 Gtpbp1 -0.94  21.64 22.58 71.24 
Nucleolar GTP-binding protein 1 Gtpbp4 NaN  21.31   9.59 
GTP-binding protein 8 Gtpbp8 NaN  18.81   4.31 
Guanylate kinase Guk1 -0.07  22.67 22.74 13.78 
PTB domain-containing engulfment 
adapter protein 1 
Gulp1 NaN    20.47 4.17 
Beta-glucuronidase Gusb -3.27 + 21.92 25.19 127.10 
Glucoside xylosyltransferase 2 Gxylt2 -0.94  20.97 21.91 18.34 
Glycogenin-1 Gyg 0.56  20.41 19.86 13.63 
Glycogen [starch] synthase, muscle Gys1 0.20  23.15 22.95 28.82 
Histone H1.0 H1f0 2.48  23.99 21.51 24.13 
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 H1fx 1.09  22.42 21.33 9.54 
H-2 class I histocompatibility antigen, 
D-B alpha chain 
H2-D1 0.93  22.89 21.95 10.94 
Estradiol 17-beta-dehydrogenase 8 H2-Ke6 -0.96  20.45 21.42 68.87 
Histone H2A H2afv 0.05  27.92 27.88 55.27 
Core histone macro-H2A.1 H2afy -0.49  23.81 24.30 122.92 
Histone H3 H3f3a 1.06  24.39 23.34 8.06 
GDH/6PGL endoplasmic bifunctional 
protein 
H6pd NaN    20.54 18.54 
Hydroxyacyl-coenzyme A 
dehydrogenase, mitochondrial 
Hadh -0.80 + 24.53 25.33 42.46 
Trifunctional enzyme subunit alpha, 
mitochondrial 
Hadha -0.18  27.03 27.21 323.31 
Trifunctional enzyme subunit beta, 
mitochondrial 
Hadhb -0.30  24.92 25.22 101.12 
Hemoglobin subunit alpha haemaglobin 
alpha 2 
NaN  22.92   2.45 
Hydroxyacylglutathione hydrolase, 
mitochondrial 
Hagh -1.00 + 19.89 20.89 6.00 
Histidine--tRNA ligase, cytoplasmic Hars 0.34  25.27 24.94 315.95 
Histone acetyltransferase type B 
catalytic subunit 
Hat1 1.22 + 24.25 23.02 106.92 
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 Haus6 NaN    15.31 7.45 
HBS1-like protein Hbs1l 0.78  22.21 21.42 4.54 
Host cell factor 1 Hcfc1 -0.08  23.78 23.86 81.15 
Histone deacetylase Hdac1 -0.46  22.31 22.77 66.93 
Histone deacetylase 10 Hdac10 1.07  22.74 21.67 4.41 
Histone deacetylase 2 Hdac2 0.24  24.32 24.08 139.06 
Histone deacetylase Hdac3 NaN  19.90   7.28 
Histone deacetylase 4 Hdac4 0.18  21.51 21.34 10.04 
Histone deacetylase 6 Hdac6 NaN    19.67 5.49 
Histone deacetylase 7 Hdac7 -0.69  19.57 20.26 5.29 
HD domain-containing protein 2 Hddc2 -0.45  22.26 22.72 88.00 
Hepatoma-derived growth factor Hdgf -0.43  25.32 25.75 126.50 
Hepatoma-derived growth factor-
related protein 2 
Hdgfrp2 0.54  21.34 20.80 311.42 
Haloacid dehalogenase-like hydrolase 
domain-containing protein 2 
Hdhd2 -0.11  23.64 23.75 20.42 
Vigilin Hdlbp -0.36 + 27.95 28.31 323.31 
 Heatr1 -0.26  22.83 23.08 10.15 
HEAT repeat-containing protein 3 Heatr3 0.41  22.40 22.00 9.41 
HEAT repeat-containing protein 5A Heatr5a -0.50  21.32 21.82 44.90 
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HEAT repeat-containing protein 5B Heatr5b -0.18  19.49 19.67 3.65 
HEAT repeat-containing protein 6 Heatr6 0.45  19.38 18.93 7.42 
Heme-binding protein 1 Hebp1 -0.62 + 23.66 24.28 65.99 
Heme-binding protein 2 Hebp2 -1.10  21.05 22.14 84.13 
E3 ubiquitin-protein ligase HECTD1 Hectd1 0.01  21.58 21.58 14.36 
E3 ubiquitin-protein ligase HECTD3 Hectd3 -1.08 + 20.03 21.11 5.56 
DNA helicase B Helb NaN    20.76 11.54 
Lymphocyte-specific helicase Hells NaN    18.30 1.76 
Beta-hexosaminidase Hexa -2.70 + 23.59 26.29 323.31 
Beta-hexosaminidase Hexb -2.77 + 22.22 24.99 65.09 
Protein HEXIM1 Hexim1 0.23  19.70 19.47 4.85 
Protein HGH1 homolog Hgh1 -0.21  20.63 20.84 18.00 
Hepatocyte growth factor-regulated 
tyrosine kinase substrate 
Hgs -0.95  21.57 22.52 23.41 
3-hydroxyisobutyrate dehydrogenase Hibadh -0.36  24.62 24.98 128.23 
3-hydroxyisobutyryl-CoA hydrolase, 
mitochondrial 
Hibch -0.71 + 22.87 23.57 81.77 
Histidine triad nucleotide-binding 
protein 1 
Hint1 -0.37 + 26.35 26.72 31.13 
Histidine triad nucleotide-binding 
protein 2, mitochondrial 
Hint2 0.84  23.62 22.78 35.74 
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Huntingtin-interacting protein 1 Hip1 0.10  23.19 23.09 65.75 
Histone H1.1 Hist1h1a NaN  18.83   3.96 
Histone H1.5 Hist1h1b 2.82 + 25.57 22.75 94.25 
Histone H1.2 Hist1h1c 3.17 + 27.50 24.32 94.19 
Histone H1.3 Hist1h1d 1.87 + 24.36 22.49 27.81 
Histone H1.4 Hist1h1e 3.36 + 26.66 23.30 35.10 
Histone H2A Hist1h2ah -1.28 + 28.09 29.37 108.51 
Histone H2A Hist1h2al -0.61 + 29.82 30.44 277.81 
Histone H2B Hist1h2bj -0.16  30.34 30.50 180.50 
Histone H4 Hist2h4 0.33  28.25 27.92 171.29 
Hexokinase Hk1 -0.87 + 24.67 25.54 323.31 
Hexokinase-2 Hk2 -0.31  21.33 21.64 29.71 
Putative hexokinase HKDC1 Hkdc1 -1.19  20.27 21.46 2.25 
Porphobilinogen deaminase Hmbs -0.86  19.79 20.65 25.66 
High mobility group protein HMGI-C Hmga2 0.86  21.14 20.28 114.74 
High mobility group protein B1 Hmgb1 0.05  27.44 27.39 167.85 
High mobility group protein B2 Hmgb2 0.60  25.57 24.96 24.13 
Hydroxymethylglutaryl-CoA lyase, 
mitochondrial 





Hmgcs1 0.95 + 24.02 23.07 138.70 
 Hmgcs1 NaN    21.36 202.49 
Non-histone chromosomal protein 
HMG-14 
Hmgn1 0.18  21.42 21.24 31.93 
High mobility group nucleosome-
binding domain-containing protein 5 
Hmgn5 NaN    15.21 4.04 
Heme oxygenase 1 Hmox1 0.72 + 21.95 21.23 24.55 
Heme oxygenase 2 Hmox2 NaN  20.62   5.08 
Hematological and neurological 
expressed 1 protein 
Hn1 0.63 + 24.77 24.15 56.12 
Hematological and neurological 
expressed 1-like protein 
Hn1l 1.13  24.05 22.91 54.45 
Heterogeneous nuclear 
ribonucleoprotein A0 
Hnrnpa0 0.49 + 26.36 25.87 153.13 
Heterogeneous nuclear 
ribonucleoprotein A1 
Hnrnpa1 1.24 + 27.76 26.52 323.31 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
Hnrnpa2b1 0.31 + 28.89 28.58 323.31 
Heterogeneous nuclear 
ribonucleoprotein A3 
Hnrnpa3 NaN    18.97 2.26 
Heterogeneous nuclear 
ribonucleoprotein A/B 





Hnrnpd 0.40  26.31 25.90 202.51 
Heterogeneous nuclear 
ribonucleoprotein D-like 
Hnrnpdl 0.39  23.88 23.49 132.19 
Heterogeneous nuclear 
ribonucleoprotein F 
Hnrnpf 0.40  27.64 27.24 323.31 
Heterogeneous nuclear 
ribonucleoprotein H 
Hnrnph1 0.70 + 26.70 25.99 323.31 
Heterogeneous nuclear 
ribonucleoprotein H2 
Hnrnph2 -0.34  23.93 24.27 169.56 
 Hnrnph3 NaN    22.01 31.45 
Heterogeneous nuclear 
ribonucleoprotein K 
Hnrnpk 0.53 + 28.82 28.29 323.31 
Heterogeneous nuclear 
ribonucleoprotein L 
Hnrnpl -0.60 + 26.95 27.55 294.14 
Heterogeneous nuclear 
ribonucleoprotein L-like 
Hnrnpll -0.18  24.30 24.48 31.07 
Heterogeneous nuclear 
ribonucleoprotein M 
Hnrnpm 0.03  28.09 28.06 323.31 
 Hnrnpr -0.58  23.86 24.44 218.07 
Heterogeneous nuclear 
ribonucleoprotein U-like protein 1 




ribonucleoprotein U-like protein 2 
Hnrnpul2 -0.91 + 24.12 25.03 134.43 
Homer protein homolog 3 Homer3 -0.68  21.29 21.97 5.35 
Protein Hook homolog 2 Hook2 NaN    18.43 3.92 
Protein Hook homolog 3 Hook3 -0.13  24.45 24.58 175.27 
Heterochromatin protein 1-binding 
protein 3 
Hp1bp3 0.15  21.81 21.67 10.10 
Hippocalcin-like protein 1 Hpcal1 1.48 + 23.42 21.94 51.30 
Hypoxanthine-guanine 
phosphoribosyltransferase 
Hprt -0.09  24.82 24.91 124.89 
Ribonuclease UK114 Hrsp12 -0.49  21.41 21.90 8.39 
HCLS1-binding protein 3 Hs1bp3 -0.90 + 21.15 22.05 66.17 
Heat shock factor-binding protein 1 Hsbp1 -3.18 + 20.90 24.08 43.34 
3-hydroxyacyl-CoA dehydrogenase 
type-2 
Hsd17b10 0.33  26.26 25.93 323.31 
Estradiol 17-beta-dehydrogenase 11 Hsd17b11 0.67  22.52 21.85 8.05 
Very-long-chain 3-oxoacyl-CoA 
reductase 
Hsd17b12 0.80  21.48 20.68 12.16 
Peroxisomal multifunctional enzyme 
type 2 
Hsd17b4 -0.35 + 24.23 24.58 129.20 
3-keto-steroid reductase Hsd17b7 0.34  21.38 21.04 55.51 
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Heat shock protein HSP 90-alpha Hsp90aa1 0.45 + 27.69 27.24 323.31 
Heat shock protein HSP 90-beta Hsp90ab1 0.22  30.64 30.42 323.31 
Endoplasmin Hsp90b1 -0.17  28.94 29.11 323.31 
Heat shock 70 kDa protein 12B Hspa12b 0.31  20.43 20.12 3.46 
Heat shock 70 kDa protein 14 Hspa14 0.54  23.88 23.34 60.70 
Heat shock 70 kDa protein 1A Hspa1b -0.30  24.15 24.45 63.09 
Heat shock-related 70 kDa protein 2 Hspa2 -0.39  22.53 22.93 6.06 
Heat shock 70 kDa protein 4 Hspa4 0.00  27.33 27.33 323.31 
78 kDa glucose-regulated protein Hspa5 0.36 + 30.06 29.70 323.31 
Heat shock cognate 71 kDa protein Hspa8 -0.02  30.40 30.42 323.31 
Stress-70 protein, mitochondrial Hspa9 1.11 + 28.61 27.50 323.31 
Heat shock protein beta-8 Hspb8 NaN    22.52 6.18 
Hsp70-binding protein 1 Hspbp1 NaN    20.24 6.07 
60 kDa heat shock protein, 
mitochondrial 
Hspd1 0.62 + 28.64 28.02 323.31 
10 kDa heat shock protein, 
mitochondrial 
Hspe1 0.45  27.07 26.62 148.81 
Basement membrane-specific heparan 
sulfate proteoglycan core protein 
Hspg2 -0.74 + 27.92 28.65 323.31 
Heat shock protein 105 kDa Hsph1 1.78 + 25.13 23.35 323.31 
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HIV Tat-specific factor 1 homolog Htatsf1 0.20  20.90 20.71 61.38 
Serine protease HTRA1 Htra1 -3.84 + 22.33 26.18 64.70 
Serine protease HTRA2, mitochondrial Htra2 NaN    20.69 13.30 
Huntingtin Htt 1.22  19.85 18.62 8.45 
E3 ubiquitin-protein ligase HUWE1 Huwe1 -0.16  23.24 23.40 190.68 
Hypoxia up-regulated protein 1 Hyou1 0.48  25.10 24.63 251.96 
Huntingtin-interacting protein K Hypk 0.30  21.30 21.00 4.70 
Isoamyl acetate-hydrolyzing esterase 1 
homolog 
Iah1 NaN    23.24 25.99 
Isoleucine--tRNA ligase, cytoplasmic Iars 1.23 + 26.53 25.30 323.31 
Isoleucine--tRNA ligase, mitochondrial Iars2 0.58  23.22 22.64 19.39 
Bone sialoprotein 2 Ibsp NaN    20.80 1.59 
Insulin-degrading enzyme Ide -0.68  23.72 24.40 88.95 
Isocitrate dehydrogenase [NADP] Idh1 -1.13 + 26.32 27.45 323.31 
Isocitrate dehydrogenase [NADP], 
mitochondrial 
Idh2 0.25  26.92 26.67 192.42 
Isocitrate dehydrogenase [NAD] 
subunit alpha, mitochondrial 
Idh3a 0.12  24.72 24.60 174.37 
Isocitrate dehydrogenase [NAD] 
subunit, mitochondrial 
Idh3b 0.20  23.52 23.31 119.10 
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Isocitrate dehydrogenase [NAD] 
subunit, mitochondrial 
Idh3g 0.55  22.47 21.93 76.41 
Isopentenyl-diphosphate Delta-
isomerase 1 
Idi1 1.17  24.60 23.43 177.33 
Interferon-activable protein 204 Ifi204 NaN    15.50 48.69 
Interferon-induced 35 kDa protein 
homolog 
Ifi35 0.57  21.94 21.36 33.81 
 Ifi47 0.53  20.93 20.40 11.28 
Interferon-induced transmembrane 
protein 3 
Ifitm3 1.04 + 24.10 23.07 86.53 
Intraflagellar transport protein 122 
homolog 
Ift122 0.02  21.35 21.33 6.23 
 Ift140 NaN  19.88   3.20 
Intraflagellar transport protein 43 
homolog 
Ift43 -0.39  17.97 18.36 14.69 
Immunoglobulin-binding protein 1 Igbp1 -0.16  22.08 22.24 178.28 
Insulin-like growth factor 2 mRNA-
binding protein 1 
Igf2bp1 0.03  24.69 24.66 77.39 
Insulin-like growth factor 2 mRNA-
binding protein 2 
Igf2bp2 NaN    17.39 8.78 
Insulin-like growth factor 2 mRNA-
binding protein 3 





Igf2r -0.28  21.84 22.12 12.18 
Immunoglobulin superfamily member 
10 
Igsf10 0.61  23.30 22.69 19.63 
Protein Red Ik -0.93 + 21.99 22.92 56.94 
Inhibitor of nuclear factor kappa-B 
kinase-interacting protein 
Ikbip -0.63 + 21.74 22.37 196.33 
Inhibitor of nuclear factor kappa-B 
kinase-interacting protein 
Ikbip 0.75  23.78 23.02 140.93 
Elongator complex protein 1 Ikbkap -0.01  24.21 24.22 323.31 
Inhibitor of nuclear factor kappa-B 
kinase subunit beta 
Ikbkb -0.25  20.45 20.70 107.60 
NF-kappa-B essential modulator Ikbkg 0.77  21.48 20.71 24.94 
Interleukin-6 receptor subunit beta Il6st NaN  23.44   2.73 
Interleukin enhancer-binding factor 2 Ilf2 -0.50 + 24.93 25.43 193.91 
Interleukin enhancer-binding factor 3 Ilf3 0.06  24.34 24.28 97.09 
Integrin-linked protein kinase Ilk -0.67 + 24.49 25.17 70.06 
Integrin-linked kinase-associated 
serine/threonine phosphatase 2C 
Ilkap -0.27  20.61 20.87 10.60 
MICOS complex subunit Mic60 Immt 0.92  23.36 22.44 165.15 
U3 small nucleolar ribonucleoprotein 
protein IMP3 
Imp3 0.85  21.55 20.69 14.06 
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Inositol monophosphatase 1 Impa1 -0.47  23.46 23.93 39.84 
Inositol monophosphatase 2 Impa2 -0.16  20.62 20.78 14.13 
Protein IMPACT Impact 0.67  21.66 20.99 9.65 
Inosine-5-monophosphate 
dehydrogenase 
Impdh1 -0.56  20.78 21.34 18.05 
Inosine-5-monophosphate 
dehydrogenase 
Impdh2 0.80 + 25.18 24.38 95.90 
Inverted formin-2 Inf2 -0.70 + 24.22 24.92 323.31 
Inositol polyphosphate 1-phosphatase Inpp1 -0.91 + 22.74 23.66 323.31 
Type I inositol 3,4-bisphosphate 4-
phosphatase 
Inpp4a -0.58  21.64 22.22 9.98 
Phosphatidylinositol 3,4,5-
trisphosphate 5-phosphatase 2 
Inppl1 -0.71  21.69 22.40 67.53 
Integrator complex subunit 1 Ints1 0.11  21.03 20.91 19.95 
Integrator complex subunit 10 Ints10 NaN    19.70 5.48 
Integrator complex subunit 2 Ints2 0.19  20.33 20.13 2.02 
Integrator complex subunit 3 Ints3 0.06  21.92 21.86 323.31 
Integrator complex subunit 4 Ints4 0.93 + 20.89 19.96 24.14 
Integrator complex subunit 7 Ints7 NaN    18.58 17.63 
Integrator complex subunit 9 Ints9 -0.61  19.39 20.01 24.68 
Importin-11 Ipo11 1.97 + 22.05 20.08 82.93 
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Importin-13 Ipo13 0.81  21.99 21.17 2.46 
Importin-4 Ipo4 0.18  23.43 23.25 115.62 
Importin-5 Ipo5 0.90 + 26.81 25.90 323.31 
Importin-7 Ipo7 -0.03  24.21 24.24 234.57 
Importin-8 Ipo8 0.40  21.25 20.85 6.27 
Importin-9 Ipo9 0.46  25.75 25.29 211.78 
Ras GTPase-activating-like protein 
IQGAP1 
Iqgap1 -0.29 + 28.30 28.60 323.31 
 Iqgap3 0.07  21.04 20.97 9.65 
IQ motif and SEC7 domain-containing 
protein 1 
Iqsec1 0.16  20.40 20.25 27.07 
Interferon regulatory factor 2-binding 
protein 1 
Irf2bp1 0.70  21.66 20.96 3.88 
Interferon regulatory factor 2-binding 
protein 2 
Irf2bp2 0.20  22.09 21.89 25.51 
Interferon regulatory factor 2-binding 
protein-like 
Irf2bpl NaN    20.89 10.91 
Interferon regulatory factor 3 Irf3 0.15  20.91 20.76 82.51 
Immunity-related GTPase family M 
protein 1 
Irgm1 2.10 + 23.02 20.93 52.57 
Immunity-related GTPase family Q 
protein 
Irgq NaN    19.14 17.17 
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Insulin receptor substrate 1 Irs1 0.54 + 25.09 24.55 212.10 
Isochorismatase domain-containing 
protein 1 
Isoc1 -0.02  22.66 22.68 12.13 
Isochorismatase domain-containing 
protein 2A, mitochondrial 
Isoc2a NaN  21.57   8.10 
IST1 homolog Ist1 -1.34  21.42 22.76 22.97 
Pre-mRNA-splicing factor ISY1 
homolog 
Isy1 -0.24  20.49 20.73 5.12 
 Itga10 -1.25  21.45 22.71 14.65 
Integrin alpha-11 Itga11 1.23 + 22.69 21.46 10.76 
Integrin alpha-3 Itga3 1.37  21.08 19.71 12.51 
Integrin alpha-5 Itga5 0.60  23.13 22.53 18.02 
Integrin alpha-V Itgav -0.32 + 23.95 24.27 116.49 
Integrin beta-1 Itgb1 1.41 + 25.10 23.69 88.94 
Integrin beta-3 Itgb3 -0.98  17.85 18.83 30.12 
Integrin beta Itgb5 -0.49  22.15 22.64 77.06 
Integrin beta Itgb6 NaN    21.59 2.59 
Inosine triphosphate pyrophosphatase Itpa -0.31  20.87 21.18 21.05 
Intersectin-1 Itsn1 -0.35  22.57 22.92 58.97 
Isovaleryl-CoA dehydrogenase, 
mitochondrial 
Ivd -1.00 + 21.54 22.53 12.84 
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Protein IWS1 homolog Iws1 NaN    20.33 3.40 
Tyrosine-protein kinase Jak1 -0.32  18.96 19.28 31.80 
Transcription factor jun-D Jund NaN    17.71 2.71 
Kalirin Kalrn NaN  16.68   2.04 
 Kank1 -0.51  18.39 18.91 20.22 
KN motif and ankyrin repeat domain-
containing protein 2 
Kank2 -1.79 + 23.04 24.83 323.31 
Lysine--tRNA ligase Kars 0.34  26.76 26.43 274.58 
KIF1-binding protein Kbp -0.06  21.26 21.31 19.69 
Kelch repeat and BTB domain-
containing protein 4 
Kbtbd4 NaN    18.65 3.02 
E3 ubiquitin-protein ligase KCMF1 Kcmf1 -0.24  21.26 21.50 199.08 
 Kctd17 -0.31  19.27 19.58 11.69 
BTB/POZ domain-containing protein 
KCTD5 
Kctd5 -0.45  20.82 21.27 30.54 
KDEL motif-containing protein 1 Kdelc1 0.71  22.44 21.74 40.61 
 Kdelc2 -1.32  21.72 23.03 89.60 
Lysine-specific histone demethylase 1A Kdm1a -1.44  21.01 22.45 65.00 
Lysine-specific demethylase 5B Kdm5b NaN  16.65   2.63 
KH domain-containing, RNA-binding, 
signal transduction-associated protein 




Protein KHNYN Khnyn NaN    18.20 4.89 
Far upstream element-binding protein 2 Khsrp 0.13  26.95 26.82 323.31 
WASH complex subunit strumpellin Kiaa0196 -0.71  21.44 22.15 37.27 
WASH complex subunit 7 Kiaa1033 -0.63  21.91 22.54 92.46 
Kinesin-like protein KIF11 Kif11 NaN    18.21 3.96 
Kinesin-like protein Kif13b -0.41  21.66 22.07 108.74 
Kinesin-like protein Kif16b -0.32  18.29 18.61 3.08 
Kinesin-like protein KIF1B Kif1b 0.01  19.42 19.41 5.22 
Kinesin-like protein Kif1c NaN    19.75 48.52 
Kinesin-like protein Kif21a NaN    17.77 4.64 
Kinesin-like protein KIF2A Kif2a 0.27  20.84 20.57 106.51 
Kinesin-like protein Kif3b -0.74  20.43 21.17 58.03 
Kinesin-1 heavy chain Kif5b -0.13  25.07 25.20 323.31 
Kinesin-associated protein 3 Kifap3 -0.23  20.55 20.77 186.06 
Kinesin-like protein Kifc5b NaN  20.39   6.35 
Kin of IRRE-like protein 1 Kirrel 0.92  20.53 19.61 4.83 
Kinesin light chain 1 Klc1 0.58  22.96 22.38 80.78 
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Kinesin light chain 4 Klc4 -0.50  20.66 21.16 16.57 
Kelch domain-containing protein 4 Klhdc4 0.29  19.49 19.20 3.38 
Kelch-like protein 11 Klhl11 NaN    18.73 16.90 
Kelch-like protein 22 Klhl22 0.67  21.87 21.20 8.18 
Kelch-like protein 42 Klhl42 NaN    19.94 29.98 
Kinetochore-associated protein 1 Kntc1 NaN  20.82   2.21 
Importin subunit alpha-5 Kpna1 -0.47  19.85 20.32 4.46 
Importin subunit alpha Kpna2 1.17 + 24.27 23.10 118.59 
Importin subunit alpha Kpna3 1.48  21.75 20.27 16.78 
Importin subunit alpha Kpna4 0.29  21.73 21.45 104.42 
Importin subunit alpha Kpna6 -0.69  22.50 23.19 101.25 
Importin subunit beta-1 Kpnb1 0.71 + 28.19 27.48 323.31 
Kinectin Ktn1 1.13  19.40 18.26 27.24 
Ubiquitin-60S ribosomal protein L40 Kxd1 2.09 + 27.14 25.05 106.43 
Protein Hikeshi L7rn6 NaN    19.43 4.20 
Beta-lactamase-like protein 2 Lactb2 1.50  21.75 20.25 12.34 
Laminin subunit alpha-4 Lama4 -0.87  19.94 20.81 59.11 
Laminin subunit beta-1 Lamb1 1.70 + 22.98 21.28 190.99 
Laminin subunit beta-2 Lamb2 NaN    19.35 12.26 
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Laminin subunit gamma-1 Lamc1 0.79  20.38 19.60 12.55 
Lysosome-associated membrane 
glycoprotein 1 
Lamp1 -0.45  22.50 22.95 12.16 
Lysosome-associated membrane 
glycoprotein 2 
Lamp2 -0.89 + 23.82 24.71 42.55 
Ragulator complex protein LAMTOR1 Lamtor1 0.20  22.61 22.41 21.03 
Ragulator complex protein LAMTOR2 Lamtor2 -0.92  21.05 21.97 10.93 
Ragulator complex protein LAMTOR3 Lamtor3 -0.17  23.00 23.17 13.45 
Ragulator complex protein LAMTOR4 Lamtor4 0.93  21.43 20.50 19.68 
Ragulator complex protein LAMTOR5 Lamtor5 -0.15  23.14 23.29 66.32 
LanC-like protein 1 Lancl1 NaN    21.16 6.47 
LanC-like protein 2 Lancl2 -0.12  21.49 21.60 30.47 
Cytosol aminopeptidase Lap3 -0.06  25.73 25.80 283.59 
La-related protein 1 Larp1 0.27  24.02 23.74 82.59 
La-related protein 4 Larp4 -0.14  20.14 20.28 95.53 
La-related protein 6 Larp6 NaN    20.50 29.92 
La-related protein 7 Larp7 1.20 + 21.72 20.52 4.39 
Leucine--tRNA ligase, cytoplasmic Lars 0.54 + 25.82 25.28 277.78 
Ribosomal biogenesis protein LAS1L Las1l 0.48  21.69 21.21 15.65 
LIM and SH3 domain protein 1 Lasp1 -0.07  26.43 26.50 253.49 
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Protein LBH Lbh NaN    19.04 32.12 
 Lcmt1 NaN    21.44 11.43 
L-lactate dehydrogenase Ldha -0.80  21.20 21.99 4.19 
Prolyl 3-hydroxylase 3 Leprel2 -1.63 + 22.59 24.22 101.90 
Synaptonemal complex protein SC65 Leprel4 -1.26  22.33 23.60 115.44 
LETM1 and EF-hand domain-containing 
protein 1, mitochondrial 
Letm1 NaN  20.39   6.96 
Galectin-1 Lgals1 -0.97 + 28.11 29.08 323.31 
Galectin Lgals3 -1.84 + 26.11 27.95 65.63 
Galectin Lgals9 0.86  22.13 21.27 21.07 
Galectin-related protein Lgalsl -0.74  22.75 23.49 25.58 
Legumain Lgmn NaN    20.56 3.66 
DNA ligase Lig1 NaN    19.65 1.91 
DNA ligase 1 Lig1 1.41  22.67 21.26 31.78 
DNA ligase Lig3 0.06  21.65 21.59 84.77 
LIM domain and actin-binding protein 1 Lima1 -0.99 + 24.43 25.42 110.57 
Protein lin-7 homolog C Lin7c 1.02  24.23 23.21 1.62 
Lipase Lipa -2.82 + 20.20 23.01 300.82 
Lethal(2) giant larvae protein homolog 
1 
Llgl1 NaN  19.36   15.37 
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Protein LLP homolog Llph -0.15  20.36 20.51 10.15 
Protein ERGIC-53 Lman1 0.14  23.75 23.61 54.37 
Vesicular integral-membrane protein 
VIP36 
Lman2 0.46  23.11 22.65 42.02 
Probable lysosomal cobalamin 
transporter 
Lmbrd1 NaN    18.49 2.09 
LIM and cysteine-rich domains protein 
1 
Lmcd1 -0.93  23.20 24.12 43.93 
Lipase maturation factor 2 Lmf2 0.83  21.69 20.87 60.53 
Prelamin-A/C Lmna -0.89 + 30.13 31.02 323.31 
Lamin-B1 Lmnb1 -0.04  26.94 26.98 323.31 
Lamin-B2 Lmnb2 -1.39  20.95 22.34 180.37 
 Lmo7 0.12  25.02 24.90 288.54 
 Lmo7 NaN    22.80 69.54 
Leiomodin-1 Lmod1 1.36 + 22.58 21.22 41.66 
Leucyl-cystinyl aminopeptidase Lnpep 0.65  23.87 23.22 323.31 
Lon protease homolog, mitochondrial Lonp1 0.29  25.69 25.40 212.48 
Lon protease homolog 2, peroxisomal Lonp2 0.40  20.72 20.32 4.74 
Protein-lysine 6-oxidase Lox -0.79 + 22.99 23.77 21.83 
Lysyl oxidase homolog 3 Loxl3 NaN    20.19 2.11 
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Lysyl oxidase homolog 4 Loxl4 -0.60  20.46 21.06 6.26 
Lysophospholipid acyltransferase 5 Lpcat3 NaN    18.03 1.58 
Latrophilin-2 Lphn2 0.40  21.55 21.15 38.59 
Phosphatidate phosphatase LPIN3 Lpin3 NaN    18.47 22.09 
Lipoma-preferred partner homolog Lpp -0.17  25.73 25.91 276.73 
Leucine-rich repeat and calponin 
homology domain-containing protein 3 
Lrch3 NaN    21.14 8.25 
Prolow-density lipoprotein receptor-
related protein 1 
Lrp1 -0.46 + 26.60 27.06 323.31 
Low-density lipoprotein receptor-
related protein 4 
Lrp4 NaN    17.34 1.87 
Alpha-2-macroglobulin receptor-
associated protein 
Lrpap1 0.09  23.81 23.71 78.24 
Leucine-rich PPR motif-containing 
protein, mitochondrial 
Lrpprc 0.55  25.26 24.71 266.86 
Leucine-rich repeat-containing protein 
16A 
Lrrc16a -1.46  21.15 22.61 45.43 
Leucine-rich repeat-containing protein 
20 
Lrrc20 NaN    19.13 5.21 
Leucine-rich repeat-containing protein 
40 
Lrrc40 0.80 + 22.62 21.82 23.94 




Leucine-rich repeat-containing protein 
47 
Lrrc47 -0.45  22.36 22.82 44.11 
Leucine-rich repeat-containing protein 
58 
Lrrc58 -0.32  22.30 22.63 104.18 
Leucine-rich repeat-containing protein 
59 
Lrrc59 0.08  25.11 25.03 48.82 
Leucine-rich repeat flightless-
interacting protein 1 
Lrrfip1 -0.67  21.41 22.08 25.98 
Leucine-rich repeat flightless-
interacting protein 1 
Lrrfip1 -0.71  22.66 23.37 160.43 
Leucine-rich repeat flightless-
interacting protein 2 
Lrrfip2 NaN    20.36 45.45 
Large subunit GTPase 1 homolog Lsg1 -1.29  18.99 20.28 8.49 
U6 snRNA-associated Sm-like protein 
LSm1 
Lsm1 -0.42  21.94 22.36 4.27 
Protein LSM12 homolog Lsm12 0.39  22.12 21.73 4.70 
U6 snRNA-associated Sm-like protein 
LSm2 
Lsm2 -0.13  24.01 24.14 81.38 
U6 snRNA-associated Sm-like protein 
LSm3 
Lsm3 -0.25  23.37 23.62 221.31 
U6 snRNA-associated Sm-like protein 
LSm4 
Lsm4 -0.03  22.92 22.96 5.89 
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U6 snRNA-associated Sm-like protein 
LSm5 
Lsm5 -0.26  22.92 23.18 39.70 
U6 snRNA-associated Sm-like protein 
LSm7 
Lsm7 -1.20 + 22.77 23.97 13.99 
U6 snRNA-associated Sm-like protein 
LSm8 
Lsm8 -0.35  23.61 23.96 323.31 
Lanosterol synthase Lss NaN    21.26 31.49 
Leukotriene A-4 hydrolase Lta4h -1.11 + 25.74 26.84 323.31 
Latent-transforming growth factor beta-
binding protein 1 
Ltbp1 0.08  21.96 21.88 10.45 
E3 ubiquitin-protein ligase listerin Ltn1 -0.51  20.80 21.30 7.57 
Protein LTV1 homolog Ltv1 -0.69  19.80 20.49 41.63 
Putative RNA-binding protein Luc7-like 
1 
Luc7l 0.45  21.60 21.15 137.91 
Putative RNA-binding protein Luc7-like 
2 
Luc7l2 -0.49  23.27 23.76 110.37 
Luc7-like protein 3 Luc7l3 -0.16  23.15 23.31 308.89 
Lumican Lum NaN    20.17 12.04 
Leucine zipper protein 1 Luzp1 -0.48  21.41 21.89 35.07 
Latexin Lxn 0.35  23.42 23.07 245.42 
Cell growth-regulating nucleolar 
protein 
Lyar 0.00  19.11 19.10 304.67 
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Acyl-protein thioesterase 1 Lypla1 -0.82  23.89 24.71 54.04 
Lysophospholipase-like protein 1 Lyplal1 NaN    19.01 2.17 
Protein LZIC Lzic -0.89 + 21.95 22.84 52.16 
Leucine zipper transcription factor-like 
protein 1 
Lztfl1 -0.76  19.70 20.46 38.57 
Cation-dependent mannose-6-
phosphate receptor 
M6pr 0.37  23.23 22.86 47.03 
O-acetyl-ADP-ribose deacetylase 
MACROD1 
Macrod1 0.51  22.81 22.30 16.94 
Mitotic spindle assembly checkpoint 
protein MAD1 
Mad1l1 0.01  20.77 20.75 15.62 
Melanoma-associated antigen D1 Maged1 -0.32  20.41 20.73 47.42 
 Maged2 -1.94  20.61 22.55 51.15 
Protein mago nashi homolog Magoh 0.87  24.20 23.33 50.48 
Protein MAK16 homolog Mak16 -1.04  20.75 21.79 6.11 
Alpha-mannosidase 2 Man2a1 0.49  22.11 21.62 39.46 
Alpha-mannosidase Man2b1 -1.15 + 23.51 24.66 114.41 
Epididymis-specific alpha-
mannosidase 
Man2b2 -0.58  24.60 25.18 300.29 
Alpha-mannosidase Man2c1 -1.19 + 19.25 20.44 55.97 





Manf 1.44  20.81 19.37 6.71 
Amine oxidase [flavin-containing] A Maoa 0.34  22.40 22.05 17.00 
Microtubule-associated protein 1A Map1a -1.02  23.35 24.37 298.03 
Microtubule-associated protein 1B Map1b -1.13 + 24.00 25.14 323.31 
Microtubule-associated proteins 1A/1B 
light chain 3B 
Map1lc3b -1.38 + 21.67 23.05 3.13 
Microtubule-associated protein 1S Map1s -0.64  21.94 22.58 21.36 
Dual specificity mitogen-activated 
protein kinase kinase 1 
Map2k1 0.25  22.24 21.99 91.49 
Dual specificity mitogen-activated 
protein kinase kinase 2 
Map2k2 -0.44  22.03 22.47 31.91 
Dual specificity mitogen-activated 
protein kinase kinase 3 
Map2k3 0.68  21.86 21.18 44.86 
Dual specificity mitogen-activated 
protein kinase kinase 4 
Map2k4 0.60  23.01 22.42 67.11 
Mitogen-activated protein kinase kinase 
kinase 3 
Map3k3 0.55 + 20.25 19.70 19.19 
Microtubule-associated protein Map4 -1.07 + 25.54 26.61 323.31 
Mitogen-activated protein kinase kinase 
kinase kinase 
Map4k2 NaN    17.61 22.34 
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Mitogen-activated protein kinase kinase 
kinase kinase 
Map4k3 0.14  21.38 21.24 39.25 
Mitogen-activated protein kinase kinase 
kinase kinase 4 
Map4k4 1.27  19.15 17.88 7.66 
Mitogen-activated protein kinase kinase 
kinase kinase 5 
Map4k5 0.87  21.01 20.14 17.44 
Microtubule-associated protein 6 Map6 -1.55  18.58 20.13 13.76 
MAP7 domain-containing protein 1 Map7d1 NaN    21.64 6.17 
Mitogen-activated protein kinase Mapk1 1.05 + 24.29 23.24 22.59 
Mitogen-activated protein kinase 14 Mapk14 0.21  23.43 23.22 54.71 
Mitogen-activated protein kinase 3 Mapk3 -0.18  24.07 24.25 126.97 
Mitogen-activated protein kinase 7 Mapk7 NaN  21.34   5.17 
MAP kinase-activated protein kinase 2 Mapkapk2 0.31  21.41 21.10 32.99 
 Mapkbp1 NaN    24.31 2.21 
Microtubule-associated protein RP/EB 
family member 1 
Mapre1 0.03  25.11 25.08 167.59 
Microtubule-associated protein RP/EB 
family member 2 
Mapre2 0.00  22.53 22.53 16.97 
Microtubule-associated protein RP/EB 
family member 3 
Mapre3 -1.21 + 22.31 23.52 19.09 
 Mapre3 NaN    18.84 8.77 
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Myristoylated alanine-rich C-kinase 
substrate 
Marcks 1.17  25.83 24.66 227.68 
Serine/threonine-protein kinase MARK2 Mark2 NaN    19.52 4.26 
Methionine--tRNA ligase, cytoplasmic Mars 0.68  24.19 23.51 138.95 
Methionine--tRNA ligase, mitochondrial Mars2 NaN    17.03 1.87 
S-adenosylmethionine synthase Mat2a 0.21  24.75 24.53 56.12 
Methionine adenosyltransferase 2 
subunit beta 
Mat2b 0.16  23.06 22.90 136.47 
Matrilin-2 Matn2 NaN    21.53 4.03 
Matrilin-4 Matn4 -2.70  20.68 23.38 76.84 
Matrin-3 Matr3 0.19 + 27.12 26.93 323.31 
Methyl-CpG-binding domain protein 3 Mbd3 0.49  21.80 21.31 26.55 
Muscleblind-like protein 1 Mbnl1 0.10  24.06 23.96 33.30 
Muscleblind-like protein 2 Mbnl2 -0.39  22.83 23.23 9.21 
 Mcc 1.23  20.79 19.56 32.06 
Methylcrotonoyl-CoA carboxylase 
subunit alpha, mitochondrial 
Mccc1 0.54  20.92 20.38 27.70 
Methylcrotonoyl-CoA carboxylase beta 
chain, mitochondrial 
Mccc2 0.01  21.73 21.71 25.91 
40S ribosomal protein S21 mCG_6739 -0.24  25.22 25.47 132.11 
DNA helicase Mcm2 0.95 + 25.39 24.43 323.31 
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DNA helicase Mcm3 0.96 + 26.17 25.21 323.31 
DNA replication licensing factor MCM4 Mcm4 0.83  25.05 24.22 223.62 
DNA helicase Mcm5 0.91 + 25.36 24.44 85.60 
DNA helicase Mcm6 1.71 + 25.61 23.90 297.27 
DNA helicase Mcm7 0.82 + 25.89 25.07 323.31 
Mini-chromosome maintenance 
complex-binding protein 
Mcmbp 0.51  20.54 20.04 41.78 
Malignant T-cell-amplified sequence 1 Mcts1 -0.81 + 21.38 22.19 33.17 
Calcium uniporter protein, 
mitochondrial 
Mcu NaN  19.67   1.41 
Mediator of DNA damage checkpoint 
protein 1 
Mdc1 0.69  20.77 20.08 3.70 
Malate dehydrogenase, cytoplasmic Mdh1 -0.69 + 26.29 26.98 171.28 
Malate dehydrogenase, mitochondrial Mdh2 0.19  27.99 27.80 323.31 
 Mdn1 0.54  21.49 20.96 6.06 
Magnesium-dependent phosphatase 1 Mdp1 -0.51  21.78 22.29 139.11 
Malic enzyme Me1 -0.79 + 25.89 26.67 323.31 
NAD-dependent malic enzyme, 
mitochondrial 
Me2 -1.76 + 22.46 24.22 132.64 
Trans-2-enoyl-CoA reductase, 
mitochondrial 
Mecr -0.71 + 20.66 21.37 13.90 
392 
 
Mediator of RNA polymerase II 
transcription subunit 1 
Med1 -0.11  19.54 19.65 95.98 
Mediator of RNA polymerase II 
transcription subunit 11 
Med11 NaN    20.50 20.06 
Mediator of RNA polymerase II 
transcription subunit 12 
Med12 -0.40  19.30 19.69 8.49 
Mediator of RNA polymerase II 
transcription subunit 14 
Med14 NaN    19.93 7.85 
Mediator of RNA polymerase II 
transcription subunit 15 
Med15 0.77  19.06 18.29 5.85 
Mediator of RNA polymerase II 
transcription subunit 16 
Med16 NaN    20.43 2.44 
Mediator of RNA polymerase II 
transcription subunit 22 
Med22 NaN  18.68   1.60 
Mediator of RNA polymerase II 
transcription subunit 23 
Med23 NaN  20.56   8.86 
Mediator of RNA polymerase II 
transcription subunit 27 
Med27 NaN    17.49 2.24 
Mediator of RNA polymerase II 
transcription subunit 31 
Med31 -0.44  18.99 19.43 87.77 
Protein MEMO1 Memo1 0.75 + 24.68 23.94 74.69 
LDLR chaperone MESD Mesdc2 -0.16  21.85 22.01 1.52 
Mesoderm-specific transcript protein Mest 0.23  20.81 20.59 16.23 
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Methionine aminopeptidase 2 Metap2 -0.50  23.01 23.51 115.30 
Methyltransferase-like protein 13 Mettl13 0.00  21.06 21.06 15.80 
Methyltransferase-like protein 2 Mettl2 NaN  19.77   4.25 
RNA-binding protein MEX3D Mex3d 0.38  19.02 18.65 8.07 
Microfibrillar-associated protein 1 Mfap1 -0.08  19.74 19.82 91.75 
Lactadherin Mfge8 -1.38 + 21.63 23.01 17.51 
Protein O-GlcNAcase Mgea5 0.06  22.20 22.13 25.75 
Matrix Gla protein Mgp -1.08  23.27 24.35 196.98 
Melanoma inhibitory activity protein 3 Mia3 -0.04  19.18 19.22 4.33 
E3 ubiquitin-protein ligase MIB1 Mib1 NaN    18.94 2.69 
Protein-methionine sulfoxide oxidase 
MICAL1 
Mical1 -0.88  22.83 23.71 113.17 
Protein-methionine sulfoxide oxidase 
MICAL3 
Mical3 NaN    21.70 2.43 
Calcium uptake protein 1, 
mitochondrial 
Micu1 -0.12  19.81 19.93 34.07 
Calcium uptake protein 2, 
mitochondrial 
Micu2 NaN  20.76   16.99 
E3 ubiquitin-protein ligase Midline-1 Mid1 NaN    17.45 3.19 




demethylase and histidyl-hydroxylase 
MINA 
Mina -0.77  21.10 21.87 6.57 
Multiple inositol polyphosphate 
phosphatase 1 
Minpp1 1.06  21.34 20.28 2.67 
 mKIAA0224 -0.08  19.65 19.73 10.10 
CAP-Gly domain-containing linker 
protein 2 
mKIAA0291 -0.86  18.94 19.80 12.83 
Kinesin-like protein mKIAA0531 NaN  19.96   3.96 
Dynamin-like 120 kDa protein, 
mitochondrial 
mKIAA0567 NaN    22.07 10.37 
 mKIAA0577 0.47  20.93 20.46 6.84 
Cullin-3 mKIAA0617 -0.57  23.23 23.80 323.31 
Serine/threonine-protein kinase OSR1 mKIAA1101 -0.18  22.50 22.68 18.94 
Conserved oligomeric Golgi complex 
subunit 1 
mKIAA1381 -0.44  21.61 22.05 18.43 
MKL/myocardin-like protein 1 Mkl1 0.55  19.93 19.38 21.95 
MKL/myocardin-like protein 2 Mkl2 0.01  20.26 20.25 6.43 
Malectin Mlec 0.82  20.85 20.03 18.41 
Mixed lineage kinase domain-like 
protein 
Mlkl 0.92 + 23.57 22.65 61.00 
Afadin Mllt4 0.38  22.93 22.54 81.93 
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Neprilysin Mme -1.28  21.64 22.92 249.60 
Collagenase 3 Mmp13 NaN    19.86 1.98 
Matrix metalloproteinase-14 Mmp14 -1.39  21.81 23.20 94.81 
72 kDa type IV collagenase Mmp2 -1.77 + 23.27 25.05 39.46 
MMS19 nucleotide excision repair 
protein homolog 
Mms19 -0.64  21.82 22.46 150.52 
Interferon-activable protein 205-B Mnda -0.65  21.15 21.80 11.43 
MOB kinase activator 1A Mob1a -0.28  22.19 22.47 13.27 
MOB-like protein phocein Mob4 -0.26  22.08 22.34 37.56 
Molybdenum cofactor biosynthesis 
protein 1 
Mocs1 -1.12  18.75 19.87 7.05 
Adenylyltransferase and 
sulfurtransferase MOCS3 
Mocs3 NaN    18.93 3.97 
Mannosyl-oligosaccharide glucosidase Mogs -0.69  20.96 21.65 32.32 
Protein MON2 homolog Mon2 -1.11 + 21.87 22.98 45.23 
Putative helicase MOV-10 Mov10 0.96 + 21.60 20.65 8.90 
U3 small nucleolar ribonucleoprotein 
protein MPP10 
Mphosph10 1.35 + 21.25 19.90 3.69 
Mannose-6-phosphate isomerase Mpi -0.49  20.09 20.58 46.50 
MPN domain-containing protein Mpnd NaN    18.65 48.12 
55 kDa erythrocyte membrane protein Mpp1 0.91  23.18 22.27 130.51 
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Myosin phosphatase Rho-interacting 
protein 
Mprip -0.57 + 24.15 24.72 232.84 
Sulfurtransferase Mpst -0.03  23.30 23.32 57.56 
C-type mannose receptor 2 Mrc2 -1.78 + 23.11 24.89 273.04 
Double-strand break repair protein 
MRE11A 
Mre11a 0.10  22.40 22.30 19.75 
MORF4 family-associated protein 1 Mrfap1 -0.13  21.22 21.36 36.28 
Methylthioribose-1-phosphate 
isomerase 
Mri1 -0.43 + 23.62 24.04 39.51 
39S ribosomal protein L10, 
mitochondrial 
Mrpl10 0.60  21.84 21.23 27.82 
39S ribosomal protein L12, 
mitochondrial 
Mrpl12 0.45  23.59 23.15 62.64 
39S ribosomal protein L13, 
mitochondrial 
Mrpl13 NaN    19.52 2.47 
39S ribosomal protein L23, 
mitochondrial 
Mrpl23 0.41  21.93 21.52 8.10 
39S ribosomal protein L37, 
mitochondrial 
Mrpl37 NaN  20.38   29.80 
39S ribosomal protein L39, 
mitochondrial 
Mrpl39 0.42  19.96 19.54 2.28 
39S ribosomal protein L4, 
mitochondrial 
Mrpl4 0.70  24.60 23.90 6.55 
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39S ribosomal protein L40, 
mitochondrial 
Mrpl40 0.59  20.32 19.73 2.62 
39S ribosomal protein L44, 
mitochondrial 
Mrpl44 0.33  19.72 19.39 11.03 
39S ribosomal protein L45, 
mitochondrial 
Mrpl45 0.36  20.46 20.10 1.79 
39S ribosomal protein L53, 
mitochondrial 
Mrpl53 -0.03  20.10 20.14 6.44 
28S ribosomal protein S11, 
mitochondrial 
Mrps11 NaN    19.36 23.20 
28S ribosomal protein S14, 
mitochondrial 
Mrps14 0.54  19.96 19.42 2.60 
28S ribosomal protein S2, 
mitochondrial 
Mrps2 0.76 + 21.91 21.15 46.51 
28S ribosomal protein S22, 
mitochondrial 
Mrps22 1.36 + 21.71 20.36 23.83 
28S ribosomal protein S23, 
mitochondrial 
Mrps23 NaN  18.07   133.29 
28S ribosomal protein S28, 
mitochondrial 
Mrps28 0.19  20.65 20.46 18.32 
28S ribosomal protein S30, 
mitochondrial 
Mrps30 NaN  19.02   6.29 
28S ribosomal protein S31, 
mitochondrial 
Mrps31 1.33  20.98 19.65 78.56 
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28S ribosomal protein S34, 
mitochondrial 
Mrps34 1.80  20.60 18.79 6.60 
28S ribosomal protein S35, 
mitochondrial 
Mrps35 NaN  20.90   3.55 
28S ribosomal protein S36, 
mitochondrial 
Mrps36 0.40  20.91 20.51 33.40 
28S ribosomal protein S5, 
mitochondrial 
Mrps5 -0.70  20.08 20.78 4.55 
28S ribosomal protein S9, 
mitochondrial 
Mrps9 NaN    21.18 5.93 
Ribosome-recycling factor, 
mitochondrial 
Mrrf -0.10  20.49 20.59 9.58 
mRNA turnover protein 4 homolog Mrto4 -0.61  20.28 20.89 6.47 
DNA mismatch repair protein Msh2 Msh2 0.71 + 22.99 22.29 176.62 
DNA mismatch repair protein Msh6 Msh6 0.81  23.20 22.39 62.91 
RNA-binding protein Musashi homolog 
2 
Msi2 -1.25  19.93 21.18 33.01 
Moesin Msn -0.14  28.69 28.82 323.31 
Methionine-R-sulfoxide reductase B3, 
mitochondrial 
Msrb3 0.22  24.92 24.70 33.20 
Protein misato homolog 1 Msto1 NaN    19.45 3.78 
Cytochrome c oxidase subunit 2 mt-Co2 0.34  23.02 22.68 3.57 
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Metastasis-associated protein MTA1 Mta1 NaN    17.08 3.64 
 Mta1 -0.60  22.45 23.05 198.43 
Metastasis-associated protein MTA2 Mta2 -0.21  20.98 21.19 50.64 
Metastasis-associated protein MTA3 Mta3 0.26  19.52 19.26 178.74 
Mitochondrial carrier homolog 1 Mtch1 0.42  19.71 19.29 3.27 
Mitochondrial carrier homolog 2 Mtch2 0.51  20.58 20.07 50.57 
Protein LYRIC Mtdh NaN    19.61 35.15 
C-1-tetrahydrofolate synthase, 
cytoplasmic 
Mthfd1 0.20  25.88 25.68 236.87 
Monofunctional C1-tetrahydrofolate 
synthase, mitochondrial 




Mthfd2 0.91 + 23.07 22.16 27.43 
Translation initiation factor IF-2, 
mitochondrial 
Mtif2 NaN    17.90 7.38 
Myotubularin-related protein 2 Mtmr2 NaN  21.34   1.83 
Myotubularin-related protein 3 Mtmr3 0.30  22.13 21.83 9.14 
Myotubularin-related protein 6 Mtmr6 0.18  22.72 22.55 3.18 
Myotubularin-related protein 9 Mtmr9 NaN    20.06 3.13 
Myotrophin Mtpn -0.25  25.61 25.86 323.31 
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Methionine synthase Mtr 0.32  21.48 21.16 16.67 
MTSS1-like protein Mtss1l 0.01  21.25 21.25 43.53 
Metaxin-1 Mtx1 NaN    21.06 7.50 
Metaxin-2 Mtx2 0.27  22.84 22.57 97.61 
Muscle-related coiled-coil protein Murc -0.79 + 20.80 21.59 234.90 
Methylmalonyl-CoA mutase, 
mitochondrial 
Mut -0.16  22.55 22.71 34.71 
Diphosphomevalonate decarboxylase Mvd 0.31  21.72 21.41 2.84 
Mevalonate kinase Mvk -0.28  21.81 22.09 45.16 
Major vault protein Mvp -1.03 + 25.31 26.34 197.36 
Myeloid-associated differentiation 
marker 
Myadm 2.14  22.39 20.25 12.30 
Myb-binding protein 1A Mybbp1a 0.35  26.52 26.18 323.31 
E3 ubiquitin-protein ligase MYCBP2 Mycbp2 -0.63  18.92 19.54 22.52 
Myeloid differentiation primary 
response protein MyD88 
Myd88 -0.44  20.42 20.86 62.19 
Myeloid-derived growth factor Mydgf -0.50  24.83 25.33 109.50 
Myelin expression factor 2 Myef2 0.03  23.33 23.30 202.59 
Myeloma-overexpressed gene 2 protein 
homolog 
Myeov2 -0.61  22.15 22.76 18.63 
UPF0160 protein MYG1, mitochondrial Myg1 -0.70 + 25.04 25.74 162.63 
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Myosin-10 Myh10 0.74 + 28.01 27.27 323.31 
Myosin-14 Myh14 0.16  24.45 24.29 22.46 
Myosin-9 Myh9 0.19  31.61 31.42 323.31 
 Myl12a 0.64 + 27.78 27.14 323.31 
Myosin light polypeptide 6 Myl6 0.62 + 28.77 28.14 282.36 
Myosin regulatory light polypeptide 9 Myl9 0.45  22.32 21.87 56.10 
Myosin light chain kinase, smooth 
muscle 
Mylk -0.93  22.33 23.26 86.75 
Unconventional myosin-X Myo10 NaN  19.64   5.94 
Unconventional myosin-XVIIIa Myo18a -1.31  21.90 23.21 288.06 
 Myo18a NaN    15.28 1.54 
Unconventional myosin-Ib Myo1b -0.37 + 25.73 26.10 323.31 
Unconventional myosin-Ic Myo1c 0.42 + 27.19 26.77 323.31 
Unconventional myosin-Id Myo1d -1.55 + 23.58 25.13 267.38 
Unconventional myosin-Ie Myo1e -0.20  21.05 21.25 8.11 
Unconventional myosin-Va Myo5a 1.44  23.53 22.09 55.71 
Unconventional myosin-VI Myo6 -1.16 + 21.96 23.12 271.21 
Unconventional myosin-VIIa Myo7a -0.12  21.54 21.65 14.42 
Unconventional myosin-IXb Myo9b -1.63  20.57 22.20 126.91 
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Myoferlin Myof 0.99  24.95 23.96 323.31 
Mitotic-spindle organizing protein 2 Mzt2 0.49  21.43 20.93 31.24 
NEDD4-binding protein 1 N4bp1 NaN  19.83   3.80 
 N6amt1 0.83  21.82 20.99 3.97 
N-alpha-acetyltransferase 10 Naa10 -0.71  20.90 21.61 35.36 
N-alpha-acetyltransferase 15, NatA 
auxiliary subunit 
Naa15 0.38  23.03 22.65 19.53 
N-alpha-acetyltransferase 25, NatB 
auxiliary subunit 
Naa25 0.41  22.16 21.76 167.57 
N-alpha-acetyltransferase 50 Naa50 0.25  21.57 21.33 3.94 
NGFI-A-binding protein 2 Nab2 -0.61  20.34 20.96 7.66 
Nascent polypeptide-associated 
complex subunit alpha 
Naca 0.27  26.49 26.22 323.31 
NEDD8-activating enzyme E1 
regulatory subunit 
Nae1 0.27  23.26 22.98 46.33 
Alpha-N-acetylgalactosaminidase Naga -4.55 + 21.18 25.73 129.01 
N-acetyl-D-glucosamine kinase Nagk 0.17  22.97 22.80 32.72 
 Naglu -2.18 + 23.82 26.00 323.31 
N-acetylglucosamine-1-phosphodiester 
alpha-N-acetylglucosaminidase 
Nagpa NaN    18.62 20.47 






Nampt -1.13 + 23.51 24.64 243.81 
 Nans -0.75 + 25.93 26.68 247.38 
Nucleosome assembly protein 1-like 1 Nap1l1 0.21  27.21 27.00 323.31 
Nucleosome assembly protein 1-like 4 Nap1l4 0.19  26.39 26.20 323.31 
Alpha-soluble NSF attachment protein Napa -0.46  24.65 25.11 323.31 
Gamma-soluble NSF attachment 
protein 
Napg 0.29  20.99 20.70 37.70 
Cytosolic Fe-S cluster assembly factor 
NARFL 
Narfl 0.22  20.17 19.95 63.62 
Asparagine--tRNA ligase, cytoplasmic Nars 0.39 + 25.47 25.08 139.60 
Nuclear autoantigenic sperm protein Nasp 0.85 + 24.20 23.35 142.00 
N-acetyltransferase 10 Nat10 -0.21  21.70 21.91 56.94 
Arylamine N-acetyltransferase 2 Nat2 -0.05  20.09 20.14 69.00 
 Nbas -0.53  21.25 21.77 126.99 
 Nbeal1 NaN    19.85 18.47 
Nibrin Nbn -0.34  19.94 20.29 148.49 
Neural cell adhesion molecule 1 Ncam1 0.95  21.99 21.04 44.92 
Condensin complex subunit 1 Ncapd2 1.57  22.09 20.52 54.59 
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 Ncapg 1.79 + 23.43 21.65 119.71 
Condensin complex subunit 2 Ncaph -0.03  21.49 21.51 147.46 
Condensin-2 complex subunit H2 Ncaph2 -0.49  17.68 18.17 8.28 
Nuclear cap-binding protein subunit 1 Ncbp1 0.23  22.89 22.66 65.20 
Neurochondrin Ncdn NaN    15.36 2.03 
Nck-associated protein 1 Nckap1 -0.39 + 22.98 23.38 42.39 
Nucleolin Ncl 0.45 + 28.78 28.33 323.31 
Nuclear receptor coactivator 5 Ncoa5 0.09  22.27 22.18 6.18 
Nuclear receptor coactivator 7 Ncoa7 NaN    19.40 1.54 
Nuclear receptor corepressor 1 Ncor1 0.27  21.43 21.15 27.99 
Nuclear receptor corepressor 2 Ncor2 0.85  19.52 18.68 26.77 
Nicastrin Ncstn -0.59  21.75 22.35 63.26 
Nucleoporin NDC1 Ndc1 NaN  20.22   8.43 
Nuclear distribution protein nudE 
homolog 1 
Nde1 0.29  18.86 18.58 5.72 
Nuclear distribution protein nudE-like 1 Ndel1 -0.81  20.62 21.42 35.50 
Protein NDRG1 Ndrg1 -0.68  24.38 25.07 117.15 
Protein NDRG3 Ndrg3 -1.00 + 21.84 22.84 46.59 
 Ndrg3 NaN    19.23 2.47 
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NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 10, 
mitochondrial 
Ndufa10 0.08  23.70 23.62 72.11 
NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 12 
Ndufa12 -0.65  22.31 22.96 12.40 
NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 13 
Ndufa13 0.39  20.27 19.87 2.78 
Cytochrome c oxidase subunit NDUFA4 Ndufa4 NaN    22.18 3.21 
NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 5 
Ndufa5 -0.64  21.28 21.92 39.04 
NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 6 
Ndufa6 0.80 + 22.20 21.40 7.50 
NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 8 
Ndufa8 0.43 + 22.51 22.09 3.74 
NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 9, 
mitochondrial 
Ndufa9 -0.59 + 23.51 24.10 161.53 
NADH dehydrogenase [ubiquinone] 
complex I, assembly factor 7 
Ndufaf7 1.08 + 22.08 20.99 15.34 
NADH dehydrogenase [ubiquinone] 1 
beta subcomplex subunit 10 
Ndufb10 NaN  22.15   12.77 
NADH dehydrogenase [ubiquinone] 1 
beta subcomplex subunit 3 
Ndufb3 NaN  20.35   4.16 
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NADH dehydrogenase [ubiquinone] 1 
beta subcomplex subunit 4 
Ndufb4 0.75  21.04 20.28 3.08 
NADH-ubiquinone oxidoreductase 75 
kDa subunit, mitochondrial 
Ndufs1 0.16  24.68 24.53 105.02 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 2, mitochondrial 
Ndufs2 0.83  23.64 22.81 238.92 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 3, mitochondrial 
Ndufs3 0.12  24.07 23.95 101.38 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 4, mitochondrial 
Ndufs4 NaN    20.62 6.17 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 5 
Ndufs5 NaN  19.89   8.89 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 6, mitochondrial 
Ndufs6 1.60  20.09 18.48 3.53 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 7, mitochondrial 
Ndufs7 -0.47  20.59 21.06 5.32 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 8, mitochondrial 
Ndufs8 NaN    23.01 27.48 
NADH dehydrogenase [ubiquinone] 
flavoprotein 1, mitochondrial 
Ndufv1 0.18  21.73 21.55 7.10 
NADH dehydrogenase [ubiquinone] 
flavoprotein 2, mitochondrial 
Ndufv2 0.82  22.95 22.13 54.51 
 Ndufv3 NaN    20.64 1.79 
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Adaptin ear-binding coat-associated 
protein 1 
Necap1 -0.50  20.53 21.03 2.34 
Adaptin ear-binding coat-associated 
protein 2 
Necap2 -1.17  20.89 22.06 9.61 
Protein NEDD1 Nedd1 0.16  20.32 20.16 5.29 
E3 ubiquitin-protein ligase NEDD4 Nedd4 0.53 + 26.63 26.10 323.31 
E3 ubiquitin-protein ligase NEDD4-like Nedd4l -0.80  21.88 22.67 30.94 
NEDD8 Nedd8 -0.30  24.61 24.92 61.60 
Serine/threonine-protein kinase Nek7 Nek7 -0.41  21.11 21.53 49.85 
Serine/threonine-protein kinase Nek9 Nek9 NaN    20.61 17.74 
Negative elongation factor A Nelfa NaN    20.75 4.48 
Negative elongation factor B Nelfb -0.60  20.29 20.89 4.82 
Negative elongation factor D Nelfcd -0.23  20.11 20.34 25.69 
Negative elongation factor E Nelfe 0.02  20.37 20.34 17.25 
Neudesin Nenf 1.05  23.48 22.43 55.96 
Sialidase-1 Neu1 -1.89  20.33 22.22 30.55 
Nexilin Nexn -0.37  19.92 20.30 17.64 
Neurofibromin Nf1 0.62  20.96 20.34 6.73 
Nuclear factor of activated T-cells 5 Nfat5 NaN    18.82 1.71 




Nuclear factor 1 Nfib -0.08  20.45 20.52 49.83 
Nuclear factor 1 C-type Nfic -0.33  22.56 22.89 43.61 
Nuclear factor 1 Nfix 0.24  23.57 23.33 106.39 
Nuclear factor NF-kappa-B p105 
subunit 
Nfkb1 -0.40  21.41 21.81 6.41 
Nuclear factor NF-kappa-B p100 
subunit 
Nfkb2 -0.49  21.73 22.22 20.33 
Cysteine desulfurase, mitochondrial Nfs1 -0.16  20.57 20.74 25.60 
NFU1 iron-sulfur cluster scaffold 
homolog, mitochondrial 
Nfu1 0.63  23.03 22.40 17.32 
Neuroguidin Ngdn 0.51  18.96 18.45 5.49 
Peptide-N(4)-(N-acetyl-beta-
glucosaminyl)asparagine amidase 
Ngly1 NaN  21.11   29.01 
NHL repeat-containing protein 2 Nhlrc2 -0.27  21.92 22.20 45.40 
NHL repeat-containing protein 3 Nhlrc3 -0.70  21.06 21.76 19.49 
H/ACA ribonucleoprotein complex 
subunit 2 
Nhp2 0.06  22.57 22.51 40.76 
NHP2-like protein 1 Nhp2l1 0.15  24.55 24.40 10.69 
Nidogen-2 NID-2 0.71 + 25.87 25.16 209.31 
NIF3-like protein 1 Nif3l1 -0.67 + 22.43 23.10 32.99 
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MKI67 FHA domain-interacting 
nucleolar phosphoprotein 
Nifk 0.55  23.01 22.46 22.84 
60S ribosome subunit biogenesis 
protein NIP7 homolog 
Nip7 NaN  20.75   2.07 
Nipped-B-like protein Nipbl -1.46  17.52 18.98 5.24 
Protein NipSnap homolog 3B Nipsnap3b 0.97  22.58 21.61 8.27 
Nischarin Nisch -0.77  22.25 23.02 43.92 
Nitrilase homolog 1 Nit1 -0.47  22.14 22.61 12.83 
Omega-amidase NIT2 Nit2 -0.24  22.92 23.16 135.21 
Notchless protein homolog 1 Nle1 0.71  21.46 20.74 56.27 
Neurolysin, mitochondrial Nln 0.66  23.05 22.39 34.28 
60S ribosomal export protein NMD3 Nmd3 -0.26  18.80 19.07 3.83 
Nucleoside diphosphate kinase Nme1 -2.21 + 22.37 24.58 42.99 
Nucleoside diphosphate kinase Nme4 1.19  20.46 19.27 16.94 
N-myc-interactor Nmi 0.82  20.75 19.92 4.86 
NmrA-like family domain-containing 
protein 1 
Nmral1 -1.50  22.43 23.94 84.97 
Glycylpeptide N-
tetradecanoyltransferase 
Nmt1 0.25  24.49 24.24 323.31 
Glycylpeptide N-
tetradecanoyltransferase 
Nmt2 -0.72  21.43 22.15 12.62 
410 
 
Nicotinamide N-methyltransferase Nnmt 0.41  21.42 21.02 2.73 
NAD(P) transhydrogenase, 
mitochondrial 
Nnt 1.53  20.57 19.04 26.88 
Nucleolar complex protein 2 homolog Noc2l -0.48  20.94 21.41 15.10 
Nucleolar complex protein 4 homolog Noc4l 1.12  19.77 18.65 8.16 
Nucleolar protein 10 Nol10 0.26  18.76 18.50 3.35 
Nucleolar protein 11 Nol11 NaN  20.41   1.71 
Nucleolar protein 3 Nol3 -0.39  22.28 22.67 135.03 
Nucleolar protein 6 Nol6 0.76  22.36 21.60 27.81 
Nucleolar protein 7 Nol7 NaN    20.09 27.36 
Nucleolar protein 8 Nol8 0.53  22.04 21.50 9.24 
 Nolc1 0.05  23.12 23.08 79.66 
Nodal modulator 1 Nomo1 0.76 + 22.37 21.61 24.32 
Non-POU domain-containing octamer-
binding protein 
Nono -0.09  26.92 27.01 323.31 
H/ACA ribonucleoprotein complex 
subunit 3 
Nop10 -0.55  21.99 22.54 33.46 
Nucleolar protein 14 Nop14 -0.30  19.03 19.33 23.84 
Nucleolar protein 16 Nop16 -1.24  19.95 21.20 4.30 
Probable 28S rRNA (cytosine-C(5))-
methyltransferase 
Nop2 0.63  23.03 22.39 46.61 
411 
 
Nucleolar protein 56 Nop56 -1.78 + 23.78 25.56 302.85 
Nucleolar protein 58 Nop58 -0.28  25.01 25.29 323.31 
Nostrin Nostrin -3.28 + 11.92 15.20 53.88 
Neurogenic locus notch homolog 
protein 2 
Notch2 0.15  17.75 17.61 10.96 
Niemann-Pick C1 protein Npc1 NaN    21.12 2.13 
Probable aminopeptidase NPEPL1 Npepl1 -0.84 + 21.38 22.22 162.79 
Puromycin-sensitive aminopeptidase Npepps -0.34 + 26.05 26.39 277.08 
Nuclear protein localization protein 4 
homolog 
Nploc4 -0.40  23.25 23.65 49.62 
Nucleophosmin Npm1 0.58 + 28.87 28.29 323.31 
Nucleoplasmin-3 Npm3 1.00  24.49 23.49 145.01 
Nephronectin Npnt -0.09  24.06 24.14 21.52 
NAD(P)H dehydrogenase [quinone] 1 Nqo1 -0.67 + 23.60 24.28 109.87 
Glucocorticoid receptor Nr3c1 -0.30  21.68 21.98 181.03 
GTPase NRas Nras 1.50 + 22.13 20.62 19.18 
Nuclear receptor-binding factor 2 Nrbf2 -1.48 + 19.05 20.53 22.14 
Nuclear receptor-binding protein Nrbp1 0.87 + 24.09 23.22 27.01 
Nardilysin Nrd1 -0.30  21.86 22.16 74.75 





Nsdhl 0.36  21.66 21.30 13.15 
Vesicle-fusing ATPase Nsf -0.74 + 24.41 25.16 234.54 
NSFL1 cofactor p47 Nsfl1c 0.13  26.30 26.17 323.31 
Protein FAN Nsmaf NaN    18.47 3.03 
tRNA (cytosine(34)-C(5))-
methyltransferase 
Nsun2 0.03  24.15 24.12 145.92 
Putative methyltransferase NSUN6 Nsun6 -0.09  18.83 18.92 6.70 
5(3)-deoxyribonucleotidase, cytosolic 
type 
Nt5c -0.92 + 24.43 25.35 153.79 
Cytosolic purine 5-nucleotidase Nt5c2 0.37  21.01 20.64 11.57 
7-methylguanosine phosphate-specific 
5-nucleotidase 
Nt5c3b -0.76  23.62 24.38 108.70 
 Nt5dc2 -0.55  22.30 22.85 68.98 
5-nucleotidase domain-containing 
protein 3 
Nt5dc3 1.18  21.69 20.52 10.76 
5-nucleotidase Nt5e NaN    21.21 11.11 
N-terminal Xaa-Pro-Lys N-
methyltransferase 1 
Ntmt1 -0.09  20.98 21.08 40.04 
Cancer-related nucleoside-
triphosphatase homolog 
Ntpcr NaN  20.41   3.77 
NEDD8 ultimate buster 1 Nub1 0.01  22.65 22.63 55.52 
413 
 
Cytosolic Fe-S cluster assembly factor 
NUBP2 
Nubp2 0.09  23.36 23.27 27.37 
Nucleobindin-1 Nucb1 -0.65  24.02 24.67 219.21 
Nucleobindin-2 Nucb2 -0.78 + 23.70 24.47 246.07 
Nuclear ubiquitous casein and cyclin-
dependent kinase substrate 1 
Nucks1 NaN    16.91 4.30 
Nuclear migration protein nudC Nudc -0.04  23.87 23.90 88.33 
NudC domain-containing protein 1 Nudcd1 0.23  22.64 22.42 125.13 
NudC domain-containing protein 2 Nudcd2 -0.74  22.25 22.98 184.09 
NudC domain-containing protein 3 Nudcd3 -1.34  20.65 21.98 7.63 
U8 snoRNA-decapping enzyme Nudt16 NaN    18.91 9.91 
Protein syndesmos Nudt16l1 -0.01  21.67 21.69 3.44 
Nucleoside diphosphate-linked moiety 
X motif 17 
Nudt17 NaN    17.34 3.28 
Bis(5-nucleosyl)-tetraphosphatase 
[asymmetrical] 
Nudt2 0.11  21.97 21.86 8.39 
Cleavage and polyadenylation 
specificity factor subunit 5 
Nudt21 0.27  25.29 25.02 86.25 
Diphosphoinositol polyphosphate 
phosphohydrolase 1 
Nudt3 1.18  22.40 21.21 11.52 
Diphosphoinositol polyphosphate 
phosphohydrolase 2 
Nudt4 -1.46  19.98 21.45 16.08 
414 
 
ADP-sugar pyrophosphatase Nudt5 -0.34  22.38 22.71 4.60 
ADP-ribose pyrophosphatase, 
mitochondrial 
Nudt9 -0.55 + 21.53 22.08 37.24 
Nuclear fragile X mental retardation-
interacting protein 2 
Nufip2 -0.27  21.37 21.64 20.47 
 Numa1 -0.84  23.75 24.59 323.31 
Nuclear pore complex protein Nup107 Nup107 0.04  22.33 22.29 95.38 
Nuclear pore complex protein Nup133 Nup133 0.58  23.16 22.57 193.07 
 Nup153 0.09  21.78 21.69 62.59 
Nuclear pore complex protein Nup155 Nup155 -0.04  23.92 23.95 230.73 
Nuclear pore complex protein Nup160 Nup160 -0.63  22.23 22.86 122.81 
Nucleoporin NUP188 homolog Nup188 0.43  20.72 20.29 26.50 
 Nup205 -0.09  22.22 22.31 100.35 
 Nup205 NaN    13.48 2.96 
Nuclear pore complex protein Nup214 Nup214 -0.01  23.26 23.27 107.77 
Nucleoporin NUP53 Nup35 0.69  22.34 21.65 23.37 
Nucleoporin Nup37 Nup37 0.19  22.18 21.99 9.15 
Nucleoporin Nup43 Nup43 0.64  22.32 21.67 13.61 
Nuclear pore complex protein Nup54 Nup54 0.04  22.57 22.52 152.76 
Nuclear pore glycoprotein p62 Nup62 -0.13  22.09 22.21 60.32 
415 
 
Nuclear pore complex protein Nup85 Nup85 -1.40  18.80 20.20 17.98 
Nuclear pore complex protein Nup88 Nup88 0.02  20.73 20.71 18.57 
Nuclear pore complex protein Nup93 Nup93 -0.29  23.36 23.66 123.60 
Nuclear pore complex protein Nup98-
Nup96 
Nup98 0.20  23.57 23.38 241.83 
Nucleoporin p58/p45 Nupl1 -0.17  22.45 22.62 29.84 
Nuclear transport factor 2 Nutf2 -0.26  23.09 23.35 27.13 
Nuclear valosin-containing protein-like Nvl 1.26  21.32 20.06 4.89 
Nuclear RNA export factor 1 Nxf1 0.71  22.48 21.77 96.05 
Nucleoredoxin Nxn 0.09  24.73 24.65 128.01 
Ornithine aminotransferase, 
mitochondrial 
Oat 0.02  26.92 26.90 323.31 
CST complex subunit STN1 Obfc1 -0.13  21.58 21.72 8.24 
Obscurin-like protein 1 Obsl1 -0.02  21.18 21.19 151.40 
OCIA domain-containing protein 1 Ociad1 NaN  19.88   6.28 
2-oxoglutarate dehydrogenase, 
mitochondrial 
Ogdh -0.74 + 24.53 25.27 207.43 
 Ogdhl 0.78  23.52 22.74 20.12 
Opioid growth factor receptor Ogfr 0.60  22.49 21.89 168.85 




acetylglucosaminyltransferase 110 kDa 
subunit 
Ogt -0.20  22.21 22.41 73.31 
UDP-N-acetylglucosamine--peptide N-
acetylglucosaminyltransferase 110 kDa 
subunit 
Ogt NaN    20.26 5.76 
Obg-like ATPase 1 Ola1 -0.25  25.48 25.73 173.05 
Olfactomedin-like protein 3 Olfml3 NaN    22.84 9.15 
Osteomodulin Omd -2.66  21.79 24.46 24.70 
Optineurin Optn -0.38 + 21.76 22.14 38.96 
Protein OS-9 Os9 -1.07  15.82 16.88 12.79 
Oxysterol-binding protein 1 Osbp -0.36  23.83 24.19 79.63 
Oxysterol-binding protein Osbpl11 0.10  21.89 21.79 25.12 
Oxysterol-binding protein-related 
protein 1 
Osbpl1a -0.09  24.61 24.70 7.36 
Oxysterol-binding protein Osbpl2 0.08  21.29 21.21 7.80 
Oxysterol-binding protein Osbpl3 NaN    21.42 19.99 
Oxysterol-binding protein Osbpl9 0.51  21.30 20.79 4.98 
Protein OSCP1 Oscp1 NaN    19.78 1.95 
Probable tRNA N6-adenosine 
threonylcarbamoyltransferase 
Osgep -0.41  20.03 20.44 89.82 
417 
 
Osteoclast-stimulating factor 1 Ostf1 -0.06  24.46 24.53 103.65 
Ubiquitin thioesterase OTUB1 Otub1 0.33 + 26.74 26.41 194.01 
OTU domain-containing protein 4 Otud4 0.73  19.58 18.85 3.68 
OTU domain-containing protein 6B Otud6b 0.58  23.25 22.67 24.68 
 Otud6b 1.02  23.54 22.52 1.67 
OTU domain-containing protein 7B Otud7b NaN    17.68 5.93 
Succinyl-CoA:3-ketoacid coenzyme A 
transferase 1, mitochondrial 
Oxct1 0.08  26.23 26.15 323.31 
Oxidation resistance protein 1 Oxr1 -0.23  20.71 20.94 34.98 
Prolyl 3-hydroxylase 1 P3h1 -1.19 + 24.00 25.20 144.63 
Prolyl 4-hydroxylase subunit alpha-1 P4ha1 -1.39 + 26.21 27.59 323.31 
Prolyl 4-hydroxylase subunit alpha-1 P4ha1 -2.80 + 21.77 24.57 22.18 
Prolyl 4-hydroxylase subunit alpha-2 P4ha2 -2.28 + 24.70 26.99 323.31 
Prolyl 4-hydroxylase subunit alpha-2 P4ha2 NaN    21.76 7.07 
Prolyl 4-hydroxylase subunit alpha-3 P4ha3 NaN  22.32   7.38 
Protein disulfide-isomerase P4hb -0.25  29.40 29.65 323.31 
Proliferation-associated protein 2G4 Pa2g4 0.20  26.38 26.18 295.97 
Polyadenylate-binding protein Pabpc1 0.18  27.60 27.42 323.31 
Polyadenylate-binding protein Pabpc4 -0.79 + 24.49 25.29 78.77 
418 
 
Polyadenylate-binding protein 2 Pabpn1 -0.11  23.36 23.46 75.66 
Phosphofurin acidic cluster sorting 
protein 1 
Pacs1 -0.28  20.75 21.04 5.45 
Phosphofurin acidic cluster sorting 
protein 2 
Pacs2 NaN    19.77 6.58 
Protein kinase C and casein kinase 
substrate in neurons protein 2 
Pacsin2 -1.06  21.99 23.05 116.33 
Protein kinase C and casein kinase II 
substrate protein 3 
Pacsin3 1.12  21.58 20.47 42.76 
RNA polymerase II-associated factor 1 
homolog 
Paf1 -1.37  19.97 21.34 9.47 
Platelet-activating factor 
acetylhydrolase IB subunit alpha 
Pafah1b1 -0.06  24.85 24.91 275.90 
Platelet-activating factor 
acetylhydrolase IB subunit beta 
Pafah1b2 -0.10  24.63 24.73 137.64 
Platelet-activating factor 
acetylhydrolase IB subunit gamma 
Pafah1b3 -0.60  23.66 24.25 64.29 
Multifunctional protein ADE2 Paics -0.32  24.72 25.05 188.14 
Polyadenylate-binding protein-
interacting protein 2 
Paip2 NaN    21.23 21.60 
Non-specific serine/threonine protein 
kinase 
Pak1 NaN    17.82 8.13 




Serine/threonine-protein kinase PAK 2 Pak2 -0.21  24.23 24.44 189.33 
Non-specific serine/threonine protein 
kinase 
Pak3 -0.52  20.60 21.12 9.90 
Serine/threonine-protein kinase PAK 4 Pak4 NaN    20.41 76.32 
A-kinase anchor protein 2 Pakap 0.50 + 26.03 25.53 323.31 
Paladin Pald1 -0.70  19.66 20.36 16.36 
Palladin Palld 0.39 + 26.11 25.72 323.31 
Palladin Palld NaN  21.99   13.76 
Paralemmin-1 Palm NaN  19.59   44.80 
Paralemmin-2 Palm2 1.87  22.82 20.95 7.69 
Pantothenate kinase 1 Pank1 NaN    16.95 217.13 
 Pank2 -0.31  19.49 19.80 47.87 
Pantothenate kinase 3 Pank3 NaN    19.54 1.66 
Pannexin Panx3 -1.19 + 21.31 22.51 54.42 
Poly(A) polymerase alpha Papola -0.41  19.21 19.62 47.11 
Bifunctional 3-phosphoadenosine 5-
phosphosulfate synthase 1 
Papss1 -0.20  23.33 23.53 69.85 
Bifunctional 3-phosphoadenosine 5-
phosphosulfate synthase 2 
Papss2 -0.39  22.13 22.53 28.95 
420 
 
Partitioning defective 3 homolog Pard3 0.34  21.63 21.29 41.71 
Poly(ADP-ribose) glycohydrolase Parg NaN    18.69 2.05 
Protein deglycase DJ-1 Park7 -0.77 + 23.99 24.77 120.07 
Poly(A)-specific ribonuclease PARN Parn -1.49  20.28 21.77 13.89 
Poly [ADP-ribose] polymerase 1 Parp1 1.04  22.72 21.68 50.22 
 Parp10 NaN    20.45 6.11 
 Parp3 1.21  22.72 21.51 137.08 
Poly [ADP-ribose] polymerase 9 Parp9 0.49  20.37 19.88 3.82 
Alpha-parvin Parva -0.34  24.00 24.33 234.92 
Protein PAT1 homolog 1 Patl1 -0.34  19.47 19.81 9.20 
PRKC apoptosis WT1 regulator protein Pawr -1.51  20.29 21.80 24.02 
PAX3- and PAX7-binding protein 1 Paxbp1 0.20  19.53 19.33 3.11 
Protein PBDC1 Pbdc1 0.42  22.48 22.06 32.84 
Lymphokine-activated killer T-cell-
originated protein kinase 
Pbk NaN    19.97 1.61 
Poly(rC)-binding protein 1 Pcbp1 -0.21  26.95 27.17 113.54 
Poly(rC)-binding protein 2 Pcbp2 0.16  26.65 26.50 323.31 
Propionyl-CoA carboxylase alpha 
chain, mitochondrial 
Pcca -0.53  21.72 22.25 21.92 
421 
 
Propionyl-CoA carboxylase beta chain, 
mitochondrial 
Pccb -0.49  22.35 22.83 107.02 
PCI domain-containing protein 2 Pcid2 0.34  22.20 21.86 13.46 
Phosphorylated CTD-interacting factor 
1 
Pcif1 NaN    19.55 7.71 
Phosphoenolpyruvate carboxykinase 
[GTP], mitochondrial 
Pck2 0.74 + 26.31 25.57 312.37 
Pericentriolar material 1 protein Pcm1 0.25  20.24 19.99 10.39 
Protein-L-isoaspartate O-
methyltransferase 
Pcmt1 0.76  25.25 24.50 38.63 
Proliferating cell nuclear antigen Pcna 0.69 + 26.50 25.81 187.46 
PEST proteolytic signal-containing 
nuclear protein 
Pcnp -0.36  22.65 23.01 41.15 
Pericentrin Pcnt NaN    17.85 24.30 
Procollagen C-endopeptidase enhancer 
1 
Pcolce -2.86 + 22.44 25.30 202.26 
Pyruvate carboxylase Pcx -0.13  24.28 24.41 133.88 
Prenylcysteine oxidase Pcyox1 -0.20  23.94 24.14 222.50 
Prenylcysteine oxidase-like Pcyox1l NaN  21.06   30.29 
Choline-phosphate cytidylyltransferase 
A 
Pcyt1a -1.60 + 21.94 23.54 76.34 




28 kDa heat- and acid-stable 
phosphoprotein 
Pdap1 0.36  24.08 23.72 123.35 
Programmed cell death protein 10 Pdcd10 -0.53 + 22.39 22.92 62.16 
Protein RRP5 homolog Pdcd11 -1.15 + 20.42 21.57 46.08 
Programmed cell death protein 4 Pdcd4 0.81  22.87 22.07 24.31 
Programmed cell death protein 5 Pdcd5 0.55  24.47 23.92 130.75 
Programmed cell death protein 6 Pdcd6 -1.19 + 22.86 24.05 91.94 
Programmed cell death 6-interacting 
protein 
Pdcd6ip 0.18  26.46 26.29 323.31 
Phosducin-like protein 3 Pdcl3 0.04  22.37 22.33 52.79 
Parkinson disease 7 domain-containing 
protein 1 
Pddc1 -0.59  21.34 21.93 19.91 
2,5-phosphodiesterase 12 Pde12 0.07  20.49 20.42 6.62 
Myomegalin Pde4dip 0.38  19.86 19.49 2.79 
Platelet-derived growth factor receptor 
beta 
Pdgfrb 1.61  22.47 20.85 12.83 
Pyruvate dehydrogenase E1 
component subunit alpha 
Pdha1 0.01  22.66 22.65 34.48 
Pyruvate dehydrogenase E1 
component subunit beta, mitochondrial 
Pdhb -0.09  24.96 25.05 132.80 
423 
 
Pyruvate dehydrogenase protein X 
component, mitochondrial 
Pdhx 0.26  21.60 21.34 4.96 
Protein disulfide-isomerase A3 Pdia3 0.19  29.40 29.21 323.31 
Protein disulfide-isomerase A4 Pdia4 0.29  27.57 27.28 323.31 
Protein disulfide-isomerase A5 Pdia5 -2.64 + 21.48 24.12 56.24 
Protein disulfide-isomerase A6 Pdia6 0.01  27.88 27.87 323.31 
[Pyruvate dehydrogenase (acetyl-
transferring)] kinase isozyme 1, 
mitochondrial 
Pdk1 NaN    21.05 8.83 
[Pyruvate dehydrogenase (acetyl-
transferring)] kinase isozyme 3, 
mitochondrial 
Pdk3 0.05  21.86 21.81 71.79 
PDZ and LIM domain protein 1 Pdlim1 -0.47  25.16 25.63 90.49 
PDZ and LIM domain protein 2 Pdlim2 -0.38  22.43 22.81 103.81 
PDZ and LIM domain protein 5 Pdlim5 0.18  25.38 25.20 130.47 




Pdp1 0.52  21.49 20.97 22.32 
3-phosphoinositide-dependent protein 
kinase 1 
Pdpk1 0.30  21.80 21.50 14.63 
424 
 
Pyruvate dehydrogenase phosphatase 
regulatory subunit, mitochondrial 
Pdpr 0.13  20.20 20.08 27.77 
Sister chromatid cohesion protein 
PDS5 homolog A 
Pds5a -1.00 + 20.98 21.98 284.06 
Sister chromatid cohesion protein 
PDS5 homolog B 
Pds5b 0.25  22.42 22.16 160.67 
Pyridoxal-dependent decarboxylase 
domain-containing protein 1 
Pdxdc1 -0.39  24.79 25.18 323.31 
Pyridoxal kinase Pdxk 0.13  22.33 22.20 10.74 
E3 ubiquitin-protein ligase PDZRN3 Pdzrn3 -0.38  25.37 25.75 3.99 
Astrocytic phosphoprotein PEA-15 Pea15 0.54 + 21.92 21.39 14.14 
Phosphatidylethanolamine-binding 
protein 1 
Pebp1 -0.90 + 26.42 27.33 180.77 
Peroxisomal trans-2-enoyl-CoA 
reductase 
Pecr -0.17  19.36 19.53 8.63 
Peflin Pef1 -0.79  21.16 21.95 15.96 
Protein pelota homolog Pelo -0.34  21.92 22.25 163.63 
Proline-, glutamic acid- and leucine-rich 
protein 1 
Pelp1 -0.22  23.05 23.27 154.83 
Xaa-Pro dipeptidase Pepd 0.12  23.02 22.90 59.83 
Pescadillo homolog Pes1 -1.52  19.18 20.70 21.29 
Peroxisomal biogenesis factor 19 Pex19 -0.22  21.73 21.95 295.99 
425 
 
Peroxisomal targeting signal 1 receptor Pex5 0.10  21.56 21.46 114.16 
Phosphoribosylformylglycinamidine 
synthase 
Pfas -0.81  24.36 25.17 319.04 
Prefoldin subunit 1 Pfdn1 1.08  22.90 21.83 6.01 
Prefoldin subunit 2 Pfdn2 -0.53  23.98 24.51 188.95 
Prefoldin subunit 4 Pfdn4 1.08  22.68 21.60 56.96 
Prefoldin subunit 5 Pfdn5 0.00  23.86 23.86 153.90 
Prefoldin subunit 6 Pfdn6 0.06  22.97 22.90 80.37 
ATP-dependent 6-
phosphofructokinase, liver type 
Pfkl -1.44 + 25.51 26.95 323.31 
ATP-dependent 6-
phosphofructokinase, muscle type 
Pfkm -0.94  22.63 23.56 296.23 
ATP-dependent 6-
phosphofructokinase, platelet type 
Pfkp 0.18  24.68 24.49 194.35 
Profilin-2 Pfn2 -1.44  21.23 22.67 15.63 
Phosphoglycerate mutase 1 Pgam1 -2.05 + 27.73 29.78 323.31 
Serine/threonine-protein phosphatase 
PGAM5, mitochondrial 
Pgam5 NaN    18.45 1.67 
6-phosphogluconate dehydrogenase, 
decarboxylating 
Pgd -0.50 + 25.61 26.11 323.31 
Phosphoglycerate kinase 1 Pgk1 -1.32 + 28.95 30.27 323.31 
426 
 
Phosphoglycerate kinase 2 Pgk2 NaN    24.14 1.63 
6-phosphogluconolactonase Pgls -0.51 + 26.15 26.66 183.93 
Phosphoglucomutase-1 Pgm2 -1.33 + 24.95 26.28 323.31 
Phosphoglucomutase-2 Pgm2 0.11  23.06 22.95 22.00 
Phosphoacetylglucosamine mutase Pgm3 -1.04 + 23.23 24.27 69.39 
Phosphoglucomutase-like protein 5 Pgm5 NaN    20.10 20.87 
Phosphoglycolate phosphatase Pgp -1.53 + 22.50 24.03 11.08 
Pyroglutamyl-peptidase 1 Pgpep1 0.47  21.03 20.56 13.03 
Membrane-associated progesterone 
receptor component 1 
Pgrmc1 1.64  22.03 20.39 16.71 
Membrane-associated progesterone 
receptor component 2 
Pgrmc2 1.87  21.23 19.36 13.44 
Prohibitin Phb -0.25  26.11 26.36 315.82 
Prohibitin-2 Phb2 -0.08  26.13 26.21 323.31 
Polyhomeotic-like protein 1 Phc1 NaN    19.33 9.71 
PHD finger protein 10 Phf10 NaN    18.41 3.42 
 Phf3 NaN    19.14 47.26 
D-3-phosphoglycerate dehydrogenase Phgdh 1.00 + 27.06 26.05 244.92 
PH-interacting protein Phip -0.05  19.35 19.40 6.24 
427 
 
Pleckstrin homology-like domain family 
B member 1 
Phldb1 -0.34  22.39 22.73 53.70 
Pleckstrin homology-like domain family 
B member 2 
Phldb2 0.26  19.22 18.96 4.22 
Phosphoethanolamine/phosphocholine 
phosphatase 
Phospho1 NaN    24.87 21.41 
14 kDa phosphohistidine phosphatase Phpt1 -2.30 + 21.83 24.13 94.01 
Phosphatidylinositol 4-kinase type 2-
alpha 
Pi4k2a NaN    20.02 3.75 
 Pi4ka -0.05  21.12 21.16 67.32 
Phosphatidylinositol-binding clathrin 
assembly protein 
Picalm -0.15  24.68 24.83 170.53 
GPI transamidase component PIG-S Pigs 0.39  21.97 21.58 67.60 
GPI transamidase component PIG-T Pigt -0.53  19.54 20.07 2.98 
PIH1 domain-containing protein 1 Pih1d1 -0.11  20.70 20.81 49.99 
Phosphatidylinositol 4-phosphate 3-
kinase C2 domain-containing subunit 
alpha 
Pik3c2a NaN    19.25 2.85 
Phosphatidylinositol 3-kinase catalytic 
subunit type 3 
Pik3c3 -0.39  20.34 20.73 23.71 
Phosphatidylinositol 3-kinase 
regulatory subunit alpha 




regulatory subunit beta 
Pik3r2 NaN  18.64   4.15 
Phosphoinositide 3-kinase regulatory 
subunit 4 
Pik3r4 0.20  23.07 22.87 7.68 
Peptidyl-prolyl cis-trans isomerase 
NIMA-interacting 1 
Pin1 0.08  22.62 22.54 7.64 
Peptidyl-prolyl cis-trans isomerase 
NIMA-interacting 4 
Pin4 -0.66  21.38 22.04 11.59 
Phosphatidylinositol 5-phosphate 4-
kinase type-2 alpha 
Pip4k2a NaN    20.53 11.11 
Phosphatidylinositol 5-phosphate 4-
kinase type-2 beta 
Pip4k2b -1.99  19.41 21.40 38.86 
Phosphatidylinositol 5-phosphate 4-
kinase type-2 gamma 
Pip4k2c -0.22  21.51 21.73 10.07 
Phosphatidylinositol 4-phosphate 5-
kinase type-1 gamma 
Pip5k1c NaN    20.63 6.03 
Pirin Pir -0.81  21.12 21.93 13.31 
Phosphatidylinositol transfer protein 
alpha isoform 
Pitpna 0.62  24.04 23.41 17.38 
Phosphatidylinositol transfer protein 
beta isoform 
Pitpnb 0.28  22.79 22.51 5.01 
Membrane-associated 
phosphatidylinositol transfer protein 1 
Pitpnm1 -0.17  21.68 21.85 14.22 
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Presequence protease, mitochondrial Pitrm1 0.39 + 23.85 23.47 30.25 
Pyruvate kinase PKM Pkm -0.62 + 29.84 30.46 323.31 
Pyruvate kinase PKM Pkm NaN    23.26 2.61 
Serine/threonine-protein kinase N1 Pkn1 -0.66 + 20.76 21.43 38.63 
Serine/threonine-protein kinase N2 Pkn2 0.52  22.34 21.82 13.50 
Group XV phospholipase A2 Pla2g15 -2.23 + 21.23 23.45 36.24 
HRAS-like suppressor 3 Pla2g16 -2.22 + 19.78 22.00 44.01 
Cytosolic phospholipase A2 Pla2g4a -0.30  22.84 23.13 118.08 
Phospholipase A-2-activating protein Plaa 0.11  22.70 22.58 123.58 
Putative phospholipase B-like 2 Plbd2 -3.13 + 22.83 25.96 323.31 








Plcd3 NaN  21.62   3.79 
Phosphoinositide phospholipase C Plcg1 -0.29  20.66 20.95 7.88 
Phospholipase D3 Pld3 -0.04  22.72 22.76 28.24 
Plectin Plec -0.25 + 30.91 31.16 323.31 
Plectin Plec NaN    17.09 9.72 
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Plectin Plec 0.11  21.02 20.91 20.40 
 Plekha5 -0.42  22.99 23.41 99.89 
Pleckstrin homology domain-
containing family F member 1 
Plekhf1 -0.18  22.16 22.35 67.80 
Pleckstrin homology domain-
containing family G member 5 
Plekhg5 NaN    20.11 3.35 
Pleckstrin homology domain-
containing family H member 2 
Plekhh2 NaN    19.23 1.56 
Perilipin Plin2 -1.50  20.62 22.13 37.12 
Perilipin-3 Plin3 -0.40  26.52 26.92 323.31 
Procollagen-lysine,2-oxoglutarate 5-
dioxygenase 1 
Plod1 -1.10 + 23.64 24.74 210.15 
Procollagen-lysine,2-oxoglutarate 5-
dioxygenase 2 
Plod2 -0.27  24.16 24.43 323.31 
Procollagen-lysine,2-oxoglutarate 5-
dioxygenase 3 
Plod3 -0.18  24.74 24.92 123.41 
Pleiotropic regulator 1 Plrg1 1.07  23.46 22.39 37.18 
Plastin-3 Pls3 -0.98 + 25.75 26.74 283.10 
Phospholipid scramblase 3 Plscr3 0.11  21.82 21.71 82.18 
Phospholipid transfer protein Pltp -2.34 + 21.09 23.44 47.05 
Plexin-A4 Plxna4 2.44  22.26 19.82 3.22 
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Plexin-B2 Plxnb2 0.83  23.90 23.06 191.51 
Protein PML Pml 0.08  20.27 20.19 2.41 
Phosphomannomutase Pmm2 NaN    19.19 2.86 
Mitochondrial-processing peptidase 
subunit alpha 
Pmpca -1.10  21.17 22.27 39.94 
Mitochondrial-processing peptidase 
subunit beta 
Pmpcb 0.61  21.79 21.18 14.14 
Bifunctional polynucleotide 
phosphatase/kinase 
Pnkp -0.53  21.04 21.57 64.58 
Pinin Pnn -0.56  21.02 21.58 56.64 
RNA-binding protein PNO1 Pno1 0.68  22.13 21.45 48.57 
Purine nucleoside phosphorylase Pnp 0.08  25.52 25.44 106.93 
Polyribonucleotide 
nucleotidyltransferase 1, mitochondrial 
Pnpt1 0.55  21.12 20.57 3.40 
GDP-fucose protein O-
fucosyltransferase 1 
Pofut1 0.77  22.69 21.92 141.90 
GDP-fucose protein O-
fucosyltransferase 2 
Pofut2 -2.31  21.52 23.84 32.31 
Protein O-glucosyltransferase 1 Poglut1 -1.06  21.32 22.38 19.68 
Pogo transposable element with ZNF 
domain 
Pogz NaN    18.14 4.51 
DNA polymerase alpha subunit B Pola2 NaN    19.53 2.86 
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DNA polymerase beta Polb NaN    20.63 7.86 
DNA polymerase Pold1 0.26  21.57 21.31 14.45 
DNA polymerase delta subunit 2 Pold2 -0.31 + 21.54 21.85 14.75 
Polymerase delta-interacting protein 2 Poldip2 1.01  21.90 20.89 19.22 
Polymerase delta-interacting protein 3 Poldip3 -0.40  21.67 22.07 23.28 
DNA polymerase epsilon subunit 3 Pole3 -0.26  22.02 22.28 30.00 
DNA-directed RNA polymerases I and III 
subunit RPAC1 
Polr1c 0.50  20.70 20.20 5.45 
DNA-directed RNA polymerase Polr2a -0.62 + 22.96 23.58 58.26 
DNA-directed RNA polymerase II 
subunit RPB2 
Polr2b 0.19  21.70 21.51 56.47 
DNA-directed RNA polymerase II 
subunit RPB3 
Polr2c 0.20  21.88 21.68 65.23 
DNA-directed RNA polymerase II 
subunit RPB4 
Polr2d -0.01  20.70 20.71 40.83 
DNA-directed RNA polymerases I, II, 
and III subunit RPABC1 
Polr2e 1.12  21.07 19.95 118.86 
DNA-directed RNA polymerase II 
subunit RPB7 
Polr2g -0.38  20.92 21.30 6.63 
DNA-directed RNA polymerases I, II, 
and III subunit RPABC3 
Polr2h -0.41  22.43 22.84 73.49 




 Pop1 1.11  20.25 19.14 7.49 
NADPH--cytochrome P450 reductase Por 1.91  19.83 17.92 19.21 
Periostin Postn -4.40 + 24.03 28.42 323.31 
 Ppa1 -0.05  25.86 25.91 99.88 
Inorganic pyrophosphatase 2, 
mitochondrial 
Ppa2 -0.20  20.52 20.72 2.49 
 Ppfia1 -0.07  21.48 21.55 25.03 
Liprin-beta-1 Ppfibp1 0.17  25.82 25.65 323.31 
Peptidyl-prolyl cis-trans isomerase Ppia 0.09  30.28 30.19 323.31 
Peptidyl-prolyl cis-trans isomerase Ppib -0.55 + 27.07 27.62 151.93 
Peptidyl-prolyl cis-trans isomerase Ppic 0.67  25.54 24.87 161.93 
Peptidyl-prolyl cis-trans isomerase D Ppid -0.58  23.38 23.97 82.52 
Peptidyl-prolyl cis-trans isomerase Ppig -1.52  19.73 21.25 2.89 
Peptidyl-prolyl cis-trans isomerase Ppil1 -0.68  22.63 23.31 43.28 
Peptidyl-prolyl cis-trans isomerase-like 
2 
Ppil2 -0.42  19.55 19.97 32.80 
Peptidyl-prolyl cis-trans isomerase-like 
3 
Ppil3 0.27  21.19 20.92 11.63 
Peptidyl-prolyl cis-trans isomerase-like 
4 
Ppil4 -1.09  18.58 19.67 16.70 
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Protein phosphatase 1A Ppm1a NaN    18.04 3.65 
Protein phosphatase 1B Ppm1b -0.13  22.15 22.28 71.98 
Protein phosphatase 1F Ppm1f -0.02  20.85 20.86 59.17 
Protein phosphatase 1G Ppm1g 0.08  23.82 23.74 39.63 
Protein phosphatase methylesterase 1 Ppme1 -0.30  22.50 22.80 118.69 
Protoporphyrinogen oxidase Ppox 0.11  20.38 20.27 17.18 
Serine/threonine-protein phosphatase 
PP1-alpha catalytic subunit 
Ppp1ca 0.81 + 26.14 25.33 167.61 
Serine/threonine-protein phosphatase 
PP1-beta catalytic subunit 
Ppp1cb 0.35  24.08 23.73 56.29 
Serine/threonine-protein phosphatase 
PP1-gamma catalytic subunit 
Ppp1cc -0.10  22.41 22.51 3.23 
Protein phosphatase 1 regulatory 
subunit 11 
Ppp1r11 -1.36  20.95 22.32 9.27 
Protein phosphatase 1 regulatory 
subunit 12A 
Ppp1r12a -0.42 + 24.57 24.99 323.31 
Protein phosphatase 1 regulatory 
subunit 
Ppp1r12b NaN    18.65 23.17 
Protein phosphatase 1 regulatory 
subunit 12C 
Ppp1r12c -0.09  20.24 20.33 3.68 
RelA-associated inhibitor Ppp1r13l 0.69  22.19 21.50 28.87 




Phostensin Ppp1r18 0.61  21.08 20.47 26.81 
Protein phosphatase 1 regulatory 
subunit 21 
Ppp1r21 -0.82  22.70 23.52 75.88 
Protein phosphatase 1 regulatory 
subunit 7 
Ppp1r7 0.03  24.64 24.61 323.31 
Nuclear inhibitor of protein 
phosphatase 1 
Ppp1r8 0.08  21.08 21.00 33.95 
Neurabin-2 Ppp1r9b -0.16  20.99 21.14 22.93 
Serine/threonine-protein phosphatase Ppp2cb 0.37  24.81 24.45 179.42 
Serine/threonine-protein phosphatase 
2A 65 kDa regulatory subunit A alpha 
isoform 
Ppp2r1a 0.18  26.76 26.58 262.64 
Serine/threonine-protein phosphatase 
2A 65 kDa regulatory subunit A beta 
isoform 
Ppp2r1b 1.99  20.45 18.45 4.87 
Serine/threonine-protein phosphatase 
2A 55 kDa regulatory subunit B 
Ppp2r2a 0.16  23.73 23.57 130.36 
Serine/threonine-protein phosphatase 
2A 55 kDa regulatory subunit B delta 
isoform 
Ppp2r2d NaN    19.20 3.19 
Serine/threonine-protein phosphatase 
2A activator 




2A 56 kDa regulatory subunit alpha 
isoform 
Ppp2r5a -0.29  19.81 20.10 6.31 
 Ppp2r5b NaN    18.56 13.64 
Serine/threonine-protein phosphatase 
2A 56 kDa regulatory subunit gamma 
isoform 
Ppp2r5c -0.14  20.37 20.51 7.04 
 Ppp2r5d -0.27  24.33 24.60 323.31 
Serine/threonine-protein phosphatase 
2A 56 kDa regulatory subunit epsilon 
isoform 
Ppp2r5e NaN    20.62 1.79 
Serine/threonine-protein phosphatase Ppp3ca -0.80 + 23.22 24.01 20.56 
Calcineurin subunit B type 1 Ppp3r1 -1.41 + 20.69 22.11 7.21 
Serine/threonine-protein phosphatase Ppp4c 0.10  22.09 21.99 16.14 
Serine/threonine-protein phosphatase 4 
regulatory subunit 1 
Ppp4r1 0.15  21.49 21.34 126.46 
Serine/threonine-protein phosphatase 4 
regulatory subunit 2 
Ppp4r2 NaN  18.88   7.70 
Serine/threonine-protein phosphatase Ppp5c 0.10  22.37 22.28 39.65 
Serine/threonine-protein phosphatase 6 
catalytic subunit 
Ppp6c 0.69  23.05 22.36 43.78 
Serine/threonine-protein phosphatase 6 
regulatory subunit 1 
Ppp6r1 -0.78  19.86 20.64 97.60 
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Serine/threonine-protein phosphatase 6 
regulatory subunit 2 
Ppp6r2 NaN    19.95 5.83 
Serine/threonine-protein phosphatase 6 
regulatory subunit 3 
Ppp6r3 0.45  22.33 21.87 23.61 
Palmitoyl-protein thioesterase 1 Ppt1 -1.07  22.32 23.39 49.16 
Peptidylprolyl isomerase domain and 
WD repeat-containing protein 1 
Ppwd1 -0.87 + 19.52 20.39 45.54 
Polyglutamine-binding protein 1 Pqbp1 0.28  20.63 20.35 19.15 
PRA1 family protein 2 Praf2 0.37  21.64 21.28 12.75 
Lysosomal Pro-X carboxypeptidase Prcp 0.10  22.08 21.98 40.04 
Peroxiredoxin-1 Prdx1 -0.16  28.02 28.18 93.67 
Peroxiredoxin-2 Prdx2 -0.39 + 27.02 27.41 143.15 
Thioredoxin-dependent peroxide 
reductase, mitochondrial 
Prdx3 -0.22  25.02 25.24 145.01 
Peroxiredoxin-4 Prdx4 0.14  26.98 26.85 131.85 
Peroxiredoxin-5, mitochondrial Prdx5 -0.45 + 27.23 27.68 216.73 
Peroxiredoxin-6 Prdx6 -0.43 + 26.02 26.45 259.38 
Prolargin Prelp -5.58 + 22.98 28.55 323.31 
Prolyl endopeptidase Prep 1.11 + 26.83 25.72 323.31 
DNA primase large subunit Prim2 -0.18  21.20 21.38 23.37 
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5-AMP-activated protein kinase 
catalytic subunit alpha-1 
Prkaa1 0.03  22.88 22.84 33.34 
cAMP-dependent protein kinase 
catalytic subunit alpha 
Prkaca -0.05  24.11 24.16 97.32 
cAMP-dependent protein kinase 
catalytic subunit beta 
Prkacb 0.44  23.83 23.39 15.41 
5-AMP-activated protein kinase subunit 
gamma-1 
Prkag1 -0.54  20.64 21.17 12.96 
cAMP-dependent protein kinase type I-
alpha regulatory subunit 
Prkar1a -0.06  25.30 25.36 210.47 
cAMP-dependent protein kinase type II-
alpha regulatory subunit 
Prkar2a 0.19  22.56 22.38 115.45 
cAMP-dependent protein kinase type II-
beta regulatory subunit 
Prkar2b -1.46  22.65 24.11 222.08 
Protein kinase C Prkca -0.26  21.98 22.24 10.49 
Protein kinase C delta type Prkcd -0.56  21.67 22.23 53.28 
Protein kinase C delta-binding protein Prkcdbp -0.46  23.69 24.15 39.08 
Protein kinase C Prkci NaN    20.39 4.02 
Glucosidase 2 subunit beta Prkcsh -0.06  24.32 24.38 120.60 
Protein kinase C Prkd3 0.53  20.18 19.65 1.41 
DNA-dependent protein kinase catalytic 
subunit 




RNA-dependent protein kinase 
activator A 
Prkra 0.39  22.23 21.84 7.41 
Protein arginine N-methyltransferase 1 Prmt1 0.38  24.35 23.97 39.13 
Protein arginine N-methyltransferase 3 Prmt3 NaN  18.18   2.76 
Protein arginine N-methyltransferase 5 Prmt5 0.99  21.94 20.95 17.41 
Protein arginine N-methyltransferase 7 Prmt7 NaN  21.70   33.78 
Prolyl-tRNA synthetase associated 
domain-containing protein 1 
Prorsd1 -1.73 + 22.29 24.02 47.55 
Proline synthase co-transcribed 
bacterial homolog protein 
Prosc -0.61 + 23.22 23.84 87.49 
Pre-mRNA-processing factor 19 Prpf19 -0.05  24.81 24.86 64.12 
U4/U6 small nuclear ribonucleoprotein 
Prp31 
Prpf31 -0.26  22.70 22.96 107.12 
Pre-mRNA-splicing factor 38A Prpf38a -0.01  20.14 20.15 27.37 
Pre-mRNA-splicing factor 38B Prpf38b NaN    21.15 47.83 
Pre-mRNA-processing factor 39 Prpf39 NaN    18.91 3.63 
U4/U6 small nuclear ribonucleoprotein 
Prp4 
Prpf4 -0.68  20.29 20.97 3.03 
Pre-mRNA-processing factor 40 
homolog A 
Prpf40a -0.05  23.21 23.26 71.01 




Pre-mRNA-processing factor 6 Prpf6 -0.10  21.46 21.56 25.93 
Pre-mRNA-processing-splicing factor 8 Prpf8 -0.55  25.53 26.08 323.31 
 Prps1l1 NaN  17.47   20.80 
Ribose-phosphate pyrophosphokinase 
2 
Prps2 0.06  23.79 23.73 112.35 
Phosphoribosyl pyrophosphate 
synthase-associated protein 1 
Prpsap1 -0.03  24.24 24.27 91.32 
Phosphoribosyl pyrophosphate 
synthase-associated protein 2 
Prpsap2 -0.70  21.66 22.36 45.30 
Protein PRRC1 Prrc1 -2.83 + 22.24 25.06 130.13 
Protein PRRC2A Prrc2a -0.55  22.58 23.13 49.47 
Protein PRRC2B Prrc2b -1.10  23.41 24.51 33.61 
Protein PRRC2C Prrc2c -0.83 + 22.90 23.73 63.57 
Paired mesoderm homeobox protein 1 Prrx1 0.21  24.17 23.96 39.60 
Protein prune homolog Prune 0.75  21.53 20.78 17.54 
Protein prune homolog 2 Prune2 0.30  23.45 23.15 50.96 
Prosaposin Psap -0.58  23.59 24.17 10.40 
Phosphoserine aminotransferase Psat1 1.78 + 27.96 26.18 278.64 
PC4 and SFRS1-interacting protein Psip1 0.46  23.12 22.66 33.37 
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Proteasome subunit alpha type Psma1 -0.18  25.92 26.10 211.04 
Proteasome subunit alpha type-2 Psma2 0.27  26.37 26.10 277.16 
Proteasome subunit alpha type Psma3 -0.57 + 25.42 25.99 55.38 
Proteasome subunit alpha type Psma4 -0.43  24.15 24.59 41.79 
Proteasome subunit alpha type Psma5 -0.37  25.62 25.99 126.30 
Proteasome subunit alpha type-6 Psma6 0.56 + 26.40 25.84 63.42 
Proteasome subunit alpha type Psma7 0.08  26.19 26.12 323.31 
Proteasome subunit beta type Psmb1 -0.68 + 25.84 26.52 170.69 
Proteasome subunit beta type Psmb10 -0.36  20.93 21.29 31.90 
Proteasome subunit beta type-2 Psmb2 -0.35  25.54 25.88 121.26 
Proteasome subunit beta type Psmb3 -0.10  26.15 26.25 160.12 
Proteasome subunit beta type-4 Psmb4 -0.20  25.96 26.16 138.49 
Proteasome subunit beta type-5 Psmb5 0.30  25.86 25.56 129.58 
Proteasome subunit beta type-6 Psmb6 0.33 + 25.16 24.83 36.15 
Proteasome subunit beta type Psmb7 -0.19  23.38 23.58 95.80 
Proteasome subunit beta type Psmb8 -0.96  21.99 22.95 60.99 
Proteasome subunit beta type Psmb9 -1.13  19.50 20.63 16.07 
26S protease regulatory subunit 4 Psmc1 -0.36  25.02 25.37 323.31 
26S protease regulatory subunit 7 Psmc2 -0.27 + 26.13 26.39 255.93 
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 Psmc3 -0.29 + 26.25 26.54 323.31 
26S protease regulatory subunit 6B Psmc4 0.13  25.85 25.72 323.31 
26S protease regulatory subunit 8 Psmc5 -0.02  26.10 26.12 323.31 
26S protease regulatory subunit 10B Psmc6 -0.41 + 26.18 26.60 259.42 
26S proteasome non-ATPase 
regulatory subunit 1 
Psmd1 0.19  25.94 25.74 323.31 
26S proteasome non-ATPase 
regulatory subunit 11 
Psmd11 0.03  26.69 26.66 206.85 
26S proteasome non-ATPase 
regulatory subunit 12 
Psmd12 0.15  25.61 25.46 323.31 
26S proteasome non-ATPase 
regulatory subunit 13 
Psmd13 -0.08  25.62 25.70 206.88 
26S proteasome non-ATPase 
regulatory subunit 14 
Psmd14 -0.13  25.53 25.66 72.93 
26S proteasome non-ATPase 
regulatory subunit 2 
Psmd2 -0.06  26.44 26.50 323.31 
26S proteasome non-ATPase 
regulatory subunit 3 
Psmd3 -0.22  26.49 26.71 293.21 
26S proteasome non-ATPase 
regulatory subunit 4 
Psmd4 0.12  24.70 24.58 266.32 
26S proteasome non-ATPase 
regulatory subunit 4 
Psmd4 NaN  20.84   3.46 
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26S proteasome non-ATPase 
regulatory subunit 5 
Psmd5 0.04  25.93 25.89 261.32 
26S proteasome non-ATPase 
regulatory subunit 6 
Psmd6 0.32  25.76 25.44 222.53 
26S proteasome non-ATPase 
regulatory subunit 7 
Psmd7 0.49 + 26.71 26.21 263.05 
26S proteasome non-ATPase 
regulatory subunit 8 
Psmd8 0.66  24.72 24.06 56.41 
26S proteasome non-ATPase 
regulatory subunit 9 
Psmd9 0.12  22.34 22.22 24.59 
Proteasome activator complex subunit 
1 
Psme1 -0.17  25.30 25.46 299.51 
Proteasome activator complex subunit 
2 
Psme2 0.23  25.89 25.66 267.05 
Proteasome activator complex subunit 
3 
Psme3 0.48  24.25 23.77 275.44 
Proteasome inhibitor PI31 subunit Psmf1 NaN    20.83 3.74 
Paraspeckle component 1 Pspc1 0.26 + 24.61 24.35 113.55 
Phosphoserine phosphatase Psph 1.29  24.15 22.85 23.00 
 Ptar1 -0.43  21.13 21.57 10.09 
Polypyrimidine tract-binding protein 1 Ptbp1 0.42 + 28.19 27.77 323.31 




containing protein 3, mitochondrial 
Ptcd3 -1.17  21.44 22.61 141.15 
Phosphatidylinositol 3,4,5-
trisphosphate 3-phosphatase and dual-
specificity protein phosphatase PTEN 
Pten NaN    19.78 5.26 
Phosphotriesterase-related protein Pter -0.64  22.42 23.07 55.43 
Prostaglandin E synthase 2 Ptges2 0.10  21.59 21.49 48.40 
Prostaglandin F2 receptor negative 
regulator 
Ptgfrn -0.87  19.70 20.57 4.54 
Prostaglandin reductase 1 Ptgr1 -0.96 + 23.68 24.64 144.44 
Prostaglandin reductase 2 Ptgr2 NaN    21.10 40.66 
Parathyroid hormone/parathyroid 
hormone-related peptide receptor 
Pth1r NaN    19.14 1.63 
Focal adhesion kinase 1 Ptk2 0.10  22.19 22.09 112.00 
Protein-tyrosine kinase 2-beta Ptk2b NaN    19.65 6.01 
Inactive tyrosine-protein kinase 7 Ptk7 0.36  23.50 23.14 77.24 
Prothymosin alpha Ptma 1.00  25.50 24.51 140.28 
Parathymosin Ptms NaN    23.56 14.31 
Protein tyrosine phosphatase type IVA 
2 
Ptp4a2 0.50  22.42 21.92 12.46 
Phosphatidylglycerophosphatase and 
protein-tyrosine phosphatase 1 





Ptpn1 0.41  18.34 17.92 7.89 
Tyrosine-protein phosphatase non-
receptor type 11 
Ptpn11 0.32  23.83 23.51 47.98 
Tyrosine-protein phosphatase non-
receptor type 12 
Ptpn12 -1.35 + 21.36 22.71 90.82 
Tyrosine-protein phosphatase non-
receptor type 13 
Ptpn13 -2.38 + 19.21 21.59 55.09 
Tyrosine-protein phosphatase non-
receptor type 14 
Ptpn14 -1.82  18.20 20.03 11.35 
Tyrosine-protein phosphatase non-
receptor type 
Ptpn2 -0.61  19.22 19.83 9.63 
Tyrosine-protein phosphatase non-
receptor type 23 
Ptpn23 -0.54  22.94 23.48 166.88 
Protein-tyrosine-phosphatase Ptpn9 0.74  19.90 19.16 7.48 
Receptor-type tyrosine-protein 
phosphatase S 
Ptprs NaN    20.27 3.55 
Polymerase I and transcript release 
factor 
Ptrf 0.30  27.25 26.95 323.31 
Peptidyl-tRNA hydrolase 2, 
mitochondrial 
Ptrh2 1.00 + 22.40 21.40 12.78 
Poly(U)-binding-splicing factor PUF60 Puf60 0.02  25.24 25.22 124.24 
Pumilio homolog 1 Pum1 -0.38  21.09 21.47 43.68 
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Pumilio homolog 2 Pum2 NaN    19.96 2.31 
Transcriptional activator protein Pur-
alpha 
Pura 0.05  22.69 22.64 54.09 
Transcriptional activator protein Pur-
beta 
Purb -0.87  22.24 23.11 272.36 
Putative tRNA pseudouridine synthase 
Pus10 
Pus10 -0.95  20.06 21.01 16.72 
 Pus7 -0.07  22.52 22.59 93.02 
Periodic tryptophan protein 1 homolog Pwp1 NaN    18.47 2.00 
Periodic tryptophan protein 2 homolog Pwp2 0.57  20.91 20.33 34.35 
Peroxidasin homolog Pxdn NaN  18.93   2.82 
Paxillin Pxn -0.77  20.20 20.97 103.01 
Pyrroline-5-carboxylate reductase Pycr1 -0.40  23.96 24.36 119.32 
 Pycr1 NaN    19.83 1.48 
Pyrroline-5-carboxylate reductase Pycr2 0.22  22.29 22.07 12.29 
Pyrroline-5-carboxylate reductase 3 Pycrl 1.00  23.67 22.66 15.22 
Alpha-1,4 glucan phosphorylase Pygb -0.24  25.50 25.74 162.10 
Glycogen phosphorylase, muscle form Pygm NaN    20.64 18.20 
 Pygo2 NaN    21.17 3.47 
 Qars -0.62 + 24.17 24.79 78.20 
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Dihydropteridine reductase Qdpr -0.94 + 22.83 23.77 137.96 
Protein QIL1 Qil1 NaN    21.50 21.66 
Protein quaking Qki 0.15  23.93 23.78 49.60 
Sulfhydryl oxidase 2 Qsox2 NaN    20.18 2.20 
Queuine tRNA-ribosyltransferase Qtrt1 NaN    18.35 2.03 
R3H and coiled-coil domain-containing 
protein 1 
R3hcc1 NaN    17.63 186.98 
Ras-related protein Rab-1A Rab1 0.20  25.94 25.73 241.28 
Ras-related protein Rab-10 Rab10 0.28  23.03 22.74 98.57 
Ras-related protein Rab-11A Rab11a NaN    18.56 4.40 
Ras-related protein Rab-11B Rab11b 0.42 + 25.29 24.87 119.08 
Rab11 family-interacting protein 5 Rab11fip5 -1.51  22.51 24.02 97.54 
Ras-related protein Rab-12 Rab12 NaN    18.98 1.88 
Ras-related protein Rab-14 Rab14 0.61 + 24.96 24.35 121.90 
Ras-related protein Rab-18 Rab18 -0.23  21.78 22.01 17.90 
Ras-related protein Rab-1B Rab1b -0.02  23.34 23.36 116.65 
Ras-related protein Rab-21 Rab21 -0.07  22.24 22.30 19.92 
Ras-related protein Rab-2A Rab2a -1.29  24.54 25.83 323.31 
Ras-related protein Rab-31 Rab31 -0.80  20.11 20.91 2.63 
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Ras-related protein Rab-34 Rab34 NaN  17.65   2.05 
Ras-related protein Rab-39A Rab39 NaN    18.62 1.90 
Rab3 GTPase-activating protein 
catalytic subunit 
Rab3gap1 0.30  20.41 20.12 14.94 
Rab3 GTPase-activating protein non-
catalytic subunit 
Rab3gap2 -0.48  21.67 22.15 56.56 
Ras-related protein Rab-4B Rab4b -1.91  19.62 21.54 26.93 
Ras-related protein Rab-5A Rab5a 0.01  22.16 22.15 8.64 
Ras-related protein Rab-5B Rab5b NaN  20.98   4.51 
Ras-related protein Rab-5C Rab5c 0.31  24.57 24.25 82.63 
Ras-related protein Rab-6A Rab6a -0.80  23.90 24.69 57.14 
Ras-related protein Rab-7a Rab7 -0.19  25.47 25.67 284.52 
Ras-related protein Rab-8A Rab8a NaN    21.60 65.49 
Ras-related protein Rab-9A Rab9 NaN    19.44 1.54 
Rab GTPase-binding effector protein 1 Rabep1 -0.30  21.54 21.84 66.74 
Rab GTPase-binding effector protein 2 Rabep2 0.08  21.10 21.02 72.54 
Rab9 effector protein with kelch motifs Rabepk 0.52  20.32 19.80 57.34 
Rab GTPase-activating protein 1 Rabgap1 0.14  21.67 21.54 74.71 
Rab-like protein 6 Rabl6 -0.68  20.85 21.53 12.81 




Double-strand-break repair protein 
rad21 homolog 
Rad21 -0.11  21.33 21.44 61.02 
 Rad23a 0.87  22.61 21.74 12.87 
UV excision repair protein RAD23 
homolog B 
Rad23b -0.23  25.93 26.16 193.21 
DNA repair protein RAD50 Rad50 -0.63  21.52 22.15 100.32 
mRNA export factor Rae1 -0.82  21.77 22.60 15.07 
RAF proto-oncogene serine/threonine-
protein kinase 
Raf1 NaN    20.02 1.51 
Ankycorbin Rai14 -0.38  23.81 24.20 285.02 
Ras-related protein Ral-A Rala 0.13  20.94 20.81 10.27 
RNA-binding protein Raly Raly 0.27  24.27 24.00 73.58 
GTP-binding nuclear protein Ran Ran 0.29  27.77 27.49 266.98 
Ran-specific GTPase-activating protein Ranbp1 0.53 + 25.67 25.15 73.14 
E3 SUMO-protein ligase RanBP2 Ranbp2 -0.22  23.25 23.47 323.31 
Ran-binding protein 3 Ranbp3 0.34  24.28 23.94 124.48 
Ran-binding protein 9 Ranbp9 0.24  19.83 19.59 18.00 
Ran GTPase-activating protein 1 Rangap1 -0.28  22.60 22.88 43.12 
Ras-related protein Rap-1b Rap1b 1.03 + 23.69 22.66 98.72 
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Rap1 GTPase-activating protein 1 Rap1gap NaN    19.34 9.86 
 Rap1gds1 -0.16  24.09 24.26 114.91 
Ras-related protein Rap-2a Rap2a NaN  18.36   5.61 
Ras-related protein Rap-2c Rap2c NaN    17.14 2.99 
 Rapgef1 0.36  20.45 20.09 3.09 
Rap guanine nucleotide exchange 
factor 2 
Rapgef2 NaN  19.79   3.60 
 Raph1 -0.94 + 21.88 22.81 22.90 
Arginine--tRNA ligase, cytoplasmic Rars 0.25 + 26.32 26.07 200.82 
Probable arginine--tRNA ligase, 
mitochondrial 
Rars2 NaN  20.78   21.85 
 Rasa1 0.11  21.81 21.71 47.77 
Ras GTPase-activating protein 3 Rasa3 -1.43 + 20.32 21.75 16.58 
Ras GTPase-activating protein 4 Rasa4 NaN  20.30   2.38 
Ras association domain-containing 
protein 2 
Rassf2 -0.24  25.07 25.31 33.25 
Ribonucleoprotein PTB-binding 1 Raver1 0.07  23.23 23.16 217.19 
Histone-binding protein RBBP4 Rbbp4 0.18  24.78 24.61 99.33 
Histone-binding protein RBBP7 Rbbp7 -0.88 + 24.99 25.87 105.12 
Putative hydrolase RBBP9 Rbbp9 -0.58  22.48 23.06 13.69 
451 
 
RNA binding protein fox-1 homolog 2 Rbfox2 -0.01  22.93 22.95 66.11 
RNA-binding protein 10 Rbm10 0.06  22.01 21.96 14.19 
RNA-binding protein 14 Rbm14 0.22  24.39 24.18 44.59 
 Rbm15 0.47  22.18 21.70 11.43 
Splicing factor 45 Rbm17 -0.95  20.12 21.07 27.70 
Probable RNA-binding protein 19 Rbm19 -0.68  17.04 17.72 61.60 
Pre-mRNA-splicing factor RBM22 Rbm22 0.26  20.97 20.71 11.67 
RNA-binding protein 25 Rbm25 -1.24 + 21.42 22.66 40.11 
RNA-binding protein 26 Rbm26 0.05  19.70 19.64 5.97 
 Rbm3 0.28  28.07 27.78 271.36 
RNA-binding protein 39 Rbm39 0.45  24.46 24.01 157.63 
RNA-binding protein 5 Rbm5 0.46  20.48 20.02 6.21 
RNA-binding protein 8A RBM8 0.18  23.01 22.83 113.13 
RNA-binding motif, single-stranded-
interacting protein 1 
Rbms1 -0.33  22.49 22.82 35.97 
RNA-binding motif, single-stranded-
interacting protein 2 
Rbms2 0.38  22.40 22.01 17.46 
RNA-binding motif, single-stranded-
interacting protein 3 
Rbms3 NaN    19.59 2.38 
 Rbms3 NaN  15.88   81.40 
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RNA binding motif protein, X-linked-
like-1 
Rbmxl1 -0.54 + 25.35 25.89 277.69 
Rabenosyn-5 Rbsn 0.13  21.14 21.01 69.27 
E3 ubiquitin-protein ligase RBX1 Rbx1 0.32  21.82 21.50 85.89 
Roquin-2 Rc3h2 NaN    22.73 2.61 
Regulator of chromosome 
condensation 
Rcc1 -0.69 + 23.52 24.21 72.39 
Protein RCC2 Rcc2 0.45  24.50 24.05 173.59 
Reticulocalbin-1 Rcn1 0.77  25.58 24.81 152.93 
Reticulocalbin-2 Rcn2 0.19  24.10 23.90 323.31 
Reticulocalbin-3 Rcn3 -1.74 + 25.89 27.63 323.31 
REST corepressor 1 Rcor1 0.38  20.67 20.28 6.11 
REST corepressor 3 Rcor3 NaN    19.40 1.73 
Retinol dehydrogenase 14 Rdh14 -1.01  18.21 19.22 1.57 
Radixin Rdx 0.97  23.82 22.85 238.56 
Proto-oncogene c-Rel Rel 1.06  19.41 18.35 3.94 
Transcription factor p65 Rela -1.02  22.26 23.28 3.74 
RalBP1-associated Eps domain-
containing protein 1 
Reps1 0.57  21.78 21.21 7.93 
Oligoribonuclease, mitochondrial Rexo2 -0.26  22.79 23.05 99.89 
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Replication factor C subunit 2 Rfc2 0.32  21.96 21.64 12.84 
Replication factor C subunit 3 Rfc3 1.00  20.67 19.67 40.02 
Replication factor C subunit 4 Rfc4 NaN  21.01   2.93 
Replication factor C subunit 5 Rfc5 0.59  22.02 21.43 11.60 
Riboflavin kinase Rfk -0.55  20.86 21.41 9.43 
Regulator of G-protein signaling 10 Rgs10 0.67  22.67 21.99 133.19 
GTP-binding protein Rheb Rheb 0.71  22.54 21.83 3.78 
Transforming protein RhoA Rhoa 1.54 + 23.66 22.11 189.39 
Rho-related GTP-binding protein RhoC Rhoc NaN  21.34   10.53 
Rho-related GTP-binding protein RhoG Rhog 1.52  21.97 20.45 16.52 
Synembryn-A Ric8a -0.20  21.32 21.51 212.45 
Synembryn-B Ric8b NaN    15.92 1.59 
RILP-like protein 1 Rilpl1 -0.76  19.24 20.00 7.20 
Ras and Rab interactor 1 Rin1 0.55  21.41 20.86 13.23 
E3 ubiquitin-protein ligase RING1 Ring1 -1.48 + 19.11 20.60 68.30 
RAD50-interacting protein 1 Rint1 -1.39  19.15 20.53 14.52 
Receptor-interacting serine/threonine-
protein kinase 1 
Ripk1 2.16  20.46 18.30 3.07 
Regulator of microtubule dynamics 
protein 3 
Rmdn3 0.21  18.14 17.94 5.75 
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Ribonuclease H2 subunit A Rnaseh2a NaN    18.93 3.90 
Rho-related GTP-binding protein RhoE Rnd3 2.16  21.56 19.40 2.65 
E3 ubiquitin-protein ligase RNF114 Rnf114 -0.61 + 19.89 20.50 4.08 
E3 ubiquitin-protein ligase RNF14 Rnf14 -1.91  17.76 19.67 40.76 
E3 ubiquitin-protein ligase BRE1A Rnf20 0.17  21.60 21.42 39.25 
E3 ubiquitin-protein ligase RNF213 Rnf213 0.61  22.22 21.61 50.68 
E3 ubiquitin-protein ligase RNF25 Rnf25 -0.20  18.99 19.19 3.19 
Ribonuclease inhibitor Rnh1 -0.68  25.27 25.95 219.22 
mRNA cap guanine-N7 
methyltransferase 
Rnmt -0.50  22.71 23.21 87.32 
Aminopeptidase B Rnpep -0.16  23.85 24.01 70.81 
RNA-binding protein with serine-rich 
domain 1 
Rnps1 -1.37 + 22.47 23.84 25.97 
Rho-associated protein kinase 1 Rock1 NaN    22.73 3.90 
Rho-associated protein kinase Rock2 -1.04 + 23.20 24.24 104.47 
Replication protein A 70 kDa DNA-
binding subunit 
Rpa1 0.28  22.68 22.40 24.68 
Replication protein A 32 kDa subunit Rpa2 0.36  19.40 19.04 6.36 
Replication protein A 14 kDa subunit Rpa3 -1.17 + 22.77 23.94 68.99 
RNA polymerase II-associated protein 1 Rpap1 NaN    18.24 3.30 
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RNA polymerase II-associated protein 3 Rpap3 1.12  22.31 21.19 5.64 
Ribulose-phosphate 3-epimerase Rpe 0.23  23.12 22.89 35.51 
Protein fantom Rpgrip1l NaN  22.50   2.43 
Ribose-5-phosphate isomerase Rpia 0.39  22.22 21.83 3.07 
60S ribosomal protein L10 Rpl10 -0.38  26.00 26.38 192.20 
Ribosomal protein Rpl10a -0.23  25.46 25.69 80.21 
60S ribosomal protein L12 Rpl12 0.69  27.28 26.60 123.46 
60S ribosomal protein L13 Rpl13 0.46 + 26.65 26.19 264.72 
60S ribosomal protein L13a Rpl13a 0.32  25.87 25.55 37.41 
60S ribosomal protein L14 Rpl14 2.62 + 26.34 23.73 96.75 
Ribosomal protein L15 Rpl15 0.62  25.99 25.37 82.84 
60S ribosomal protein L17 Rpl17 1.46 + 25.56 24.09 61.30 
60S ribosomal protein L18 Rpl18 1.68 + 27.26 25.58 161.98 
60S ribosomal protein L18a Rpl18a -0.49  22.91 23.39 11.54 
Ribosomal protein L19 Rpl19 -0.87  23.68 24.56 74.88 
60S ribosomal protein L21 Rpl21 0.02  26.47 26.45 83.41 
60S ribosomal protein L22 Rpl22 -0.16  25.62 25.78 104.68 
60S ribosomal protein L22-like 1 Rpl22l1 0.55  26.34 25.79 127.57 
60S ribosomal protein L23 Rpl23 -0.40  24.82 25.21 16.43 
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60S ribosomal protein L23a Rpl23a 0.59 + 26.73 26.14 26.31 
60S ribosomal protein L24 Rpl24 1.46 + 26.02 24.56 78.92 
60S ribosomal protein L26 Rpl26 0.67 + 24.85 24.18 10.00 
60S ribosomal protein L27 Rpl27 0.87 + 26.62 25.75 38.91 
60S ribosomal protein L27a Rpl27a -0.01  26.26 26.27 33.74 
60S ribosomal protein L28 Rpl28 0.44  24.56 24.12 6.48 
60S ribosomal protein L3 Rpl3 0.59 + 27.54 26.95 165.56 
60S ribosomal protein L30 Rpl30 -0.34  24.51 24.85 15.77 
60S ribosomal protein L31 Rpl31 1.50  24.76 23.26 68.97 
60S ribosomal protein L32 Rpl32 -0.14  23.64 23.78 10.91 
60S ribosomal protein L34 Rpl34 1.25 + 24.06 22.81 4.03 
60S ribosomal protein L35 Rpl35 0.78 + 25.77 24.99 109.08 
60S ribosomal protein L35a Rpl35a 0.50  24.77 24.27 3.77 
60S ribosomal protein L36 Rpl36 -0.04  25.15 25.19 85.62 
60S ribosomal protein L38 Rpl38 -0.01  26.15 26.16 62.52 
60S ribosomal protein L4 Rpl4 0.32  27.67 27.35 116.46 
60S ribosomal protein L5 Rpl5 -0.29  27.06 27.35 135.15 
60S ribosomal protein L6 Rpl6 1.43 + 27.86 26.43 239.70 
60S ribosomal protein L7 Rpl7 1.24 + 27.10 25.86 226.70 
457 
 
60S ribosomal protein L7a Rpl7a 1.47 + 27.36 25.89 180.60 
60S ribosomal protein L8 Rpl8 1.15 + 25.04 23.89 104.13 
60S ribosomal protein L9 Rpl9 -0.42 + 25.84 26.26 93.33 
60S acidic ribosomal protein P0 Rplp0 0.61 + 27.69 27.08 323.31 
60S acidic ribosomal protein P1 Rplp1 -1.81 + 25.38 27.19 37.72 
60S acidic ribosomal protein P2 Rplp2 0.28  28.21 27.93 323.31 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 1 
Rpn1 0.52  24.76 24.24 165.94 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 2 
Rpn2 0.39  25.19 24.79 323.31 
Ribonuclease P protein subunit p30 Rpp30 0.36  20.73 20.36 7.43 
Regulation of nuclear pre-mRNA 
domain-containing protein 1A 
Rprd1a NaN    18.42 3.38 
Regulation of nuclear pre-mRNA 
domain-containing protein 1B 
Rprd1b -0.25  23.13 23.38 134.86 
40S ribosomal protein S10 Rps10 -0.20  27.07 27.27 199.87 
40S ribosomal protein S11 Rps11 0.42  24.15 23.73 42.76 
40S ribosomal protein S12 Rps12 -0.07  26.62 26.68 323.31 
40S ribosomal protein S13 Rps13 0.57 + 26.88 26.31 59.63 
40S ribosomal protein S14 rps14 -0.05  26.12 26.17 46.75 
40S ribosomal protein S15 Rps15 -1.67 + 25.05 26.72 133.81 
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 Rps15 NaN    16.16 1.50 
40S ribosomal protein S15a Rps15a -0.23  26.66 26.89 72.34 
40S ribosomal protein S16 Rps16 0.51 + 26.93 26.42 112.30 
40S ribosomal protein S17 Rps17 -0.55 + 26.42 26.97 147.58 
40S ribosomal protein S18 Rps18 -0.55 + 26.14 26.69 161.78 
40S ribosomal protein S19 Rps19 -0.67 + 26.15 26.82 77.39 
Active regulator of SIRT1 Rps19bp1 NaN  19.97   11.91 
40S ribosomal protein S2 Rps2 0.10  26.79 26.70 204.92 
40S ribosomal protein S20 Rps20 0.51  27.06 26.55 48.97 
40S ribosomal protein S23 Rps23 1.38  25.67 24.29 68.51 
40S ribosomal protein S24 Rps24 0.03  26.19 26.16 79.53 
40S ribosomal protein S25 Rps25 0.30  26.32 26.02 53.61 
40S ribosomal protein S26 Rps26 0.53  25.42 24.89 47.94 
40S ribosomal protein S27 Rps27 1.24  22.76 21.52 3.17 
40S ribosomal protein S27 Rps27l 0.32  26.13 25.81 23.88 
40S ribosomal protein S28 Rps28 -0.42 + 25.55 25.97 178.44 
40S ribosomal protein S29 Rps29 -0.26  23.89 24.15 31.65 
40S ribosomal protein S3 Rps3 -0.28 + 28.26 28.54 299.52 
40S ribosomal protein S3a Rps3a1 0.17  26.91 26.73 269.39 
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40S ribosomal protein S4 Rps4x 0.35 + 26.71 26.35 177.01 
40S ribosomal protein S5 Rps5 -0.96 + 24.29 25.26 190.98 
40S ribosomal protein S6 Rps6 0.19  26.25 26.06 51.65 
Ribosomal protein S6 kinase alpha-3 Rps6ka3 0.69  22.86 22.17 47.08 
Ribosomal protein S6 kinase alpha-4 Rps6ka4 -0.21  20.99 21.20 14.25 
Ribosomal protein S6 kinase alpha-5 Rps6ka5 1.70  22.76 21.06 37.36 
40S ribosomal protein S8 Rps8 0.32  27.78 27.46 323.31 
40S ribosomal protein S9 Rps9 0.72 + 26.68 25.95 39.50 
40S ribosomal protein SA Rpsa -0.01  29.19 29.20 323.31 
Cell differentiation protein RCD1 
homolog 
Rqcd1 0.12  22.58 22.46 28.47 
Ras-related GTP-binding protein A Rraga -0.61  21.30 21.91 128.30 
Ras-related GTP-binding protein C Rragc -0.28  21.58 21.86 53.71 
Ras-related protein R-Ras Rras 1.48 + 21.41 19.93 88.70 
Ribosome-binding protein 1 Rrbp1 -1.82 + 25.32 27.14 323.31 
Ribonucleoside-diphosphate reductase Rrm1 0.91 + 24.23 23.31 78.72 
Ribonucleoside-diphosphate reductase 
subunit M2 
Rrm2 1.78  21.44 19.67 9.59 
Ribosomal RNA processing protein 1 
homolog A 
Rrp1 1.38  21.32 19.94 20.05 
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RRP12-like protein Rrp12 0.47  21.43 20.96 45.95 
Ribosomal RNA processing protein 1 
homolog B 
Rrp1b 0.10  19.76 19.66 56.68 
Ribosomal RNA-processing protein 7 
homolog A 
Rrp7a 0.20  20.68 20.48 50.88 
U3 small nucleolar RNA-interacting 
protein 2 
Rrp9 -0.39  20.76 21.15 323.31 
Ribosome biogenesis regulatory 
protein homolog 
Rrs1 -0.78  20.04 20.82 6.40 
 Rsf1 -0.24  22.41 22.66 15.76 
Ribosomal L1 domain-containing 
protein 1 
Rsl1d1 1.65 + 22.77 21.11 43.56 
Ras suppressor protein 1 Rsu1 -0.02  26.17 26.19 117.42 
RNA 3-terminal phosphate cyclase Rtca NaN    21.82 6.09 
tRNA-splicing ligase RtcB homolog Rtcb -0.38 + 25.95 26.33 314.74 
RNA polymerase-associated protein 
RTF1 homolog 
Rtf1 -0.87  18.54 19.41 3.31 
Reticulon Rtn4 NaN    18.42 5.25 
Reticulon-4 Rtn4 1.19 + 25.01 23.81 95.43 
Runt-related transcription factor 2 Runx2 NaN    22.33 19.07 
Runt-related transcription factor 3 Runx3 0.17  20.45 20.28 7.34 
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RuvB-like 1 Ruvbl1 0.46 + 25.89 25.44 311.71 
RuvB-like 2 Ruvbl2 -0.22  25.46 25.67 273.23 
RWD domain-containing protein 1 Rwdd1 -0.82 + 21.90 22.72 30.81 
RWD domain-containing protein 4 Rwdd4a NaN    19.13 5.29 
Retinoic acid receptor RXR-alpha Rxra NaN  17.43   29.59 
Retinoic acid receptor RXR-beta Rxrb NaN    17.74 12.00 
RING1 and YY1-binding protein Rybp -0.99  19.85 20.83 41.15 
Protein S100 S100a1 -0.59  21.09 21.68 23.03 
Protein S100-A10 S100a10 -0.44  27.07 27.51 168.43 
Protein S100-A11 S100a11 0.33  27.56 27.23 323.31 
Protein S100-A13 S100a13 -0.15  22.48 22.62 20.23 
Protein S100 S100a4 -0.61 + 27.57 28.18 74.56 
Protein S100 S100a6 -0.64  25.19 25.83 28.35 
Protein SAAL1 Saal1 0.15  20.52 20.37 120.12 
Phosphatidylinositide phosphatase 
SAC1 
Sacm1l 0.43  20.68 20.25 10.01 
SUMO-activating enzyme subunit 1 Sae1 0.58  24.55 23.97 188.29 
Scaffold attachment factor B1 Safb -0.09  22.64 22.72 55.37 
Scaffold attachment factor B2 Safb2 -0.56  20.23 20.79 8.02 
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Protein Smaug homolog 1 Samd4a NaN    20.26 17.21 
Protein Smaug homolog 2 Samd4b NaN    16.77 5.65 
Sterile alpha motif domain-containing 
protein 9-like 
Samd9l 0.26  21.59 21.33 94.43 
Deoxynucleoside triphosphate 
triphosphohydrolase SAMHD1 
Samhd1 -0.15  26.54 26.69 323.31 
GTP-binding protein SAR1a Sar1a -0.46 + 25.89 26.34 193.11 
GTP-binding protein SAR1b Sar1b 0.93 + 22.80 21.87 10.46 
Sarcosine dehydrogenase, 
mitochondrial 
Sardh 0.20  23.01 22.81 22.31 
Serine--tRNA ligase, cytoplasmic Sars -0.05  26.11 26.16 256.70 
U4/U6.U5 tri-snRNP-associated protein 
1 
Sart1 -0.53  21.76 22.29 180.21 
Squamous cell carcinoma antigen 
recognized by T-cells 3 
Sart3 -0.61  22.00 22.61 182.91 
DNA-binding protein SATB Satb2 0.73  20.41 19.68 44.50 
Ribosome maturation protein SBDS Sbds 0.66  22.42 21.75 40.05 
Myotubularin-related protein 5 Sbf1 -0.40  20.96 21.36 21.99 
Protein strawberry notch homolog 1 Sbno1 NaN  18.95   2.44 
Protein SCAF8 Scaf8 0.27  22.51 22.24 8.43 




Secretory carrier-associated membrane 
protein 3 
Scamp3 0.28  23.12 22.83 52.41 
Scavenger receptor class B member 1 Scarb1 0.37  20.33 19.96 9.91 
Lysosome membrane protein 2 Scarb2 NaN    21.99 12.16 
Scavenger receptor class F member 2 Scarf2 NaN    20.67 3.98 
Sec1 family domain-containing protein 
1 
Scfd1 -0.62 + 25.11 25.73 323.31 
Sec1 family domain-containing protein 
2 
Scfd2 -3.42 + 17.88 21.30 45.31 
Selenocysteine lyase Scly -1.17  19.50 20.67 6.07 
Short coiled-coil protein Scoc 1.27  23.65 22.38 153.02 
Non-specific lipid-transfer protein Scp2 -0.63 + 23.58 24.21 36.30 
Retinoid-inducible serine 
carboxypeptidase 
Scpep1 -1.49 + 24.52 26.01 260.65 
Protein scribble homolog Scrib 1.38  21.93 20.55 19.73 
Secernin-1 Scrn1 0.07  23.49 23.42 44.09 
Secernin-2 Scrn2 -1.03  22.11 23.14 21.29 
N-terminal kinase-like protein Scyl1 -1.42 + 22.56 23.99 43.82 
SCY1-like protein 2 Scyl2 -0.98  20.35 21.33 116.83 
Syntenin-1 Sdcbp -0.52 + 22.14 22.66 36.18 
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Stromal cell-derived factor 2 Sdf2 -0.97  20.65 21.62 33.59 
Stromal cell-derived factor 2-like 
protein 1 
Sdf2l1 -0.29  22.53 22.81 40.82 
Succinate dehydrogenase [ubiquinone] 
flavoprotein subunit, mitochondrial 
Sdha 0.04  25.11 25.06 260.31 
Succinate dehydrogenase [ubiquinone] 
iron-sulfur subunit, mitochondrial 
Sdhb 0.21  23.43 23.22 53.69 
Serum deprivation-response protein Sdpr 2.09 + 23.53 21.44 21.32 
Protein SEC13 homolog Sec13 -1.90 + 23.95 25.85 46.53 
 Sec16a -0.64  23.19 23.83 116.60 
Vesicle-trafficking protein SEC22b Sec22b -0.69  23.22 23.91 167.73 
Protein transport protein Sec23A Sec23a -1.10 + 26.52 27.62 323.31 
Protein transport protein Sec23B Sec23b -0.05  24.55 24.60 145.84 
SEC23-interacting protein Sec23ip -1.38 + 23.00 24.38 51.82 
Protein transport protein Sec24A Sec24a -0.34  23.04 23.38 146.77 
 Sec24b -0.26  23.37 23.63 96.89 
 Sec24c -1.46 + 23.03 24.48 102.31 
 Sec24d -1.24 + 24.62 25.86 134.81 
Protein transport protein Sec31A Sec31a -0.56 + 27.18 27.74 323.31 
Protein transport protein Sec61 subunit 
alpha isoform 1 
Sec61a1 -0.45  20.80 21.25 93.24 
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Protein transport protein Sec61 subunit 
gamma 
Sec61g NaN  21.63   6.03 
Nucleoporin SEH1 Seh1l -0.46  21.17 21.63 26.10 
Selenium-binding protein 1 Selenbp1 -1.82  21.28 23.09 57.58 
Selenoprotein M Selm -1.57 + 21.75 23.32 105.50 
Selenoprotein O Selo -0.85  21.29 22.14 6.31 
Sentrin-specific protease 3 Senp3 -0.30  21.62 21.92 37.07 
Sentrin-specific protease 7 Senp7 -1.63  18.80 20.43 4.13 
Selenide, water dikinase 1 Sephs1 0.07  25.01 24.93 101.92 
O-phosphoseryl-tRNA(Sec) selenium 
transferase 
Sepsecs -1.33  18.52 19.86 11.30 
Plasminogen activator inhibitor 1 RNA-
binding protein 
Serbp1 -0.10  24.77 24.87 224.01 
Leukocyte elastase inhibitor A Serpinb1a 0.28  24.03 23.75 29.37 
Serpin B6 Serpinb6a -1.00 + 26.14 27.14 323.31 
 Serpinb9 0.17  20.65 20.48 32.49 
Antithrombin-III Serpinc1 NaN  20.07   1.70 
Glia-derived nexin Serpine2 -2.24  21.56 23.80 69.86 
Pigment epithelium-derived factor Serpinf1 -2.54 + 22.98 25.52 176.94 
Serpin H1 Serpinh1 -0.22 + 30.49 30.71 323.31 
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SEC14 domain and spectrin repeat-
containing protein 1 
Sestd1 NaN    21.89 5.42 
Protein SET Set 0.38 + 27.25 26.87 323.31 
Histone-lysine N-methyltransferase Setd1a 2.82 + 26.30 23.48 2.18 
Histone-lysine N-methyltransferase 
setd3 
Setd3 -0.10  21.68 21.78 36.07 
Histone-lysine N-methyltransferase 
SETD7 
Setd7 NaN    20.23 3.97 
Splicing factor 1 Sf1 0.07  24.47 24.40 75.69 
Splicing factor 3A subunit 1 Sf3a1 -0.06  24.53 24.59 323.31 
Splicing factor 3A subunit 2 Sf3a2 -0.48  22.09 22.57 68.39 
Splicing factor 3A subunit 3 Sf3a3 -0.18  24.57 24.75 323.31 
Splicing factor 3B subunit 1 Sf3b1 -0.11  25.52 25.62 323.31 
 Sf3b2 0.06  25.49 25.43 323.31 
Splicing factor 3B subunit 3 Sf3b3 0.11  26.43 26.32 323.31 
Splicing factor 3B subunit 4 Sf3b4 -0.15  22.11 22.26 11.05 
Splicing factor 3B subunit 5 Sf3b5 -0.06  23.58 23.64 28.79 
Splicing factor 3B subunit 6 Sf3b6 -0.02  22.53 22.56 22.75 
Splicing factor, proline- and glutamine-
rich 
Sfpq 0.09  27.47 27.38 323.31 
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Swi5-dependent recombination DNA 
repair protein 1 homolog 
Sfr1 -1.17  18.73 19.90 2.88 
Sideroflexin-1 Sfxn1 0.53  22.38 21.85 40.34 
Sideroflexin-3 Sfxn3 -0.22  22.73 22.95 37.45 
Delta-sarcoglycan Sgcd 1.40 + 22.81 21.41 8.44 
 Sgsh -0.63  21.05 21.68 1.45 
Small glutamine-rich tetratricopeptide 
repeat-containing protein alpha 
Sgta -0.09  23.60 23.68 27.30 
SH3 domain-binding glutamic acid-rich-
like protein 
Sh3bgrl -0.30  25.02 25.32 85.36 
SH3 domain-binding glutamic acid-rich-
like protein 3 
Sh3bgrl3 0.19  23.99 23.80 3.71 
SH3 domain-binding protein 1 Sh3bp1 -0.87  20.97 21.84 169.37 
SH3 domain-containing protein 19 Sh3d19 -0.42  20.79 21.20 60.76 
Endophilin-A2 Sh3gl1 -0.34  24.46 24.81 218.69 
Endophilin-B1 Sh3glb1 -0.21  23.41 23.62 44.96 
Endophilin-B2 Sh3glb2 -0.22  22.87 23.09 16.18 
SH3 domain-containing kinase-binding 
protein 1 
Sh3kbp1 0.00  23.49 23.49 253.82 
SH3 and PX domain-containing protein 
2A 
Sh3pxd2a -1.95  19.83 21.77 106.22 
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SH3 and PX domain-containing protein 
2B 
Sh3pxd2b -0.06  21.59 21.65 52.69 
SHC-transforming protein 1 Shc1 NaN    20.52 5.21 
Serine hydroxymethyltransferase Shmt2 0.99 + 27.66 26.67 323.31 
Leucine-rich repeat protein SHOC-2 Shoc2 -0.09  20.49 20.58 93.28 
Protein SHQ1 homolog Shq1 NaN    17.91 3.58 
Serine/threonine-protein kinase SIK3 Sik3 0.74  21.39 20.64 12.32 
Nucleotide exchange factor SIL1 Sil1 NaN    20.75 9.53 
Paired amphipathic helix protein Sin3a Sin3a 0.20  20.20 20.00 15.12 
NAD-dependent protein deacetylase 
sirtuin-2 
Sirt2 -1.71  20.95 22.66 78.32 
Homeobox protein SIX1 Six1 2.00  20.98 18.99 3.53 
 Skiv2l -0.22  22.63 22.85 21.80 
Superkiller viralicidic activity 2-like 2 Skiv2l2 -1.39 + 20.78 22.17 129.40 
S-phase kinase-associated protein 1 Skp1a -0.73  23.39 24.11 140.91 
SLAIN motif-containing protein 2 Slain2 -0.47  18.51 18.99 7.76 
Solute carrier family 12 member 4 Slc12a4 0.22  19.27 19.06 44.89 
Solute carrier family 12 member 7 Slc12a7 1.99  20.79 18.80 17.90 





Slc25a11 1.37  22.68 21.31 63.34 
Calcium-binding mitochondrial carrier 
protein Aralar1 
Slc25a12 1.42  23.82 22.40 116.61 
Calcium-binding mitochondrial carrier 
protein Aralar2 
Slc25a13 0.91  22.10 21.19 39.56 
Peroxisomal membrane protein PMP34 Slc25a17 -2.55  19.69 22.24 4.74 
Calcium-binding mitochondrial carrier 
protein SCaMC-1 
Slc25a24 0.38  21.70 21.33 76.78 
Phosphate carrier protein, 
mitochondrial 
Slc25a3 0.70  24.28 23.57 45.00 
ADP/ATP translocase 1 Slc25a4 0.22  25.97 25.75 119.19 
 Slc25a4 NaN    18.06 3.78 
ADP/ATP translocase 2 Slc25a5 0.98  23.01 22.03 48.61 
Sulfate transporter Slc26a2 NaN  19.11   3.74 
Long-chain fatty acid transport protein 
3 
Slc27a3 -1.88  19.36 21.24 12.58 
Solute carrier family 2, facilitated 
glucose transporter member 1 
Slc2a1 -0.17  19.65 19.83 11.69 
Solute carrier family 35 member E1 Slc35e1 0.65  19.91 19.26 2.22 
Putative sodium-coupled neutral amino 
acid transporter 10 
Slc38a10 -0.06  17.89 17.95 61.18 
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Zinc transporter SLC39A7 Slc39a7 0.09  21.98 21.89 42.58 
4F2 cell-surface antigen heavy chain Slc3a2 2.17 + 26.94 24.76 120.81 
4F2 cell-surface antigen heavy chain Slc3a2 NaN  20.49   2.93 
Large neutral amino acids transporter 
small subunit 1 
Slc7a5 3.15 + 23.71 20.56 20.25 
Y+L amino acid transporter 2 Slc7a6 1.00  20.97 19.97 7.34 
Na(+)/H(+) exchange regulatory 
cofactor NHE-RF 
Slc9a3r1 -0.76  20.75 21.51 21.23 
Na(+)/H(+) exchange regulatory 
cofactor NHE-RF 
Slc9a3r2 -0.08  20.97 21.05 3.36 
SRA stem-loop-interacting RNA-binding 
protein, mitochondrial 
Slirp -0.18  21.61 21.79 2.80 
Slit homolog 2 protein Slit2 0.45  20.61 20.16 3.81 
STE20-like serine/threonine-protein 
kinase 
Slk -0.47  21.81 22.28 255.04 
SAFB-like transcription modulator Sltm -0.68  20.79 21.47 75.35 
Mothers against decapentaplegic 
homolog 1 
Smad1 NaN  20.87   5.92 
Mothers against decapentaplegic 
homolog 2 
Smad2 -1.03  21.28 22.31 50.84 
Mothers against decapentaplegic 
homolog 5 
Smad5 NaN    19.81 2.77 
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Small acidic protein Smap -0.55  22.71 23.25 222.28 
Stromal membrane-associated protein 
1 
Smap1 0.18  22.67 22.49 5.48 
Probable global transcription activator 
SNF2L2 
Smarca2 -0.78  20.08 20.86 95.00 
Transcription activator BRG1 Smarca4 0.04  22.07 22.03 154.03 
SWI/SNF-related matrix-associated 
actin-dependent regulator of chromatin 
subfamily A member 5 
Smarca5 -0.09  23.24 23.32 323.31 
SWI/SNF-related matrix-associated 
actin-dependent regulator of chromatin 
subfamily A containing DEAD/H box 1 
Smarcad1 NaN    19.63 3.95 
SWI/SNF-related matrix-associated 
actin-dependent regulator of chromatin 
subfamily A-like protein 1 
Smarcal1 NaN    17.86 66.68 
SWI/SNF-related matrix-associated 
actin-dependent regulator of chromatin 
subfamily B member 1 
Smarcb1 0.46  22.44 21.98 112.53 
SWI/SNF complex subunit SMARCC1 Smarcc1 1.48 + 22.09 20.61 251.87 
SWI/SNF complex subunit SMARCC2 Smarcc2 -0.78  23.03 23.81 277.60 
SWI/SNF-related matrix-associated 
actin-dependent regulator of chromatin 
subfamily D member 2 




actin-dependent regulator of chromatin 
subfamily D member 3 
Smarcd3 NaN  18.71   9.15 
SWI/SNF-related matrix-associated 
actin-dependent regulator of chromatin 
subfamily E member 1 
Smarce1 -0.02  21.64 21.66 98.36 
Structural maintenance of 
chromosomes protein 1A 
Smc1a -0.70  22.43 23.13 201.83 
Structural maintenance of 
chromosomes protein 
Smc2 1.71 + 24.24 22.53 211.99 
Structural maintenance of 
chromosomes protein 
Smc3 -0.02  23.90 23.92 323.31 
Structural maintenance of 
chromosomes protein 
Smc4 1.49 + 23.03 21.54 68.76 
Structural maintenance of 
chromosomes flexible hinge domain-
containing protein 1 
Smchd1 -0.52  22.62 23.15 31.10 
Essential MCU regulator, mitochondrial Smdt1 0.92  18.89 17.97 2.48 
Serine/threonine-protein phosphatase 4 
regulatory subunit 3A 
Smek1 -0.47  19.99 20.46 23.96 
Serine/threonine-protein phosphatase 4 
regulatory subunit 3B 
Smek2 -0.04  19.64 19.68 76.63 
Serine/threonine-protein kinase SMG1 Smg1 NaN  20.95   2.52 
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Telomerase-binding protein EST1A Smg6 NaN    20.30 5.63 
Protein SMG8 Smg8 NaN    20.02 9.05 
Protein SMG9 Smg9 0.37  20.58 20.21 2.48 
Survival of motor neuron-related-
splicing factor 30 
Smndc1 -0.68  19.74 20.42 23.46 
Acid sphingomyelinase-like 
phosphodiesterase 3b 
Smpdl3b 0.18  22.02 21.85 4.79 
Spermine synthase Sms NaN    19.50 34.65 
Smoothelin Smtn -1.55 + 19.88 21.43 195.03 
WD40 repeat-containing protein SMU1 Smu1 0.16  23.74 23.57 121.83 
SET and MYND domain-containing 
protein 5 
Smyd5 -0.32  20.95 21.27 37.20 
Synaptosomal-associated protein Snap23 0.41  21.18 20.77 41.35 
Synaptosomal-associated protein 47 Snap47 0.10  21.43 21.33 35.27 
SNARE-associated protein Snapin Snapin -0.60  22.34 22.94 84.96 
Staphylococcal nuclease domain-
containing protein 1 
Snd1 -0.30 + 28.48 28.78 323.31 
Vacuolar-sorting protein SNF8 Snf8 -0.01  21.67 21.68 25.58 
U5 small nuclear ribonucleoprotein 200 
kDa helicase 
Snrnp200 -0.07  25.69 25.76 323.31 
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U4/U6.U5 small nuclear 
ribonucleoprotein 27 kDa protein 
Snrnp27 -0.50  19.11 19.61 8.47 
U5 small nuclear ribonucleoprotein 40 
kDa protein 
Snrnp40 0.42  23.85 23.42 106.42 
U1 small nuclear ribonucleoprotein 70 
kDa 
Snrnp70 0.07  23.10 23.03 20.06 
U1 small nuclear ribonucleoprotein A Snrpa 0.42  23.49 23.06 45.18 
U2 small nuclear ribonucleoprotein A Snrpa1 0.42  24.08 23.66 182.74 
Small nuclear ribonucleoprotein-
associated protein B 
Snrpb -0.07  24.48 24.55 44.93 
U2 small nuclear ribonucleoprotein B Snrpb2 0.03  22.27 22.24 11.21 
U1 small nuclear ribonucleoprotein C Snrpc -1.75 + 22.31 24.07 17.70 
Small nuclear ribonucleoprotein Sm D1 Snrpd1 -0.20  25.67 25.87 70.85 
Small nuclear ribonucleoprotein Sm D2 Snrpd2 -0.34  23.21 23.55 9.52 
Small nuclear ribonucleoprotein Sm D3 Snrpd3 -0.67  24.63 25.29 29.50 
Small nuclear ribonucleoprotein E Snrpe -1.47  23.87 25.33 16.63 
Small nuclear ribonucleoprotein F Snrpf -0.67  22.17 22.84 148.02 
Small nuclear ribonucleoprotein-
associated protein 
Snrpn NaN    17.19 2.53 
Alpha-1-syntrophin Snta1 NaN    21.50 79.73 
Beta-2-syntrophin Sntb2 1.12  23.21 22.09 17.18 
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SNW domain-containing protein 1 Snw1 0.21  24.05 23.83 97.70 
Sorting nexin-1 Snx1 -1.09 + 23.67 24.76 119.51 
Sorting nexin-12 Snx12 0.14  22.33 22.20 45.52 
Sorting nexin-17 Snx17 -2.39 + 19.03 21.42 41.59 
Sorting nexin Snx18 0.34  21.96 21.62 16.22 
Sorting nexin-2 Snx2 -0.65  24.83 25.48 323.31 
 Snx21 NaN    18.97 5.08 
Sorting nexin-3 Snx3 -0.26  24.79 25.05 111.18 
Sorting nexin-30 Snx30 -0.42  20.15 20.57 12.72 
Sorting nexin-33 Snx33 -0.35  20.27 20.62 4.09 
Sorting nexin-4 Snx4 -0.35 + 24.70 25.05 236.67 
Sorting nexin-5 Snx5 -0.97 + 24.08 25.05 107.44 
Sorting nexin-6 Snx6 -0.98  22.81 23.78 196.76 
 Snx7 -0.70 + 23.72 24.42 76.05 
Sorting nexin Snx9 -0.74  22.99 23.72 162.38 
Superoxide dismutase [Cu-Zn] Sod1 1.89 + 26.18 24.29 133.02 
Superoxide dismutase Sod2 -0.87 + 24.57 25.44 135.58 
Superoxide dismutase [Cu-Zn] Sod3 -0.85  20.56 21.40 2.51 
Protein SON Son -0.68  21.48 22.17 32.58 
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Sorbin and SH3 domain-containing 
protein 1 
Sorbs1 0.23  20.87 20.64 20.98 
Vinexin Sorbs3 0.03  21.78 21.75 23.06 
VPS10 domain-containing receptor 
SorCS2 
Sorcs2 -1.53  24.49 26.02 9.39 
Sorbitol dehydrogenase Sord 0.20  23.55 23.35 23.33 
Son of sevenless homolog 1 Sos1 NaN    17.25 10.31 
Transcription factor Sp1 Sp1 NaN    19.94 56.00 
Sperm-associated antigen 7 Spag7 -0.74 + 20.62 21.36 28.07 
C-Jun-amino-terminal kinase-
interacting protein 4 
Spag9 -0.44  23.42 23.85 323.31 
SPARC Sparc -0.74 + 25.82 26.56 51.67 
Spastin Spast NaN    19.25 4.88 
Spermatogenesis-associated protein 5 Spata5 0.22  25.85 25.62 25.02 
Spermatogenesis-associated serine-
rich protein 2 
Spats2 0.05  20.60 20.54 81.78 
Kinetochore protein Spc25 Spc25 NaN    17.64 17.95 
Signal peptidase complex subunit 2 Spcs2 NaN  20.08   13.54 
Cytospin-B Specc1 -0.01  21.84 21.84 62.54 
Cytospin-A Specc1l 0.62  22.51 21.89 22.71 
Spatacsin Spg11 -0.26  20.36 20.62 32.95 
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Spartin Spg20 NaN  21.24   16.21 
Maspardin Spg21 -0.84  20.26 21.10 11.27 
Sphingosine kinase 1 Sphk1 NaN    21.35 2.70 
Osteopontin Spp1 NaN    21.69 236.75 
Sepiapterin reductase Spr -0.50 + 25.35 25.86 130.66 
SPRY domain-containing protein 4 Spryd4 NaN    20.77 3.17 
Spectrin alpha chain, non-erythrocytic 
1 
Sptan1 0.53 + 28.61 28.08 323.31 
Spectrin beta chain, non-erythrocytic 1 Sptbn1 0.43 + 28.37 27.94 323.31 
Serine palmitoyltransferase 2 Sptlc2 0.03  19.97 19.94 6.46 
Sulfide:quinone oxidoreductase, 
mitochondrial 
Sqrdl 0.01  22.48 22.48 99.83 
Sequestosome-1 Sqstm1 0.16  22.97 22.81 180.88 
Steroid receptor RNA activator 1 Sra1 -0.88  22.75 23.63 64.57 
Non-specific protein-tyrosine kinase Src NaN  20.68   5.41 
Splicing regulatory glutamine/lysine-
rich protein 1 
Srek1 0.62  22.14 21.52 59.79 
SLIT-ROBO Rho GTPase-activating 
protein 2 
Srgap2 0.25  21.76 21.51 133.69 
SLIT-ROBO Rho GTPase-activating 
protein 3 
Srgap3 -0.11  20.55 20.66 83.47 
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Sorcin Sri 0.20  23.51 23.31 26.78 
Spermidine synthase Srm -0.30  25.04 25.34 75.11 
Signal recognition particle 14 kDa 
protein 
Srp14 0.27  23.94 23.67 246.06 
Signal recognition particle 54 kDa 
protein 
Srp54 -1.11 + 24.10 25.21 323.31 
Signal recognition particle subunit 
SRP68 
Srp68 -0.49  24.45 24.94 97.96 
Signal recognition particle subunit 
SRP72 
Srp72 -0.11  24.61 24.71 323.31 
Signal recognition particle 9 kDa 
protein 
Srp9 NaN    22.74 14.36 
SRSF protein kinase 1 Srpk1 0.32  21.27 20.94 13.77 
Sushi-repeat-containing protein SRPX Srpx -2.84 + 21.57 24.41 231.23 
Sushi repeat-containing protein SRPX2 Srpx2 NaN    24.90 207.86 
Serine racemase Srr NaN    19.15 2.24 
Serine/arginine repetitive matrix protein 
1 
Srrm1 -0.55  21.22 21.77 12.43 
Serine/arginine repetitive matrix protein 
2 
Srrm2 0.15  25.95 25.80 323.31 
Serrate RNA effector molecule homolog Srrt -0.34 + 22.96 23.29 163.99 
Serine/arginine-rich splicing factor 1 Srsf1 0.27  25.42 25.15 43.51 
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Serine/arginine-rich splicing factor 10 Srsf10 -0.36  23.58 23.95 8.83 
 Srsf11 -0.02  23.64 23.66 37.78 
Serine/arginine-rich splicing factor 2 Srsf2 -0.01  25.78 25.79 195.94 
Serine/arginine-rich splicing factor 3 Srsf3 0.36 + 26.21 25.85 53.49 
Serine/arginine-rich splicing factor 4 Srsf4 -1.92  17.38 19.30 31.47 
Serine/arginine-rich splicing factor 5 Srsf5 0.04  23.37 23.33 20.44 
Serine/arginine-rich splicing factor 6 Srsf6 -1.07 + 24.04 25.10 12.76 
Serine/arginine-rich splicing factor 7 Srsf7 0.28  25.75 25.47 23.69 
Serine/arginine-rich splicing factor 9 Srsf9 0.12  21.40 21.28 5.19 
Lupus La protein homolog Ssb 0.02  24.74 24.72 237.62 
Single-stranded DNA-binding protein Ssbp1 NaN    19.93 2.27 
Sperm-specific antigen 2 homolog Ssfa2 NaN    18.30 3.61 
Protein phosphatase Slingshot 
homolog 3 
Ssh3 NaN    17.01 14.00 
Translocon-associated protein subunit 
alpha 
Ssr1 0.93  21.76 20.83 124.09 
Translocon-associated protein subunit 
delta 
Ssr4 0.02  24.37 24.36 51.58 
FACT complex subunit SSRP1 Ssrp1 0.81  24.01 23.20 323.31 
Sjoegren syndrome/scleroderma 
autoantigen 1 homolog 
Sssca1 -0.67  19.43 20.10 2.53 
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Hsc70-interacting protein St13 -0.13  25.74 25.87 182.49 
Cohesin subunit SA-1 Stag1 NaN    20.15 39.77 
Cohesin subunit SA-2 Stag2 0.28  21.84 21.56 63.21 
Signal transducing adapter molecule 1 Stam -0.59  21.90 22.49 22.35 
Signal transducing adapter molecule 2 Stam2 NaN    22.69 14.30 
STAM-binding protein Stambp 0.64  22.06 21.43 12.20 
Signal transducer and activator of 
transcription 
Stat1 0.64 + 23.27 22.63 29.96 
Signal transducer and activator of 
transcription 
Stat2 NaN    19.49 3.22 
Signal transducer and activator of 
transcription 
Stat3 -0.50  25.12 25.62 285.98 
Signal transducer and activator of 
transcription 
Stat5a 0.30  20.73 20.42 5.69 
Signal transducer and activator of 
transcription 5B 
Stat5b -0.13  22.22 22.36 33.61 
Signal transducer and activator of 
transcription 
Stat6 0.56  21.74 21.18 10.82 
Double-stranded RNA-binding protein 
Staufen homolog 1 
Stau1 -0.31  22.01 22.32 24.82 
Stress-induced-phosphoprotein 1 Stip1 0.15  27.39 27.24 323.31 
Serine/threonine-protein kinase 10 Stk10 NaN    19.33 53.40 
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Serine/threonine-protein kinase 24 Stk24 -0.36  22.63 22.99 101.32 
Serine/threonine-protein kinase 25 Stk25 NaN    17.79 2.68 
Serine/threonine-protein kinase 3 Stk3 -0.30  22.86 23.16 40.76 
Serine/threonine-protein kinase 38 Stk38 0.71  22.00 21.29 10.55 
Stathmin Stmn1 1.64 + 25.52 23.88 73.82 
Erythrocyte band 7 integral membrane 
protein 
Stom 0.49  20.00 19.51 37.57 
Stomatin-like protein 2, mitochondrial Stoml2 0.24  24.25 24.01 89.76 
Stonin-1 Ston1 0.84  22.26 21.42 20.34 
Serine-threonine kinase receptor-
associated protein 
Strap 0.15  25.10 24.95 175.49 
Spermatid perinuclear RNA-binding 
protein 
Strbp NaN    17.32 2.04 
Striatin-interacting protein 1 Strip1 -0.32  19.88 20.20 8.57 
Striatin Strn -1.07  23.32 24.39 300.12 
Striatin-3 Strn3 0.80  22.61 21.81 23.96 
Striatin-4 Strn4 NaN  18.63   4.63 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 
STT3A 
Stt3a -1.09  20.97 22.07 7.45 




Syntaxin-12 Stx12 -0.04  22.35 22.39 165.49 
Syntaxin-2 Stx2 -0.57  17.86 18.43 3.60 
Syntaxin-5 Stx5a -1.91 + 21.41 23.31 151.71 
Syntaxin-6 Stx6 NaN    19.48 29.86 
Syntaxin-7 Stx7 0.80  22.43 21.63 16.73 
Syntaxin-8 Stx8 NaN    22.23 17.05 
Syntaxin-binding protein 1 Stxbp1 -0.35  22.65 23.00 39.01 
Syntaxin-binding protein 3 Stxbp3 0.15  20.89 20.74 194.04 
Activated RNA polymerase II 
transcriptional coactivator p15 
Sub1 -1.81 + 21.80 23.61 58.97 
Succinyl-CoA ligase subunit beta Sucla2 1.09  23.84 22.75 77.93 
Succinyl-CoA ligase [ADP/GDP-
forming] subunit alpha, mitochondrial 
Suclg1 -0.47 + 23.83 24.29 18.46 
Succinyl-CoA ligase [GDP-forming] 
subunit beta, mitochondrial 
Suclg2 0.14  24.85 24.71 316.44 
SURP and G-patch domain-containing 
protein 1 
Sugp1 -0.19  19.35 19.54 5.80 
Suppressor of G2 allele of SKP1 
homolog 
Sugt1 0.09  23.57 23.49 111.69 
Sulfatase-modifying factor 1 Sumf1 1.09 + 23.79 22.70 26.61 
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Small ubiquitin-related modifier 1 Sumo1 0.52  20.26 19.74 4.39 
SUN domain-containing protein 2 Sun2 NaN  19.91   3.08 
FACT complex subunit SPT16 Supt16 0.53  24.28 23.75 167.29 
Transcription elongation factor SPT5 Supt5h -0.25  22.35 22.60 155.34 
Transcription elongation factor SPT6 Supt6h -0.19  22.59 22.77 109.61 
Surfeit locus protein 4 Surf4 -0.92 + 22.91 23.83 137.31 
Surfeit locus protein 6 Surf6 -0.17  20.19 20.36 7.90 
Supervillin Svil -0.64  22.23 22.86 215.62 
Switch-associated protein 70 Swap70 -1.08 + 23.18 24.26 323.31 
DNA repair protein SWI5 homolog Swi5 NaN    22.12 8.26 
Synapse-associated protein 1 Syap1 -0.12  23.11 23.24 21.17 
Tyrosine-protein kinase Syk -0.67  21.15 21.82 21.99 
Symplekin Sympk -0.73  22.51 23.25 118.82 
Synapsin-1 Syn1 -0.24  16.95 17.19 46.10 
Heterogeneous nuclear 
ribonucleoprotein Q 
Syncrip -0.15  26.46 26.61 323.31 
Nesprin-1 Syne1 -0.08  21.00 21.07 3.52 
Synaptojanin-1 Synj1 0.13  17.69 17.56 32.38 
Synaptojanin-2 Synj2 NaN    23.10 20.25 
484 
 
Synemin Synm -0.44 + 20.45 20.89 23.88 
Synaptopodin Synpo -0.23  22.40 22.63 37.00 
Synaptophysin-like protein 1 Sypl NaN  18.91   5.48 
SUZ domain-containing protein 1 Szrd1 -1.04  20.22 21.27 196.95 
TGF-beta-activated kinase 1 and 
MAP3K7-binding protein 1 
Tab1 0.21  21.77 21.56 74.86 
TGF-beta-activated kinase 1 and 
MAP3K7-binding protein 2 
Tab2 1.32  21.48 20.16 60.87 
Transforming acidic coiled-coil-
containing protein 1 
Tacc1 -0.57  18.19 18.76 57.38 
Transforming acidic coiled-coil-
containing protein 2 
Tacc2 NaN    14.14 2.56 
Translational activator of cytochrome c 
oxidase 1 
Taco1 0.28  21.14 20.86 17.65 
Transcriptional adapter 1 Tada1 NaN  16.07   3.74 
 Taf15 -0.25  22.51 22.75 33.16 
 Taf4a 0.27  18.48 18.21 8.10 
Transcription initiation factor TFIID 
subunit 6 
Taf6 NaN    18.24 2.78 
Transgelin Tagln 0.26  27.05 26.78 323.31 
Transgelin-2 Tagln2 -0.28  28.82 29.10 323.31 
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Transaldolase Taldo1 -1.31 + 24.27 25.58 82.09 
Phosphatidate cytidylyltransferase, 
mitochondrial 
Tamm41 0.98  21.35 20.37 6.19 
Protein TANC1 Tanc1 0.08  20.92 20.84 41.94 
Serine/threonine-protein kinase TAO1 Taok1 0.48  20.54 20.06 13.81 
Serine/threonine-protein kinase TAO3 Taok3 NaN    18.21 3.49 
TAR DNA-binding protein 43 Tardbp -0.56 + 25.66 26.22 323.31 
Threonine--tRNA ligase, cytoplasmic Tars -0.11  25.92 26.03 323.31 
Putative deoxyribonuclease TATDN1 Tatdn1 NaN    18.73 5.69 
Tax1-binding protein 1 homolog Tax1bp1 NaN  19.70   2.71 
Tax1-binding protein 3 Tax1bp3 0.24  23.17 22.93 45.41 
TBC1 domain family member 15 Tbc1d15 -0.22  23.40 23.62 129.54 
TBC1 domain family member 17 Tbc1d17 NaN  21.95   11.72 
TBC1 domain family member 4 Tbc1d4 NaN    20.12 4.87 
TBC1 domain family member 5 Tbc1d5 -0.23  22.88 23.11 21.98 
TBC1 domain family member 8B Tbc1d8b -0.99  21.56 22.55 37.50 
TBC1 domain family member 9B Tbc1d9b -1.17 + 21.46 22.63 180.70 
Tubulin-specific chaperone A Tbca 0.86  22.22 21.36 12.53 
Tubulin-folding cofactor B Tbcb -0.10  21.58 21.68 95.97 
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Tubulin-specific chaperone C Tbcc 1.27  22.80 21.53 43.51 
Tubulin-specific chaperone D Tbcd -0.06  23.63 23.69 183.52 
Tubulin-specific chaperone cofactor E-
like protein 
Tbcel NaN    20.24 3.12 
TBC domain-containing protein kinase-
like protein 
Tbck 0.26  23.20 22.94 1.47 
Serine/threonine-protein kinase TBK1 Tbk1 -0.23  21.27 21.49 34.43 
F-box-like/WD repeat-containing 
protein TBL1X 
Tbl1x 0.82  21.72 20.90 130.14 
F-box-like/WD repeat-containing 
protein TBL1XR1 
Tbl1xr1 0.38  22.28 21.90 245.22 
Transducin beta-like protein 2 Tbl2 0.16  22.56 22.40 32.27 
Transducin beta-like protein 3 Tbl3 1.46  23.39 21.92 92.76 
Transcription elongation factor A 
protein 1 
Tcea1 0.22  24.81 24.59 98.12 
Transcription elongation factor B 
polypeptide 1 
Tceb1 1.11  25.02 23.91 91.41 
Transcription elongation factor B 
polypeptide 2 
Tceb2 -0.43 + 23.35 23.78 16.15 
Transcription elongation regulator 1 Tcerg1 -0.01  21.95 21.96 22.30 
Transcription factor 20 Tcf20 -0.75  22.41 23.16 2.26 
Transcription factor 25 Tcf25 -0.54  20.30 20.83 8.89 
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V-type proton ATPase subunit a Tcirg1 0.07  21.75 21.68 25.13 
Treacle protein Tcof1 0.10  23.07 22.97 156.28 
T-complex protein 1 subunit alpha Tcp1 0.28  28.25 27.97 323.31 
Tudor domain-containing protein 3 Tdrd3 NaN    19.17 5.71 
Tudor domain-containing protein 7 Tdrd7 NaN    23.72 20.95 
Transcriptional enhancer factor TEF-1 Tead1 NaN    18.85 2.35 
Transcriptional enhancer factor TEF-5 Tead3 NaN    19.04 40.66 
Tectonin beta-propeller repeat-
containing protein 1 
Tecpr1 NaN    20.33 8.57 
Very-long-chain enoyl-CoA reductase Tecr 4.49  21.04 16.55 2.98 
Telomere length regulation protein 
TEL2 homolog 
Telo2 -0.18  19.10 19.29 4.56 
Telomeric repeat-binding factor 2-
interacting protein 1 
Terf2ip -0.51  20.19 20.70 10.93 
Testis-expressed sequence 10 protein Tex10 -0.47  21.35 21.82 18.11 
Alpha-globin transcription factor CP2 Tfcp2 -0.93  20.15 21.08 50.29 
 Tfg -0.32  24.21 24.54 44.91 
Tuftelin-interacting protein 11 Tfip11 -0.49  21.62 22.11 20.09 
Transferrin receptor protein 1 Tfrc NaN  21.27   22.82 
Transforming growth factor beta-1 Tgfb1 -1.23  20.49 21.72 55.55 
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Transforming growth factor beta-1-
induced transcript 1 protein 
Tgfb1i1 -0.20  23.03 23.23 288.60 
Transforming growth factor-beta-
induced protein ig-h3 
Tgfbi NaN    22.36 18.10 
TGF-beta receptor type-2 Tgfbr2 NaN  21.56   3.48 
Protein-glutamine gamma-
glutamyltransferase 2 
Tgm2 NaN    20.53 7.58 
Thyroid adenoma-associated protein 
homolog 
Thada 0.45  21.61 21.16 9.59 
THAP domain-containing protein 11 Thap11 NaN    17.25 1.69 
 Thbs1 -5.54 + 23.07 28.61 323.31 
Thrombospondin-2 Thbs2 -5.45 + 20.17 25.61 161.37 
Thrombospondin-3 Thbs3 NaN    19.37 2.59 
Threonine synthase-like 2 Thnsl2 -0.30  22.02 22.32 73.85 
THO complex subunit 1 Thoc1 0.13  21.13 21.00 39.99 
THO complex subunit 2 Thoc2 0.10  21.01 20.91 105.29 
THO complex subunit 3 Thoc3 NaN    19.64 1.93 
THO complex subunit 5 homolog Thoc5 0.52  20.88 20.36 9.16 
THO complex subunit 6 homolog Thoc6 0.95  22.56 21.62 25.04 
Thimet oligopeptidase Thop1 -0.07  24.51 24.59 151.48 




THUMP domain-containing protein 1 Thumpd1 0.29  22.19 21.90 110.44 
Nucleolysin TIA-1 Tia1 0.72  22.68 21.95 31.19 
Nucleolysin TIAR Tial1 NaN    18.95 2.80 
Mitochondrial import inner membrane 
translocase subunit Tim13 
Timm13 -0.33  23.30 23.63 49.13 
Mitochondrial import inner membrane 
translocase subunit TIM44 
Timm44 0.04  22.07 22.03 98.03 
Mitochondrial import inner membrane 
translocase subunit Tim8 A 
Timm8a1 0.10  22.49 22.39 35.00 
Mitochondrial import inner membrane 
translocase subunit Tim8 B 
Timm8b NaN    16.72 58.58 
Mitochondrial import inner membrane 
translocase subunit Tim9 
Timm9 1.56  21.62 20.06 3.69 
Metalloproteinase inhibitor 2 Timp2 NaN    20.58 16.22 
Metalloproteinase inhibitor 3 Timp3 NaN  22.33   3.58 
TIP41-like protein Tiprl -0.11  23.29 23.40 50.91 
Tight junction-associated protein 1 Tjap1 -0.51  20.57 21.08 30.59 
Tight junction protein ZO-1 Tjp1 -0.64  22.45 23.09 100.86 
Tight junction protein ZO-2 Tjp2 -0.03  19.89 19.93 8.36 
Transketolase Tkt -0.36  28.19 28.55 323.31 
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TLD domain-containing protein 1 Tldc1 -1.19  18.14 19.33 5.85 
Transducin-like enhancer protein 3 Tle3 0.68  20.65 19.97 2.35 
Talin-1 Tln1 0.26 + 29.82 29.56 323.31 
Talin-2 Tln2 -1.05  21.67 22.71 277.19 
Transmembrane 9 superfamily member 
3 
Tm9sf3 0.02  22.05 22.03 38.15 
Transmembrane 9 superfamily member 
4 
Tm9sf4 0.25  22.69 22.44 9.89 
Transmembrane emp24 domain-
containing protein 1 
Tmed1 NaN    19.71 13.41 
Transmembrane emp24 domain-
containing protein 10 
Tmed10 -0.31  24.39 24.70 59.02 
Transmembrane emp24 domain-
containing protein 2 
Tmed2 NaN  20.86   8.57 
Transmembrane emp24 domain-
containing protein 4 
Tmed4 NaN    20.99 3.45 
 Tmed7 0.00  22.56 22.56 13.98 
Transmembrane emp24 domain-
containing protein 9 
Tmed9 -0.30  23.21 23.51 92.61 
Transmembrane protein 2 Tmem2 1.05  20.17 19.12 12.28 
Transmembrane protein 263 Tmem263 -1.03 + 25.20 26.22 69.43 
Cell cycle control protein 50A Tmem30a NaN    17.54 9.04 
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Transmembrane protein 43 Tmem43 1.31  23.89 22.59 88.59 
Type 2 phosphatidylinositol 4,5-
bisphosphate 4-phosphatase 
Tmem55a NaN    20.23 7.29 
CSC1-like protein 1 Tmem63a -0.36  19.25 19.61 3.94 
Transmembrane protein 9B Tmem9b NaN  21.88   2.38 
TATA element modulatory factor Tmf1 NaN    20.66 4.21 
Trimethyllysine dioxygenase, 
mitochondrial 
Tmlhe NaN    20.70 8.77 
Tropomodulin-1 Tmod1 NaN    18.54 23.21 
Tropomodulin-3 Tmod3 -0.09  25.25 25.34 221.02 
Lamina-associated polypeptide 2, 
isoforms alpha/zeta 
Tmpo 1.52 + 25.44 23.91 238.92 
Lamina-associated polypeptide 2, 
isoforms beta/delta/epsilon/gamma 
Tmpo 2.34  24.06 21.72 25.25 
Thymosin beta-10 Tmsb10 0.03  28.54 28.51 323.31 
Thymosin beta-4 Tmsb4x 1.58 + 28.39 26.81 168.26 
Protein disulfide-isomerase TMX3 Tmx3 1.87  19.43 17.56 3.92 
Tenascin Tnc -5.16 + 23.50 28.66 323.31 
Tenascin Tnc -1.26  20.00 21.26 4.41 
Tumor necrosis factor alpha-induced 
protein 2 
Tnfaip2 NaN    17.91 1.73 
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Tumor necrosis factor alpha-induced 
protein 8 
Tnfaip8 -1.38  19.33 20.71 57.20 
Tumor necrosis factor receptor 
superfamily member 11B 
Tnfrsf11b NaN    21.74 4.78 
182 kDa tankyrase-1-binding protein Tnks1bp1 0.07  24.31 24.24 323.31 
Transportin-1 Tnpo1 -0.19  23.46 23.64 112.92 
Transportin-2 Tnpo2 -1.12  20.56 21.68 46.31 
Transportin-3 Tnpo3 0.35  23.30 22.94 97.71 
Trinucleotide repeat-containing gene 
6B protein 
Tnrc6b -1.13 + 18.29 19.42 275.95 
Trinucleotide repeat-containing gene 
6C protein 
Tnrc6c NaN    17.95 18.17 
 Tns1 NaN    20.33 12.98 
Tensin-3 Tns3 0.45 + 23.83 23.37 87.99 
Target of EGR1 protein 1 Toe1 0.71  20.98 20.27 17.63 
Toll-interacting protein Tollip -1.19 + 22.04 23.23 14.73 
Target of Myb protein 1 Tom1 -1.87 + 22.24 24.11 168.78 
TOM1-like protein 2 Tom1l2 -1.20  21.89 23.09 59.01 
Mitochondrial import receptor subunit 
TOM22 homolog 
Tomm22 2.43  22.72 20.29 85.41 




DNA topoisomerase 1 Top1 0.68  20.04 19.36 9.31 
DNA topoisomerase 2-alpha Top2a 0.08  23.06 22.98 137.57 
DNA topoisomerase 2-beta Top2b -0.51  22.67 23.17 74.89 
DNA topoisomerase Top3b -0.52  19.91 20.42 15.18 
Torsin-1A-interacting protein 1 Tor1aip1 1.90  19.06 17.16 106.38 
Torsin-1A-interacting protein 2, isoform 
IFRG15 
Tor1aip2 -1.22 + 21.35 22.57 25.82 
Torsin-1B Tor1b 0.91  22.24 21.33 11.33 
Torsin-3A Tor3a NaN    17.50 11.95 
TOX high mobility group box family 
member 4 
Tox4 NaN    16.98 11.14 
Tumor protein D54 Tpd52l2 -0.55  25.51 26.06 96.93 
Triosephosphate isomerase Tpi1 -1.88 + 27.97 29.86 281.07 
Tropomyosin beta chain Tpm2 NaN  19.91   1.68 
Tropomyosin alpha-4 chain Tpm4 0.22  29.30 29.08 323.31 
Tripeptidyl-peptidase 1 Tpp1 -1.70 + 23.70 25.40 111.49 
Tripeptidyl-peptidase 2 Tpp2 -0.20  25.01 25.21 323.31 
Tubulin polymerization-promoting 
protein family member 3 
Tppp3 NaN    20.24 3.63 
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Nucleoprotein TPR Tpr -0.06  24.94 25.00 323.31 
Translationally-controlled tumor 
protein 
Tpt1 0.18  26.79 26.60 80.19 
Transformer-2 protein homolog alpha Tra2a 0.27  23.32 23.04 22.79 
Transformer-2 protein homolog beta Tra2b 0.75  24.30 23.55 21.56 
Tumor necrosis factor receptor type 1-
associated DEATH domain protein 
Tradd 0.07  23.04 22.98 176.49 
TRAF-type zinc finger domain-
containing protein 1 
Trafd1 2.65 + 24.34 21.69 10.48 
Heat shock protein 75 kDa, 
mitochondrial 
Trap1 0.54 + 25.59 25.05 230.79 
Trafficking protein particle complex 
subunit 10 
Trappc10 NaN    22.98 1.58 
Trafficking protein particle complex 
subunit 12 
Trappc12 0.65  20.06 19.41 129.15 
Trafficking protein particle complex 
subunit 3 
Trappc3 -0.13  22.40 22.53 3.23 
Trafficking protein particle complex 
subunit 4 
Trappc4 NaN    20.86 11.18 
 Trappc8 0.09  19.72 19.63 49.39 
 Trim12c NaN    18.79 2.95 
Tripartite motif-containing protein 16 Trim16 0.09  20.72 20.63 7.72 
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Tripartite motif-containing protein 2 Trim2 0.03  19.27 19.25 51.40 
Transcription intermediary factor 1-
alpha 
Trim24 NaN  19.42   5.73 
E3 ubiquitin/ISG15 ligase TRIM25 Trim25 -0.88 + 20.32 21.20 5.28 
Transcription intermediary factor 1-beta Trim28 -0.10  26.10 26.20 215.71 
Tripartite motif-containing protein 3 Trim3 -0.09  21.06 21.15 6.69 
E3 ubiquitin-protein ligase TRIM32 Trim32 -0.18  20.68 20.87 10.02 
E3 ubiquitin-protein ligase TRIM33 Trim33 -0.09  18.98 19.07 2.85 
Tripartite motif-containing protein 47 Trim47 -0.79 + 23.16 23.96 64.43 
Tripartite motif-containing protein 47 Trim47 NaN    17.05 73.91 
E3 ubiquitin-protein ligase TRIM56 Trim56 -0.30  19.70 20.00 14.82 
Triple functional domain protein Trio 0.38 + 19.88 19.49 24.08 
TRIO and F-actin-binding protein Triobp -0.19  19.57 19.76 78.47 
Cdc42-interacting protein 4 Trip10 -0.51  22.12 22.63 60.84 
 Trip11 -1.93 + 21.53 23.47 153.90 
E3 ubiquitin-protein ligase TRIP12 Trip12 -0.02  22.39 22.42 174.02 
Pachytene checkpoint protein 2 
homolog 
Trip13 0.62  20.38 19.76 6.66 
Activating signal cointegrator 1 Trip4 NaN    19.46 6.06 





Trmt11 NaN    20.84 4.30 
Multifunctional methyltransferase 
subunit TRM112-like protein 
Trmt112 -0.45  23.74 24.19 47.19 
TRMT1-like protein Trmt1l -0.02  21.21 21.23 62.12 
tRNA (uracil-5-)-methyltransferase 
homolog A 
Trmt2a NaN    19.46 2.23 
tRNA (guanine(37)-N1)-
methyltransferase 
Trmt5 -1.07  19.45 20.52 7.19 
tRNA (adenine(58)-N(1))-
methyltransferase non-catalytic subunit 
TRM6 
Trmt6 -0.16  21.82 21.98 64.61 
tRNA (adenine(58)-N(1))-
methyltransferase catalytic subunit 
TRMT61A 
Trmt61a 0.03  22.47 22.44 54.58 
CCA tRNA nucleotidyltransferase 1, 
mitochondrial 
Trnt1 -0.31 + 23.79 24.10 64.05 
60 kDa SS-A/Ro ribonucleoprotein Trove2 -0.54  23.52 24.06 48.25 
Tumor suppressor p53-binding protein 
1 
Trp53bp1 -0.06  21.77 21.83 38.21 
Apoptosis-stimulating of p53 protein 2 Trp53bp2 -0.12  19.76 19.88 8.87 
 Trp53rk 0.15  21.98 21.83 38.85 





Trrap -0.67  26.20 26.87 2.70 
Hamartin Tsc1 NaN    20.91 9.57 
Tuberin Tsc2 NaN    20.57 3.62 
TSC22 domain family protein 1 Tsc22d1 -0.98  21.56 22.54 23.62 
TSC22 domain family protein 3 Tsc22d3 NaN  18.92   3.56 
tRNA-splicing endonuclease subunit 
Sen34 
Tsen34 -0.12  21.66 21.78 3.18 
Elongation factor Ts Tsfm NaN    21.10 1.42 
Tumor susceptibility gene 101 protein Tsg101 0.07  21.51 21.43 61.76 
Translin Tsn -0.23  25.19 25.42 249.80 
Translin-associated protein X Tsnax -1.18 + 23.03 24.21 109.65 
Translocator protein Tspo -1.25  19.05 20.30 13.24 
Pre-rRNA-processing protein TSR1 
homolog 
Tsr1 -0.27  22.10 22.37 65.73 
Pre-rRNA-processing protein TSR2 
homolog 
Tsr2 NaN    17.47 93.98 
Protein TSSC1 Tssc1 NaN    19.82 1.45 
GDP-L-fucose synthase Tsta3 0.51  23.77 23.26 55.67 
Tetratricopeptide repeat protein 1 Ttc1 0.08  21.30 21.22 63.91 
Tetratricopeptide repeat protein 27 Ttc27 0.40  21.46 21.06 56.41 
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Tetratricopeptide repeat protein 28 Ttc28 0.09  21.06 20.97 125.85 
E3 ubiquitin-protein ligase TTC3 Ttc3 NaN  19.40   2.72 
Tetratricopeptide repeat protein 33 Ttc33 -0.41  20.63 21.05 15.17 
 Ttc37 -0.51  22.55 23.06 99.35 
Tetratricopeptide repeat protein 39B Ttc39b 0.32  19.10 18.78 50.80 
Tetratricopeptide repeat protein 7A Ttc7 NaN    18.92 26.48 
Tetratricopeptide repeat protein 9C Ttc9c 0.04  20.93 20.89 3.47 
TELO2-interacting protein 1 homolog Tti1 NaN    22.81 2.44 
Tubulin--tyrosine ligase-like protein 12 Ttll12 0.04  24.77 24.73 86.33 
Titin Ttn 0.71  23.06 22.35 1.62 
Protein tweety homolog 3 Ttyh3 0.03  20.86 20.83 16.30 
Tubulin alpha-1A chain Tuba1a 0.69  26.89 26.20 98.75 
Tubulin alpha-1C chain Tuba1c NaN    19.08 128.37 
Tubulin alpha chain-like 3 Tubal3 NaN  21.73   2.09 
Tubulin beta-2A chain Tubb2a -0.31  26.36 26.67 186.85 
Tubulin beta-3 chain Tubb3 0.36  24.50 24.15 89.98 
Tubulin beta-4A chain Tubb4a NaN    23.35 67.83 
Tubulin beta-4B chain Tubb4b -0.41 + 27.77 28.18 309.55 
Tubulin beta-5 chain Tubb5 -0.15  31.20 31.35 323.31 
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Tubulin beta-6 chain Tubb6 0.42 + 26.64 26.22 230.99 
Tubulin gamma chain Tubg1 -0.68 + 22.74 23.43 196.72 
Gamma-tubulin complex component 2 Tubgcp2 0.33  22.35 22.02 28.91 
Gamma-tubulin complex component 3 Tubgcp3 0.79  21.95 21.16 113.37 
Gamma-tubulin complex component 4 Tubgcp4 0.22  20.63 20.41 6.03 
Tubby-related protein 3 Tulp3 0.82  21.12 20.31 35.04 
Speckle targeted PIP5K1A-regulated 
poly(A) polymerase 
Tut1 NaN    20.24 2.70 
Twinfilin-1 Twf1 0.28  25.42 25.15 153.12 
Twinfilin-2 Twf2 0.52  24.07 23.55 71.26 
Alpha-taxilin Txlna 0.06  20.95 20.89 103.66 
Thioredoxin Txn 0.49  25.74 25.25 113.33 
Thioredoxin domain-containing protein 
12 
Txndc12 0.39  24.49 24.10 72.67 
Thioredoxin domain-containing protein 
17 
Txndc17 -0.23  24.37 24.60 52.31 
Thioredoxin domain-containing protein 
5 
Txndc5 0.40 + 25.73 25.33 153.09 
Thioredoxin domain-containing protein 
9 
Txndc9 -1.46  18.97 20.43 44.87 
Thioredoxin-like protein 1 Txnl1 0.29  25.25 24.96 250.93 
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Thioredoxin reductase 1, cytoplasmic Txnrd1 2.42 + 25.64 23.22 84.27 
Thymidylate synthase Tyms 1.13  20.93 19.80 23.15 
Splicing factor U2AF 35 kDa subunit U2af1 -0.25  23.12 23.37 52.05 
Splicing factor U2AF 65 kDa subunit U2af2 0.77 + 25.70 24.93 157.64 
U2 snRNP-associated SURP motif-
containing protein 
U2surp 0.24  21.74 21.50 28.63 
UDP-N-acetylhexosamine 
pyrophosphorylase 
Uap1 -0.19  22.71 22.89 136.24 
UDP-N-acetylhexosamine 
pyrophosphorylase-like protein 1 
Uap1l1 -1.26 + 25.62 26.89 289.48 
Ubiquitin-like modifier-activating 
enzyme 1 
Uba1 -0.10  28.49 28.60 323.31 
SUMO-activating enzyme subunit 2 Uba2 -0.52  24.08 24.60 123.20 
NEDD8-activating enzyme E1 catalytic 
subunit 
Uba3 -0.38  22.70 23.09 74.49 
Ubiquitin-like modifier-activating 
enzyme 5 
Uba5 -0.64 + 23.45 24.09 141.34 
Ubiquitin-like modifier-activating 
enzyme 6 
Uba6 -0.43  22.67 23.10 43.21 
Ubiquitin-associated protein 2 Ubap2 -0.17  23.18 23.34 257.47 
Ubiquitin-associated protein 2-like Ubap2l -0.09  24.79 24.88 318.59 
Ubiquitin-conjugating enzyme E2 D3 Ube2d3 -0.89  22.25 23.14 11.25 
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Ubiquitin-conjugating enzyme E2 G1 Ube2g1 NaN    19.72 3.35 
Ubiquitin-conjugating enzyme E2 H Ube2h 0.71  22.94 22.23 34.29 
SUMO-conjugating enzyme UBC9 Ube2i -0.26  22.58 22.85 9.19 
Ubiquitin-conjugating enzyme E2 K Ube2k -0.20  22.56 22.76 31.98 
Ubiquitin-conjugating enzyme E2 L3 Ube2l3 -0.02  26.30 26.32 106.67 
NEDD8-conjugating enzyme Ubc12 Ube2m 0.24  21.91 21.67 21.89 
Ubiquitin-conjugating enzyme E2 N Ube2n 0.19  26.74 26.55 122.28 
E2/E3 hybrid ubiquitin-protein ligase 
UBE2O 
Ube2o 0.03  21.84 21.81 30.47 
Ubiquitin-conjugating enzyme E2 Q1 Ube2q1 -0.42  19.00 19.41 2.51 
Ubiquitin-conjugating enzyme E2 R2 Ube2r2 NaN    21.46 2.69 
Ubiquitin-conjugating enzyme E2 
variant 1 
Ube2v1 -1.44 + 22.17 23.61 59.93 
Ubiquitin-conjugating enzyme E2 
variant 2 
Ube2v2 -0.73  23.84 24.57 65.53 
Ubiquitin-conjugating enzyme E2 Z Ube2z -0.64  21.63 22.27 7.38 
Ubiquitin-protein ligase E3A Ube3a -0.20  21.96 22.16 85.63 
Ubiquitin-protein ligase E3C Ube3c -0.62 + 21.49 22.11 75.21 
Ubiquitin conjugation factor E4 A Ube4a NaN    19.79 1.71 
Ubiquitin conjugation factor E4 B Ube4b 0.07  22.90 22.83 76.05 
502 
 
Ubiquitin domain-containing protein 
UBFD1 
Ubfd1 -0.75  21.30 22.05 12.50 
Ubiquitin-like protein 7 Ubl7 1.17  19.39 18.22 3.26 
Ubiquitin-like domain-containing CTD 
phosphatase 1 
Ublcp1 0.37  21.90 21.52 8.51 
Ubiquilin-1 Ubqln1 -0.76 + 23.93 24.69 309.01 
Ubiquilin-2 Ubqln2 0.14  23.83 23.70 116.32 
Ubiquilin-4 Ubqln4 -0.12  22.34 22.45 50.87 
E3 ubiquitin-protein ligase UBR1 Ubr1 -0.57  19.37 19.94 9.92 
E3 ubiquitin-protein ligase UBR2 Ubr2 0.67  21.44 20.78 38.89 
E3 ubiquitin-protein ligase UBR3 Ubr3 0.13  19.92 19.79 8.79 
E3 ubiquitin-protein ligase UBR4 Ubr4 0.30  24.07 23.77 323.31 
E3 ubiquitin-protein ligase UBR5 Ubr5 -0.03  19.10 19.13 24.40 
Nucleolar transcription factor 1 Ubtf 0.48  23.66 23.18 20.02 
UBX domain-containing protein 1 Ubxn1 -0.13  24.10 24.23 98.01 
UBX domain-containing protein 4 Ubxn4 -0.50  20.69 21.18 18.33 
UBX domain-containing protein 6 Ubxn6 -1.19  20.10 21.29 37.51 
UBX domain-containing protein 7 Ubxn7 0.02  22.22 22.20 28.29 
Ubiquitin carboxyl-terminal hydrolase 
isozyme L3 
Uchl3 -0.75 + 23.42 24.17 135.38 
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Ubiquitin carboxyl-terminal hydrolase 
isozyme L5 
Uchl5 -0.68  22.23 22.91 20.37 
Uridine-cytidine kinase-like 1 Uckl1 NaN    18.33 6.27 
Ubiquitin-fold modifier-conjugating 
enzyme 1 
Ufc1 -0.98 + 22.58 23.57 44.62 
Ubiquitin fusion degradation protein 1 
homolog 
Ufd1l -0.41  24.11 24.52 52.81 
E3 UFM1-protein ligase 1 Ufl1 -0.82 + 23.63 24.45 245.07 
Ubiquitin-fold modifier 1 Ufm1 -0.32  24.34 24.66 7.57 
Ufm1-specific protease 2 Ufsp2 -0.70  21.62 22.32 102.50 
UDP-glucose 6-dehydrogenase Ugdh -0.13  25.88 26.01 323.31 
UDP-glucose:glycoprotein 
glucosyltransferase 1 
Uggt1 -0.25  26.17 26.42 323.31 
UTP--glucose-1-phosphate 
uridylyltransferase 
Ugp2 -0.66  18.70 19.35 53.10 
UTP--glucose-1-phosphate 
uridylyltransferase 
Ugp2 0.12  26.19 26.07 250.63 
UDP-glucuronosyltransferase 1-7C Ugt1a7c -0.80  18.61 19.40 3.80 
E3 ubiquitin-protein ligase UHRF1 Uhrf1 NaN    19.61 6.84 
 Uhrf1bp1 NaN    19.15 3.66 
Uridine 5-monophosphate synthase Umps -0.26  24.38 24.64 220.98 
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Protein unc-45 homolog A Unc45a -0.67 + 20.51 21.18 97.43 
Regulator of nonsense transcripts 1 Upf1 -0.21  24.88 25.09 246.73 
 Upf2 -0.58  18.39 18.97 5.15 
Ubiquinol-cytochrome-c reductase 
complex assembly factor 1 
Uqcc1 NaN    18.75 4.76 
Cytochrome b-c1 complex subunit 9 Uqcr10 0.72  22.88 22.16 3.40 
Cytochrome b-c1 complex subunit 7 Uqcrb 0.12  21.08 20.96 4.88 
Cytochrome b-c1 complex subunit 1, 
mitochondrial 
Uqcrc1 0.31  24.95 24.64 126.06 
Cytochrome b-c1 complex subunit 2, 
mitochondrial 
Uqcrc2 -0.44  25.31 25.75 138.35 
Cytochrome b-c1 complex subunit 
Rieske, mitochondrial 
Uqcrfs1 0.56 + 22.84 22.28 16.06 
Uroporphyrinogen decarboxylase Urod -0.91  22.01 22.92 34.56 
General vesicular transport factor p115 Uso1 -0.60 + 24.85 25.45 288.23 
Ubiquitin carboxyl-terminal hydrolase 
10 
Usp10 1.51  22.05 20.53 7.14 
Ubiquitin carboxyl-terminal hydrolase Usp14 0.42 + 25.24 24.82 218.41 
Ubiquitin carboxyl-terminal hydrolase 
15 
Usp15 0.16  22.86 22.70 68.80 
Ubiquitinyl hydrolase 1 Usp16 -0.49  18.04 18.54 11.66 
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Ubiquitin carboxyl-terminal hydrolase Usp19 -0.38  21.09 21.47 26.06 
Ubiquitin carboxyl-terminal hydrolase 
22 
Usp22 NaN  20.73   4.15 
Ubiquitin carboxyl-terminal hydrolase Usp24 NaN  20.57   2.11 
Ubiquitin carboxyl-terminal hydrolase Usp34 0.83  21.49 20.66 4.41 
U4/U6.U5 tri-snRNP-associated protein 
2 
Usp39 -0.48  21.54 22.02 25.86 
Ubiquitin carboxyl-terminal hydrolase Usp4 0.07  22.21 22.14 9.94 
Ubiquitin carboxyl-terminal hydrolase 
40 
Usp40 NaN    19.33 3.17 
Ubiquitin carboxyl-terminal hydrolase 
47 
Usp47 -0.29  23.08 23.37 105.64 
Ubiquitin carboxyl-terminal hydrolase 
48 
Usp48 NaN    20.50 3.42 
Ubiquitin carboxyl-terminal hydrolase Usp5 -0.39 + 27.24 27.64 323.31 
Ubiquitin carboxyl-terminal hydrolase Usp7 -0.46  22.77 23.22 102.83 
Ubiquitin carboxyl-terminal hydrolase Usp8 -0.26  21.86 22.12 44.43 
Ubiquitin carboxyl-terminal hydrolase Usp9x -0.57  23.21 23.78 198.84 
U3 small nucleolar RNA-associated 
protein 14 homolog A 
Utp14a -0.04  19.99 20.03 11.40 
U3 small nucleolar RNA-associated 
protein 15 homolog 
Utp15 0.64  21.40 20.76 15.42 
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U3 small nucleolar RNA-associated 
protein 18 homolog 
Utp18 -0.69  19.55 20.24 5.26 
U3 small nucleolar RNA-associated 
protein 6 homolog 
Utp6 -0.21  19.98 20.19 39.81 
 Utrn 0.10  25.46 25.36 323.31 
Protein VAC14 homolog Vac14 -0.82  20.05 20.88 46.48 
Vesicle-associated membrane protein 3 Vamp3 0.64  23.12 22.47 63.14 
Vesicle-associated membrane protein 7 Vamp7 0.63  20.63 20.00 1.74 
Vesicle-associated membrane protein 8 Vamp8 0.21  21.67 21.46 10.67 
Vesicle-associated membrane protein-
associated protein A 
Vapa 0.34  21.95 21.61 10.74 
Vesicle-associated membrane protein-
associated protein B 
Vapb 1.83  21.05 19.21 3.22 
Valine--tRNA ligase Vars 0.03  27.89 27.86 323.31 
Valine--tRNA ligase, mitochondrial Vars2 NaN    19.56 5.73 
Vasorin Vasn -1.09 + 20.42 21.52 22.97 
Vasodilator-stimulated phosphoprotein Vasp 0.11  24.20 24.09 85.59 
Synaptic vesicle membrane protein 
VAT-1 homolog 
Vat1 -0.96 + 26.17 27.12 323.31 
Prefoldin subunit 3 Vbp1 -0.58 + 23.06 23.63 41.78 
Vascular cell adhesion protein 1 Vcam1 1.04  22.64 21.59 12.17 
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Versican core protein Vcan -0.11  19.43 19.54 6.19 
Vinculin Vcl -0.44 + 29.34 29.78 323.31 
Transitional endoplasmic reticulum 
ATPase 
Vcp -0.30 + 29.38 29.68 323.31 
Deubiquitinating protein VCIP135 Vcpip1 0.10  21.69 21.59 57.94 
Voltage-dependent anion-selective 
channel protein 1 
Vdac1 -0.42  24.08 24.49 109.15 
Voltage-dependent anion-selective 
channel protein 2 
Vdac2 -1.04  22.02 23.06 18.00 
Vimentin Vim 0.18  32.62 32.44 323.31 
 Vim NaN    19.50 75.21 
Spermatogenesis-defective protein 39 
homolog 
Vipas39 -0.56  17.87 18.43 25.83 
Vacuolar protein sorting-associated 
protein 11 homolog 
Vps11 -0.30  20.47 20.78 7.70 
Vacuolar protein sorting-associated 
protein 13C 
Vps13c -0.04  21.12 21.16 94.63 
Vacuolar protein sorting-associated 
protein 16 homolog 
Vps16 NaN    21.04 3.93 
Vacuolar protein sorting-associated 
protein 18 homolog 
Vps18 -0.21  21.40 21.61 116.96 




Vacuolar protein sorting-associated 
protein 26A 
Vps26a -0.26  23.59 23.85 59.09 
Vacuolar protein sorting-associated 
protein 26B 
Vps26b 0.05  21.50 21.45 37.98 
Vacuolar protein sorting-associated 
protein 28 homolog 
Vps28 2.11  22.91 20.80 4.03 
Vacuolar protein sorting-associated 
protein 29 
Vps29 -1.16 + 23.13 24.30 68.84 
Vacuolar protein sorting-associated 
protein 33A 
Vps33a -1.64 + 19.68 21.32 15.02 
Vacuolar protein sorting-associated 
protein 33B 
Vps33b -1.31  19.84 21.14 40.26 
Vacuolar protein sorting-associated 
protein 35 
Vps35 -0.05  25.91 25.95 323.31 
Vacuolar protein-sorting-associated 
protein 36 
Vps36 -0.26  22.16 22.42 37.42 
Vacuolar protein sorting-associated 
protein 37A 
Vps37a NaN    19.52 37.93 
Vacuolar protein sorting-associated 
protein 37C 
Vps37c -0.63  21.36 21.99 41.54 
Vacuolar protein sorting-associated 
protein 41 homolog 
Vps41 0.03  20.81 20.77 8.04 
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Vacuolar protein sorting-associated 
protein 45 
Vps45 0.48  21.90 21.42 18.47 
Vacuolar protein sorting-associated 
protein 4A 
Vps4a 0.02  21.71 21.69 21.77 
Vacuolar protein sorting-associated 
protein 4B 
Vps4b -0.70  22.42 23.12 132.94 
Vacuolar protein sorting-associated 
protein 51 homolog 
Vps51 -0.25  21.74 21.99 24.67 
Vacuolar protein sorting-associated 
protein 52 homolog 
Vps52 -0.50  21.90 22.40 25.58 
Vacuolar protein sorting-associated 
protein 53 homolog 
Vps53 -0.42  20.44 20.87 16.54 
Vacuolar protein sorting-associated 
protein VTA1 homolog 
Vta1 0.26 + 23.49 23.24 187.51 
Vesicle transport through interaction 
with t-SNAREs homolog 1A 
Vti1a -0.73  19.75 20.49 61.76 
Vesicle transport through interaction 
with t-SNAREs homolog 1B 
Vti1b -0.16  19.21 19.37 149.43 
von Willebrand factor A domain-
containing protein 5A 
Vwa5a -0.18  24.91 25.09 119.29 
von Willebrand factor A domain-
containing protein 8 
Vwa8 -0.48  18.53 19.01 5.78 
Wings apart-like protein homolog Wapal NaN  18.82   3.60 
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Tryptophan--tRNA ligase, cytoplasmic Wars 0.69 + 25.27 24.57 160.18 
Wiskott-Aldrich syndrome protein 
family member 1 
Wasf1 0.05  19.05 19.00 4.39 
Wiskott-Aldrich syndrome protein 
family member 2 
Wasf2 -0.65  22.35 23.00 115.44 
WAS protein family homolog 1 Wash1 -0.63  21.33 21.96 32.37 
Neural Wiskott-Aldrich syndrome 
protein 
Wasl 0.00  21.51 21.50 41.22 
WW domain-binding protein 11 Wbp11 0.80  22.05 21.25 17.35 
WD repeat and FYVE domain-
containing protein 3 
Wdfy3 0.57  21.25 20.68 6.05 
WD repeat-containing protein 1 Wdr1 -0.03  27.64 27.68 259.85 
WD repeat-containing protein 11 Wdr11 -0.30  21.98 22.29 73.35 
Ribosome biogenesis protein WDR12 Wdr12 0.26  21.68 21.42 7.88 
WD repeat-containing protein 13 Wdr13 NaN  19.38   4.83 
WD repeat-containing protein 18 Wdr18 0.33  22.02 21.68 24.29 
WD repeat-containing protein 26 Wdr26 0.45  22.40 21.95 30.47 
WD repeat-containing protein 3 Wdr3 -0.74  19.47 20.21 43.60 
pre-mRNA 3 end processing protein 
WDR33 
Wdr33 -0.15  19.15 19.30 7.60 
WD repeat-containing protein 35 Wdr35 -0.55  18.60 19.15 4.70 
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 Wdr36 0.18  21.61 21.43 15.44 
WD repeat-containing protein 43 Wdr43 1.44 + 22.36 20.92 37.65 
WD repeat-containing protein 46 Wdr46 NaN  19.12   43.87 
WD repeat-containing protein 5 Wdr5 1.29  21.13 19.84 1.60 
WD repeat-containing protein 55 Wdr55 NaN    19.56 3.26 
WD repeat-containing protein 6 Wdr6 0.29  21.90 21.61 13.13 
WD repeat-containing protein 61 Wdr61 -0.21  23.41 23.61 284.63 
Methylosome protein 50 Wdr77 NaN    21.10 1.99 
WD repeat-containing protein 81 Wdr81 0.01  20.92 20.91 8.44 
WD repeat-containing protein 82 Wdr82 -0.16  21.99 22.16 75.70 
WD repeat-containing protein 91 Wdr91 -0.28  20.08 20.36 13.26 
WD and tetratricopeptide repeats 
protein 1 
Wdtc1 NaN    18.32 2.44 
Partner of Y14 and mago Wibg -0.07  22.15 22.22 23.43 
WD repeat domain phosphoinositide-
interacting protein 1 
Wipi1 -0.13  22.57 22.70 52.50 
WD repeat domain phosphoinositide-
interacting protein 2 
Wipi2 0.63  22.33 21.70 34.65 
Protein Wiz Wiz 0.06  20.27 20.21 14.71 
Serine/threonine-protein kinase WNK1 Wnk1 0.34  22.17 21.83 270.93 
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Pre-mRNA-splicing regulator WTAP Wtap -0.35  20.42 20.77 86.61 
Protein WWC2 Wwc2 0.12  20.99 20.87 12.07 
Pre-mRNA-splicing factor SYF1 Xab2 -0.23  20.71 20.94 54.84 
Xanthine dehydrogenase/oxidase Xdh -4.60 + 21.24 25.83 258.86 
Xaa-Pro aminopeptidase 1 Xpnpep1 -0.33 + 24.97 25.30 53.29 
Exportin-1 Xpo1 0.15  25.31 25.16 308.21 
Exportin-5 Xpo5 0.86  23.94 23.08 323.31 
Exportin-7 Xpo7 0.57  21.39 20.82 12.32 
Exportin-T Xpot 1.11  23.38 22.27 46.45 
DNA repair protein XRCC1 Xrcc1 -0.12  21.31 21.43 5.74 
X-ray repair cross-complementing 
protein 5 
Xrcc5 -1.50  22.37 23.87 288.19 
X-ray repair cross-complementing 
protein 6 
Xrcc6 -0.56  21.97 22.53 57.94 
5-3 exoribonuclease 1 Xrn1 -0.47  19.22 19.69 284.21 
5-3 exoribonuclease 2 Xrn2 -0.03  22.62 22.65 47.45 
Xylulose kinase Xylb NaN    20.82 4.64 
Transcriptional coactivator YAP1 Yap1 0.23  22.36 22.14 23.02 
Tyrosine--tRNA ligase Yars 0.73 + 24.99 24.26 58.64 




Y-box-binding protein 3 Ybx3 0.86  24.43 23.57 123.39 
Y-box-binding protein 3 Ybx3 NaN  21.55   2.30 
Non-specific protein-tyrosine kinase Yes1 0.18  18.71 18.53 6.40 
Protein YIPF3 Yipf3 NaN    19.21 38.12 
Synaptobrevin homolog YKT6 Ykt6 0.87  22.61 21.75 36.00 
YLP motif-containing protein 1 Ylpm1 -0.40  21.55 21.95 233.20 
Protein yippee-like Ypel5 -0.27  19.59 19.86 4.61 
YTH domain-containing family protein 1 Ythdf1 0.36  21.66 21.30 16.49 
YTH domain-containing family protein 2 Ythdf2 NaN  20.02   1.42 
YTH domain-containing family protein 3 Ythdf3 NaN    20.43 11.75 
14-3-3 protein beta/alpha Ywhab -0.31 + 27.17 27.49 323.31 
14-3-3 protein epsilon Ywhae 0.04  28.67 28.63 323.31 
 Ywhae NaN    17.76 3.03 
14-3-3 protein gamma Ywhag 0.29  27.03 26.74 323.31 
14-3-3 protein eta Ywhah 0.10  26.40 26.30 323.31 
14-3-3 protein theta Ywhaq -0.36  26.39 26.75 323.31 
14-3-3 protein zeta/delta Ywhaz -0.02  28.44 28.46 323.31 
Transcriptional repressor protein YY1 Yy1 -0.38 + 19.48 19.85 5.51 
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Zinc-binding alcohol dehydrogenase 
domain-containing protein 2 
Zadh2 -0.56  21.05 21.62 52.66 
Mitogen-activated protein kinase kinase 
kinase MLT 
Zak -0.86 + 22.57 23.43 61.56 
Zinc finger CCCH domain-containing 
protein 11A 
Zc3h11a -1.14 + 19.45 20.59 5.93 
Zinc finger CCCH domain-containing 
protein 14 
Zc3h14 -0.70  19.74 20.44 152.68 
Zinc finger CCCH domain-containing 
protein 15 
Zc3h15 NaN    19.09 2.03 
Zinc finger CCCH domain-containing 
protein 18 
Zc3h18 0.58  21.98 21.40 18.09 
Zinc finger CCCH domain-containing 
protein 4 
Zc3h4 NaN    17.09 8.69 
 Zc3h4 0.33 + 21.19 20.86 66.16 
 Zc3h7b 0.29  21.31 21.02 22.64 
Zinc finger CCCH-type antiviral protein 
1 
Zc3hav1 0.27  21.59 21.32 52.37 
Zinc finger CCCH-type antiviral protein 
1-like 
Zc3hav1l NaN    21.29 3.93 
Nuclear-interacting partner of ALK Zc3hc1 1.03  20.06 19.02 36.46 
Terminal uridylyltransferase 7 Zcchc6 NaN    18.24 2.19 
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Zinc finger CCHC domain-containing 
protein 8 
Zcchc8 -0.26  21.49 21.75 57.19 
Zinc finger protein 638 Zfml -0.80  20.56 21.36 37.36 
Zinc finger protein 346 Zfp346 NaN    18.52 7.86 
Zinc finger protein 622 Zfp622 1.02  21.51 20.49 34.18 
E3 ubiquitin-protein ligase ZFP91 Zfp91 NaN    17.04 6.89 
Zinc finger protein-like 1 Zfpl1 NaN    19.93 1.86 
Zinc finger RNA-binding protein Zfr -0.06  21.34 21.41 302.64 
Zinc finger FYVE domain-containing 
protein 26 
Zfyve26 NaN    17.26 7.98 
CAAX prenyl protease 1 homolog Zmpste24 1.89  19.67 17.78 24.45 
 Zmynd8 -0.90  18.98 19.88 104.02 
BUB3-interacting and GLEBS motif-
containing protein ZNF207 
Znf207 -0.02  21.36 21.38 4.16 
DBIRD complex subunit ZNF326 Znf326 0.14  22.14 22.00 5.98 
Zinc finger protein 598 Znf598 0.06  21.67 21.61 33.06 
Zinc finger protein 771 Znf771 NaN    18.62 23.99 
Zinc finger protein 830 Znf830 -0.61  19.58 20.19 64.92 
Zinc finger protein ZPR1 Zpr1 0.63  21.36 20.73 2.58 
Zinc finger SWIM domain-containing 
protein 8 
Zswim8 NaN    19.58 4.44 
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Centromere/kinetochore protein zw10 
homolog 
Zw10 -0.27  22.87 23.14 132.92 
Zyxin Zyx 1.93 + 27.49 25.56 280.97 
Zinc finger ZZ-type and EF-hand 
domain-containing protein 1 
Zzef1 0.40  21.77 21.37 29.96 
 
 
